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9List of abbreviations
A2E N-retinylidene-N-retinylethanolamine 
ABCA4 ATP-binding cassette transporter A4 (gene) 
ABCR ATP-binding cassette transporter
AD autosomal dominant
ADVIRC autosomal dominant vitreoretinochoroidopathy
AFVD adult-onset foveomacular vitelliform dystrophy
aHUS atypical hemolytic uremic syndrome
AMD age-related macular degeneration
AP alternative pathway
APOE apolipoprotein E (gene)
ARMS2 age-related maculopathy susceptibility 2 (gene)
ARB autosomal recessive bestrophinopathy
atRAL all-trans-retinal
BEST1 bestrophin-1 (gene)
BLD basal laminar drusen
BVMD  Best vitelliform macular dystrophy
CACD central areolar choroidal dystrophy
CaV voltage-dependent calcium
CCP complement control protein
CERES composite exonic regulatory element of splicing
CFB complement factor B
CFH complement factor H
CFI complement factor I
CFHR complement factor H-related
CNV choroidal neovascularization
CR1 complement receptor 1  
CRP C-reactive protein
cSLO confocal scanning laser ophthalmoscope
DAF decay accelerating factor
DGGE denaturing gradient gel electrophoresis
DHPLC  denaturing high-performance liquid chromatography
DNA deoxyribonucleic acid
EFEMP1  EGF-containing fibulin-like extracellular matrix protein 1 (gene)
ELOVL4 elongation of very long chain fatty acids-like 4 (gene)
EOG electro-oculogram
ERG electroretinogram
ESE exonic splicing enhancer
ESS exonic splicing silencer
FAF fundus autofluorescence
FFA fluorescein angiography
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FHL-1 factor H-like protein 1
GAG glycosaminoglycan
GBM glomerular basal membrane
HTRA1 HtrA serine peptidase 1 (gene)
HLA human leukocyte antigen
HRA Heidelberg retina angiograph
HUS hemolytic uremic syndrome
ISCEV International Society for Clinical Electrophysiology of Vision
LOD logarithm of the odds
MCDR1 macular dystrophy, retinal, 1
MCP membrane co-factor protein
MIDD maternally inherited diabetes and deafness
MPD  multifocal pattern dystrophy simulating Stargardt disease (STGD1)/fundus 
flavimaculatus
MPGN membranoproliferative glomerulonephritis
MRCS  microcornea, rod-cone dystrophy, early-onset cataract, posterior staphyloma
NIR-FAF near-infrared fundus autofluorescence
OCT optical coherence tomography
ORL outer red line
PCR polymerase chain reaction
PE phosphatidylethanolamine
PLEKHA1   pleckstrin homology domain containing, family A (phosphoinositide 
binding specific) member 1 (gene)
PROM1 prominin 1 (gene)
RDS retinal degeneration slow
RNA ribonucleic acid
RP retinitis pigmentosa
RPA retinitis punctata albescens
RPE retinal pigment epithelium
ROM1 retinal outer segment membrane protein 1 (gene)
SCR short consensus repeat
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 (gene)
SNP single nucleotide polymorphism
SSCA single-strand conformation analysis
SSCP single-strand conformation polymorphism
STGD1 autosomal recessive Stargardt disease
TIMP-3 tissue inhibitor of metalloproteinase (gene)
TLR3 toll-like receptor 3 (gene)
TNF-α tumor necrosis factor-alpha
VEGF vascular endothelial growth factor
VMD2 vitelliform macular dystrophy 2 (gene)
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Figures marked with an asterisk are printed in color at the end of this thesis, in the 
section “Color figures”.
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Preface
The patients who are described in this thesis often experience the difficult 
consequences of their eye disease every day. These consequences may not only 
include examples such as the inability to play bridge or to sew, but also the inability 
to recognize people on the street and to perform professional activities. Macular 
degeneration is not a disease that people can easily recognize from the outside. As 
a result, a patient suffering from macular degeneration may be judged “arrogant” 
behind his or her back, if he or she is unable to recognize and thus greet an 
acquaintance who is ignorant of the nature of the disease. More public awareness of 
this group of blinding diseases is therefore desired.
The patients described in my thesis were often prepared to travel to Nijmegen, 
sometimes from the other side of the country, to undergo the extensive examinations 
that have finally resulted in this thesis. Therefore, I dedicate my thesis to these 
patients, and I hope that our findings may contribute to a better patient information 
and prognosis with regard to these severe eye disorders.
Voorwoord
De patiënten die in dit proefschrift worden beschreven ervaren vaak elke dag de 
vervelende gevolgen van hun oogziekte. Hierbij gaat het niet alleen om zaken als niet 
meer kunnen bridgen en kantklossen, maar ook om het niet meer herkennen van 
mensen op straat en het onmogelijk worden van beroepsmatige werkzaamheden. 
Maculadegeneratie is geen ziekte die je aan de buitenkant aan iemand kunt zien. 
Dit heeft heel concreet als gevolg dat iemand met maculadegeneratie soms achter 
zijn of haar rug om als “arrogant” wordt versleten, als hij of zij een bekende soms 
niet herkent en dus niet groet. Meer bekendheid voor deze groep van oogziekten is 
dus hard nodig.
De in mijn proefschrift beschreven patiënten waren vaak bereid om, soms vanuit de 
andere kant van het land, af te reizen naar Nijmegen, en een hele ochtend of middag 
onderzoeken te ondergaan die uiteindelijk hebben geleid tot dit proefschrift. Mijn 
proefschrift draag ik dan ook mede aan hen op, in de hoop dat onze bevindingen bij 
kunnen dragen aan een betere informatievoorziening en prognose ten aanzien van 
deze ernstige oogaandoeningen.
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1.1. Historical background 
The anatomical and functional complex of photoreceptors, retinal pigment epithelium, 
Bruch’s membrane, and choriocapillaris, that is essential for optimal retinal function, 
was first described by the renowned Dutch anatomist and botanist Frederik Ruysch (1638-
1731), at the end of the 17th century.1,2 Half a century later, in 1744, Rüdiger F. Ovelgün 
reported the first case of familial night blindness.3 This case is generally considered the 
first documented case of probable familial retinitis pigmentosa.
      A true revolution in ophthalmology 
started with the invention of the 
ophthalmoscope in 1851 by Hermann 
(von) Helmholtz (1821-1894), which 
allowed examination of the retina and 
the optic disc.4 Soon thereafter, in 1853, 
Adriaan C. van Trigt (1825-1864) was the 
first to publish an atlas with colored 
pictures of the normal fundus and 
several pathological retinal conditions, 
including retinitis pigmentosa (Fig. 1.1; 
figures in this thesis marked with an 
asterisk are printed in color at the end of 
this thesis, in the section “Color figures”).5 
Van Trigt concludes: “The significance of 
the ophthalmoscope for the diagnosis 
of lens opacification, disorders of the 
vitreous, as well as retinal and choroidal 
abnormalities, does not need to be 
explained at great length. The reported 
facts speak for themselves.” Drusen -the 
hallmark lesions of age-related macular 
degeneration- were first described by 
Franciscus C. Donders in 1854 (Fig. 1.2).6 
The term drusen is derived from the 
German word “Druse”, which refers 
to a geode, a rock with a cavity that is 
internally lined by crystals. Age-related 
macular degeneration was reported for 
the first time in medical literature in 
1874 by Jonathan Hutchinson (1828-1913), 
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Figure 1.1.*  
Original fundus image of 
retinitis pigmentosa, published 
by van Trigt in 1853.
Figure 1.2.  
Franciscus Cornelis Donders  
(1818-1889).
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with the description “symmetrical central choroido-retinal disease occurring in senile 
persons”.7 In 1905, the German ophthalmologist Friedrich Best (1871-1915) reported 
typical macular lesions in eight affected members of a large family, a condition which 
we now know as Best vitelliform macular dystrophy (Fig. 1.3A).8 Stargardt disease (fundus 
flavimaculatus) was named after Karl B. Stargardt (1875-1927), who described the clinical 
features of this retinal dystrophy in 1909, in seven patients from two families (Fig. 1.3B).9 
Clear-cut cases of central areolar choroidal dystrophy in multiple generations were first 
described in 1931 by Hendrik K. de Haas (1873-1953),10 followed by a more elaborate 
discussion by Arnold Sorsby (1900-1980) in 1939 (Fig. 1.3C).11 Sorsby observed that the 
age at onset of a macular dystrophy could vary considerably within a family, and also 
remarked that so-called “macular” dystrophies were often more widespread than initially 
suggested by the ophthalmoscopic picture.12 In 1949, Jules François (1907-1984) was the 
first to describe a family with autosomal dominant inheritance of a widely variable 
phenotype, ranging from Stargardt disease to retinitis pigmentosa.13 
 The remarkable clinical variations of macular dystrophies were already noted by 
Stargardt in 1917. He proposed to separate these clinical entities into different groups, 
based on the clinical presentation and ophthalmoscopic appearance.14 Nevertheless, the 
“monistic” view that all macular dystrophies represent an expression of a single clinical 
entity, advocated by for instance Leber,15 Sorsby,12 and François,16 dominated until the 
late 1960s.17 In 1967, August F. Deutman proposed a classification that differentiated 
the hereditary dystrophies of the posterior pole of the eye according to their primary 
localization within the retinal and/or choroidal layers, as evidenced by clinical, 
functional, and histopathological studies.18 In addition, he underscored the likelihood 
that these different clinical entities were caused by different genes.   
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Figure 1.3.*  
Original figures published by Best, Stargardt, and Sorsby. A. Best vitelliform macular  
dystrophy, drawing published by Friedrich Best in 1905. B. Stargardt disease,  
drawing published by Karl Stargardt in 1909. C. Central areolar choroidal dystrophy,  
drawing published by Arnold Sorsby in 1939.
19
 Sorsby was among the first to thoroughly explore and describe the role of genetics and 
heredity in ophthalmology, which resulted in his handbook “Genetics in Ophthalmology” 
(1951).19 The era of molecular genetics in ophthalmology was announced in 1984 by 
Bhattacharya and colleagues, when they mapped a gene involved in X-linked retinitis 
pigmentosa to a specific area on the X chromosome.20 The first autosomal dominant 
retinitis pigmentosa gene was subsequently identified by Dryja and co-workers in 1990,21 
whereas Cremers and colleagues identified the X-linked choroideremia gene in the same 
year.22 One year later, the peripherin/RDS gene was identified as a cause of autosomal 
dominant retinitis pigmentosa.23,24 Soon thereafter, its involvement in various macular 
dystrophies would come to light,25 including its role as a cause of central areolar choroidal 
dystrophy, which was shown by Hoyng and colleagues (1996).26 The genetic background 
of Best vitelliform macular dystrophy was elucidated in 1998, with the identification 
of the BEST1 gene (formerly known as VMD2) by Petrukhin and co-workers.27 The CFH 
protein was already identified in 1965 by Nilsson and Müller-Eberhard,28 followed by 
the identification of the gene cluster harboring the CFH gene in 1985, by Rodríguez 
de Córdoba.29 However, it would take until the year 2000 before its complex genomic 
structure would be unraveled by Male and co-workers.30
1.2. The retina and choroid
Light is converted to a neuronal signal in the retina, which is a layer of highly specialized 
neural tissue covering the posterior inner eye. The retina is as thin as 0.4 mm, and finds 
its embryologic origin in the developing forebrain. Therefore, it may be considered a 
part of the brain. The retina can be divided into the neurosensory retina and the retinal 
pigment epithelium (RPE), which are mutually dependent during their development, 
differentiation and normal function.31 Both arise from the neuroectoderm-derived 
optic vesicle, which forms the bilayered optic cup. The inner layer evolves towards the 
neuroretina, whereas the outer layer forms the RPE. The RPE is physically separated from 
the underlying capillary vascular tissue, the choriocapillaris, by Bruch’s membrane. 
1.2.1. Neurosensory retina 
Vision starts with the capture of photons by the light-sensitive cells in the retina: the 
photoreceptors. The two main types of photoreceptors, cones and rods, convert light into 
an electrical neuronal signal by means of the phototransduction cascade (Fig. 1.4).32,33 
This process takes place in the photoreceptor outer segment, that consists of up to 1000 
flat membranous structures adjacent to the RPE. These photoreceptor outer segments 
are surrounded and eventually phagocytosed by apical extensions of the retinal pigment 
epithelium (Fig. 1.7). This specific arrangement of photoreceptor outer segments greatly 
enlarge the area and thus the efficacy of phototransduction. In rod photoreceptors, 
the process of phototransduction is initiated by the absorption of a photon in the 
1
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photoreceptor outer segments by the light-sensitive rhodopsin, which is composed of 
the protein opsin and the chromophore 11-cis-retinal. Upon capture of a photon, this 
11-cis-retinal, which is a derivative of vitamin A, is transformed to its isomer all-trans-
retinal. Through a number of intermediate steps, this ultimately leads to membrane 
hyperpolarization and the release of neurotransmitters at the photoreceptor terminal 
synapse. Regeneration of rod 11-cis-retinal takes place in the RPE, wheras the regeneration 
of 11-cis-retinal in cones appears to depend on both the intraretinal Müller cells and the 
RPE.34,35 
New photoreceptor outer segments evaginate from the plasma membrane around the 
connecting cilium, while the older outer segments at the tip are shed and processed 
by the RPE.36,37 The peripherin/RDS protein, in association with the ROM1 protein, is 
essential for the normal formation of the rim area of flattened photoreceptor outer 
segments (Fig. 1.4),38 as will be discussed further in this thesis. 
The cone photoreceptors function in bright light and are essential for color vision and 
high spatial resolution. There are three different types of cones: the S cones, which are 
most sensitive to short wavelength (blue) light, the M cones, which process medium 
wavelength (green) light, and the L cones, which are particularly sensitive to light of 
long wavelength (red).39,40 The rod photoreceptors, on the other hand, enable vision in 
dim light, and are particularly sensitive to contrast, brightness, as well as motion.
 Cones and rods are not equally distributed throughout the retina. The peripheral 
retina is dominated by rods, whereas the fovea contains only cones (Fig. 1.5).41 
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Figure 1.4.  
Schematic representation 
of a rod (left) and cone 
(right) photo receptor.  
The photoreceptor outer 
segments, where photo-
transduction takes place, 
are composed of f lattened 
structures, the discs  
(in rods) and lamellae  
(in cones). The sharp edges 
of these discs and lamellae 
are called the rim area. 
Contrary to cones, the disc 
membranes in rods are  
not continuous with the 
plasma membrane. 
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Just like M and L cones, the S cones are distributed throughout the retina, except in the 
central fovea, where S cones are virtually absent.42 The fovea only contains randomly 
scattered M and L cones, whereas the parafovea mainly contains rods.41,43 Cone density is 
greater in the nasal than in the temporal peripheral retina.44 The rods in the parafoveal 
area appear to be most vulnerable to changes related to ageing and age-related 
maculopathy.43 Maximum foveal cone density as well as the ratio of L to M cones can 
show striking differences between individuals with normal color vision.39,44,45  
 After complex processing mechanisms of the resultant photoreceptor signals by cells 
within the multilayered retina itself (Fig. 1.6),46-48 these signals are transmitted to the 
brain through the optic nerve. In the brain, the modulated visual information from the 
retina is integrated through numerous visual pathways, resulting in visual images and 
interpretation.40,49 
Apart from this complex process of image forming and processing, originating in the 
rod and cone photoreceptors, a subset of retinal ganglion cells is also photosensitive, 
expressing an opsin-like protein called melanopsin.50 These ganglion cells mediate non-
image forming visual responses. As such, they play a key role in the rapid adjustment 
of pupil size, in light modulation of activity, and in the adaptation and fine tuning of 
the circadian clock to environmental light, the latter possibly through the regulation of 
pineal melatonin synthesis.51-54 These non-image forming, adaptive ocular photoresponses 
are thus important in circadian rhythm entrainment.
1
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Figure 1.5.  
The spatial density of cone and rod photoreceptors in the retina. The human eye contains  
4-6 million cones, which are densely packed in and around the fovea. The eye contains 78-110 
million rods, which are dispersed throughout the retina, except for the fovea. 
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1.2.2. Retinal pigment epithelium
The photoreceptors and the monolayer of RPE cells are intimately related, as numerous 
RPE microvilli surround the distal photoreceptor outer segments (Fig. 1.7). These apical 
microvilli greatly increase the surface of contact, and therefore optimize metabolic 
efficiency. The neuroretina is to a certain extent attached to the RPE through the so-called 
interphotoreceptor matrix that envelopes the cone photoreceptors.55,56 The proximity of 
photoreceptors and RPE enables two of the pivotal functions of the RPE: the regeneration 
of visual pigment and phagocytosis of rod and cone outer segments. Every day, the RPE 
phagocytoses approximately 10% of the photoreceptor outer segments. This distal 10% 
of the photoreceptor outer segments contains the highest concentration of by-products 
of the visual cycle, such as toxic radicals, photo-damaged proteins and lipids, that 
need to be digested by the RPE. The shed outer segments fuse with lysosomes, forming 
phagolysosomes that effectuate this degradation. 
The pigmentation of RPE cells originates from melanin, which is mainly packed in 
melanosomes in the apical part of the RPE cell. The RPE melanin has a photoprotective 
function, through the absorption of scattered light, and also has an anti-oxidant 
action.57 The concentration of RPE melanosomes is the highest in the central 
macula.58 With advancing age, melanin itself may become oxidized and the number of 
melanosomes decreases.59,60 Meanwhile, an increase in the number of complex granules 
containing melanin associations is observed, such as melanolysosomes and the toxic 
melanolipofuscin.61-63 
 In addition to these functions, the RPE is essential for many other processes.31,59 For 
instance, the RPE forms and maintains two extracellular matrixes, the interphotoreceptor 
matrix and Bruch’s membrane. Transport of metabolites and ions between the 
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Figure 1.6. 
Schematic representation  
of the retinal layers.
direction of incident light
internal limiting membrane
external limiting membrane
nerve fibre layer
ganglion cell layer
inner plexiform layer
inner nuclear layer
outer plexiform layer
outer nuclear layer
rods and cones
retinal pigment epithelium
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photoreceptors and the choriocapillaris is mediated by the RPE, which forms a selective 
blood-retinal barrier. Thus, a vectorial transport of nutrients from the choroid to the 
outer retina and the removal of waste products, water and ions in the other direction 
is tightly regulated. In normal conditions, the RPE efficiently transports water away 
from the subretinal space between the neuroretina and the RPE. In addition, the RPE 
appears to play a pivotal role in the immunological microenvironment of the retina.64-68 
Finally, the RPE also secretes a variety of growth- and structure-regulating factors, such 
as vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinases-3 
(TIMP-3).69-72 
In the healthy eye, these factors are beneficial to the structure and function of the 
eye.73 RPE-derived VEGF is presumed to play an important role in ocular development, 
especially with regard to the development and maintenance of the choriocapillaris.70,74 In 
pathological conditions, however, RPE-derived factors such as VEGF and TIMP-3 may have 
a detrimental influence. For instance, overexpression of VEGFs is known to promote the 
formation of choroidal neovascularization in age-related macular degeneration (AMD) 
and other eye diseases.75,76 Accumulation of TIMP-3 underlies Sorsby fundus dystrophy, 
1
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Figure 1.7.   
High resolution scanning electron microscopic photograph of rod photoreceptor outer  
segments (OS), surrounded by membranous extensions of the apical surface of the retinal  
pigment epithelium (RPE). The close contact between the photoreceptor OS and the RPE  
enables a highly efficient  visual pigment regeneration and phagocytosis of the OS.  
(Source: Hollenberg et al., Invest Ophthalmol Vis Sci 1988;29:1380-1390). 
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but is also seen in AMD.77,78
Just like the photoreceptors, the RPE characteristics differ between the central and 
peripheral retina.59,79 For instance, RPE cell density decreases from the fovea to the 
peripheral retina, 31,59,80 and the number of photoreceptors per RPE cell is higher in the 
macula.81,82 Macular RPE cells are taller and have a smaller diameter than peripheral RPE 
cells, and the macular RPE contains a larger amount of melanin granules.59
The aforementioned functional interaction between the RPE and photoreceptors poses 
an enormous metabolic demand on both cell populations, which are among the highest 
energy consumers in the body. Although light and oxygen are essential for vision, 
these conditions may also promote the formation of reactive oxygen species, leading 
to photochemical damage to the retina.83-85 The number of RPE cells decreases with age, 
which increases the phagocytic burden on the remaining cells.86 As a result, an age-
related accumulation of lipofuscin occurs in the RPE.61,87,88 
 Lipofuscin is a heterogeneous material composed of a mixture of lipids, proteins and 
different fluorescent compounds. More than 90% of the accumulated lipofuscin in the 
RPE originates from conjugates formed by visual cycle retinoids in photoreceptor outer 
segments that are incompletely digested by the phagolysosomes.89-91 
The exact composition of lipofuscin is still largely unknown, but an important constituent 
is the toxic fluorophore N-retinylidene-N-retinylethanolamine (A2E).92,93 The formation 
of A2E begins in the photoreceptor outer segments: rather than being converted back 
to 11-cis-retinal, two molecules of all-trans-retinal react with phosphatidylethanolamine 
(PE) to form A2-PE.92,94 A2E is subsequently formed in the RPE phagolysosomes after 
phosphate hydrolysis of A2-PE, where it impairs proper phagolysosomal degradation by 
the RPE.95,96 
As A2E formation depends on the availability of its precursor, all-trans-retinal, conditions 
that increase the amount of all-trans-retinal also increase lipofuscin formation. In turn, 
the availability of all-trans-retinal, a derivative of vitamin A, depends on dietary vitamin 
A intake.92,97,98 The turnover of all-trans-retinal and subsequent formation of A2E depends 
on the activity of the visual cycle, which is directly dependent on the amount of light 
exposure.92,92,95,99-101 Therefore, the amount of A2E formation correlates with the amount 
of vitamin A intake and light exposure.92,101,102 Once A2E is formed, the RPE appears 
unable to effectively get rid of this toxic waste product.101 
Light is not only essential for the formation of A2E, but it also plays an important role in 
the adverse effects of A2E on the RPE cells. Light with a wavelength in the blue spectrum 
is especially able to excite A2E, forming highly reactive, toxic A2E-epoxides.103,104 In 
addition, lipofuscin is a photoinducible generator of free radicals, such as the superoxide 
anion, singlet oxygen and hydrogen peroxide.105 These toxic byproducts damage DNA 
in the RPE cells,106,107 and may lead to apoptosis of RPE cells that is proportional to the 
amount of A2E.108-110 Other unfavorable consequences of A2E accumulation include 
membrane destabilization and lysosomal dysfunction.111,112 
Interestingly, photooxidation products of A2E are also able to activate the complement 
system, which plays a pivotal role in the pathogenesis of AMD.113,114 Blue light-induced 
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excitation of A2E initiates photooxidative processes in the RPE that may lead to 
upregulation of VEGF.115 The degradation of photoreceptor phospholipids by the RPE 
is also inhibited by A2E.96 The highest concentration of lipofuscin is found in the RPE 
from the parafoveal zone, where rod density is highest and where atrophic AMD often 
starts.88,116 
Lipofuscin and especially A2E are autofluorescent when excited with light from a specific 
wavelength and lie at the basis of fundus autofluorescence in normal and pathological 
conditions, which will be discussed extensively in this thesis (Chapter 2). 
 Pathologic accumulation of lipofuscin and A2E occurs in a number of retinal 
disorders. Examples include various retinal dystrophies such as Stargardt disease 
(STGD1), Best vitelliform macular dystrophy and retinal dystrophies caused by 
mutations in the peripherin/RDS gene, which is illustrated in Chapter 2.93 In these cases, 
the disease-related lipofuscin is formed at an accelerated rate and may differ from 
“normal” age-related lipofuscin in the relative levels of individual fluorophores such as 
A2E.93,117 In addition to hereditary retinal dystrophies, abnormal amounts and patterns 
of lipofuscin accumulation have also been found in AMD, among many other retinal 
diseases.80,93,118-120  
1.2.3. Bruch’s membrane
Bruch’s membrane separates the RPE from the choriocapillaris and consists of three 
layers: a central elastic layer bordered by two collagenous layers. The thickness of 
the elastic layer of Bruch’s membrane increases from the fovea to the periphery, and 
Bruch’s membrane thickens with advancing age.121,122 In the aging Bruch’s membrane, 
deposition of collagen, lipids and other substances such as complement components 
is observed.123-125 These accumulations may disturb Bruch’s membrane integrity and 
cause a sharp reduction in transepithelial fluid and nutrient transport, especially in the 
macula, where Bruch’s membrane appears to be thinnest.121,126-128 In addition, this Bruch’s 
membrane fragility that increases with age may make it more prone to neovascular 
ingrowth.121 Subretinal deposits, such as basal laminar deposits, basal linear deposits and 
drusen - the precursors of age-related macular degeneration - may preferentially develop 
at this site, between the basement membrane of the RPE and the inner collagenous layer 
of Bruch’s membrane (Fig. 1.8).125,129-131 
 Drusen contain a variety of inflammatory components, among many other 
components, and are associated with immune-mediated processes, consistent with 
chronic inflammation.125 Drusen also contain lipofuscin-rich RPE cytoplasmic fragments. 
Macrophages may be responsible for the removal of these lipofuscin-containing cellular 
derivatives.125,132-134 Drusen are often associated with decreased fundus autofluorescence 
in their central part, surrounded by a halo of increased autofluorescence.120,135-137 It 
has been speculated that this autofluorescence pattern in caused by attenuation 
of the RPE above the center of such a druse, together with an increased lipofuscin 
content and a more tangential orientation of the RPE cells at the edge of those drusen. 
Drusen also contain dendritic cells, which, apart from sustaining and amplifying the 
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inflammatory process, may be involved in angiogenesis and the formation of choroidal 
neovascularization.125,138-141
1.2.4. Choroid
The choroidal circulation shows the highest rate of blood flow in the body when 
compared to other tissues.142,143 This is especially true for the choriocapillaris, the 
capillary layer of the choroid which is separated from the RPE by Bruch’s membrane. The 
choroid, with its specialized structure, plays an important role in heat dissipation and 
in nourishment of the RPE and outer retina.142-144 More than 90% of the oxygen provided 
by the choriocapillaris is consumed by the photoreceptors.145 The choriocapillaris 
consists of large fenestrated capillaries, unlike the larger choroidal vessels. The capillary 
fenestrations allows the diffusion of small molecules such as fluorescein, which is used 
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Figure 1.8.   
Age-related changes in the human macula. Due to decades of light exposure, oxidative stress, 
and photoreceptor outer segment phagocytosis, the retinal pigment epithelium (RPE) cells 
accumulate lipofuscin and its toxic constituent A2E. Drusen, which are subretinal deposits 
containing a mixture of cellular and inf lammatory components, form between the RPE  
and Bruch’s membrane. Bruch’s membrane itself thickens and becomes more fragile with 
advancing age. (Source: de Jong, N Engl J Med 2006;355:1474-1485)   
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in fluorescein angiography, while forming a barrier to larger molecules such as the 
plasma proteins albumin and IgG.146,147 
The architectural pattern of the choriocapillaris in the posterior pole is unique in that 
it consists of a mosaic of vascular lobules that operate independently.148 Towards the 
periphery, the vascular pattern of the choriocapillaris becomes more ladder-like, with 
the choriocapillaris connecting the arterioles and venules at right angles. This difference 
in vascular architecture may largely explain the increased choroidal blood flow in 
the macula,149 owing to the more efficient lobular pattern in this area. The structural 
integrity of the choriocapillaris depends on the adjacent RPE, which has a trophic effect 
on the choriocapillaris and also induces endothelial fenestration.70,73,150 As mentioned 
in the previous section, RPE-derived VEGFs have a trophic and structural influence on 
the adjacent choriocapillaris.70,74 Animal studies indicate that choriocapillaris atrophy 
occurs only after RPE degeneration.151,152 Choriocapillaris blood flow and choriocapillary 
density and diameter in the macula decreases with age, especially in AMD.122,153 With RPE 
thinning or atrophy, the underlying choriocapillaris becomes less fenestrated, reducing 
molecular transport.
1.3. Clinical evaluation of retinal anatomy and function
1.3.1. Introduction
The clinical evaluation of retinal dystrophies starts with careful history taking. The 
family history may provide valuable information about the possible mode of inheritance. 
Results of visual acuity measurement under standardized conditions indicate the degree 
of foveal involvement and are important to determine disease progression in follow-
up examinations. The aspect of the retina on ophthalmoscopy often gives important 
clues about the nature of the disease. A thorough evaluation of retinal anatomy and 
function in a certain retinal dystrophy often suggests a specific diagnosis, and allows 
to evaluate the severity of the disease as well as the extent of the lesions. Moreover, the 
clinically gathered information may point to a specific underlying genetic defect. As 
will be illustrated in this thesis, establishing a clinical diagnosis may nevertheless be 
challenging, as many retinal dystrophies may have considerable overlapping features. 
Nowadays, the molecular genetic findings may be leading in establishing the correct 
diagnosis.  
1.3.2. Retinal imaging
1.3.2.1. Ophthalmoscopy
A detailed examination of the retinal appearance starts with stereoscopic indirect 
ophthalmoscopy through well-dilated pupils. An overview of the retina may be obtained 
by examination with a binocular (or monocular) indirect ophthalmoscope and a +20 
diopter lens. For a detailed examination of the macula, the (mid-)peripheral retina, the 
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optic disc and the retinal vasculature, slit lamp examination with a +90, +78, or a +60 
diopter lens is generally preferred. For better comparison of follow-up examinations, 
color fundus photographs may be taken at regular intervals.
1.3.2.2. Fluorescein angiography
Fluorescein angiography permits the study of the retinal and choroidal circulation 
in normal and diseased states. Photographs are taken after intravenous or oral 
administration of sodium fluorescein, which normally does not pass the blood-retinal 
barriers of the RPE and retinal vessels. Lesions on fluorescein angiography may show 
variable degrees of hyperfluorescence or hypofluorescence, depending on the nature and 
site of the lesion relative to the normal anatomical structures. To better visualize the 
choroidal circulation, indocyanine green angiography may be used.
1.3.2.3. Optical coherence tomography
Optical coherence tomography (OCT) offers a high resolution cross-sectional view of 
the retina, somewhat similar to a histopathological specimen. This high resolution 
is achieved through the principle of low-coherence interferometry, which is based on 
measurements of differences in light reflectivity of different tissue components. Most 
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Figure 1.9.    
Comparison of images obtained with the Stratus optical coherence tomography (OCT)  
(left) and the Spectralis high resolution OCT (right), illustrating the difference in spatial 
resolution. When enlarging the central part of the high resolution OCT image, a detailed 
image of the retinal layers can be seen. Black asterisk, cone nuclei; white asterisk, rod 
nuclei; RNFL, retinal nerve fiber layer; GCL, ganglion cell layer; IPL, inner plexiform layer; 
INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; 1, external 
limiting membrane; 2, photoreceptor inner/outer segment junction; 3, photoreceptor outer 
segment - retinal pigment epithelium (RPE) interdigitation; 4, RPE/Bruch’s membrane  
complex; 5, choriocapillaris.   
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commonly used time domain OCT scanners in clinical practice, such as the Stratus OCT, 
currently provide a resolution of 8-10 μm. High resolution spectral domain OCT scanners, 
such as the Spectralis OCT, that have more recently become commercially available that 
provide a maximum resolution of 3 μm or even better (Fig. 1.9). For comparison, the axial 
length of a photoreceptor is approximately 30 μm.
1.3.2.4. Fundus autofluorescence
Fundus autofluorescence (FAF) is a relatively new non-invasive imaging technique 
that allows topographical mapping of lipofuscin distribution in the RPE, when using 
an excitation wavelength in the short (blue) range.120,154 As discussed previously, RPE 
lipofuscin is a mixture of degradation products that include toxic retinoid fluorophores. 
Increased FAF is seen in areas of increased amounts of RPE lipofuscin. Decreased FAF is 
observed for instance in areas of RPE atrophy. FAF reflects metabolic changes at the RPE 
level in vivo and thus provides functional information that can not be obtained with 
conventional imaging techniques such as fluorescein angiography and OCT. Therefore, 
FAF may be used as an additional imaging tool in the clinical evaluation and follow-
up of many retinal dystrophies that are associated with alterations in RPE lipofuscin, 
including those described in this thesis. The retinal diseases described in this thesis, 
caused by mutations in the peripherin/RDS gene, the BEST1 gene, and the CFH gene, have all 
been evaluated with FAF. Therefore, FAF will be discussed more elaborately in Chapter 2. 
1.3.3. Retinal function tests
1.3.3.1. Electroretinography
The full-field electroretinogram (ERG) measures a mass electrical response of an action 
potential produced by the entire retina when stimulated by illumination. A full-field 
ERG can be performed under photopic (light-adapted) conditions, evoking a response 
that originates exclusively from the cone photoreceptors. Conversely, under scotopic 
(dark-adapted) conditions, the rod responses may be measured, as well as mixed cone-
responses, depending on the used light stimuli. In this thesis, the scotopic ERG will 
be used to predominantly elicit a rod mass response. Thus, the photopic full-field ERG 
reflects the functioning of the entire cone photoreceptor system, whereas the scotopic 
full-field ERG roughly reflects pan-retinal rod photoreceptor function. 
 The multifocal ERG produces a topographical map of many local, simultaneously 
recorded, cone-derived ERG responses.155 The multifocal ERG records ERG responses of 
the central 50° of the retina, subdivided in typically 61 or 103 small areas (hexagons) 
that each produces its own ERG response (Fig. 1.10). These ERG responses are not simply 
“small full-field ERGs”, but are derived from specific mathematical extractions. The 
multifocal ERG may be used for instance to specifically evaluate macular function, and 
may differentiate between specific areas of the macula, especially when the full-field ERG 
yields normal responses. 
 To be able to facilitate comparison of studies, test conditions of electrophysiological 
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tests have been standardized by the International Society for Clinical Electrophysiology 
of Vision (ISCEV, see www.iscev.org) for full-field ERG and multifocal ERG.156,157
1.3.3.2. Electro-oculography
The electro-oculogram (EOG) measures the standing potential (a voltage difference between 
the RPE and the cornea), that originates from differences in the ionic composition at the 
apical and basal membranes of the RPE. A voltage change is seen when comparing the 
standard potential in the light-adapted state to that in the dark. In general, the voltage 
amplitude is about twice as high in light conditions compared to the dark-adapted state. 
The test results are usually reported as the Arden ratio, which is obtained by dividing the 
light voltage peak by the voltage level in the dark. The EOG also is a mass response, which 
originates from the entire monolayer of RPE cells instead of from the photoreceptors 
in full-field ERG. The EOG may be useful in evaluating RPE function in various diseases 
that affect the RPE, but is especially useful in the clinical diagnosis of Best vitelliform 
macular dystrophy.158 ISCEV guidelines are also used for EOG recording.159
1.3.3.3. Dark adaptation
Dark adaptation is tested by measuring the absolute thresholds of cone and rod sensitivity 
after exposure to light. Although the recovery of sensitivity is faster in cones than in 
rods, the absolute level of sensitivity is greater in rods. The sensitivity measurements are 
plotted against time, so that a dark adaptation curve can be drawn. In clinical practice, 
dark adaptation measurement is useful in the evaluation of night blindness, for instance 
in conditions such as retinitis pigmentosa. In some instances, dark adaptation may be 
more sensitive than the full-field ERG as an indicator of pathologic conditions affecting 
the rod photoreceptor system.
1.3.3.4. Color vision 
The perception of color originates from the absorption of electromagnetic energy by the 
visual pigments in the cone photoreceptor outer segments, at wavelengths between 400 
and 700 nm. As mentioned previously, there are three different types of cones that each 
have their different but overlapping spectrum of wavelength sensitivity. Clinical tests 
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Figure 1.10.     
Multifocal electroretinography (mfERG). 
The mfERG is able to simultaneously 
record local ERG responses from specific 
retinal areas. Each of these areas produces 
a small ERG response, as shown in the 
figure.   
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of color vision include screening tests for rapid and coarse identification of color vision 
abnormalities, as well as sensitive tests of color matching and discrimination.160
1.3.3.5. Contrast sensitivity
The perception of contrast is essential in daily life, for instance for the ability to 
discriminate and recognize objects and peoples faces. Patients with relatively good visual 
acuity may have poor contrast vision, that may cause significant visual difficulties in 
daily life. Contrasts of light and/or colors are recognized after integration of these stimuli 
by the integrative cells of the retina and the higher visual centers. There are several chart 
tests of contrast sensitivity. The usefulness of each test depends on the range of spatial 
frequencies that has to be tested.161 As there are no disease-specific diagnostic patterns of 
deficiency in contrast sensitivity, the value of contrast sensitivity testing in a diagnostic 
clinical setting is limited.
1.3.3.6. Visual fields
Visual field testing is able to locate areas in the visual field that show a decreased or 
absent sensitivity to stimuli. If such an area of sensitivity loss is surrounded by a zone 
of relatively normal sensitivity, it is called a scotoma. Kinetic perimetry, for instance 
with the Goldmann perimeter, is able to plot the peripheral visual field with the use 
of moving stimuli of variable intensity, and may also roughly locate central relative 
or absolute scotomas. Static perimetry, for instance with the Humphrey visual field 
analyzer, uses non-moving stimuli of variable luminance to evaluate sensitivity defects 
in the central visual field in detail. These visual field test, when performed repeatedly at 
certain intervals, may also be useful for follow-up purposes.
1.4. Introduction to molecular genetics
1.4.1. Basic principles of molecular genetics and heredity
1.4.1.1. Introduction 
The human DNA (deoxyribonucleic acid) consists of a sequence of four different 
nucleotides (adenine, thymine, guanine, and cytosine), which in total is called the 
genome. The genome comprises approximately 3.3 billion base pairs and is organized 
into 46 chromosomes that reside in the cell nucleus. Two of these chromosomes are sex 
chromosomes: two X chromosomes in females, one X and one Y chromosome in males. 
The other chromosomes, also known as autosomes, form 22 different chromosome pairs. 
Each pair of chromosomes carries one paternal and one maternal chromosome. Each 
of these homologous pairs carry a DNA sequence that is almost identical. The human 
genome encodes approximately 20.000 to 25.000 genes, which are specific DNA sequences 
that encode instructions for the ultimate formation of RNA molecules and proteins. 
In reproduction cycles, chromosome pairs exchange segments of DNA, a process known 
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as recombination or “crossing over”. Genetic recombination increases genetic diversity 
throughout evolution. In addition to nuclear chromosomes, a small amount of circular 
DNA (16.569 base pairs) is also present in multiple copies in mitochondria. An allele is 
one of the variant forms of a gene at a particular location, or locus, on a chromosome. 
In general, an individual possesses two copies of a gene (one on each chromosome 
of a chromosome pair) and thus two alleles. The term genotype refers to the genetic 
constitution of an individual, whereas the observable (clinical) characteristics of this 
individual constitute the phenotype.
 Most genes contain protein-coding regions, the exons, interspersed by non-coding 
regions or introns. Through the mechanism of transcription, DNA is transcribed in the 
nucleus into a primary RNA (ribonucleic acid) sequence that incorporates the transcript 
of both the exons and the introns (Fig. 1.11). The subsequent process of cleavage and 
splicing removes the non-coding intronic parts at the splice sites, leaving only the 
protein-coding exons to form the so-called messenger RNA. This messenger RNA (mRNA) 
also consists of a sequence of bases (the same as in DNA, except thymine, which is 
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Figure 1.11.    
Summary of the process from DNA to protein formation. In the cell nucleus, the DNA is 
transcribed into primary RNA. Removal of the non-coding introns results in the formation  
of the messenger RNA (mRNA). This mRNA is transported from the nucleus to the ribosomes 
in the cytoplasm, where translation to the primary protein and posttranslational protein 
processing take place.   
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replaced by uracil). The next phase is the translation of mRNA into a specific amino acid 
sequence that will form the primary protein. This phase is performed in the cytoplasm 
of the cell. Different combinations of three adjacent bases (triplets or codons) form the 
code for different amino acids. Three specific triplets (TAG, TAA, and TGA) do not encode 
an amino acid but form the code to stop the translation from mRNA to protein, and 
are therefore called stop codons. After several posttranslational modification processes, 
the final functional or structural protein is formed, with its unique three-dimensional 
structure. 
 Gene variants may be inherited in several ways. In autosomal dominant inheritance, 
a variant or mutation in one of the two gene copies is enough to inherit a specific trait 
or disease. A carrier of an autosomal dominant mutation has a probability of 50% to 
transmit the mutation to his orr her offspring. Theoretically, 50% of his children would 
thus inherit the disease associated with the mutation. However, as will be illustrated in 
this thesis, not all carriers of a dominant mutation may develop a clinically apparent 
disease. This phenomenon of non-penetrance or decreased penetrance is due to additional 
modifying genetic and/or environmental factors that are often unknown. Such decreased 
penetrance may consequently mask the dominant mode of inheritance.
When a mutation on both gene copies is required to cause a disease phenotype, the 
mode of inheritance is called autosomal recessive. When an affected person carries two 
identical mutations, the mutations are called homozygous. On the other hand, an affected 
individual is a compound heterozygous mutation carrier when the two alleles contain 
two different mutations. A person carrying only one autosomal recessive mutation will 
not develop the disease. When two members of a couple each carry one mutation, there 
is a 25% chance that a child will inherit both mutations and thus develop a disease 
phenotype.
The X chromosome may also carry disease-associated mutations and causes an X-linked 
inheritance pattern. In these cases, females are carriers and are usually not affected by 
disease as they also carry a second, normal X chromosome. Male offspring consequently 
has a 50% chance of carrying a mutant gene, and affected males will develop disease as 
they carry only one (affected) X chromosome. 
Finally, genetic disorders may also be caused by mutations in the non-chromosomal DNA 
of the mitochondria, which encodes 37 genes. This mitochondrial DNA is maternally 
inherited, but may affect both men and women. The amount of mutant mitochondrial 
DNA may vary considerably between persons, but also between tissues and even cells of 
an individual, accounting for the remarkable inter- and intraindividual variation of the 
phenotype.  
1.4.1.2. Single nucleotide polymorphisms, haplotypes and haplotype analysis
A single nucleotide polymorphism (SNP) is a single nucleotide change in the DNA sequence 
of different individuals. Due to genetic variations between different populations, the 
frequency of a SNP may vary considerably between different geographic and ethnic 
groups. SNPs may be found in protein-coding DNA regions, but also in non-coding 
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regions that are involved in for instance gene processing (splicing) or transcription factor 
binding. SNPs are found at a rate of approximately 1 per 500 base pairs in the human 
genome, which makes it possible to use them as “landmarks” on a genetic map.162
 A haplotype is a chromosomal region with certain genetic variants that can be 
shared between individuals (http://www.hapmap.org/originhaplotype.html.en). Over 
the course of many generations, segments of chromosomes in a certain population are 
intermingled through repeated recombination events. Some of these DNA segments or 
haplotypes, however, remain shared by multiple individuals that are not closely related. 
Through various mechanisms, the frequency of haplotypes varies from region to region. 
As a consequence, a certain haplotype may occur at different frequencies in different 
populations, especially when those populations are widely separated and are thus 
unlikely to exchange DNA through reproduction. Haplotype studies enable the search 
for candidate genes that are involved in monogenic diseases, as well as the identification 
of genes involved in gene-gene and gene-environment interaction. 
1.4.1.3. Gene identification
In monogenic disease of unknown cause, the classical first step towards identification of 
the underlying disease-causing gene is to determine its chromosomal location by linkage 
analysis. Linkage analysis is based on the observation that genes and their adjacent SNPs 
tend to be inherited together during segregation within a family. If a certain gene and its 
surrounding SNP markers cosegregate in a significant number of affected individuals, the 
likelihood increases that this gene is in fact the disease-causing gene. This likelihood of 
true linkage of the gene to the disease is reflected in the LOD (logarithm of the odds ratio) 
score, which is is a statistical test that is often used in linkage analysis. 163 By convention, 
a LOD score of greater than 3.0 is considered evidence for genetic linkage.
 When a disease is linked to a chromosomal region which contains several genes, a 
candidate gene approach may identify the specific gene that is involved. Candidate genes, 
for instance genes that are known to possess functions related to the disease process, may 
then be analysed for mutations by DNA sequence analysis. If a putative mutation is found, 
this mutation must segregate with disease within the family. Linkage analysis has also 
been successful in identifying a broad range of genes that cause autosomal dominant, 
autosomal recessive, as well as X-linked disease. However, the ability of linkage analysis 
to identify unknown genes is limited by the size of the families and number of affected 
persons that are required to obtain a significant LOD score.
 Patients with recessive disease, who are born from parents who are to a certain degree 
consanguineous, are more likely to be homozygous for the disease-causing mutation and 
surrounding polymorphisms. The explanation for this observation is found in the fact 
that persons who are closely or more distantly related are more likely to share identical 
areas of DNA sequences. The strategy of homozygosity mapping is therefore an effective 
approach in addition to linkage analysis, especially in medium-sized consanguineous 
families in which no significant LOD score can be obtained with linkage analysis. In 
rare recessive diseases in families with no reported consanguinity, the frequency of 
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homozygous mutations may also be relatively high. This is due to a distant common 
ancestor of the parents, constituting a distant consanguineous link. Specific mapping 
strategies using high-density SNP analysis may detect homozygous regions from a 
common ancestor who lived as long as 10 generations ago.164,165 The chance to find the 
chromosomal region harboring the disease-causing gene is highest in the homozygous 
regions that are largest.164,166 To subsequently find the actual disease-causing gene, the 
candidate gene approach can be used.
1.4.1.4. Mutations, polymorphisms, and pathogenicity
A pathologic gene mutation is defined as an alteration of the DNA sequence that causes a 
partial or complete impairment of protein function. A mutant gene or allele is the opposite 
of the so-called wild-type allele, referring to the most common allele in the normal 
population. A mutation may cause an adverse effect through different mechanisms. A 
dominant negative mutation leads to a protein that adversely affects the normal, wild-
type protein. Haploinsufficiency occurs when an individual has only a single functional 
gene. This single copy does not produce sufficient amounts of normal gene product to 
result in a normal phenotype, leading to disease. Gene mutations sometimes result in 
disease, which is appropriately referred to as a genetic disorder. If such a mutation is 
also present in a germ cell, it may be inherited by offspring and the disease is therefore 
a hereditary disorder. Mutations may result from for instance nucleotide substitutions, 
deletions, insertions, or duplications. 
The term “polymorphism” refers to an allele that is relatively frequent in the general 
population, and that is not directly associated with disease. A polymorphism may 
concern a single nucleotide change (a SNP), but also an amino acid change (which may be 
caused by a single nucleotide changes in the DNA sequence), as well as larger alterations 
of the coding or non-coding DNA sequence. 
 There are several types of mutations. A missense mutation is an alteration in the 
DNA sequence that leads to substitution of one amino acid by another amino acid in the 
protein product. Even such a single amino acid change may considerably change protein 
structure and function, and may eventually cause disease. Missense mutations are 
very common in genetic disorders. The majority of mutations in the BEST1 gene in Best 
vitelliform macular dystrophy, for instance, are missense mutations (see Chapter 3). A 
frameshift mutation is caused by insertions or deletions of a number of nucleotides that 
is not divisable by three (the triplet of bases coding a single amino acid). As a result, the 
DNA reading frame is completely changed, leading to a completely altered amino acid 
sequence of a protein. This obviously causes a significantly changed protein structure and 
functionality, often resulting in non-functional protein products. Frameshift mutations 
in the peripherin/RDS gene are common in multifocal pattern dystrophy simulating 
Stargardt disease/STGD1 (Chapter 4). If a mutation leads to a premature stop codon, the 
mutation is called a nonsense mutation. An abnormally short or “truncated” protein 
will be the end result, which is often associated with severe phenotypic abnormalities. 
A splice site mutation changes the DNA sequence that denotes the site at which splicing 
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of one or more introns normally takes place. Consequently, one or more introns remain 
in the mature messenger RNA, or one or more exons are skipped, and can disrupt the 
generation of a normal protein product. A null mutation, for instance a nonsense or a 
splice site mutation, is a mutation that results in either the absence of a gene product or 
the absence of any protein function.
 It may be challenging to establish whether a gene sequence variant is the cause of 
a disease. Pathogenicity is more easily assumed in mutations that severely alter protein 
structure and/or length, such as nonsense mutations. It is often more difficult to 
determine if a single amino acid change is a disease-causing missense mutation or merely 
a benign polymorphism. To add proof to supposed pathogenicity of such a missense 
variant, additional support is often needed from different lines of evidence. First of all, the 
sequence variant(s) should segregate with the disease in the respective family as expected 
for dominant or recessive mutations. If the variant concerns a change to an amino acid 
with very different structural and electrical properties, this may point to significant 
consequences for protein structure and function. This is more likely when the missense 
change is located in a region of the protein that is known to be functionally important. 
Protein modeling by specific computer programmes may be helpful in these cases.
Another relative argument may be provided by the finding that a specific genetic variant 
is conserved in numerous species throughout evolution. This would then indicate that 
this specific variant is functionally important and that alteration of this specific sequence 
is disadvantageous. Another clue of pathogenicity may be provided by the absence of the 
variant in a considerable control group of persons without the phenotype. However, this 
is a statistical argument that does not unequivocally exclude the possibility that the 
genetic variant is a rare non-pathogenic variant.
 The distinction between a polymorphism and a pathologic mutation is sometimes 
clear, but may also be rather artificial. For example, relatively common polymorphisms 
may show a strong association with certain diseases, for instance in AMD (see paragraph 
6 of this introduction). On the other hand, some mutations are not invariably associated 
with a disease phenotype, due to non-penetrance as a result of genetic and environmental 
modifying factors.  
1.4.2. Mutation detection in monogenic disease
The identification of the underlying mutation(s) in a monogenic disease is important for 
a number of reasons. Detection of the underlying mutation(s) may confirm or change a 
clinical diagnosis. Especially in the case of a retinal dystrophy that shows non-specific, 
overlapping phenotypic features, molecular genetic analysis may unequivocally point 
to a specific underlying defect and thus helps to establish a definite diagnosis. This is 
important to the patient, as genotype-phenotype correlation studies can help to provide 
the patient with adequate information about the prognosis of the disease. In addition, 
information about the underlying genetic defect facilitates genetic counseling. 
To date, knowledge on the genetic cause of a retinal disease rarely has therapeutic 
consequences. Although the first human gene therapeutic studies in retinal dystrophies 
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are emerging, only patients with specific mutations in specific genes are currently 
eligible for inclusion in these experimental trials.167,168 
 There are several mutation detection strategies to test the presence or absence of 
one or more mutations in specific genes. In general, the DNA-strands of interest are first 
amplified with polymerase chain reaction (PCR) technique. Sequence analysis of the 
possibly involved gene may be used when a small number of candidate genes with a 
limited number of exons are involved. In larger genes, this method is time consuming 
and costly, but is able to detect new mutations. 
The method of single strand conformational polymorphism analysis (SSCP) was widely 
used until recently. This technique is based on the principle that DNA fragments, that differ 
as a result of a mutation, will show a different migration pattern on gel electrophoresis 
due to conformational differences. Comparison of affected and unaffected individuals 
will thus reveal DNA alterations in a specific region of a gene (often in the exons). 
The sensitivity of this test is approximately 80%  and the test is relatively cheap, making 
it a good screening method prior to sequencing.169 
Other PCR-based mutation detection techniques include heteroduplex analysis,170 
denaturating gradient gel electrophoresis (DGGE),171 and denaturating high performance 
liquid chromatography (DHPLC).172 All of these techniques have their individual 
advantages and disadvantages, their sensitivities depending on optimization of several 
test conditions. As automated sequence analysis has become cheaper in the last 10 years, 
this is currently the preferred method for mutation analysis. 
 The gene microarray (“gene chip”) is a method that allows fast, cheap, and reliable 
simultaneous screening of multiple (hundreds of) known mutations in multiple genes.173 
By using an available microarray, patients with a specific retinal dystrophy can be 
prescreened for already known mutations and other gene variants with this relatively 
cheap and fast method. If no mutations are found, more expensive methods such as 
DGGE and/or nucleotide sequencing can be applied to detect new mutations.
1.4.3. Molecular genetic analysis of complex multigenic disease
A complex genetic disease does not show a clearly definable genetic inheritance pattern, 
despite evidence of a strong genetic basis. In these cases, abnormalities in multiple genes 
may be suspected, possibly in conjunction with environmental factors. Family studies are 
essential to investigate whether a disease has a significant inherited component. Familial 
aggregation of disease means that the risk of a disease is higher in an individual that is 
related to an affected individual, compared to a person without affected family members. 
In this respect, studies on monozygotic twins are especially helpful, as they are genetically 
identical. Previous twin studies in AMD clearly alluded to the importance of genetic 
factors in the pathogenesis of AMD, as monozygotic twins showed high concordance 
of disease features in intermediate and late-stage AMD.174,175 The polygenic nature of 
such complex disease, in which multiple genes each contribute to a relatively modest 
extent, makes the detection of these genes more difficult. Phenotypic variability and 
environmental influences add up to this challenge. Some of the clinical features may 
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have a more significant genetic determination than others. Small peripheral drusen, for 
instance, appear to have a strong familial preponderance.176,177 How to find these disease-
associated genes in complex multigenic disease?
 Classical linkage studies are problematic in the analysis of complex disease, as there 
is often no clear inheritance pattern and an apparently low penetrance. In complex 
multigenic disease, large samples of families and sib-pairs are required to conduct genetic 
linkage analysis. Even then, it remains difficult to reach adequate statistical power.178 
Complex disease often shows considerable phenotypic variability. Selecting only specific 
phenotypic subtypes in a specific (for instance ethnic and/or geographic) population for 
linkage studies, in an attempt to obtain homogeneous groups, leads to further loss of 
statistical power. Even small degrees of misclassification can also cause substantial loss 
of statistical power.179
 Other strategies are therefore required. Progression in the study of complex multigenic 
diseases greatly relies on the accomplishments of large-scale genetic projects such as the 
Human Genome Project (http://www.genome.gov/10001772), which identified the entire 
human DNA sequence and the approximately 25.000 genes of the human genome, and 
the International HapMap Project (http://www.hapmap.org/), which develops a haplotype 
map of the human genome. Genetic association studies that use case-control cohorts and 
inherited SNP landmarks of specific haplotypes have a much greater ability to detect a 
genetic risk association and to find disease-associated genes. Compared to linkage studies, 
these association studies do not require families with specific inheritance patterns and 
require smaller sample sizes than linkage analysis to detect disease-associated genes. 
 If a particular haplotype is found more frequently in individuals affected by a 
specific disease, compared to healthy controls, a gene influencing this disease may be 
located within or near this haplotype. SNP-based genome-wide association studies use 
SNP landmarks in combination with haplotype information to find these genes. These 
strategies have become a powerful and cost-effective tool in genetic association studies, 
particularly in the search of genes associated with complex diseases such as AMD.180,181
1.4.4.  Genotype-phenotype correlation versus genetic and phenotypic 
heterogeneity
The association of a specific genetic defect (genotype) with a specific clinical picture 
(phenotype) is called genotype-phenotype correlation. In a broad sense, genotype-
phenotype correlation refers to the association of alterations of a specific gene with a 
specific clinical picture, such as the association of mutations in the BEST1 gene with Best 
vitelliform macular dystrophy and rhodopsin gene mutations with retinitis pigmentosa. In 
a strict sense, strong genotype-phenotype correlation is found when specific mutations in 
a specific gene are invariably associated with a specific phenotype. Some genes and their 
defects, for instance the ACBA4 gene and its associated phenotypes,182 show a considerable 
degree of genotype-phenotype correlation. 
Mutations in other genes, such as the peripherin/RDS and BEST1 gene described in this 
thesis, are associated with striking phenotypic heterogeneity. Most mutations in these 
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genes show very limited genotype-phenotype correlation. Non-penetrance of a genetic 
defect may also be observed, meaning that an underlying mutation does not result in 
a corresponding phenotype. By definition, monogenic disease is caused by one or more 
mutations in a single gene. Nevertheless, there are many examples of so-called monogenic 
diseases in which the resultant phenotype is highly variable, even in individuals carrying 
an identical mutation. In these cases, the clinical outcome is strongly influenced by 
additional modifying factors, such as modifying genes,183-186 and possibly environmental 
modifying factors such as nutritional factors,98,187 light exposure,85 and smoking.188-190 
The genes associated with the retinal diseases described in this thesis are examples of 
such a variability. Retinal disorders (for instance retinitis pigmentosa) may also show 
considerable genetic heterogeneity, meaning that mutations in different genes result in 
clinically similar phenotypes.
1.5.  Clinical and molecular genetic characteristics of 
hereditary retinal dystrophies
Monogenic hereditary retinal dystrophies affect approximately one in every 3000 
individuals.191 The group of retinal dystrophies shows broad genetic and phenotypic 
heterogeneity.192-195 Clinical classifications encounter difficulties, as there is an ongoing 
debate concerning the clinical parameters that should be used for characterization. 
Some classifications use ophthalmoscopic features, others use electrophysiologic 
findings, whereas some classifications include both. Moreover, newer techniques such 
as FAF and OCT provide further clinical information that may strengthen or weaken 
existing classifications. On the other hand, a classification based solely on the underlying 
molecular genetic defect(s) is at present also unpractical. Mutations in several genes, 
such as for instance the BEST1 gene, the peripherin/RDS gene, and the ABCA4 gene are 
associated with remarkable clinical heterogeneity. As indicated in the previous section, 
the clinical outcome of a single genetic defect is modified by additional genetic factors 
in these cases. Moreover, environmental factors may play a modifying role. Therefore, a 
genetic classification is an oversimplification of the clinical reality until we are able to 
map most of the influencing genetic and environmental interactions in an individual.
Still, a correct clinical diagnosis is very important, not only to give direction to the 
search for the underlying genetic defect, but also to be able to provide the patient with 
accurate information about the disease and its prognosis. For this reason, the current 
classification of retinal dystrophies is based on the clinical findings, whenever possible 
supplemented by the underlying genetic cause.
1.5.1. Macular dystrophies
Patients with a macular dystrophy typically experience loss of visual acuity, sometimes 
accompanied by metamorphopsia and/or central scotomata. The term “macular” 
dystrophy suggests pathology limited to the macular area of the retina. It should be 
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noted, however, that many of these dystrophies may be considered disorders that affect 
the entire retina on the molecular level. In addition, electrophysiological examination 
(full-field ERG and EOG), and sometimes ophthalmoscopy, may also indicate pan-retinal 
photoreceptor dysfunction, especially when the disease progresses. In this thesis, a 
macular dystrophy will be broadly defined as a retinal phenotype that is largely confined 
to the central fundus on ophthalmoscopy, with a generally normal photopic and scotopic 
full-field ERG earlier in the course of the disease. In macular dystrophies, the macular 
region often merely shows a greater susceptibility to clinically manifest degeneration 
than the peripheral retina.
 Macular dystrophies are associated with a broad range of underlying genetic causes. 
Most macular dystrophies, for instance those caused by BEST1 (Chapter 3) and peripherin/
RDS mutations (Chapter 4), are inherited in an autosomal dominant fashion. However, 
the most frequent macular dystrophy, Stargardt disease (STGD1), is caused by autosomal 
recessively inherited mutations in the ABCA4 gene. As mentioned previously, it is 
important to realize that dystrophies associated with a single genetic defect may still 
show considerable phenotypic variability.  
 On the other hand, different macular dystrophies with different underlying 
genetic causes may share phenotypic features. For example, drusen are a rather non-
specific ophthalmoscopic finding. Drusen may be described as round, white to yellow 
accumulations between the RPE and Bruch’s membrane, sometimes with a crystalline 
aspect, that are often most prominent in the macula. They are not only the hallmark 
lesions of AMD, but drusen-like lesions may also be encountered in several autosomal 
dominant macular dystrophies, such as central areolar choroidal dystrophy (caused by 
peripherin/RDS mutations),196,197 Sorsby fundus dystrophy (caused by mutations in the TIMP3 
gene),198-200 malattia leventinese (also known as Doyne’s honeycomb retinal degeneration, 
caused by EFEMP-1 mutations),201-203 North Carolina macular dystrophy (linked to the 
MCDR1 locus),204,205 as well as in retinal disorders such as basal laminar drusen (see 
Chapter 5).206,207 The term “dominant drusen” is a generalizing description, referring to 
a broad range of macular diseases of autosomal dominant inheritance associated with 
drusen, including some of the aforementioned phenotypes.208 These phenotypes may also 
share the complication of choroidal neovasculation, which is also seen in neovascular 
AMD.197,199,205,209 
Another example are the yellow-white, “pisciform” lesions in the central retina in 
Stargardt disease/STGD1. Virtually identical lesions may also be observed in autosomal 
dominant STGD3 (caused by mutations in the ELOVL4 gene on chromosome 6),210-212 STGD4 
(mapped to chromosome 4),213,214 as well as in multifocal pattern dystrophy simulating 
STGD1 (see Chapter 4, section 4.3).215,216 
Areas of chorioretinal atrophy may be encountered in the advanced stages of many 
macular dystrophies, such as STGD1, central areolar choroidal dystrophy, Best vitelliform 
macular dystrophy, and North Carolina macular dystrophy.  
In summary, the aforementioned monogenic phenotypes may all share ophthalmoscopic 
features such as drusen, choroidal neovascularization, yellow-white flecks, as well 
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as chorioretinal atrophy, features that are also observed in AMD. Since many of these 
dystrophies may occur in late-onset variants,182,202,217 and may show overlapping and/
or atypical phenotypic features with AMD, differentiation with AMD is sometimes 
difficult. These findings and the studies that will be described in this thesis illustrate 
that the dividing line between many macular dystrophies and AMD is not as clear and 
straightforward as once thought. 
 However, AMD has been conclusively shown to be associated with many genes that all 
increase the risk of AMD to a certain degree, but neither of these genetic variants on itself 
has been shown to be the direct underlying cause of AMD. Environmental influences, 
such as smoking and dietary factors, are significant modifiers of disease risk in AMD. Due 
to this complex multifactorial etiology, AMD is generally not considered to be a macular 
dystrophy, as the latter group consists of diseases that are in principle monogenic and 
have an earlier mean age at onset than AMD.
 An overview of all macular dystrophies is beyond the scope of this general introduction. 
A summary of macular dystrophies and associated genes is given in Table 1.1. For a 
comprehensive overview, the reader is advised to consult the following references in 
superscript.194,218-220
1.5.2. Progressive cone and cone-rod dystrophies
The group of progressive cone and cone-rod dystrophies also shows marked clinical and 
genetic heterogeneity.195 Progressive cone and cone-rod dystrophies usually present in 
childhood or early adult life, as opposed to the stationary cone dysfunction syndromes 
that often present shortly after birth or in infancy. In general, patients experience loss of 
visual acuity, photophobia, color vision abnormalities, and may develop nyctalopia (night 
blindness) in the later stages of the disease. Patients rarely display a fine pendular nystagmus, 
although this feature is more typical for stationary cone dysfunction syndromes such as 
achromatopsia. The aforementioned symptoms may precede the fundus abnormalities. 
Fundus examination typically show a “bull’s eye” maculopathy or, less frequently, more 
discrete RPE alterations in the fovea. In some cases, sparing of the fovea is observed on 
ophthalmoscopy as well as on central visual field testing. In progressive cone dystrophy, the 
full-field ERG shows markedly abnormal cone-mediated (photopic) responses with normal 
rod-mediated (scotopic) responses.195 Many patients that initially display a progressive cone 
dystrophy phenotype, eventually also develop generalized rod dysfunction, reflected in an 
abnormal scotopic full-field ERG. This is reflected in the finding that several genes are 
associated with both progressive cone and cone-rod dystrophy. Many cases of progressive 
cone and cone-rod dystrophy are sporadic, but autosomal dominant, autosomal recessive, 
and X-linked inheritance have also been described. 
1.5.3. Retinitis pigmentosa (rod-cone dystrophy)
Retinitis pigmentosa (RP) is a generic term, encompassing a group of progressive retinal 
dystrophies in which -in early stages- rod photoreceptor dysfunction is equally or more 
pronounced that cone dysfunction.193 Although clinical findings in this group of retinal 
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dystrophies may be highly variable, patients with this disease generally experience night 
blindness, associated with progressive loss of the (mid)peripheral visual field. Typically, 
ophthalmoscopy shows (mid)peripheral areas of intraretinal hyperpigmentation, often 
in a “bone-spicule” configuration, together with a pale, waxy optic disc and attenuated 
retinal arterioles (Fig. 1.12). The full-field ERG is crucial for the diagnosis of RP, showing 
abnormal rod photoreceptor responses that predominate cone dysfunction earlier in the 
course of the disease. In cases of RP that are caused by defects in genes that are found 
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Disease OMIM  Mode of  Associated  Reference(s) 
 number inheritance gene or locus
adult-onset foveomacular  608161 AD peripherin/RDS 221
vitelliform dystrophy   BEST1 222
autosomal dominant bull’s  608051 AD PROM1 218,223 
eye macular dystrophy  AR ABCA4 224
Best vitelliform macular 153700 AD BEST1 27  
dystrophy
central areolar choroidal   215500 AD peripherin/RDS 26
dystrophy   17p13 225
dominant cystoid macular    153880 AD 7p15.3 226
dystrophy
Doyne honeycomb retinal   126600 AD EFEMP1 203 
dystrophy   (fibulin-3)
(malattia leventinese)
juvenile retinoschizis   312700 XL XLRS 227
North Carolina macular    136550 AD unknown  228-230
dystrophy   (MCDR1 locus)
pattern dystrophy   169150 AD peripherin/RDS 231
   5q21.2-q33.2 232
progressive bifocal    600790 AD 6q14-q16.2 233
chorioretinal atrophy
Sorsby fundus dystrophy   136900 AD TIMP3 200
Stargardt disease (STGD1) 248200 AR ABCA4 234
Stargardt-like macular   600110 AD ELOVL4 212
dystrophy (STGD3)
Stargardt-like macular     603786 AD PROM1 213,218
dystrophy (STGD4)
AD, autosomal dominant; AR, autosomal recessive; OMIM, Online Mendelian Inheritance in 
Man (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim); XL, X-linked.
Table 1.1.
 Summary of the identified genes and loci in macular dystrophies. 
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exclusively in rods, secondary cone photoreceptor loss was postulated to be caused by 
the sharp decrease of rod-derived cone viability factor.235,236 In later stages, both cone and 
rod responses may become non-recordable, and widespread chorioretinal atrophy may 
occur. In end-stage RP, patients may retain only a small residual area of central visual 
field (“tunnel vision”). Visual acuity may also show a progressive decline, as central cone 
function also becomes compromised later in the course of the disease.193,237
Besides phenotypic heterogeneity, RP also shows marked genetic heterogeneity. 
The disease can be inherited as an autosomal recessive (50-60% of cases), autosomal 
dominant (30-40%), or X-linked (5-15%) trait, besides a small proportion of other modes of 
inheritance.193 In addition to isolated RP, the condition may also be associated with more 
than 30 different syndromes.193 A certain degree of genotype-phenotype correlation is 
observed in RP, that may be useful in the classification of various forms of RP.238 
1.5.4. Leber congenital amaurosis
Leber congenital amaurosis is considered the most severe form of inherited retinal 
blindness, as this photoreceptor dystrophy usually presents within the first weeks of 
life.239 In most cases, the visual acuity is below 20/200 early in the course of the disease. 
Leber congenital amaurosis is a genetically and clinically heterogeneous disease, that is 
often inherited in an autosomal recessive fashion. For an extensive overview, the reader 
is advised to consult an extensive review by den Hollander and colleagues.239
1.6.  Clinical and molecular genetic characteristics of age-
related macular degeneration
Inherited retinal degenerations may share clinical features with age-related macular 
degeneration (AMD), the leading cause of blindness in people above 60 years of age in 
the Western world.240 The characteristic signs of AMD are drusen, deposits in Bruch’s 
membrane that underlie the RPE.240 Drusen appear as yellow-white dots concentrated in 
the macula and sometimes the peripheral retina on ophthalmoscopy (Fig. 1.13A). Several 
clinical classification systems for AMD have been proposed.241-244 These classification 
systems use several characteristics to grade AMD, including the size, number, and 
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Figure 1.12.     
Retinitis pigmentosa. Note the bone- 
spicule hyperpigmentation outside the 
macula, a waxy pale optic disc, and 
attenuated retinal arteries.   
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type of drusen, as well as pigmentary abnormalities, resulting in the development of 
severity scales. Late stages of AMD, when visual loss becomes manifest, are subdivided 
into two broad categories. Atrophic (“dry”) AMD is characterized by a certain degree of 
chorioretinal atrophy (in advanced stages known as “geographic atrophy”) in the macula, 
without the presence of choroidal neovascularization (Fig. 1.13B). In neovascular (“wet”) 
AMD, new vessels arise from the choriocapillaris, that overcome Bruch’s membrane and 
sometimes the RPE barrier, to grow under or into the neuroretina (Fig. 1.13C). This results 
in subretinal and/or intraretinal fluid accumulation, hemorrhages and scar formation, 
leading to a relatively rapid drop in visual acuity. Atrophic AMD may evolve towards 
neovascular AMD, and vice versa.245 As atrophic and neovascular AMD may resemble end 
stages of other retinal diseases, including several retinal dystrophies, late AMD could 
be considered a diagnosis of exclusion, although it is much more frequent than those 
retinal dystrophies.240 
Before the finding of significant gene associations in AMD, several twin-based and other 
familial studies already indicated that AMD has an important genetic component: close 
relatives were shown to have a strongly increased risk of developing AMD.174,246,247 
 Mutations in a broad range of genes cause phenotypes that may closely mimic 
AMD. In general, these retinal disorders occur at an earlier age and follow a specific 
inheritance pattern. Logically, the search for AMD-associated genetic factors started 
with the screening of genes that were known to be involved with monogenic retinal 
dystrophies. Studies have implicated a broad range of those genes in AMD (Table 1.2), but 
many studies remained inconclusive or controversial.248 
 The great breakthrough in the quest for AMD-associated genes came in 2005, 
when four papers simultaneously provided compelling evidence that a specific SNP 
in the Complement Factor H (CFH) gene significantly increases the risk of AMD.293-296 This 
polymorphism encodes a tyrosine to histidine amino acid change at position 402 
(p.Tyr402His) of the CFH protein. In brief, the CFH protein is a major inhibitor of the 
alternative pathway of the complement system. The complement system is an important 
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Figure 1..13.*   
Age-related macular degeneration (AMD). A. Soft drusen in the macula, that merge to a  
larger pigment epithelial detachment with hyperpigmentation. B. Advanced atrophic AMD, 
showing profound chorioretinal, “geographic”atrophy of the macula, surrounded by large 
drusen. C. Neovascular AMD, associated with hemorrhages within the lesion.
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component of innate immunity, consisting of three pathways including the alternative 
pathway.297 This alternative pathway is a safeguard system of the human body that 
recognizes, attacks, and eliminates microbes and modified tissue cells,297 which is 
spontaneously activated throughout the body under normal conditions.298 To prevent 
overactivation, several factors are present that inhibit this activation of the alternative 
pathway under circumstances where complement activation is unwanted. The CFH 
protein is a central player in this down-regulation of alternative pathway complement 
activation.299 A detailed discussion of the structure, function and disease associations of 
CFH will be presented in Chapter 5.
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Gene Normal function of Reference(s)
 protein product
CFH inhibition of alternative  249-253
 complement pathway 
CFB activation of alternative  254-258 
 complement pathway 
C2 activation of classical   254-256,258
 complement pathway 
C3 central complement activator  254,259-262 
deletion of CFHR1  overlapping function with CFH?  263-265
and CFHR3  
SERPING1 inhibition of classical   266 
 complement pathway 
HTRA1 serine protease  267-271
ARMS2 unknown function in   272-275 
(LOC387715) mitochondria? 
PLEKHA1 unknown  269,273,276
TLR3 host defense against viruses  277 
APOE lipid transport and metabolism  278-282
ABCA4 retinoid transporter in   283,284 
 photoreceptors
fibulin-5  extracellular matrix glycoprotein   285-287
 involved in elastogenesis,
 present in Bruch’s membrane 
fibulin-6  unknown   288-291 
(hemicentin-1)  
VEGF angiogenesis  292-294 
HLA antigen presentation  339,340
Table 1.2.
 Genes associated with age-related macular degeneration.
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To date, the CFH p.Tyr402His variant has been shown to be the most important genetic 
risk factor in AMD in the Caucasian population. The odds ratios for the development 
of AMD (soft drusen, geographic atrophy, as well as neovascular AMD) range from 2.45 
to 7.4, depending on the study design and population, as well as the heterozygous or 
homozygous presence of the p.Tyr402His risk allele.293,295,296,300 Other CFH haplotypes may 
also increase susceptibility to AMD independently of the p.Tyr402His variant, although 
the effect still appears less pronounced than that of p.Tyr402His.297 Further support for 
the role of dysregulation of the alternative complement pathway in AMD comes from the 
finding that variants in other complement genes also alter the risk of AMD (Table 1.2). 
 Other genes of largely unknown function, LOC387715/ARMS2,273,275 HTRA1,268,271 and 
PLEKHA1,273 that lie in the vicinity of each other on chromosome 10q26 confer a strong 
risk for the development of AMD. Both the CFH p.Tyr402His and the LOC387715/ARMS2 
p.Ala69Ser risk variant are associated with progression of AMD.301 Several studies 
indicate that additional polymorphisms in LOC387715/ARMS2 may also increase the risk 
of AMD.274,302 A frequent variant in the LOC387715/ARMS2 gene leads to the deletion of 
the polyadenylation signal and consequent instability of the mRNA, resulting in the 
absence of ARMS2 protein expression in homozygotes.272,303 The ARMS2 protein has been 
proposed to play a role in mitochondrial function,272,274 although this is contradicted by 
other findings.304
 Genetic susceptibility to AMD shows important ethnic variations. For instance, the 
CFH p.Tyr402His risk variant is not significantly associated with AMD in the Japanese 
population,305,306 and plays only a modest role in the Chinese population.307 Other coding 
and non-coding CFH variants do appear to moderately influence the risk of AMD in these 
ethnic groups.308 In contrast, several polymorphisms in the LOC387715/HTRA1 gene loci 
are strongly associated with AMD in both Japanese and Chinese.189,309,310 These different 
genetic backgrounds, different risk factor associations, as well as the different prevalence 
numbers of risk modifying polymorphisms,311 may account for the different patterns of 
disease and phenotypic subgroups in different ethnic subgroups.312,313
While the population risk of AMD is 3%, individuals carrying all risk genotypes in 5 
variants in CFH, LOC387715, and C2/CFB were calculated to have an absolute AMD risk 
of approximately 35%.314,315 In contrast, those who carry none of these risk genotypes 
have an absolute AMD risk of 0.17%. Specific clinical features of AMD appear to show 
a stronger genetic association. For example, large numbers of hard drusen and the 
presence of peripheral drusen (such as in some basal laminar drusen phenotypes) have a 
strong familial preponderance.176,177,316 
 Over the last decades, various animal models have been developed, displaying features 
of human AMD.317 Although there still is no exact animal model of AMD, these models 
have been able to increase our understanding of the underlying molecular mechanisms 
in AMD. Also, these animal models are invaluable for the development of new therapeutic 
approaches.
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1.7. Aims and outline of this thesis
This thesis aims to add to the insight in the clinical and genetic characteristics of 
retinal diseases caused by mutations in the BEST1 gene and the peripherin/RDS gene. In 
addition, it aims to evaluate the role of the CFH gene in the phenotype of basal laminar 
drusen, an early-onset drusen phenotype that may closely resemble age-related macular 
degeneration. As will be illustrated, BEST1 mutations, peripherin/RDS mutations, as well 
as variants in the CFH gene, are associated with specific phenotypic spectra. These 
phenotypic spectra show a certain degree of genotype-phenotype correlation. However, 
as will be discussed, a striking phenotypic variability is also seen, that often cannot 
simply be explained by the specific type of mutation.  
 Chapter 1 serves as a general introduction, providing the reader with information on 
the basic aspects of retinal anatomy and function, as well as the clinical and molecular 
genetic methods that may be applied in the analysis of retinal disease. The general aspects 
of retinal dystrophies are highlighted. In addition, the general characteristics of age-
related macular degeneration are described, as several of the retinal diseases described 
in this thesis may closely resemble this most common macular disease.
 Chapter 2 describes the principles of fundus autofluorescence, a relatively new imaging 
technique, which is highly relevant to the clinical evaluation of the retinal dystrophies 
that are studied in this thesis. An overview of the fundus autofluorescence findings in 
several retinal dystrophies is given, including those caused by mutations in the BEST1 
and peripherin/RDS gene.
 Chapter 3 concerns the clinical and genetic analysis of retinal dystrophies caused 
by mutations in the BEST1 gene. It starts with a description of the BEST1 gene and its 
protein product, followed by an overview of the broad clinical spectrum of ocular 
diseases associated with BEST1 mutations, as well as a discussion of the pathophysiologic 
mechanisms in these diseases (Section 3.1). Section 3.2 offers an analysis of the usefulness 
of fundus autofluorescence, optical coherence tomography, and fluorescein angiography 
in Best vitelliform macular dystrophy. The clinical variability of Best vitelliform macular 
dystrophy is discussed, as well as the variability in the underlying BEST1 mutations. 
Finally, possible genotype-phenotype correlations in Best vitelliform macular dystrophy 
are evaluated. Section 3.3. describes the clinical characteristics and evaluation of the 
BEST1 gene in multifocal vitelliform dystrophy.
 Chapter 4 contains a clinical and genetic analysis of retinal dystrophies caused 
by mutations in the peripherin/RDS gene. The chapter starts with a description of the 
peripherin/RDS gene and its protein product, as well as an overview of the striking variety of 
phenotypes caused by peripherin/RDS mutations. Data from animal models are discussed, 
providing evidence for specific pathophysiologic mechanisms (Section 4.1). Section 4.2 
discusses central areolar choroidal dystrophy, a phenotype caused by specific peripherin/
RDS mutations, that may closely mimic atrophic age-related macular degeneration. 
Section 4.3 describes the phenotype of multifocal pattern dystrophy simulating Stargardt 
disease (STGD1)/fundus flavimaculatus, caused by peripherin/RDS mutations, which shows 
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close resemblance to Stargardt disease.
 Chapter 5 first discusses the complement factor H (CFH) gene and the structure and 
function of its gene product, the CFH protein. The broad range of diseases associated with 
CFH gene variants is reviewed, as well as the genotype-phenotype correlations (Section 
5.1.). In Section 5.2, the phenotype of basal laminar drusen is discussed, as well as the 
results of analysis of the CFH gene in this early-onset drusen phenotype that strongly 
resembles age-related macular degeneration.
 The studies described in this thesis are further discussed and integrated in Chapter 6, 
which serves as a general discussion. A synopsis of the findings in this thesis is provided 
in Chapter 7. 
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2.1. Fundus autofluorescence
Introduction
Fluorescence is an optical phenomenon, in which absorption of light of a given 
wavelength by a certain exogenous substance results in the emission of light of a 
longer wavelength by the same substance. In contrast to fluorescence, autofluorescence 
is an intrinsic property of cells. In the case of autofluorescence, exposure of cells to a 
specific wavelength results in the emission of light of a higher wavelength, arising from 
endogenous fluorophores. Such autofluorescence phenomena may also be observed in 
the human eye.
Origin of fundus autofluorescence
Short-wavelength fundus autofluorescence
The primary source of fundus autofluorescence (FAF) is lipofuscin within the retinal 
pigment epithelium (RPE). Although the RPE is very efficient in the phagocytosis and 
degradation of photoreceptor outer segments (OS), a small fraction of incompletely 
digestable products accumulates in the RPE lysosomes. This mixture of substances forms 
lipofuscin. Over the course of a lifetime, a single RPE cell is estimated to phagocytose 
more than 3.000.000.000 photoreceptor OS.1 Granules containing lipofuscin and 
melanofuscin, a compound product of lipofuscin and melanin, may occupy as much as 
20 to 33% of the free cytoplasmic space of an RPE cell above the age of 70.2 
Lipofuscin comprises autofluorescent fluorophores, that mostly originate from the light- 
and vitamin A-dependent visual cycle that takes place in the photoreceptor OS.3 Some 
of these fluorophores have toxic properties. The exact composition of lipofuscin is still 
largely unknown, but an important constituent is the toxic fluorophore N-retinylidene-
N-retinylethanolamine (A2E).3,4 The formation of lipofuscin and A2E is dependent on 
light exposure and the dietary intake of vitamin A, the precursor of 11-cis-retinal.5-7 With 
age, as the total amount of light exposure and vitamin A-intake increases, the amount of 
lipofuscin accumulation in the RPE increases,8-10 corresponding with an increase of FAF.11 
Besides A2E, several other constituents of RPE lipofuscin have been described that may 
contribute to the FAF signal.12 Iso-A2E is formed by photo-isomerization of A2E.13 All-trans-
retinal dimer phosphatidylethanolamine (atRAL dimer-PE) and all-trans-retinal dimer 
ethanolamine (atRAL dimer-E) are formed by pathways distinct from that of A2E, but are 
also formed from two all-trans-retinal molecules that condensate.12,14 Just like A2E, atRAL 
dimer-PE and atRAL dimer-E are also present at elevated levels in the lipofuscin-engorged 
RPE of Abca4 mutant mice, as a result of disturbed retinoid transport.15-17
Lipofuscin and especially A2E are autofluorescent when excited with light from a specific 
wavelength and lie at the basis of FAF in normal and pathological conditions. FAF from 
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RPE lipofuscin can be excited with light of a wavelength between 430 and 600 nm, with 
a peak of excitation efficiency reached with excitation wavelengths between 480 and 
510 nm (blue-green light).18,19 The emission spectrum of lipofuscin is also broad (480-
800 nm), with a maximum in the 600 to 640 nm range.1,18 Other unidentified lipofuscin 
fluorophores, besides A2E and its derivatives that are described in the following section, 
also likely contribute to the FAF signal.18 
The excitation wavelength that is generally used in clinical practice is 488 nm, generated 
by an argon laser or an optically pumped solid state laser in a confocal scanning laser 
ophthalmoscope (cSLO). FAF imaging can be performed at low excitation energies, that 
are well below the maximum safety limits of laser light exposure.1,20-22 
 In normal individuals, retinal FAF images show a typical pattern (Fig. 2.1). A dark-
grey area is seen in the fovea, due to the absorption of FAF by macular pigment and 
attenuation of FAF by RPE melanin.18,23 In addition, the rate of lipofuscin formation as 
a result of cone OS shedding may be considerably slower, compared to rods, which are 
located extrafoveally.24 Accordingly, a histological study has revealed a dip in lipofuscin 
concentration just below the fovea, together with an increase of RPE melanin.25 FAF 
gradually increases to lighter grey, with a maximum at 7-13° from the fovea, after which 
it decreases towards the peripheral retina.8 The optic disc normally shows absence of FAF 
due to a lack of RPE and lipofuscin. FAF is also absent at the site of the retinal vessels, 
because of the absorption of the light by blood.
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Figure 2.1.   
Normal short-wavelength fundus autof luorescence (FAF) image (left), showing decreased 
FAF in the fovea, and absent FAF corresponding to the retinal vasculature and optic disc. 
On normal near-infrared FAF (right image), the fovea shows the highest signal, as opposed 
to short-wavelength FAF.
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Near-infrared fundus autofluorescence
FAF images may be obtained not only with short-wavelength excitation (488 nm with 
the cSLO, see section 2.1), but also with near-infrared excitation (787 nm with the cSLO). 
Such near-infrared FAF (NIR-FAF), excited with a wavelength of 787 nm, and detected 
above 810 nm, recorded with the cSLO, produces a signal that is 60-100 times less intense 
than that obtained with short-wavelength FAF.18,26
Although little is known about the exact origin of NIR-FAF, its main source is thought 
to arise from melanin and its derivatives,18,25-29 such as melanolipofuscin and oxidized 
melanin.2,18,30-33 Contrary to short-wavelength FAF, high NIR-FAF is seen in the fovea of 
normal subjects (Fig. 2.1), corresponding to higher RPE melanin in this area. Higher NIR-
FAF is also seen in association with increased pigment, for instance in naevi (Fig. 2.2). 
 
Abnormal NIR-FAF may be observed in a broad range of pathological retinal and/or 
choroidal dystrophic or degenerative conditions, such as Stargardt disease/STGD1 (Fig. 
2.3A-C), multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus (Fig. 
2.3D-E), central areolar choroidal dystrophy (Fig. 2.2). In STGD1 and multifocal pattern 
dystrophy simulating STGD1/fundus flavimaculatus, lesions on NIR-FAF seem to exceed 
those on short-wavelength FAF both in size and number (Fig. 2.3). This could indicate 
that changes in melanin are more widespread than lipofuscin abnormalities and 
possibly even precede lipofuscin changes in these conditions. Distinct patterns of NIR-
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Figure 2.2.*    
Pigmented choroidal naevus (black arrowheads), corresponding to focally increased  
near- infrared fundus autof luorescence (NIR-FAF, white arrowheads). The overlying retinal 
pigment epithelium (RPE) in atrophic in this patient with central areolar choroidal  
dystrophy. This RPE atrophy corresponds to decreased NIR-FAF, bordered by f lecks of mildly 
increased NIR-FAF.
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FAF abnormalities are also seen in retinitis pigmentosa,34-37 chloroquine retinopathy,38 as 
well as in age-related macular degeneration.28
In the following sections, the term FAF will be reserved for short-wavelength FAF. NIR-FAF 
will not be discussed in further detail, as relatively little is known about its origin and 
clinical applications.
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Figure 2.3.*    
(A-C) Stargardt disease (STGD1)/fundus f lavimaculatus, caused by autosomal recessive 
ABCA4 gene mutations. A. Fundus photograph of STGD1, showing multiple yellowish,  
irregular f lecks throughout the fundus, as well as a “beaten bronze” chorioretinal atrophy of 
the macula. B. Short-wavelength fundus autof luorescence (FAF) shows increased FAF of the 
f lecks, and mottled areas of decreased FAF in the macula. C. On near-infrared fundus 
autof luorescence (NIR-FAF), the lesions are clearly larger and more numerous. On NIR-FAF, 
most lesions have a decreased intensity. (D-F) Multifocal pattern dystrophy simulating 
STGD1/fundus f lavimaculatus, caused by an autosomal dominant mutation in the 
peripherin/RDS gene. The irregular yellowish f lecks are highly similar to those in STGD1, on 
ophthalmoscopy (D), short-wavelength FAF (E), as well as NIR-FAF (F). The macular lesion in 
this patient, however, appears smaller and less atrophic.    
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Methods of fundus autofluorescence measurement
Fundus autofluorescence imaging with the confocal scanning laser 
ophthalmoscope
The use of confocal optics enables the suppression of out-of-focus light, and therefore 
enhances the image contrast.39 FAF imaging with the cSLO was first described by von 
Rückmann and colleagues in 1995.40 The FAF signal has a low intensity in comparison to 
fluorescein angiography and fundus reflectance. Therefore, a series of single FAF images 
is generally recorded, a mean image is subsequently calculated from these images, and 
pixel values are normalized, resulting in a sharp and detailed FAF image (Fig. 2.1A).1 
As mentioned previously, the cSLO uses an excitation wavelength of 488 nm generated 
by an argon laser or a solid-state laser. With the use of a band-pass barrier filter, with a 
short wavelength cut-off point at 500-525 nm (depending on the type of cSLO system), 
most of the reflected light is blocked, whereas autofluorescence light is allowed to pass 
and reach the detector. In ideal conditions (good patient cooperation, clear optical media, 
and sufficient amounts of lipofuscin accumulation in RPE cells), modern cSLO systems 
are able to visualize the human polygonal RPE cell pattern in vivo.41,42 The cSLO obtains 
monochromatic images, as it translates the polychromatic FAF signal, elicited by a single 
excitation wavelength, to an image composed of grey values. As a result, the image 
contrast is enhanced, although this implies a loss of information on the differentially 
emitted wavelengths. This technical limitation currently precludes the acquisition of 
color images with the cSLO. Using other techniques, this polychromatic signal may 
be recorded, and signals that arise from different fluorophores may be separated.43 
The practical details of acquiring FAF images with the cSLO can be found in section 2.2 
of this chapter.
Fundus autofluorescence imaging with the fundus camera
A conventional fundus camera, using the excitation and emission filters as in fluorescein 
angiography, results in FAF images of poorer quality compared to cSLO FAF images.44 
This suboptimal FAF quality is caused by non-confocality of the camera system, which 
increases the unwanted registration of scattered light, a relatively low FAF signal, 
absorption of short-wavelength light by the crystalline lens, and fluorescence from the 
crystalline lens. However, modifications of the conventional fundus camera, by means 
of changing the excitation and barrier filters by moving their wavelengths to the higher 
(“red”) end of the spectrum, are able to limit the adverse effects of for instance the 
crystalline lens on the FAF image.1,44-46 Compared to this modified fundus camera-based 
acquisition of FAF images, the mean image obtained with the cSLO still results in FAF 
images with a better signal-to-noise ratio and better visualization of details, and less 
pseudofluorescence.44 As the modified fundus camera uses longer excitation wavelengths 
(500-610 nm) than the cSLO, FAF from other fluorophores than those seen with the cSLO 
may also be detected.44     
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Clinical applications of fundus autofluorescence
Introduction
Since the introduction of FAF in clinical practice, it has been used in a wide range 
of ocular diseases affecting the posterior segment of the eye. These diseases not only 
include age-related macular degeneration and retinal dystrophies, which will be 
discussed separately, but also conditions such as central serous chorioretinopathy,47,48 
choroidal melanocytic lesions,49-52 macular hole,53,54 as well as various forms of posterior 
uveitis.55-59 In many of these diseases, FAF is often able to visualize more detailed and/or 
widespread abnormalities than would be suspected by other means of imaging. However, 
the clinical implications and relevance of FAF in most of these diseases has not yet been 
firmly established.
Retinal dystrophies
The broad range of retinal dystrophies is associated with an equally broad range of 
genetic causes, which may markedly influence the phenotypic outcome and prognosis. 
The impact of the underlying genetic defect on the function of cones, rods, as well as 
the RPE, may affect the FAF signal and the pattern of FAF abnormalities. Depending on 
the genetic defect, FAF abnormalities of lesions in predominantly macular phenotypes 
such as STGD1 (Fig. 2.3A-C, 2.4), multifocal pattern dystrophy simulating STGD1/fundus 
flavimaculatus (Fig. 2.3D-F), Best vitelliform macular dystrophy, and central areolar 
choroidal dystrophy, may only be observed in the centre of the macula, or may extend 
well beyond the anatomical borders of the macula. This will be illustrated and discussed 
more elaborately in section 2.2 of this chapter, as well as in the chapters dealing with 
several of these phenotypes separately. 
Conversely, FAF abnormalities may also be predominantly present in the peripheral and 
midperipheral retina, while appearing to relatively spare the macula, such as in various 
forms of retinitis pigmentosa. Ring-shaped areas of increased FAF, that do not have a visible 
correlate on ophthalmoscopy, may be observed within the macular area that appears 
to be spared, for instance in retinitis pigmentosa and cone-rod dystrophy of different 
genetic backgrounds.37,60,61 These ring-shaped zones may migrate with time, narrowing 
concentrically in many cases of retinitis pigmentosa, and apparently demarcate areas of 
impaired retinal function.61,62 These findings point to a common downstream pathway in 
these diseases, involving a “wavefront” of degeneration of lipofuscin-filled RPE. Therefore, 
FAF in these retinal conditions has a clear functional and prognostic correlate that may 
prove to be of use in the follow-up of these diseases.           
Some hereditary retinal dystrophies are associated with a markedly decreased to absent 
FAF signal. A striking example in this regard is early-onset severe rod-cone dystrophy, also 
known as Leber congenital amaurosis type 2, caused by autosomal recessive mutations 
in the RPE65 gene.63 This gene defect leads to a virtual absence of rhodopsin, all-trans-
retinal, 11-cis-retinal, and - consequently - an absence of lipofuscin fluorophores, despite 
a relative sparing of photoreceptor viability.64 Interestingly, recent pioneering studies 
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have been published on gene therapy in such patients with severe RPE65 mutations.65-67 
In these patients, RPE65 gene delivery was achieved by subretinal injection of viral 
vectors loaded with this gene. In none of these preliminary studies, FAF was an outcome 
parameter, although one study measured FAF before starting therapy.65 It would be 
interesting to see if an increase of FAF intensity may be noted in these or future cases, 
which could be regarded as an indirect indication of successful gene transfer. However, 
such measurements would ideally require reliable quantification of FAF, which is at 
present insufficiently possible, as discussed further on in this introduction. 
Age-related macular degeneration
Lipofuscin accumulation is the characteristic feature of RPE cell aging. Excessive 
lipofuscin accumulation and its previously discussed adverse effects has been shown 
to be linked with complement activation, inflammation, and oxidative damage.68 As all 
of these factors play a role in age-related macular degeneration (AMD), FAF appears a 
suitable imaging modality to evaluate AMD.
 In early AMD, alterations of FAF do not necessarily correlate with lesions on 
ophthalmoscopy and/or fluorescein angiography, such as drusen.69-71 Drusen may show 
either increased, decreased, or normal FAF intensity.69,72,73 Larger, soft and confluent 
drusen often show a patchy, mildly increased FAF pattern.69,70,74 Such a FAF pattern 
appears to be associated with an especially high risk for the development of choroidal 
neovascularization.70,74,75 Increased FAF intensities in areas of hyperpigmentation are 
thought to be at least partially due to the accumulation of melanolipofuscin, whereas 
a decreased FAF signal would correspond to absence of RPE cells or a decrease in their 
lipofuscin content as a result of degenerative processes.71,73 Different patterns of FAF can 
be observed in early AMD, although it is unknown if these patterns are associated with 
a different genetic background, and their possible prognostic implications are largely 
unclear.69 Areas of increased FAF in patients with early AMD and a normal visual acuity 
correspond to decreased sensitivity on microperimetry and fine matrix mapping.76,77 
Geographic atrophy, characterized by areas of profound chorioretinal atrophy that often 
initially occur in the parafoveal area, tends to spare the fovea for a prolonged period 
during progression.78,79 Such foveal sparing may not only be observed in atrophic AMD, 
but also in macular dystrophies such as central areolar choroidal dystrophy, pattern 
dystrophy associated with maternally inherited diabetes and deafness, and Stargardt 
disease (Fig. 2.4).  
 Histopathological studies have shown that ophthalmocopically visible areas of 
geographic atrophy correspond to atrophy of the photoreceptor-RPE-choriocapillaris 
complex.80-83 Such an area of profound atrophy is generally bordered by a junctional zone 
of lipofuscin- and melanolipofuscin-filled RPE cells. These observations correspond to 
FAF findings, often showing absence of FAF in the area of geographic atrophy, which is 
bordered by a junctional zone of increased FAF.84,85 This zone of high FAF, which usually 
does not have a visible correlate on ophthalmoscopy or other imaging methods, often 
precedes a loss of FAF and enlargement of the atrophic area.85,86 The zone of high FAF also 
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correlates functionally with already decreased retinal sensitivity, affecting rods more 
than cones.77,87 This area of increased FAF may therefore represent a “wavefront” of RPE 
and photoreceptors that is still functional, but already going through a degenerative 
process involving lipofuscin accumulation. These findings are reminiscent of the 
aforementioned rings of increased FAF in some retinal dystrophies that also demarcate 
areas of impaired retinal function, indicating some common downstream pathway that 
is visualized by FAF. 
Distinct FAF patterns of the zone of increased FAF surrounding the geographic atrophy 
may be observed, which show high intraindividual symmetry.84,88,89 There is a high 
interindividual variability in the rate of geographic atrophy progression in atrophic 
AMD.90 These variable growth rates significantly correlate with the underlying different 
FAF patterns of the surrounding zone.91 At present, it is unknown if these different 
patterns relate to different genetic backgrounds. These findings underscore the 
importance of lipofuscin accumulation in the pathogenesis of atrophic AMD, as well as 
the role of FAF in the identification of prognostic markers and high-risk characteristics 
for progression of geographic atrophy.91 In this sense, FAF may prove to be a useful tool 
not only in natural history studies, but possibly also in future interventional clinical 
trials,90-92 provided that reliable quantification becomes possible.93-95
 FAF and its implications have been less well characterized in neovascular AMD 
compared to atrophic AMD. An increased FAF signal appears to be less common in 
choroidal neovascularization,96,97 feeding the speculation that RPE lipofuscin may 
not play an important role in the formation of choroidal neovascularization. In early 
choroidal neovascularization, normal FAF correlates with visual acuity, lesion size, and 
symptom length.98 Certain FAF patterns in choroidal neovascularization may predict the 
visual outcome better than fluorescein angiography.99 These findings indicate that there 
may be a role for FAF in future treatment protocols in neovascular AMD. FAF may also be 
useful in the follow-up after autologous transplantation of RPE and choroid in atrophic 
and neovascular AMD.100-102 
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Figure 2.4.      
Fundus autof luorescence image of foveal 
sparing in a patient with Stargardt 
disease. An island of fovea remains in 
the macula, in the midst of an area of 
profound atrophy of the retinal pigment 
epithelium.
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Future perspectives in fundus autofluorescence
Combination of fundus autofluorescence and high-resolution spectral 
domain optical coherence tomography
Further development of the cSLO has lead to the recent commercial availability of the 
Spectralis HRA/optical coherence tomography (OCT) (Heidelberg Engineering, Heidelberg, 
Germany). This instrument combines FAF imaging and high-resolution spectral domain 
OCT in one, together with an eye tracking system that minimizes movement artefacts. As 
such, this technique allows the simultaneous recording and accurate orientation of FAF 
and high-resolution OCT sections at anatomic sites of interest. A pixel-to-pixel correlation 
may be achieved, allowing in vivo high-resolution, three-dimensional mapping and 
follow-up of retinal structures and their abnormalities.103,104 Structures on FAF may be 
reliably compared with their correlate on the high-resolution OCT, making this combined 
imaging technique very promising to obtain further insight into the pathogenesis of a 
multitude of retinal diseases. Owing to the eye tracking system, specific lesion sites may 
be exactly located and compared on follow-up images.
Quantification of fundus autofluorescence
The FAF signal of a certain location is generally categorized as normal, increased, or 
decreased, compared to the normal background signal of the same image. A major 
challenge remains the exact quantification of absolute FAF intensity.95,105 As the cSLO 
normally processes and normalizes FAF images, which are therefore not suitable for 
quantitative FAF analyses, the image processing software should be turned off for 
quantitative measurement purposes. When comparing absolute FAF intensities between 
different examinations and different patients, several variables must be taken into 
account.105 First, variations in technical image acquisition such as laser power and 
detector sensitivity must be avoided and standardized. In addition, patient variables 
such as eye movements, positioning, pupil size, refractive error, and the degree of lens 
and vitreous opacities must be taken in account. Finally, dynamic metabolic processes 
of lipofuscin accumulation, dark adaptation, and bleaching effects may represent 
confounding factors. It appears impossible to standardize all these factors. It is only when 
most of these factors can be dealt with sufficiently that reliable FAF signal quantification 
comes within reach.
Analysis of visual pigment by fundus autofluorescence
Irradiation with short-wavelength visible light is able to bleach retinal photopigments, 
starting with the dissociation of rhodopsin into opsin and 11-cis-retinal, which changes 
the optical density of the photoceptors.11,106,107 During this photopigment bleaching 
with light from a wavelength of 488 nm, using the cSLO, an increase of FAF is observed, 
according to an asymptotical, illumination-dependent kinetics (Fig. 2.5).108 Such an 
increase in the level of FAF is presumed to originate from the reduced absorption of light 
by the bleached photoreceptor pigments. In retinal dystrophies, visual pigment density 
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may be altered, which may be objectively analyzed by such visual pigment measurement 
techniques.108 However, a number of difficulties in these measurements remain to be 
resolved, such as incomplete bleaching of the fovea due to absorption of light by macular 
pigment, the difficulty of accurate visual pigment density calculations in large areas of 
RPE atrophy, and the previously discussed problems in quantification of FAF.108 Should 
these difficulties be overcome, analysis of visual pigment by FAF may prove to be of value 
in the early diagnosis, an improved understanding of pathophysiologic mechanisms, as 
well as a better follow-up in retinal dystrophies.
Other imaging techniques
Adaptive optics technology is able to improve the spatial resolution by reducing the 
effects of rapidly changing optical distortion.109,110 Using adaptive optics, individual 
cellular structures, such as the photoreceptors and RPE, may be visualized with a 
lateral resolution of ~2 μm.
22,110-114 Adaptive optics imaging in various retinal dystrophies 
indicates that macular cones may display distinct characteristics that appear to depend 
on the genetic background of the underlying disease.115 The adaptive optics technique 
may therefore provide additional ultrahigh resolution insight into the mechanisms of 
photoreceptor and RPE degeneration.
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Figure 2.5.   
Left image: short-wavelength fundus autof luorescence (FAF) image recorded with the 
Heidelberg Retina Angiograph 2 (HRA 2) (using a 55° lens), taken immediately after an  
initial 30° exam with the same illumination settings. The site of the previous FAF 
 examination is outlined as a bright area with the shape of the internal mirror of the  
HRA 2 camera. This area corresponds to bleached visual pigments. Right image: during 
short-wavelength FAF illumination, FAF intensity increases during photopigment bleaching, 
as depicted by this gray value plot. The FAF increase due to bleaching is most pronounced  
in a circular area around the fovea.
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 Metabolic mapping with FAF imaging of fluorophores involved in cell metabolism 
may give information on the metabolic state of healthy and diseased retinal cells.43,105,116,117 
To be able to record such a very weak FAF signal, it must be separated from lipofuscin-
derived FAF and influences from the crystalline lens.105 
 Two-photon excited fluorescence imaging, using infrared light, is able to more 
effectively concentrate excitation energy both spatially and temporally.105 This technique 
may therefore potentially result in a better signal-to-noise ratio and better image 
contrast, although little is known about the exact structures and fluorophores that are 
visualized. In addition, a biologically safe level of laser energy is not yet available with 
this technique.
 Blood flow characteristics may be measured when Doppler flowmetry can be 
added to FAF and/or OCT imaging modalities.109,118 A combination of FAF, OCT, and 
electrophysiological information from multifocal electroretinography, could represent 
an elegant means to simultaneously obtain detailed morphological and functional 
information in different retinal conditions.109,119
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2.2. Fundus autofluorescence imaging of retinal dystrophies
Abstract
Objective: To illustrate the spectrum of short-wavelength fundus autofluorescence (FAF) 
abnormalities in a variety of retinal dystrophies. 
Methods: We examined 112 patients with retinal dystrophies, including Stargardt 
disease (8 patients), Best vitelliform macular dystrophy (27 patients), central areolar 
choroidal dystrophy (48 patients), and various pattern dystrophies (29 patients). All 
retinal dystrophies were confirmed by molecular genetic analysis. FAF imaging was 
performed with a confocal scanning laser ophthalmoscope. 
Results: A broad range of characteristic FAF patterns was observed in Stargardt disease, 
Best vitelliform macular dystrophy, central areolar choroidal dystrophy, as well as the 
pattern dystrophies. FAF imaging provided qualitative information, reflecting the degree 
of accumulation of lipofuscin and its related fluorophores.
Conclusion: FAF imaging constitutes a useful additive tool in the diagnosis and follow-up 
of various retinal dystrophies.
Introduction
During the last decade, fundus autofluorescence (FAF) imaging of the retina has emerged 
as a useful, non-invasive imaging technique in the diagnosis and follow-up of several 
retinal dystrophies.1-5 Obtaining sufficient-quality FAF images generally becomes feasible 
starting from 5 years of age.5 Short-wavelength excited FAF origins from fluorophores 
within the retinal pigment epithelium (RPE), and RPE lipofuscin distribution is the 
principal cause for the observed FAF patterns.6 Lipofuscin contains a mixture of 
fluorescent molecules that are by-products of the visual cycle, many of which have not 
been thoroughly characterized to date.6-9
 The major lipofuscin fluorophore is N-retinylidene-N-retinylethanolamine (A2E), 
which exerts diverse toxic effects on the RPE.9-18 While the slight and diffuse increase 
of lipofuscin with ageing is physiologic, extensive and focal accumulation of lipofuscin 
is pathologic and may be encountered in a variety of retinal dystrophies.13,14,17,19 
Histopathological studies have found an excessive accumulation of lipofuscin and/or A2E 
in several retinal dystrophies, including those associated with mutations in the ABCA4 
gene, the BEST1 (VMD2) gene, and the peripherin/RDS gene.20-22 The present study illustrates 
the appearance of characteristic FAF patterns in selected, relatively frequent retinal 
dystrophies. 
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Material and methods
Autofluorescence imaging
FAF imaging was performed with a confocal scanning laser ophthalmoscope (cSLO, 
Heidelberg Retina Angiograph 2; Heidelberg Engineering, Dossenheim, Germany) and 
all images were acquired by the same operator (C.J.F. Boon). After pupil dilation to at 
least 6 mm with one drop of phenylephrine and one drop of tropicamide, FAF imaging 
was performed using the 30º field of view and a resolution of 1536 x 1536 pixels, using 
an optically pumped solid state laser (488 nm) for excitation. A barrier filter (500 nm) 
suppressed blue argon excitation light at 488 nm, so that reflectance signals did not 
contribute to the FAF image obtained from the posterior pole of the examined eye. 
 For the acquisition of FAF images, a standard procedure was followed, which 
included focusing of the retinal image in the infrared reflection mode at 820 nm, 
sensitivity adjustment at 488 nm and acquisition of 9 single 30° x 30° FAF images which 
encompassed the entire macular area and at least part of the optic disc. In order to 
improve the signal-to-noise ratio of the FAF signal, the nine single images were aligned 
and a mean image was calculated after detection and correction of eye movements 
using the software provided by the manufacturer (Heidelberg Eye Explorer, Heidelberg 
Engineering, Dossenheim, Germany). Images were digitized and saved on hard disc 
for further analysis and processing. In general, areas of increased FAF are believed to 
represent lipofuscin increase either within or outside RPE cells, whereas decreased FAF 
may indicate RPE cell death and atrophy of the RPE-photoreceptor complex.
Patients
A total of 112 patients with a variety of retinal dystrophies participated in the study. 
All examinations were undertaken with the understanding and written consent of 
each subject, and all procedures were conducted in accordance with the Declaration 
of Helsinki. All patients were consecutively seen in a tertiary referral setting at the 
Department of Ophthalmology of the Radboud University Nijmegen Medical Centre, 
Nijmegen, the Netherlands. 
 We included 8 patients with autosomal recessive Stargardt disease/fundus 
flavimaculatus (STGD1), 27 patients with Best vitelliform macular dystrophy (BVMD), 48 
patients with central areolar choroidal dystrophy (CACD), and 29 patients with some form 
of pattern dystrophy: 9 of these patients had the adult-onset foveomacular vitelliform 
dystrophy (AFVD) subtype, 16 patients were diagnosed with multifocal pattern dystrophy 
simulating STGD1, one patient had butterfly-shaped pattern dystrophy, and 3 patients 
had pattern dystrophy related to maternally inherited diabetes and deafness (MIDD). 
 In all STGD1 patients, the diagnosis was confirmed by the identification of 2 
compound heterozygous mutations in the ABCA4 gene. In all 27 BVMD patients, the 
diagnosis was confirmed by an absent light rise on the electro-oculogram and the 
finding of a specific variant in the BEST1 gene. All patients with CACD and multifocal 
pattern dystrophy simulating STGD1, as well as the patient with butterfly-shaped pattern 
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dystrophy, carried mutations in the peripherin/RDS gene. The study population of patients 
with multifocal pattern dystrophy simulating STGD1 was a subset of recently reported 
patients.23 In the AFVD patients, no mutations in BEST1 or peripherin/RDS were identified. 
This is in accordance with a recent study that found that mutations in these genes are 
relatively rare in AFVD patients.24 The patients with MIDD-related pattern dystrophy 
carried a mitochondrial m.3243A>G mutation.
 After their medical history was obtained, all patients underwent an extensive 
ophthalmic examination, including best-corrected Snellen visual acuity, indirect 
ophthalmoscopy and fundus photography. In addition to FAF imaging, subsequent 
examination included optical coherence tomography and, in selected cases, fluorescein 
angiography, electroretinography and electro-oculography. 
Results 
Autosomal recessive Stargardt disease / fundus flavimaculatus (STGD1) 
In our study group, all STGD1 patients displayed FAF abnormalities. Six STGD1 patients 
showed areas of focally increased FAF, sometimes bordered by a zone of decreased FAF. 
In addition, spots of decreased FAF were visible in these patients. In two patients, these 
areas of altered FAF were restricted to the macula (Fig. 2.6A), whereas four patients 
showed a distribution of these flecks throughout or beyond the posterior pole. Many 
of these flecks corresponded with irregular yellowish flecks on ophthalmoscopy, but 
some flecks of increased FAF were not seen on ophthalmoscopy. The highest number of 
these extramacular flecks was seen in the nasal retina (Fig. 2.6B). Two patients showed a 
diffusely increased FAF pattern throughout the fundus, with a speckled pattern of small 
areas of decreased FAF. In these patients, a large area of markedly decreased FAF could 
be observed in the macula (Fig. 2.6C). Seven patients showed relatively normal FAF in the 
parapapillary zone, but one patient showed parapapillary FAF abnormalities (Fig. 2.6C).
Best vitelliform macular dystrophy 
All patients with Best vitelliform macular dystrophy in our study group displayed 
FAF abnormalities, except both patients who were in the carrier stage, in whom 
FAF abnormalities were either very discrete or absent (Fig. 2.7A). In lesions in earlier 
stages, in which vitelliform material appeared more abundant on ophthalmoscopy, 
FAF imaging displayed areas of markedly increased FAF. In the vitelliform stage, the 
round lesions showed homogeneously increased FAF (Fig. 2.7B). In the pseudohypopyon 
stage, FAF was visible mainly in the inferior portion of the lesion, co-locating with the 
ophthalmoscopically visible pseudohypopyon (Fig. 2.7C). In the vitelliruptive or scrambled-
egg stage, the amount of autofluorescent material was reduced to a certain extent and 
condensed mainly at the borders of the lesion, whereas the central part of the lesion 
showed slightly decreased FAF (Fig. 2.7D). In the atrophic stage, areas corresponding with 
chorioretinal atrophy corresponded with a major decrease of the FAF signal (Fig. 2.7E). 
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Reduced FAF also dominated in the cicatricial stage. However, some spots of discretely 
increased FAF were present within these areas of decreased FAF (Fig. 2.7F). In general, FAF 
imaging was able to visualize even very small amounts of vitelliform material that were 
not readily seen on ophthalmoscopy. Finally, one patient displayed a spoke-like pattern 
of FAF changes simulating macular pattern dystrophy (Fig. 2.7G), and another patient 
had multifocal vitelliform lesions (Fig. 2.7H).
Central areolar choroidal dystrophy 
In central areolar choroidal dystrophy (CACD), we will describe FAF characteristics 
in the stages of CACD as described by Hoyng and Deutman (1996). In stage I CACD, a 
discrete speckled increase of FAF was observed in the parafoveal area (Fig. 2.8A). The FAF 
abnormalities corresponding with early stage II involved a speckled, round to oval area 
of predominantly increased FAF. This area of abnormal FAF enlarged towards late stage II, 
and the spots of increased FAF within the lesion decreased in favor of speckles of decreased 
FAF. Stage III was characterized by the appearance of well-defined areas of absent FAF 
outside the fovea, which corresponded with chorioretinal atrophy on ophthalmoscopy 
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Figure 2.6.     
Fundus autof luorescence (FAF) in autosomal recessive Stargardt disease (STGD1) A. FAF 
image of a 30-year old STGD1 patient (p.Gly1961Glu and p.Lys969Arg mutations in the 
ABCA4 gene), showing FAF changes that are restricted to the macula. Flecks of increased 
and decreased FAF surround the fovea, whereas the central fovea has a relatively normal 
appearance. The visual acuity was 20/20. B. Composition of FAF images of a 29-year-old 
patient with STGD1 (p.Gly863Ala and p.Arg2030X mutation in the ABCA4 gene). The macula 
shows mottled FAF changes, surrounded by irregular f lecks of increased FAF, some of which 
are bordered by a zone of decreased FAF. The number of f lecks on FAF increases outside the 
macula, and the f lecks are most numerous in the nasal retina. These FAF changes are absent 
in the peripapillary area. The visual acuity was 20/200. C. Composition of FAF images of a 
20-year-old STGD1 patient (p.Tyr1779X and IVS38-10T>C mutation in ABCA4), displaying 
markedly decreased FAF in the central macula. Outside this area, diffusely increased FAF is 
observed, with speckled areas of decreased FAF. In contrast to the patient described in (B), 
the peripapillary retina is not spared by these FAF changes. The visual acuity was 20/200.    
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Figure 2.7.     
Fundus autof luorescence (FAF) in Best 
vitelliform macular dystrophy (BVMD).  
A. Patient in the carrier stage, with no 
evident FAF abnormalities. The visual 
acuity (VA) was 20/20. A p.Thr6Pro 
 variant in the BEST1 gene was found in 
this patient. B. Vitelliform stage of 
BVMD, showing a round macular lesion 
with an intensely increased FAF, 
 corresponding with the yellow subretinal 
material seen on ophthalmoscopy.  
This patient, who carried a p.Thr6Pro 
variant in BEST1, had a VA of 20/20.  
C. In the pseudohypopyon stage, material 
of highly increased FAF is seen inferiorly. 
Some small spots of increased FAF are 
also observed in the superior part of the 
lesion. This patient, carrying a p.Thr6Pro 
variant in BEST1, had a VA of 20/20.  
D. Vitelliruptive or “scrambled-egg”  
stage, showing a more dispersed  
localization of material of increased FAF.  
This material is mainly situated at the 
borders of the lesion, whereas the  
central part of the lesion shows some foci 
of increased FAF.  
A p.Lys194_Ala195insVal mutation in BEST1 was identified in this patient, who had a VA  
of 20/20. E. Example of the atrophic stage, showing a well-demarcated area absent FAF,  
corresponding with chorioretinal atrophy. This patient had a VA of 20/32, and carried a 
p.Leu82Val variant in BEST1. F. Composition of FAF images of a patient in the cicatricial 
stage of BVMD, showing a central lesion of reduced FAF, bordered by a ring-shaped zone of 
slightly increased FAF. Two small extramacular lesions of increased FAF can also be 
observed. The VA was 20/125, and a p.Thr6Pro variant in BEST1 was found in this patient. 
G. Patient with BVMD showing a spoke-like distribution of FAF changes adjacent to a  
central area of decreased to absent FAF. A p.Ala243Val variant was found in BEST1 in this 
patient, who had a VA of 20/25. H. Example of FAF abnormalities in a patient with  
multifocal vitelliform dystrophy, who carried a p.Gly299Ala variant in the BEST1 gene.  
A large suprapapillary lesion shows FAF changes that resemble those in the central lesion. 
The VA was 20/80.  
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(Fig. 2.8B). These areas enlarged and multiplied on follow-up (Fig. 2.8C). Stage IV CACD 
was characterized by foveal involvement of the area of absent FAF. Eventually, a round to 
oval area of virtually absent FAF was seen in patients with end-stage CACD, bordered by 
a small band of increased FAF (Fig. 2.8D). 
Pattern dystrophies
Adult-onset foveomacular vitelliform dystrophy
The vitelliform lesions in the patients with adult-onset foveomacular vitelliform 
dystrophy corresponded with round to oval lesions with increased FAF in 8 patients 
(Fig. 2.9A), sometimes with a small spot of reduced FAF. Two patients had unilateral 
disease. In two patients, zones of increased and decreased FAF were seen within the same 
lesion. One of these patients had lesions with characteristics of the scrambled-egg and 
pseudohypopyon stage as seen in Best vitelliform macular dystrophy. In another patient, 
the lesion in one eye showed decreased FAF, corresponding with chorioretinal atrophy 
on ophthalmoscopy. Small multifocal lesions of increased FAF were seen in the macular 
area of one patient. In all patients, lesions were smaller than one disc diameter on FAF.   
Multifocal pattern dystrophy simulating STGD1 
In general, FAF in patients with multifocal pattern dystrophy simulating STGD1 shows 
changes that are very similar to the FAF changes seen in patients with the fundus 
Chapter 2
Figure 2.8.     
Fundus autof luorescence (FAF) in central areolar choroidal dystrophy (CACD). All patients 
carried a p.Arg142Trp mutation in the peripherin/RDS gene. A. FAF image of stage I CACD 
with a diffuse parafoveal increase of FAF. The visual acuity was 20/20. B. Early stage III 
CACD, showing areas of absent FAF outside the fovea, corresponding with profound  
chorioretinal atrophy, on a background of a speckled changes of increased and decreased 
FAF. C. Same patient as in panel (B), showing enlargement of the existing atrophic area 
after a follow-up period of 1.5 years. In addition, new regions of absent FAF have appeared. 
The visual acuity was still 20/20. D. Stage IV CACD, with a round macular lesion of absent 
FAF, bordered by a small band of increased FAF. Note the discrete FAF of larger choroidal 
vessel underlying the lesion. The visual acuity was 20/800.
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Figure 2.9.     
Fundus autof luorescence 
(FAF) in various pattern 
 dystrophies. A. FAF image of 
adult-onset foveo macular 
vitelliform dystrophy, sho-
wing a small foveal lesion of 
increased FAF. This patient 
had a visual acuity (VA) of 
20/32. No mutations were 
found in peripherin/RDS or 
BEST1. B. FAF of a patient 
with multifocal  pattern 
 dystrophy simulating STGD1, 
displaying irregular f lecks of 
markedly increased FAF, 
many of which show small 
adjacent zones of decreased 
FAF. The FAF characteristics 
of these lesions in the macular area and along the retinal vascular arcades are very similar to 
those observed in STGD1 (See Fig. 2.6B). The VA was 20/20. This patient carried a p.
Asp145fsX30 mutation in the peripherin/RDS gene. C. Advanced multi focal pattern dystrophy 
simulating STGD1, with a large area of speckled increase and  decrease of FAF extending 
 beyond the  retinal vascular arcades and optic disc. Multifocal, well-circumscribed patches of 
absent FAF are observed within this area,  corresponding with RPE atrophy on ophthalmoscopy. 
This patient had a VA of 20/25, and carried a p.Pro147fsX4 mutation in peripherin/RDS.  
D. FAF image of a patient with  butterf ly-shaped pigment  dystrophy. The clinically visible 
 butterf ly-shaped macular changes are also seen on FAF. The pigmented part of the lesion 
 showed increased FAF, surrounded by decreased FAF. This patient, who carried a p.
Arg220fsX34 mutation in peripherin/RDS, had a VA of 20/20. E. Patient with maternally 
inherited diabetes and deafness (MIDD)-associated pattern  dystrophy (m.3243A>G mutation), 
showing a large pseudovitelliform macular lesion of  increased FAF, surrounded by satellite 
lesions of increased FAF and dispersed spots of  decreased FAF. The visual acuity was 20/40.  
F. Pattern dystrophy in a MIDD patient (m.3243A>G mutation) with speckled changes of 
 increased and decreased FAF in the macula and surrounding the optic disc. The foveal area 
shows a relatively normal FAF aspect. The visual acuity was 20/20. G. Advanced pattern 
 dystrophy in a MIDD patient carrying the m.3243A>G mutation, showing irregular changes  
of increased and decreased FAF along the temporal retinal vascular arcades and surrounding 
the optic disc. The macula shows a large area of markedly decreased to absent FAF with the 
exception of a foveal island, which seems remarkably spared. The visual acuity was 20/20.
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flavimaculatus subtype of STGD1. In multifocal pattern dystrophy simulating STGD1, 
the STGD1-like flecks displayed highly increased FAF, often with small adjacent zones of 
decreased FAF (Fig. 2.9B). In a later stage, these flecks of increased FAF showed confluence 
towards a large ring-shaped area of mottled FAF abnormalities surrounding the macula 
and optic disc, without sparing of the parapapillary retina (Fig. 2.9C). The changes could 
gradually involve the macula (Fig. 2.9C). Within this ring-shaped area of increased FAF, 
granular zones of substantially decreased FAF appeared. After one or more decades 
of disease, profound chorioretinal atrophy of the posterior pole could occur, which 
corresponded with a severely decreased or absent FAF signal. In the macular area, FAF 
changes were variable. In 8 eyes, discrete spots of either increased or decreased FAF were 
seen in the fovea. A group of irregular flecks of mostly increased FAF, comparable to but 
often larger than the peripheral flecks, was seen in 7 eyes. 
In 8 eyes of 5 patients, large, irregularly shaped lesions were seen, showing spots of 
increased and decreased FAF. In one eye, a butterfly-shaped lesion was seen on FAF as 
well as on ophthalmoscopy. One or more well-defined areas of severely decreased FAF 
could be observed in 8 eyes of 5 patients, corresponding with profound chorioretinal 
atrophy (Fig. 2.9C). 
Butterfly-shaped pigment dystrophy
We examined one patient with butterfly-shaped pigment dystrophy, in whom the 
butterfly-shaped lesions on ophthalmoscopy were also observed on FAF (Fig. 2.9D). The 
pigmented part of the butterfly-shaped lesion showed increased FAF, and was surrounded 
by decreased FAF. 
Pattern dystrophy associated with maternally inherited diabetes and deafness (MIDD)
In one MIDD patient, spots of decreased and increased FAF were scattered throughout 
the macula, in one eye with a central area of increased FAF corresponding with a 
pseudovitelliform lesion at ophthalmoscopy (Fig. 2.9E). Another patient showed the 
same speckled aspect of spots of increased and decreased FAF, with a relatively normal 
FAF aspect of the fovea (Fig. 2.9F). The third MIDD patient who displayed advanced FAF 
changes in the posterior pole and around the optic nerve, showed apparently normal FAF 
of both foveas, corresponding with a normal visual acuity (Fig. 2.9G).
Discussion
In the present study, FAF abnormalities were observed in all examined eyes with 
ophthalmoscopically visible retinal dystrophies. Focally increased FAF was the most 
common finding, frequently accompanied by areas of decreased or even absent FAF. 
We observed specific FAF abnormalities that were dependent on the examined retinal 
disorder. 
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Fundus autofluorescence in STGD1
Autosomal recessive Stargardt disease/fundus flavimaculatus (STGD1) is caused 
by mutations in the ABCA4 gene.25 With disease progression, excessive increase of 
lipofuscin and especially A2E can be observed, which is accelerated by light exposure.26-28 
This abnormal increase of RPE lipofuscin is probably one of the first detectable 
pathophysiological changes in STGD1.26 Therefore, FAF imaging appears a promising 
method to monitor patients with STGD1.29
 In our study, central macular lesions showed largely decreased FAF, reflecting 
chorioretinal atrophy. In most patients, these central lesions were surrounded by smaller, 
well-circumscribed lesions of predominantly increased FAF, largely corresponding 
with the irregularly shaped yellowish flecks that were observed at ophthalmoscopy. 
However, some of these lesions on FAF were not readily seen at ophthalmoscopy. This 
emphasizes the potential of FAF to detect pathologic changes in STGD1 in advance to 
clinically visible abnormalities. Lesions were sometimes confined to the macula, but an 
innumerable amount of flecks of increased FAF, scattered throughout the retina, could 
also be observed. Like in the normal retina,19 the rate of lipofuscin accumulation in STGD1 
shows considerable intraretinal variation.26,30 A disease sequence of six stages in STGD1 
has been proposed by Cideciyan and colleagues,26 based on lipofuscin accumulation, 
retinoid cycle kinetics, as well as rod, cone and RPE cell loss. Stage I shows entirely 
normal results, whereas the only detectable abnormality in stage II is an increase in 
mean FAF intensity. In stage III, these changes are superimposed by a focal increase of 
FAF intensity (Fig. 2.6A and B). Different FAF patterns have been described in STGD1, 
which appear to correspond with functional abnormalities.29,31 Lesions tend to enlarge 
and show confluence, while the initially elevated FAF signal evolves towards decreased to 
absent FAF intensities. These decreasing FAF intensities are due to the loss of lipofuscin-
laden RPE cells, which is accompanied by increasing photoreceptor degeneration and 
slowing of the retinoid cycle. In stage VI (end-stage) ABCA4-related retinal degeneration, 
variably sized regions of absent FAF are observed as a consequence of complete RPE and 
photoreceptor degeneration. 
 In cases of STGD1 with abnormal cone and rod responses on electroretinography, 
most patients show a decreased FAF signal at the macula, sometimes in combination 
with patches of decreased FAF beyond the vascular arcades, corresponding with 
chorioretinal atrophy. This group of STGD1 patients also tends to show more visual loss.29 
Although there is no direct evidence that conventional short-wavelength FAF accelerates 
the disease process of ABCA4-related retinal dystrophies, there are indications that some 
retinal degenerative diseases like STGD1 may have lower light damage thresholds.21,30,32,33 
Therefore, some authors advocate the use of reduced intensity FAF imaging.32,33
Fundus autofluorescence in Best vitelliform macular dystrophy
Best vitelliform macular dystrophy (BVMD) is an autosomal dominant retinal dystrophy 
that predominantly affects the macula. BVMD is caused by mutations in the BEST1 gene.34 
Typically, BVMD patients show bilateral round to oval yellow subretinal lesions in the 
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macula that resemble an egg-yolk at a certain point of time.35 In a minority of cases, 
multifocal vitelliform lesions may be encountered.36,37 Most histopathological studies 
have found an abnormal increase of RPE lipofuscin and A2E in the RPE of donor eyes of 
BVMD patients.20,37-41 
 In our study, FAF imaging allowed a detailed appreciation of the lesions in all BVMD 
patients. FAF was also able to visualize small amounts of vitelliform material that were 
not seen at ophthalmoscopy. In early stages, BVMD lesions showed a predominantly 
increased FAF, which decreased towards later stages. This increased FAF signal may not 
only find its origin in RPE lipofuscin, but may also be derived from autofluorescent 
fluorophores within the subretinal vitelliform material. Previous studies indicate that 
BVMD lesions may remain relatively constant in size,4 but they may also enlarge when 
evolving to later stages.42,43 In virtually all patients, internal FAF characteristics change 
substantially during follow-up.4 Lower visual acuity appears to be associated with a more 
irregular pattern of increased FAF within the lesion, due to scarring or hemorrhage.4,44 
In our study, lesions in later stages of BVMD were characterized by a generally decreased 
FAF. This gradual loss of FAF in later disease stages indicates that this subretinal material 
of increased FAF gradually disappears when RPE cell death progresses and atrophy and/
or scars develop.
Fundus autofluorescence in central areolar choroidal dystrophy
Most cases of autosomal dominant CACD appear to be associated with mutations in 
the peripherin/RDS gene, but genetic heterogeneity has been described.45-47 In our study, 
patients with autosomal dominant CACD showed increased FAF in the macular area early 
in the course of the disease, suggesting lipofuscin accumulation in the macular RPE. In 
late stage II CACD, zones of decreased FAF may become more prominent, which probably 
corresponds to a gradual loss of RPE cells. Thus, our FAF findings indicate a progressive 
lipofuscin accumulation and consecutive RPE damage during the first two stages. With 
time, lesions may extend beyond the retinal vascular arcades and optic nerve head.45,48 
FAF in stage III CACD shows sharply demarcated areas of severely decreased to absent 
FAF. These atrophic areas develop within the areas of granular FAF changes. Therefore, 
the initial diffusely affected RPE may finally result in regions of total loss of RPE. These 
regions gradually enlarge and finally involve the foveal RPE in end-stage CACD. In this 
stage, a well-defined, round to oval area of absent FAF is seen, surrounded by a small band 
of increased FAF. Interestingly, FAF abnormalities may precede ophthalmoscopically 
visible changes in CACD.45 This makes FAF imaging especially suitable for non-invasive 
screening of families with CACD.
Fundus autofluorescence in pattern dystrophies
The phenotypically and genetically heterogeneous group of pattern dystrophies is 
characterized by a variety of deposits of yellow, orange or gray pigment, predominantly 
in the macular area.49-52 The classification of Gass discriminates between five main 
categories of pattern dystrophies: adult-onset foveomacular vitelliform dystrophy 
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(AFVD), butterfly-shaped pigment dystrophy, reticular dystrophy of the pigment 
epithelium, multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus 
(MPD), and fundus pulverulentus.35 In the group of AFVD patients in the present study, 
all lesions were smaller than one disc diameter in size and generally showed increased 
FAF. These results correspond with previous FAF findings in AFVD patients and with the 
histopathological finding of increased lipofuscin in AFVD lesions.53-55 Like in BVMD, AFVD 
patients may show small multifocal lesions of increased FAF, as well as a scrambled-egg 
and pseudohypopyon aspect. 
 In patients with MPD, which is often caused by peripherin/RDS mutations, the posterior 
pole may be scattered with irregular flecks resembling those in STGD1 on FAF, as well as 
on ophthalmoscopy and optical coherence tomography.23 Like in STGD1, the flecks in MPD 
may extend beyond the macular area. In later stages, these flecks may show confluence 
to a ring-shaped area of abnormal FAF, surrounding the macula and optic disc. Central 
macular lesions show a broad range of FAF changes, often with predominantly increased 
FAF, especially in earlier stages. In time, macular lesions may also show markedly 
decreased FAF due to profound chorioretinal atrophy. Therefore, it may be difficult to 
discriminate between STGD1 and MPD on the basis of the FAF aspect. Distinguishing 
features between MPD and STGD1 are the autosomal dominant pattern of inheritance, 
the relatively late age at onset, the comparatively good and stable visual acuity, and the 
absence of a “dark choroid” on fluorescein angiography.23 Molecular genetic analysis may 
aid in the differential diagnosis between these different entities.
 In butterfly-shaped pigment dystrophy, patients display macular lesions with a spoke-
like pigment pattern surrounded by a zone of depigmentation, somewhat resembling the 
shape of a butterfly.56 The phenotype of butterfly-shaped pigment dystrophy is genetically 
heterogeneous.57,58 In a case caused by a peripherin/RDS missense mutation (p.Cys213Tyr), 
increased amounts of lipofuscin have been found in the RPE on histopathologic 
examination.22 This corresponds with the finding in our study of increased FAF of the 
pigmented part of the lesion in the patient with butterfly-shaped pigment dystrophy. 
 Pattern dystrophy phenotypes may also be associated with syndromes, such as 
myotonic dystrophy, pigment dispersion syndrome, and mitochondrial syndromes 
like maternally inherited diabetes and deafness (MIDD) and MELAS (mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes) syndrome.59-63 MIDD and 
MELAS are associated with mutations in the mitochondrial DNA, with the m.3243A>G 
point mutation being the most frequently identified mutation.64 As much as 86% of 
patients with maternally inherited diabetes and deafness (MIDD) may show some form 
of pattern dystrophy. In our study, RPE changes in MIDD patients were easily defined on 
FAF as speckled areas of increased and decreased FAF in the macula and surrounding 
the optic disc. The intriguing feature of foveal sparing can be observed on FAF in a MIDD 
patient with advanced pattern dystrophy,65 which is illustrated in Fig. 2.9G.
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Conclusions
FAF imaging is a useful tool for the identification and follow-up of lesions associated 
with lipofuscin accumulation or RPE cell loss. As such, FAF imaging may yield important 
additional information in a diagnostic setting in relatively frequent retinal dystrophies, 
such as STGD1, BVMD and in retinal dystrophies associated with peripherin/RDS 
mutations. FAF may visualize more lesions compared to ophthalmoscopy. Moreover, FAF 
imaging provides qualitative information, as it reflects the lipofuscin content in lesions, 
and FAF changes appear to relate to functional abnormalities in at least some retinal 
dystrophies.1,29,66 However, non-lipofuscin accumulating parts of a lesion may be missed 
with FAF. Therefore, FAF alone may not be useful for lesion size measurement. Retinal 
dystrophies may present with a considerable clinical variability. Late stages with RPE 
cell loss may look similar in various retinal dystrophies and in other retinal disorders 
such as age-related macular degeneration. In this respect, FAF may be of limited use 
in the differential diagnosis between different forms of retinal dystrophy. Molecular 
genetic testing may be very helpful in these cases. FAF imaging is a non-invasive 
imaging modality that is a straightforward and relatively patient-friendly means to get 
an overview of the accumulation of fluorophores like lipofuscin and atrophic changes 
within the RPE-photoreceptor complex.2,6 Therefore, FAF imaging may constitute a 
convenient tool for cross-sectional and family studies, as well as in the follow-up of 
various retinal dystrophies. In addition, FAF imaging may also play a role as a parameter 
for the evaluation of therapeutic effects in future clinical treatment trials.
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3.1.  The spectrum of ocular phenotypes caused by mutations 
in the BEST1 gene
Abstract
Bestrophin-1 is an integral membrane protein, encoded by the BEST1 gene, which is located 
in the basolateral membrane of the retinal pigment epithelium. The bestrophin-1 protein 
forms a Ca2+ activated Cl- channel and is involved in the regulation of voltage-dependent 
Ca2+ channels. In addition, bestrophin-1 appears to play a role in ocular development. 
Over 120 different human BEST1 mutations have been described to date, associated with a 
broad range of ocular phenotypes. The purpose of this review is to describe this spectrum 
of phenotypes, ranging from Best vitelliform macular dystrophy and adult-onset 
foveomacular vitelliform dystrophy, autosomal dominant vitreoretinochoroidopathy, 
the microcornea, rod-cone dystrophy, cataract, posterior staphyloma (MRCS) syndrome, 
and autosomal recessive bestrophinopathy. The genotype-phenotype correlations that are 
observed in association with BEST1 mutations are discussed. In addition, in vitro studies 
and animal models that clarify the pathophysiological mechanisms are reviewed.
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Abbreviations: ADVIRC, autosomal dominant vitreoretinochoroidopathy; AFVD, adult-
onset foveomacular vitelliform dystrophy; AMD, age-related macular degeneration; ARB, 
autosomal recessive bestrophinopathy; BVMD, Best vitelliform macular dystrophy; CaV, 
voltage-dependent calcium; CERES, composite exonic regulatory element of splicing; CNV, 
choroidal neovascularization; EOG, electro-oculography; ERG, electroretinography; ESE, 
exonic splicing enhancer; ESS, exonic splicing silencer; FAF, fundus autofluorescence; 
MRCS, microcornea, rod-cone dystrophy, early-onset cataract, and posterior staphyloma; 
OCT, optical coherence tomography; RPE, retinal pigment epithelium. 
1. Introduction
Best vitelliform macular dystrophy (BVMD) is among the most frequently encountered 
autosomal dominant retinal dystrophies and predominantly affects the macula. 
BVMD was the first disease shown to be caused by mutations in the BEST1 gene, which 
encodes the bestrophin-1 protein that localizes to the retinal pigment epithelium (RPE).1 
Subsequent studies showed that BEST1 gene mutations may also be found in patients with 
adult-onset foveomacular vitelliform dystrophy (AFVD).2-4 BVMD and AFVD are related 
phenotypes, with abnormalities that are generally restricted to the macula. However, 
more widespread ocular abnormalities may arise in association with specific BEST1 
gene mutations that cause autosomal dominant vitreoretinochoroidopathy (ADVIRC) 
and the autosomal dominant microcornea, rod-cone dystrophy, early-onset cataract, 
and posterior staphyloma (MRCS) syndrome.5-8 The same applies to autosomal recessive 
bestrophinopathy (ARB), the human null phenotype of bestrophin-1, which is associated 
with high hyperopia and shallow anterior chambers.9 Therefore, ADVIRC, the MRCS 
syndrome, as well as ARB belong to a spectrum of diseases with ocular developmental 
abnormalities that extend beyond the retina.
 In this paper, we aim to review the characteristics of the BEST1 gene and its 
multifunctional protein product bestrophin-1, with an emphasis on the broad spectrum 
of ocular phenotypes associated with mutations in this gene. The effects of different BEST1 
mutations are discussed, as well as their genotype-phenotype correlations. Available in 
vitro and animal models are addressed, as well as the histopathological observations in 
BEST1-related diseases, that expand our insight in the pathogenesis. Finally, perspectives 
on future therapeutic strategies are discussed. 
2. Molecular biology of the human BEST1 gene
2.1. The BEST1 gene
The human BEST1 gene was identified in 1998 by Petrukhin and colleagues.1 BEST1 is located 
on chromosome 11q12, spans 15 kilobases of genomic DNA and contains 11 exons of 
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which 10 are protein-coding.1,10 Eight years later, the mouse ortholog was characterized.11 
An alternative name for BEST1 is VMD2, but the Human Genome Organisation and the 
Mouse Genome Database nomenclature committees recently recommended the BEST (in 
humans) and Best (in mice) nomenclature. The BEST1 gene is the founding member of a 
family of four paralogs, the other three called BEST2, BEST3, and BEST4.12-14
The BEST1 gene is expressed predominantly in the retinal pigment epithelium (RPE), 
although some expression has also been detected in kidney, brain, spinal cord, and 
testis.1,10 The RPE-specific expression is driven by a region within -154 to -104 base pairs 
of the BEST1 promoter, which contains two E-boxes.15-17 These E-boxes are able to bind 
transcription factors, such as OTX2 and MITF.15-17
2.2. The bestrophin-1 protein
Bestrophin-1 is an integral membrane protein consisting of 585 amino acids.14,18,19 The 
bestrophin-1 protein localizes to the basolateral plasma membrane of the RPE, but may 
also be present intracellularly.20 The regional expression level of bestrophin-1 is higher 
in the RPE outside the macula compared to the macular RPE.21 Consequently, it has 
been speculated that the macular phenotype associated with BEST1 mutations might be 
related to a relative insufficiency of wild-type bestrophin-1 in the macula.21 
 Two topological models of human bestrophin-1 have been proposed that are partly 
contradictory. In a model constructed by Tsunenari and colleagues, bestrophin-1 has 5 
transmembrane domains.14 In contrast, the protein is predicted to have 4 transmembrane 
domains in the model of Milenkovic and colleagues (Fig. 3.1).19 The major difference 
between these models is that amino acids ~199-233 are situated in an extracellular loop 
in the Tsunenari model, whereas these amino acids are located in a large cytoplasmic 
loop in the model by Milenkovic. Bestrophin-1 most likely oligomerizes to dimers, or 
possibly to tetramers/pentamers.12,22,23 Several splice variants of bestrophin-1 have been 
described. The mRNA from isoform 1 results from the transcription of all 11 exons and 
leads to the translation of wild-type bestrophin-1. Isoform 2 results from alternative 
splicing of exon 7, causing premature termination of the protein at amino acid 435, 
should the mRNA escape nonsense-mediated decay.1,12 In isoform 3 (498 amino acids) 
and 4 (604 amino acids), exon 2 is skipped.1,12 Isoform 3 shows an additional skipping of 
exon 8, which deletes a highly conserved transmembrane domain that is presumed to be 
essential for bestrophin Cl- channel activity.1,12 Isoform 4 produces an elongated protein 
due to additional alternative splicing of exon 10.1,12 
 Bestrophin-1 is a multifunctional protein, with activity both at the basolateral 
plasma membrane of the RPE and intracellularly.12 Several lines of evidence strongly 
indicate that bestrophin-1 functions as a Cl- channel,12,14,20,23-30 activated by intracellular 
Ca2+.12,20,23,25,26,30,31 Human bestrophin-1 is also highly permeable to HCO3-, indicating 
that it may also function as a HCO3- channel.32,33 Recent experiments suggest that the 
bestrophin-1 Cl- channel is gated through the binding of Ca2+ by the C-terminal protein 
region ranging from amino acids 312 to 323.31 This region is called EF1 and was postulated 
to be an EF hand, which is a Ca2+ binding helix-loop-helix structural protein domain.31,34 
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Two additional C-terminal domains appear to be required for this Ca2+ regulated Cl- 
channel gating.31 First, the acidic amino acid-rich region 293-308, which is located in the 
cytosol, adjacent to the last transmembrane domain. The second relatively acidic region, 
ranging from amino acids 350-390, also likely influences Ca2+ regulated Cl- channel 
gating, possibly in the oligomerized state and/or through phosphorylation processes.31 
Besides activation by Ca2+, in vitro experiments also suggest that bestrophin-1 Cl- channel 
activity is regulated by cell volume.12,35-37 The presumed Cl- channel function is further 
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Figure 3.1.*   
Protein model of bestrophin-1 (adapted from Milenkovic19). The model of Milenkovic and  
colleagues was used, as their experiments have shown that only the four domains depicted  
in the figure are located in the cell membrane. The known human disease-associated 
 mutations are indicated with colours. The protein variants found in age-related macular 
degeneration are also shown, although functional studies question their significance in 
disease pathogenesis. Coloured residue: missense mutation or in-frame deletion. Coloured 
bar: nonsense or frameshift mutation. Abbreviations: BVMD, Best vitelliform macular 
 dystrophy; AFVD, adult-onset foveomacular vitelliform dystrophy; ADVIRC, autosomal  
dominant vitreoretinochoroidopathy; ARB, autosomal recessive bestrophinopathy; AMD,  
age-related macular degeneration. 
113
supported by the observation that many disease-causing BEST1 mutations in BVMD and 
ARB result in a dysfunction of bestrophin-1 Cl- channel function.9,12,20,23,30,38 
 Bestrophin-1 also acts as an inhibitor of intracellular voltage-dependent Ca2+ (CaV) 
channels,39-42 through the interaction with the β subunit of these CaV channels.42 The 
proline-rich region ranging from amino acids 330-370, especially the Pro330XXXPro334 
domain, in the cytoplasmic C-terminus of bestrophin-1, appears important for the 
modulation of CaV channels.42 Evidence on the type of effect of bestrophin-1 on CaV 
channels is somewhat conflicting. Rosenthal and colleagues found that human 
bestrophin-1 regulates CaV channels in RPE-J cells by altering their voltage dependence 
and accelerating their activation, without changing the Ca2+ current.40 In contrast, Yu 
and co-workers did find a decrease in endogenous Ca2+ current in both RPE-J cells and 
Human Embryonic Kidney (HEK)-293 cells, without a significant effect on CaV channel 
voltage dependence.42 Possibly, the level of inhibition of CaV channels by bestrophin-1 is 
dependent on bestrophin-1 Cl- channel closure.31,42 Opening of these Cl- channel channels 
would consequently relieve this inhibition, receiving positive feedback by the subsequent 
Ca2+ influx.31,42
 The electro-oculogram (EOG) reflects the ion conductance of the RPE and its light 
peak response has been presumed to be generated by activation of a Ca2+-sensitive Cl- 
conductance.12,27 In BVMD, the EOG typically shows a markedly decreased light peak 
response,43 which may at least partly be due to bestrophin-1 dysfunction.12 However, 
in mice, disruption of Best1 does not diminish the RPE-derived light peak on the 
electroretinogram (ERG), nor does it substantially alter Ca2+-sensitive Cl- conductances.39 
These results thus challenge the hypothesis that bestrophin-1 is a classical Ca2+-sensitive Cl- 
channel and is responsible for the abnormal EOG in BVMD through this mechanism.12,39,44 
Rather than bestrophin-1 Ca2+-sensitive Cl- channel function, bestrophin-1 modulation of 
intracellular CaV channels seems to be necessary for the generation of a normal RPE-
generated ERG light peak response in mice and rats.39-41 Of note, it is unclear to what 
extent such a RPE-specific ERG light peak in mice and rats can be compared to the human 
EOG light peak.
 Clinical findings in ADVIRC, the MRCS syndrome, and ARB patients that carry 
BEST1 mutations indicate that bestrophin-1 may also be required for normal ocular 
development, although the mechanisms are as yet unclear.6-9 In mice, bestrophin-1 mRNA 
expression is relatively high during the late phase of the embryonic development and 
the early postnatal period.45 Bestrophin-1 protein expression occurs considerably later in 
mice, and appears to be a good marker of RPE differentiation.45 The onset of bestrophin-1 
protein expression in the mouse starts at postnatal day 10, and coincides with the visual 
competence of photoreceptors. 
The RPE is known to be essential in the regulation of growth factor signaling to the 
choroid and sclera, and bestrophin-1 may also prove to be of influence on these 
mechanisms.46,47 In addition to the proposed functions as a Cl- channel, a regulator of 
voltage-dependent Ca2+ channel, and the role in ocular development, bestrophin-1 may 
also play a role in epithelial secretion, like several other Ca2+-sensitive Cl- channels.24,26,48,49 
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Bestrophin-1 possibly also exerts its influence on intracellular mechanisms. The 
bestrophin-1 Cl- channel function as well as its regulating influence on intracellular Ca2+ 
currents may be able to influence intracellular processes, for instance phagocytosis and 
lysosomal function.40,46,50-52 The C-terminal cytoplasmic domain of bestrophin-1 may be 
phosphorylated and is able to interact with protein phosphatase 2A,53 which plays a role 
in intracellular signaling.54
 Bestrophin homologs have been detected in animals, fungi, and prokaryotes, but not 
in protozoans or plants.55 Phylogenetic analysis suggests that the bestrophins originated 
by duplication and divergence of a common protein at the base of the eukaryotic tree.56 
The function of the other three bestrophin paralogs in humans is unclear. In mice, Best2 
mRNA has been identified in the eye, colon, nasal epithelia, trachea, brain, lung, and 
kidney. Bestrophin-2 has been identified in mouse colon and the nonpigmented ciliary 
epithelium of the ciliary body of the eye.57 Consequently, in the latter case, there is a 
possible regulatory role in the formation of aqueous humor.57 In addition, bestrophin-2 
may have a function in the olfactory epithelium,58 although studies are contradictory in 
this regard.57 The function of human bestrophin-3 and bestrophin-4 is unknown, but in 
mice and rats, bestrophin-3 splice variants have been found in exocrine glands, heart, 
vascular smooth muscle cells, lung, testis, and kidney.59,60 Bestrophin-3 is also expressed 
in the mouse heart.61
2.3. Human BEST1 gene mutations
2.3.1. Best vitelliform macular dystrophy
The BVMD phenotype is inherited in an autosomal dominant fashion. The cloning of 
the BEST1 gene was facilitated by the identification of a large 12-generation Swedish 
family consisting of more than 250 individuals affected with BVMD.62 The causative 
gene was subsequently mapped to chromosome 11q13 by linkage analysis,63,64 and was 
characterized in 1998 by positional cloning of a retina-specific expressed sequence tag.1,10 
It was suggested that BVMD might be genetically heterogeneous,65 but this does not 
seem to be the case.66 Mutations in BEST1 are detected in nearly all BVMD cases with a 
positive family history.3,67,68 Those BVMD cases without BEST1 mutations did not have 
a positive family history, and may have either been misdiagnosed, or may represent 
phenocopies.3,67 
 To date, more than 100 different BEST1 mutations have been reported in BVMD.1,3,10,67,69-
81 An overview of BEST1 mutations can be found in the VMD2 database of the University 
of Regensburg (http://www-huge.uni-regensburg.de/VMD2_database) and on the Retina 
International website (http://www.retina-international.com/sci-news/vmd2mut.htm), and 
is depicted in Fig. 3.1. The majority (92%) of mutations identified in BVMD are missense 
mutations located in the N-terminal half of the protein (Fig. 3.1). This part of the protein 
exhibits the highest evolutionary conservation, while the C-termini differ substantially 
between paralogs.56 Only one nonsense mutation,79 one splice site mutation,3 two 
frameshift mutations,72,74 and three in-frame deletions have been reported.3,10,67 Of the 
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latter mutations, only the in-frame delation p.Ile295del and the c.1574delCA frameshift 
mutation were found in cases with well-described, stringent clinical inclusion criteria, 
as well as a positive family history of BVMD and/or segregation of the mutation in these 
families.10,72 The majority (61%) of BEST1 mutations have been found uniquely in one 
family. Seven mutations (p.Thr6Pro, p.Arg218Cys, p.Tyr227Asn, p.Ala243Val, p.Ile295del, 
p.Glu300Asp, p.Asp301Glu) have been found in more than three families.1-3,10,38,67,71,72,74,76,82 
The p.Thr6Pro mutation, for instance, is notably frequent in the Netherlands,1,83 which 
may be due to a founder effect. Three BEST1 mutations have been reported to have arisen 
de novo.69,78,81
Multifocal vitelliform dystrophy, a clinically and genetically heterogeneous condition, 
may be caused by BEST1 mutations in approximately 60% of cases.83 To date, 9 mutations 
have been described in association with multifocal vitelliform dystrophy, including 7 
missense mutations (p.Thr6Pro, p.Ser16Tyr, p.Arg92Ser, p.Ala195Val, p.Tyr227Asn, 
p.Asn296Lys, and p.Phe298Ser), one in-frame deletion (p.Asp302_Asp304del), and one 
in-frame insertion (p.Lys194_Ala195insVal).82-84 Most of these mutations were also seen 
in patients with unifocal, central BVMD and/or AFVD, indicating that BEST1-related 
multifocal vitelliform dystrophy is a multifocal variant of BVMD and/or AFVD.
2.3.2. Adult-onset foveomacular vitelliform dystrophy
Fundoscopic findings in AFVD overlap with BVMD,85 but AFVD is characterized by a 
later age at onset, a smaller lesion size, a slower progression, and a slightly subnormal 
to normal EOG.86,87 Many cases appear to be sporadic, but a small number of families 
with an autosomal dominant inheritance pattern have been reported.85,88,89 AFVD is 
genetically heterogeneous: mutations have also been reported in the peripherin/RDS 
gene.90,91 In a group of 32 AFVD patients, 8 (25%) had BEST1 mutations.3 Two of these 
mutations, p.Thr6Pro and p.Ala243Val, have also been detected in families with BVMD. 
Two other mutations, p.Arg47His and p.Asp312Asn, have only been identified in AFVD. 
In another series of 28 patients with various macular diseases, mutations were detected 
in one of three families with AFVD and in one patient with bull’s eye maculopathy.2,4 
These two mutations, p.Ala146Lys and p.Glu119Gln, have not been identified previously. 
In two other studies, no BEST1 mutations were identified in 10 and 12 AFVD patients, 
respectively.92,93 
2.3.3. Autosomal dominant vitreoretinochoroidopathy (ADVIRC) and the MRCS syndrome 
To date, three heterozygous BEST1 missense mutations have been found in ADVIRC: 
p.Val86Met,8 p.Val235Ala,5 and p.Tyr236Cys.8 One mutation, p.Val239Met, has been 
described in the MRCS syndrome, a genetically heterogeneous disease.6-8 These four 
mutations in ADVIRC and the MRCS syndrome all appear to alter normal splicing of BEST1. 
In vitro splicing assays suggest that affected individuals heterozygous for p.Val86Met, 
p.Tyr236Cys and p.Val239Met produce three different BEST1 isoforms. In addition 
to the product of the wildtype allele, each mutant allele is capable of producing two 
abnormal proteins, one containing a missense mutation, while the other one contains 
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an in-frame deletion upon exon-skipping.8 The p.Val86Met mutation leads to a deletion 
of exon 4, whereas p.Tyr236Cys and p.Val239Met cause a deletion of exon 6 and exon 
7, respectively.5,8 In vitro splicing assays indicate that the p.Val235Ala mutation causes 
a duplication of exon 6 by a rare phenomenon called trans-splicing, but it cannot be 
excluded that the duplication is an artefact of the splicing assay. The splicing defects 
caused by these mutations are likely due to the disruption of exonic splice enhancers 
(ESEs),8 which is further described in paragraph 4.1.
2.3.4. Autosomal recessive bestrophinopathy
ARB is an autosomal recessive disease caused by homozygous or compound heterozygous 
mutations in the BEST1 gene. To date, eight patients from six different families have 
been described.9,94 Two patients from the same family carried a homozygous p.Arg200X 
nonsense mutation.9 Six patients carried compound heterozygous missense mutations. 
The following combinations were encountered: p.Arg141His and p.Val317Met (one 
patient), p.Leu41Pro and p.Pro152Ala (one patient), p.Leu41Pro and p.Arg141His (one 
patient), p.Asp312Asn and p.Met325Thr (in two patients from the same family), and 
p.Leu88del17 combined with p.Ala195Val (one patient).9,94 In addition, two individuals 
from a single family were compound heterozygous for p.Arg141His and p.Tyr29X, with 
a phenotype described as atypical BVMD.79 However, the description of the phenotype 
is highly suggestive of ARB. Three of the ARB mutations, p.Leu41Pro, p.Arg141His, and 
p.Ala195Val, in a single heterozygous state, have also been reported in BVMD,3,67,74,83 
whereas p.Asp312Asn has also been reported as a single heterozygous mutation causing 
AFVD.3
2.3.5. Age-related macular degeneration
BEST1 mutation analysis in patients with age-related macular degeneration (AMD) has 
led to the identification of a small number of sequence variants with questionable 
significance. Three studies have screened the BEST1 gene in large numbers of AMD 
patients. One study did not detect any disease-associated variants in 200 AMD patients.3 
In another study, two different alterations, p.Thr216Ile and p.Leu567Phe, were detected 
in 3 (1.1%) of 259 AMD patients.2,4 In a third study, 5 different alterations were detected 
in 5 (1.5%) of 321 AMD patients.67 Three patients carried a missense change (p.Arg105Cys, 
p.Glu119Gln, p.Val275Ile), whereas two patients carried a heterozygous nonsense 
mutation (p.Lys149X). These patients may have been misdiagnosed, representing 
phenocopies that are caused by BEST1 mutations but mimic AMD.67 The p.Glu119Gln 
substitution has also been detected in a patient with bull’s eye maculopathy.2 
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3.  The clinical spectrum of ocular diseases associated with 
BEST1 gene mutations
3.1. Best vitelliform macular dystrophy
BVMD was first described in 1905 by the German ophthalmologist Friedrich Best (1871-
1965).95 Most BVMD patients experience a reduction of visual acuity as the presenting 
symptom, although photophobia, metamorphopsia, and night blindness may also be 
noted.84 The age at onset in BVMD is highly variable, ranging from the first decade to 
beyond the sixth decade, with a mean age at onset in the fourth decade.84,96-99 There 
is a significant correlation between patient age and visual acuity.100 Mild to marked 
hypermetropia is a common associated finding.101 
 Several classifications of BVMD have been proposed, based on the aspect of the lesions 
on ophthalmoscopy. In these classifications, the first stage is generally considered the 
carrier or previtelliform stage (Fig. 3.2A), in which the fovea is normal or shows discrete 
RPE alterations, in combination with an abnormal EOG. This stage may be followed by 
the vitelliform stage (Fig. 3.2B and G), in which a slightly elevated macular lesion is 
observed, that is completely filled by yellowish material, resembling an egg yolk. In the 
next stage, the previously homogeneous vitelliform material breaks up, resulting in the 
vitelliruptive or “scrambled-egg” stage (Fig. 3.2C and H). This may then be followed by the 
pseudohypopyon stage, in which a horizontal level of the yellowish vitelliform material is 
seen in the inferior part of the cystic lesion (Fig. 3.2D and J). Above this level of vitelliform 
material, the lesion contains relatively transparent fluid. With time, chorioretinal atrophy 
ensues, in the so-called atrophic stage (Fig. 3.2E). When subsequent scarring within the 
lesion appears, which is sometimes associated with choroidal neovascularization, this 
is considered the final, cicatricial and/or neovascular stage by most classifications (Fig. 
3.2F, I and K). The most frequently cited classifications are those by Deutman,101 Mohler 
and Fine,97 and Gass.102 Although these classifications largely correspond, Gass positions 
the pseudohypopyon stage before the vitelliruptive stage. However, a study by Clemett 
showed that this sequence may be reversed, and that these stages may even evolve back 
and forth for several years.96 Many patients show a different stage in each eye.96 Even eyes 
with lesions in the cicatricial stage often retain a remarkably good visual acuity, despite 
impressive central scarring.97,103 
Choroidal neovascularization (CNV) occurs in 2-9% of BVMD cases.96,97,103-105 CNV may be 
difficult to recognize in BVMD lesions, and the (former) presence of CNV in such lesions 
is often inferred from the presence of a subretinal hemorrhage or a greyish-green scar 
within a lesion, with or without leakage on fluorescein angiography.96,97,103,105 Some reports 
suggest that CNV in BVMD lesions is more likely to occur after ocular trauma.103,106,107 In 
the long term, eyes with BVMD lesions and CNV are generally associated with a drop 
in visual acuity, but patients eventually often retain a visual acuity of 20/50 or better 
without treatment,103 unlike for instance AMD.108 Case reports indicate that CNV in BVMD 
lesions may respond to various treatments, including argon laser photocoagulation,109,110 
photodynamic therapy,111 and intravitreal injection of vascular endothelial growth 
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Figure 3.2.*    
Best vitelliform macular dystrophy (BVMD). All patients in this figure had an abnormal 
electro-oculogram and a positive family history for BVMD. A. Previtelliform or carrier stage 
in a 40-year-old patient carrying a p.Tyr227Asn mutation in the BEST1 gene. The visual 
acuity (VA) was 20/16. Hypopigmented, slightly atrophic retinal pigment epithelial changes 
are seen in the fovea, which remained stationary during a follow-up period of 30 years, 
 starting at the age of 10. B. Vitelliform stage in a 41-year-old patient carrying a p.Arg25Trp 
mutation in BEST1. The lesion in entirely filled with yellowish material. C. Vitelliruptive or 
“scrambled-egg” lesion in a 12-year-old patient with a VA of 20/25. This patient carried a  
p.Lys194_Ala195insVal mutation in BEST1. Scattered yellow-white vitelliform deposits are 
observed throughout the lesion. D. Pseudohypopyon stage in a 11-year-old patient carrying  
a p.Thr6Pro BEST1 mutation. The VA was 20/25. E. Atrophic stage in a 60-year-old patient 
who carried a p.Thr6Pro mutation in BEST1. Note the multifocal atrophic lesions besides the 
central, large atrophic lesion in this patient, who had a VA of 10/100. F. Cicatricial stage in 
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factor-inhibitors such as bevacizumab or ranibizumab.112,113 A rare complication in BVMD 
is retinal detachment, which may be successfully treated with cryotherapy and retinal 
indentation surgery.96,114,115
 A characteristic finding in BVMD is a severely decreased to absent light rise on the 
EOG.43 An abnormal EOG has been considered an absolute prerequisite to establish the 
diagnosis of BVMD in patients with vitelliform lesions. In addition, it allows detection 
of asymptomatic carriers. However, although the great majority of BVMD patients 
and carriers meets this criterium, several studies indicate that the EOG may initially 
be normal or even remain normal in BEST1 mutation carriers, even in those who are 
clinically affected.81,83,84,99,116 Thus, only mutation analysis of the BEST1 gene allows 
confirmation of a clinical diagnosis of BVMD.
Photopic and scotopic full-field electroretinography (ERG) is generally normal in BVMD 
patients,83,84,99,117 although the 30-Hz flicker and dark-adapted ERG may be abnormal.84,118 
The multifocal ERG is abnormal in the majority of BVMD patients.73,84,99,117,119,120 In these 
patients, reduced amplitudes as well as increased implicit times of the multifocal ERG P1 
and N1 components are often observed, especially in the central stimulus rings.73,84,99,117,119,120 
These findings are presumed to reflect abnormal cone photoreceptor and bipolar cell 
function.121 Dark adaptation measurements in BVMD patients are generally normal.122
 Fluorescein angiography often shows hyperfluorescence in the early phase, due to a 
variable degree of RPE and/or chorioretinal atrophy, with evidence of subtle fluorescein 
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a 17-year-old patient, who also carried a p.Thr6Pro mutation in the BEST1 gene, with a VA 
of 20/100. G. Fundus autof luorescence (FAF) image of the vitelliform lesion in the patient 
described with image (B), showing an intensely increased FAF signal. H. FAF image of the 
vitelliruptive lesion of the same patient as on image (C), showing a dispersion of the 
 material of increased FAF. In addition, a small pseudohypopyon with increased FAF can be 
seen in the inferior part of the lesion. I. FAF image of the same cicatricial stage lesion as on 
image (F), showing decreased to absent FAF in the center of the scar, and increased FAF at 
the edge of the scar, as well as at the edge of the lesion. J. Vertical optical coherence 
 tomography (OCT) section of the pseudohypopyon lesion as depicted on image (D).  
The vitelliform material in the inferior part of the lesion is hyperref lective on OCT. 
Deposition of hyperref lective material is also seen on the outer retinal surface under the 
fovea. The transparent f luid in the upper part of the lesion corresponds with hypor-
ef lectivity on the OCT image. K. High-resolution spectral domain-OCT image of the same 
cicatricial lesion as on images (F) and (I), revealing an elevation of the macula with a highly 
ref lective subfoveal mass, corresponding to the scar. All retinal layers and RPE seem to be 
preserved over the entire area. The thickened photoreceptor layer at the borders of the  
retinal detachment corresponds to an outer ring of increased FAF in panel (I). An area of 
partial photoreceptor loss around the central mass co-locates to decreased perifoveal FAF.
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accumulation within the lesion in the late phase.84,102,123 However, the accumulation of 
vitelliform material in the vitelliform and pseudohypopyon stage blocks fluorescence, 
especially in the early phase.84,102,123 
Indocyanine green angiography may be able to more accurately locate possible choroidal 
neovascularization, which is often difficult to identify on fluorescein angiography.103 In 
addition, indocyanine green angiography may show hyperfluorescent changes in the 
(mid-) peripheral retina in BVMD that are not seen on ophthalmoscopy and fluorescein 
angiography.124 
On fundus autofluorescence (FAF), the yellowish subretinal vitelliform material in BVMD 
lesions shows an intensely increased FAF signal (Fig. 3.2G, H, and I).83,84,99,123,125-131 As BVMD 
lesions evolve towards later stages, this material of increased FAF becomes dispersed 
throughout the lesion in a granular fashion, with or without a pseudohypopyon of 
increased FAF in the inferior part of the lesion (Fig. 3.2H). This autofluorescent material 
consists of toxic autofluorescent components of lipofuscin that are waste products of 
the visual cycle, such as A2E and its precursors and derivatives.132-137 Such material of 
increased FAF may not only be located in the RPE,133,137 but also in the photoreceptors 
and the photoreceptor outer segments that are shed into the subretinal space in BVMD 
lesions.123,129,138-140 In the cicatricial and atrophic stage, areas of decreased FAF become 
more prominent, due to RPE atrophy and/or blockage of FAF by scar tissue, as well as a 
loss of autofluorescent material (Fig. 3.2I).99,123,125 Such a decreased, irregular FAF signal in 
BVMD lesions is generally associated with a lower visual acuity.99,141 FAF may be a helpful 
tool in the follow-up of BVMD lesions, especially as it is able to visualize abnormalities 
and changes within a lesion that are not evident on ophthalmoscopy.99,125,126 
Optical coherence tomography (OCT) enables the high-resolution visualization of 
BVMD lesions in the antero-posterior dimension.83,117,123,126,142-145 In the vitelliform, 
pseudohypopyon, and vitelliruptive stages, OCT shows a central macular detachment 
of the neurosensory retina.123,126,142-145 The space between the neuroretina and RPE may 
contain hyperreflective material, corresponding to the vitelliform material seen on 
ophthalmoscopy, and/or hyporeflective material, corresponding with transparent fluid 
on ophthalmoscopy (Fig. 3.2J).123,126,142-145 Scars and choroidal neovascularization in a 
BVMD lesion also appear hyperreflective on OCT (Fig. 3.2K).
 Follow-up studies indicate that patients in the carrier stage or mild RPE changes often 
remain asymptomatic for a prolonged period of time, with a stable ophthalmoscopic 
aspect (Fig. 3.2A).96,97 In contrast, lesions in the vitelliform, pseudohypopyon, and 
vitelliruptive stages may evolve into one another within a few years.96,97,99 Up to 88% of 
BVMD patients with a follow-up period of at least 5 years may retain a visual acuity of 
more than 20/40 in the better eye.84,96,97 In patients with early-onset BVMD, visual acuity 
often deteriorates after the fourth decade, especially in patients with long-standing 
cicatricial and/or atrophic lesions.96,97 Beyond the age of 50, many BVMD patients show a 
deterioration of the visual acuity to less than 20/40 in the better eye.96-98
 Considerable variability of lesions on ophthalmoscopy can make a clinical diagnosis 
of BVMD challenging. This is not only the case in for instance mild cases with relatively 
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discrete RPE alterations, but also in advanced cases with scarred and/or atrophic lesions. 
The latter lesions may be mistaken for AMD, especially in elderly patients from families 
with BEST1 mutations that show decreased penetrance and variable expression.2,4,82,105 
Lesions may display a spoke-like configuration of pigmentary abnormalities, which 
can mimic pattern dystrophy.114,123,125,126,146 Some patients display multifocal vitelliform 
lesions.83 In these cases, the eccentric lesions are often located superonasal to the 
optic disc and/or adjacent to the temporal retinal vascular arcades.83 These smaller 
extramacular lesions often resemble the central lesion both on ophthalmoscopy, as 
well as on FAF and OCT.83 Findings within a single family with BVMD patients carrying 
the same BEST1 mutation may be highly variable, ranging from asymptomatic carriers 
without EOG abnormalities, to typical BVMD, as well as multifocal BVMD.72,83,98,126,147-149
 Vitelliform lesions, comparable to those seen in BVMD, may also be encountered in 
several other clinical entities. Vitelliform paraneoplastic retinopathy, for instance, is a 
clinical picture that is highly comparable to BVMD, with typical vitelliform lesions,150-153 
and sometimes an abnormal EOG.150 This rare condition, which has been described 
in patients with metastatic choroidal or cutaneous malignant melanoma, may be 
associated with auto-antibodies against bestrophin-1.150 Other diseases with vitelliform 
lesions include AFVD (with or without BEST1 mutations),86,154,155 “pseudovitelliform” 
RPE detachments caused by confluence of macular drusen in basal laminar drusen and 
AMD,86,154,156 as well as acute exudative polymorphous vitelliform maculopathy.157,158 In the 
first two diseases, the EOG is generally normal, whereas the latter shows an abnormal 
EOG as well as multifocal vitelliform lesions.
3.2. Adult-onset foveomacular vitelliform dystrophy
AFVD, first described by Gass in 1974,85 is considered one of the pattern dystrophies 
according to the classification of Gass.102 The term AFVD represents a clinically and 
genetically heterogeneous group of disorders that may indeed have features of pattern 
dystrophy,3,92,93,159 but AFVD may also closely resemble BVMD or AMD, and may thus 
misdiagnosed.92,154,160-162 There is large variation in the terminology of this disorder, 
with names ranging from “adult vitelliform macular dystrophy” to “pseudovitelliform 
macular degeneration”.163,164 Most cases of AFVD are isolated,92,93 although an autosomal 
dominant inheritance and familial cases have also been described.85,88,89,165
 As in BVMD, the age at onset in AFVD is variable, with a mean beyond the fifth 
decade, which is later than in BVMD.88,92,102,155 Females appear to be somewhat more 
frequently affected.92,166 Patients often present with a relatively mild loss of visual acuity 
and metamorphopsia, sometimes accompanied by mild photophobia and/or (para-)
central visual field defects.92 Visual acuity often remains fairly good and constant for 
a prolonged period of time, but may also show a progressive and severe decline after 
several years, due to chorioretinal atrophy or CNV.92,166-168 The typical ophthalmoscopic 
aspect of AFVD is a solitary, yellow-white, round to oval, slightly elevated lesion, often 
with a central pigmented spot, in the fovea of both eyes.92,102 These lesions are usually one-
third to one disc diameter in size. However, lesions may be considerably larger and may 
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then be indistinguishable from those seen in BVMD, and lesions may also be unilateral 
or multifocal.83,92,102 CNV is an infrequent complication in AFVD, although it has been 
reported in up to 15% of cases.92,161,166,169,170
 The EOG in AFVD is normal or slightly subnormal in virtually all patients, which 
is especially important in differentiating AFVD from BVMD.88,92,167,171 The full-field ERG 
in AFVD is also generally normal, although the 30 Hz flicker response may be mildly 
reduced.92 Multifocal ERG may show an abnormal P1 amplitude and implicit time in all 
rings, but mostly in the central two rings.92,172 Color vision abnormalities, as well as a 
central scotoma on perimetry, are noted in up to half of the patients.92
 Fluorescein angiography in AFVD typically shows a central non-fluorescent area, 
surrounded by a small, irregular hyperfluorescent ring, but lesions may also display 
central, patchy hyperfluorescence with discrete late dye leakage like in BVMD.92,102,167 
AFVD lesions show variable patterns of increased FAF in most patients, especially in 
yellowish vitelliform lesions, corresponding to lipofuscin accumulation.92,173-175 OCT, 
and more specifically high-resolution OCT, often yields additional information on 
the structural abnormalities associated with AFVD.172,176-179 Smaller lesions appear as 
hyperreflective structures between the neuroretina and RPE. Larger vitelliform lesions in 
AFVD - like BVMD - show a central macular detachment of the neuroretina, with a variable 
amount of hyperreflective material (corresponding to the vitelliform material) and/or 
hyporeflective material (corresponding to translucent fluid) within the space between 
neuroretina and RPE. On high-resolution OCT, reduced thickness of the neuroretina in 
the foveola correlates with reduced visual acuity.179 
 The aforementioned characteristics of the clinical spectrum of AFVD are derived 
from studies on relatively large groups of AFVD patients, in which BEST1 mutations were 
either not found or accounted only for a small proportion of patients. Due to this low 
number of clinically specified BEST1-related AFVD cases, it is difficult to determine to 
what extent the aforementioned clinical findings may be applied to the BEST1-related 
AFVD group. As mentioned previously, AFVD may present with BVMD-like vitelliform 
lesions (i.e., yellowish “egg-yolk” lesions larger than one disc diameter). In cases that 
combine such an appearance with the presence of a BEST1 mutation, the only feature 
that distinguishes these BEST1-related AFVD cases from BVMD is an EOG that is within 
normal limits. Even then, the EOG may gradually become abnormal, illustrating the 
thin line between AFVD and BVMD in these cases.99,116 Conversely, the EOG in BVMD can 
be normal.83,99,116 Again, this indicates that the value of the EOG in establishing a specific 
diagnosis has been overestimated. In BEST1-related AFVD patients, the phenotype might 
actually be regarded as an exceptionally mild form of BVMD caused by BEST1 mutations 
with variable expressivity. Examples of such BEST1 mutations include p.Ala243Val and 
p.Thr6Pro.3
 AFVD not only borders with BVMD, but may also be confused with (“pseudo”-)
vitelliform RPE detachments as a result of confluent drusen, which may be regularly 
noted in the phenotype of basal laminar drusen.156,180,181 The differential diagnosis can be 
made on ophthalmoscopy, which shows large and small drusen surrounding the lesion, 
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as well as on fluorescein angiography, typically showing a “stars-in-the-sky” pattern of 
surrounding drusen.156,180
3.3.  Autosomal dominant vitreoretinochoroidopathy (ADVIRC) and the 
MRCS syndrome
Autosomal dominant vitreoretinochoroidopathy (ADVIRC) was first described in 1982 by 
Kaufman, and is characterized by a peripheral circumferential retinal band of pigmentary 
alterations (Fig. 3.3A), midperipheral and peripapillary chorioretinal atrophy, punctate 
white pre- or intraretinal deposits, and fibrillary vitreous condensations.8,182-184 Most 
ADVIRC patients retain a fairly good visual acuity throughout life,182,184,185 although visual 
acuity may decrease considerably due to macular edema, chorioretinal atrophy, or - 
rarely - retinal detachment and vitreous hemorrhage.183-185 A discrete rotatory nystagmus 
can be present.184 The majority of patients with ADVIRC that was genetically confirmed 
to be caused by BEST1 mutations, developed congenital or early-onset cataract, that may 
be located posterior subcapsular.8,182,184 Microcornea is common in ADVIRC (Fig. 3.3B), 
and many patients are hypermetropic or have nanophthalmos, as well as a shallow 
anterior chamber, although myopia may also be seen.5,8,182,184 As a result, ADVIRC patients 
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Figure 3.3.*      
Autosomal dominant vitreoretino-
choroidopathy (ADVIRC), in  
a 25-year-old patient carrying  
a heterozygous p.Val86Met 
(c.256G>A) mutation in the BEST1 
gene. A. On a composition image 
of colour fundus photographs, a 
circumferential hyperpigmented 
band is seen in the (mid-)
periphery. The optic disc has  
a slightly pale aspect, and 
 peripapillary chorioretinal 
 atrophy is noted. B. Photograph 
of the same patient, showing 
microcornea with a corneal 
 diameter of less than 10 mm,  
as a sign of ocular developmental 
abnormalities in ADVIRC.
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have a relatively high incidence of subacute and acute angle-closure glaucoma.8,182,184 
Some patients display retinal arteriolar narrowing and pale optic discs. Retinal edema 
due to vascular incompetence may also be observed, as well as preretinal and/or 
prepapillary neovascularization and fibrosis.183,184 Such neovascularization may regress 
after panretinal photocoagulation, even without demonstrable retinal ischemia on the 
fluorescein angiogram.184 
The EOG is severely abnormal in most BEST1-related ADVIRC patients, but may be normal 
in exceptional cases.8,184,186 The full-field ERG may show normal to severely reduced rod 
and cone responses.8,182-184 Goldmann perimetry is often initially normal, but tends to 
constrict mildly with age.184 
It has been suggested that BEST1 mutations may also be the cause of autosomal dominant 
nanophthalmos with high hyperopia and angle-closure glaucoma, a condition that was 
mapped to the NNO1 locus on chromosome 11 (like BEST1) and appears highly similar to 
ADVIRC.8,187
 The BEST1-associated MRCS syndrome caused by a BEST1 mutation, which was 
described in only one family, is characterized by microcornea, rod-cone dystrophy, 
early-onset pulverulent cataract, and posterior staphyloma.7 In the first decades, visual 
acuity may be fairly good, but beyond the age of 30 years visual acuity often becomes 
poor (less than 20/100 to absent light perception).7 Patients typically start experiencing 
night blindness in their teens. A decrease of visual acuity, presumably due to progressive 
cataract and possibly photoreceptor dysfunction, may be noted before the age of 30 years, 
often leading to cataract surgery in the second or third decade.7 On ophthalmoscopy, 
peripheral RPE atrophy and retinal pigmentary abnormalities are seen anterior to the 
posterior staphyloma in younger patients, whereas the atrophy and pigmentary changes 
may extend to the posterior pole and staphyloma with advancing age.7 
The EOG is abnormal in all patients with the MRCS syndrome.7,8 The full-field ERG 
shows subnormal photopic and scotopic responses in the first two decades, with the 
scotopic responses being more abnormal than the photopic responses, corresponding 
to rod-cone dystrophy.7,8 With time, the full-field ERG becomes extinguished, reflecting 
severe rod and cone photoreceptor dysfunction throughout the retina.7,8 Patients may 
be moderately myopic due to the posterior staphyloma and cataractous lens. Most 
patients with MRCS syndrome have posterior staphyloma in association with otherwise 
normal axial lengths.7,8 However, two patients in a family with MRCS syndrome caused 
by the p.Val239Met BEST1 mutation had nanophthalmos instead of posterior staphyloma, 
thus largely overlapping with the ADVIRC phenotype.7,8 Therefore, although the MRCS 
syndrome is generally more severe than ADVIRC, these conditions overlap and likely 
form a continuum, as both of these BEST1-related conditions show retinal pigmentary 
abnormalities, retinal dystrophy, microcornea, and early-onset cataract.7,8,184
3.4. Autosomal recessive bestrophinopathy
The phenotype of ARB has been recently described by Burgess and colleagues.9 This 
condition usually starts with central visual loss, with an age at onset ranging from 4 to 40 
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years, and a mean age at onset of approximately 23 years.9 Visual acuity often deteriorates 
to less than 20/60 in both eyes.9 Patients are generally hyperopic and show shallow anterior 
chambers, with a correspondingly increased risk of (sub-)acute angle-closure glaucoma.9 
On ophthalmoscopy, irregular RPE alterations with whitish subretinal deposits are seen 
throughout the retina, with a preference for the macula and midperipheral retina (Fig. 
3.4A and B). Retinal edema and a neurosensory retinal detachment with subretinal fluid 
may be observed in the macula, which may be confirmed on OCT (Fig. 3.4C), but patients 
do not appear to develop vitelliform lesions.9 Macular lesions may evolve towards scars, 
causing a further decrease in visual acuity. 
Like in BVMD, ADVIRC and the MRCS syndrome, the EOG shows a severely reduced to 
absent light rise.9 The pattern ERG in ARB patients is markedly abnormal, indicating 
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3Figure 3.4.*      Autosomal recessive bestro-
phinopathy (ARB) in a 45-year old 
patient who carried the compound 
heterozygous mutations  
p.Asp312Asn (c.934G>A) and  
p.Met325Thr (c.974T>C).  
A. Composition image of colour 
fundus photographs, showing 
widespread irregular retinal 
 pigment epithelial alterations 
with whitish subretinal deposits 
throughout the retina. In the 
macula, deposition of yellow-white 
material is seen. B. Fundus 
autof luorescence (FAF) image, 
 showing diffuse, discrete small 
areas of increased and decreased 
FAF. C. On a horizontal optical 
coherence tomography (OCT) 
 section of the macula, hypo-
ref lective subretinal f luid between 
the retinal pigment epithelium 
and the neurosensory retina is 
seen, as well as small hypo-
ref lective cysts of intraretinal f luid.
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severe macular dysfunction.9 Central multifocal ERG responses are also reduced.94 
Contrary to most BVMD cases, the full-field ERG also shows reduced and delayed rod 
and cone responses,9,94 which indicates panretinal photoreceptor dysfunction. On 
fluorescein angiography, widespread patchy hyperfluorescence is seen, due to RPE 
atrophy and retinal edema.9 The widespread RPE abnormalities and subretinal deposits 
correspond to irregular areas of increased FAF, reflecting lipofuscin accumulation in the 
RPE, as well as areas of decreased FAF, corresponding to a loss of RPE (Fig. 3.4C).9 High-
resolution OCT imaging in an 11-year-old asymptomatic patient with ARB showed RPE 
abnormalities, photoreceptor detachment, an elongated and thickened photoreceptor 
outer segment layer, and a preserved inner retinal layer.94 Family members who 
carried one BEST1 mutation heterozygously were entirely normal, both clinically and 
electrophysiologically.9 
4. From gene mutation to disease
4.1. Impact of BEST1 mutations on protein structure and function
There is a large body of evidence indicating that bestrophin-1 is a multifunctional protein 
in the RPE, functioning as a Ca2+-activated Cl- channel,12,20,23-25,27-30 as well as a modulator 
of intracellular CaV channels.39-42 A summary of the functional consequences of BEST1 
mutations in BVMD, AFVD, ADVIRC, the MRCS syndrome, and ARB, is given in Table 3.1.
 In general, mutant proteins in BVMD are trafficked normally into the RPE plasma 
membrane.20 Several in vitro studies have focused on the effect of BEST1 mutations 
on bestrophin-1 Cl- channel function in BVMD. Most mutations are associated with 
a greatly reduced or absent Cl- current, which is often due to a dominant negative 
mechanism.9,20,23,31,38,42 A milder Cl- current reduction to 10-40% of the wild-type current 
is seen in mutations that lead to haploinsufficiency.20,30,42 Both dominant negative and 
haploinsufficiency mechanisms may also be found in AFVD.20,30,31,42 In HEK-293 cells, 
bestrophin-1 mutations in the C-terminal region, which is important for Ca2+ binding 
(regions 293-308 and 312-323), disrupt normal Ca2+ binding to bestrophin-1 and abolish 
or greatly reduce the normal Cl- current.31
Two BEST1 variants, p.Thr216Ile and p.Leu567Phe, identified in AMD patients, did not 
affect the Cl- channel function of bestrophin-1,20 questioning their relevance in disease 
pathogenesis. The p.Glu119Gln variant, detected in bull’s eye maculopathy and in AMD, 
produced currents similar to those of wild-type bestrophin-1, but had altered relative 
permeability to large anions.20
As mentioned previously, bestrophin-1 also functions as an inhibitor of Ca2+ currents 
produced by CaV channels, through the interaction with the subunit of these channels.39-42 
Mutations that all disrupt bestrophin-1 Cl- channel function may have different effects 
on CaV channels.42 While some mutations have an inhibitory effect on CaV channels that 
is comparable to wild-type bestrophin-1, others have a decreased inhibitory effect on 
these CaV channels (Table 3.1). 
Chapter 3
127
Spectrum of BEST1-associated phenotypes
3
M
ut
at
io
n
 
A
ss
oc
ia
te
d 
M
ut
at
io
n
 e
ff
ec
t 
M
ec
h
an
is
m
 
Te
st
 s
et
ti
ng
 
R
ef
er
en
ce
(s
)
 
di
se
as
e
p.
Th
r6
Pr
o 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
p.
A
la
10
Va
l 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
p.
Il
e7
3A
sn
 
BV
M
D
 
de
fe
ct
iv
e 
m
em
br
an
e 
in
te
gr
at
io
n 
U
 
ca
n
in
e 
pa
nc
re
at
ic
 m
ic
ro
so
m
es
 
19
p.
Ty
r8
5H
is
 
BV
M
D
 
-↓
↓-
ab
se
nt
 C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
-H
EK
-2
93
 c
el
ls
 
19
,2
3
 
 
-d
ef
ec
ti
ve
 m
em
br
an
e 
in
te
gr
at
io
n 
 
-c
an
in
e 
pa
nc
re
at
ic
 m
ic
ro
so
m
es
 
p.
Va
l8
6M
et
 
A
D
V
IR
C
 
in
-fr
am
e 
de
le
ti
on
 
ex
on
 s
ki
pp
in
g 
sp
li
ce
 a
ss
ay
s 
8
p.
A
rg
92
C
ys
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
23
p.
A
rg
92
Se
r 
BV
M
D
 
-↓
↓-
ab
se
nt
 C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
,4
2
 
 
-n
or
m
al
 in
h
ib
it
or
y 
ef
fe
ct
 
 
 
on
 C
a V
 c
h
an
ne
ls
 
p.
Tr
p9
3C
ys
 
BV
M
D
 
-↓
↓ 
C
l- 
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
-H
EK
-2
93
 c
el
ls
 
9,
23
,4
0
 
 
-n
o 
ef
fe
ct
 o
n 
C
a V
 a
ct
iv
at
io
n 
 
-m
ut
an
t o
ve
re
xp
re
ss
io
n 
in
 
 
-↓
↓ 
li
gh
t p
ea
k 
am
pl
it
ud
e 
on
 
 
A
AV
-t
ra
n
sf
ec
te
d 
ra
ts
 
 
 
R
PE
-d
er
iv
ed
 E
RG
 
p.
A
sn
99
Ly
s 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
p.
A
sp
10
4G
lu
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
(p
.G
lu
11
9G
ln
) 
A
M
D
, B
u
ll
’s
 e
ye
  
-n
or
m
al
 C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
20
 
m
ac
u
lo
pa
th
y 
-a
lt
er
ed
 a
n
io
n 
pe
rm
ea
bi
li
ty
 
p.
A
la
14
1H
is
  
A
R
B 
-↓
↓ 
C
l-  
cu
rr
en
t
w
it
ho
ut
 W
T 
 
 
-n
o 
in
h
ib
it
or
y 
ef
fe
ct
 o
n 
nu
ll
 p
he
no
ty
pe
 
H
EK
-2
93
 c
el
ls
 
9
be
st
ro
ph
in
-1
 
 
C
a V
 a
ct
iv
at
io
n
Ta
bl
e 
3.
1.
 
Su
m
m
ar
y 
of
 t
h
e 
BE
ST
1 
m
u
ta
ti
on
s 
th
at
 w
er
e 
te
st
ed
 f
or
 t
h
ei
r 
im
p
ac
t 
on
 b
es
tr
op
h
in
-1
 f
u
n
ct
io
n
.
128
Chapter 3
p.
A
la
14
6L
ys
 
A
FV
D
 
-2
0-
40
%
 o
f W
T 
C
l-  
cu
rr
en
t 
h
ap
lo
in
su
ff
ic
ie
nc
y 
H
EK
-2
93
 c
el
ls
 
20
,4
2
 
 
-a
lt
er
ed
 a
n
io
n 
pe
rm
ea
bi
li
ty
 
 
-↓
 in
h
ib
it
or
y 
ef
fe
ct
 o
n 
C
aV
 c
h
an
ne
ls
 
 
p.
Pr
o1
52
A
la
  
A
R
B 
-↓
↓ 
C
l-  
cu
rr
en
t 
nu
ll
 p
he
no
ty
pe
 
H
EK
-2
93
 c
el
ls
 
9
w
it
ho
ut
 W
T 
 
 
-n
o 
in
h
ib
it
or
y 
ef
fe
ct
 o
n 
C
a V
be
st
ro
ph
in
-1
 
 
ac
ti
va
ti
on
 
(p
.T
h
r2
16
Il
e)
 
A
M
D
 
-n
or
m
al
 C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
20
 
 
-n
or
m
al
 a
n
io
n 
pe
rm
ea
bi
li
ty
 
p.
A
rg
21
8S
er
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
23
p.
A
rg
21
8C
ys
 
BV
M
D
 
-↓
↓ 
C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
-H
EK
-2
93
 c
el
ls
 
9,
40
 
 
-n
o 
ef
fe
ct
 o
n 
C
a V
 a
ct
iv
at
io
n 
 
-m
ut
an
t o
ve
re
xp
re
ss
io
n 
in
 
 
-↓
 li
gh
t p
ea
k 
am
pl
it
ud
e 
on
  
 
A
AV
-t
ra
n
sf
ec
te
d 
ra
ts
 
 
R
PE
-d
er
iv
ed
 E
RG
 
p.
G
ly
22
2G
lu
 
BV
M
D
 
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
20
,4
2
 
 
-↓
 in
h
ib
it
or
y 
ef
fe
ct
 o
n 
C
a V
 c
h
an
ne
ls
 
p.
Ty
r2
27
A
sn
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
p.
A
la
24
3T
h
r 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
p.
A
la
24
3V
al
 
BV
M
D
 
~1
0%
 o
f W
T 
C
l-  
cu
rr
en
t a
lt
er
ed
 
h
ap
lo
in
su
ff
ic
ie
nc
y 
H
EK
-2
93
 c
el
ls
 
30
 
A
FV
D
 
an
io
n 
pe
rm
ea
bi
li
ty
 
p.
Va
l2
35
A
la
 
A
D
V
IR
C
 
in
-fr
am
e 
du
pl
ic
at
io
n 
ex
on
 s
ki
pp
in
g 
sp
li
ce
 a
ss
ay
s 
5,
8
p.
Ty
r2
36
C
ys
 
A
D
V
IR
C
 
in
-fr
am
e 
de
le
ti
on
 
ex
on
 s
ki
pp
in
g 
sp
li
ce
 a
ss
ay
s 
5,
8
p.
Va
l2
39
M
et
 
M
RC
S 
sy
nd
ro
m
e 
in
-fr
am
e 
de
le
ti
on
 
ex
on
 s
ki
pp
in
g 
sp
li
ce
 a
ss
ay
s 
8
M
ut
at
io
n
 
A
ss
oc
ia
te
d 
M
ut
at
io
n
 e
ff
ec
t 
M
ec
h
an
is
m
 
Te
st
 s
et
ti
ng
 
R
ef
er
en
ce
(s
)
 
di
se
as
e
Ta
bl
e 
3.
1.
 c
on
tin
ue
d
129
Spectrum of BEST1-associated phenotypes
3
p.
Ph
e2
81
de
l 
BV
M
D
 
de
fe
ct
iv
e 
m
em
br
an
e 
in
te
gr
at
io
n 
U
 
ca
n
in
e 
pa
nc
re
at
ic
 m
ic
ro
so
m
es
 
19
p.
G
lu
29
3H
is
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
38
p.
G
lu
29
3L
ys
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
23
p.
Il
e2
95
de
l 
BV
M
D
 
ab
se
nt
 C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
-H
EK
-2
93
 c
el
ls
 
20
 
 
 
 
-R
PE
-J 
ce
ll
s 
p.
G
ly
29
9A
rg
 
BV
M
D
 
-a
bs
en
t C
l-  
cu
rr
en
t 
U
 
-H
EK
-2
93
 c
el
ls
 
42
 
 
-↓
 in
h
ib
it
or
y 
ef
fe
ct
 o
n 
C
a V
 c
h
an
ne
ls
 
 
-R
PE
-J 
ce
ll
s 
p.
G
ly
29
9G
lu
 
BV
M
D
 
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
23
,4
2
 
 
-n
or
m
al
 in
h
ib
it
or
y 
ef
fe
ct
 o
n 
 
 
C
a V
 c
h
an
ne
ls
 
p.
G
lu
30
0A
sp
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
23
p.
A
sp
30
1G
lu
 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
23
p.
Th
r3
07
Il
e 
BV
M
D
 
↓↓
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
23
p.
A
sp
31
2A
sn
 
A
FV
D
 
-a
bs
en
t C
l-  
cu
rr
en
t 
do
m
. n
eg
at
iv
e 
H
EK
-2
93
 c
el
ls
 
20
,3
1,
42
 
 
-n
or
m
al
 in
h
ib
it
or
y 
ef
fe
ct
 o
n 
 
 
C
a V
 c
h
an
ne
ls
 
 
-↓
 s
en
si
ti
vi
ty
 o
f b
es
tr
op
h
in
-1
 to
 C
a2
+  
(p
.L
eu
56
7P
he
) 
A
M
D
 
-n
or
m
al
 C
l-  
cu
rr
en
t 
U
 
H
EK
-2
93
 c
el
ls
 
20
 
 
-n
or
m
al
 a
n
io
n 
pe
rm
ea
bi
li
ty
 
A
bb
re
vi
at
io
n
s:
 ↓
↓, 
m
ar
ke
dl
y 
de
cr
ea
se
d;
 ↓,
 d
ec
re
as
ed
; C
aV
 c
h
an
ne
l, 
vo
lt
ag
e-
de
pe
nd
en
t c
al
ci
u
m
 c
h
an
ne
l; 
do
m
. n
eg
at
iv
e,
 d
om
in
an
t n
eg
at
iv
e;
 E
RG
,  
el
ec
tr
or
et
in
og
ra
ph
y;
 R
PE
, r
et
in
al
 p
ig
m
en
t e
pi
th
el
iu
m
; U
, u
n
kn
ow
n
; W
T,
 w
il
d-
ty
pe
.
130
 The experiments mentioned above illustrate the various effects caused by different 
BEST1 mutations. Such functional differentiation in the impact of mutations could be 
intuitively expected, based on the observation of variable clinical severity and different 
influences on the EOG. However, the reason why some mutations cause BVMD whereas 
others cause AFVD is far from elucidated. The establishment a genotype-phenotype 
correlation model is challenging, as the phenotypic description is incomplete in several 
studies. Moreover, the explanation for the marked phenotypic variability that may be 
observed in association with a single mutation in BVMD families also remains largely 
obscure, as will be discussed in section 4.2.
It should be noted that it is unclear to what extent in vitro experiments, as well as 
rodent studies, may be extrapolated to the function of human RPE cells in vivo. Mouse 
bestrophin-1, for instance, is only 63% identical to human bestrophin-1,45 lacking for 
instance the C-terminal Pro330XXXPro334 domain that is important for the modulation 
of CaV channel regulation in humans.42 In addition, mice do not have a macula, and Best1 
knockout mice do not show obvious retinal pathology or visual abnormalities.39 Rats 
overexpressing BEST1 mutations that cause BVMD in humans, do not show lipofuscin 
accumulation, nor do they develop vitelliform lesions.188
 In ADVIRC and the MRCS syndrome, the BEST1 mutations p.Val86Met, p.Val235Ala, 
p.Tyr236Cys, and p.Val239Met disrupt normal splicing, resulting in abnormal 
bestrophin-1 isoforms.5,8 Alternative splicing of pre-mRNA leads to the production 
of different protein isoforms and is orchestrated by the spliceosome. Normally, 
the spliceosome, which consists of small nuclear RNA proteins (snRNPs) and other 
associated proteins, recognizes exon-intron boundaries in pre-mRNA.189 This spliceosome 
subsequently induces removal the introns and proper ligation of the exons, creating 
mRNA that encodes the wild-type protein and potentially other isoforms.189 Exonic 
regions may contain elements that either enhance or decrease splicing, called exonic 
splicing enhancer (ESE) and silencer (ESS) sites.190-193 If such a site has overlapping ESE and 
ESS functions, it is called a composite exonic regulatory element of splicing (CERES).194 
Although alternative splicing has important physiological functions in creating the 
complex human proteome,195 abnormal alternative splicing due to mutations in ESE/ESS 
regions can cause diseases such as ADVIRC and the MRCS syndrome. Experiments on the 
effect of the BEST1 p.Val235Ala (c.704T>C) and p.Tyr236Cys (c.707A>G) mutations indicate 
that they are located in an area (from c.704 to c.709) in BEST1 that has a CERES function.5 
These mutations may affect proper splicing through the altered binding of modulating 
proteins (so-called serine-arginine-rich RNA binding proteins, shortly named SR proteins) 
of the spliceosome to this CERES, therefore altering exonic splicing.5 The result is an 
mRNA that either lacks exon 4, 6, or 7, or contains a duplication of exon 6.5 This most 
likely results in an in-frame alteration of bestrophin-1. In ADVIRC patients, three protein 
isoforms may thus be encountered: the wild-type protein, the protein containing a 
missense substitution, and the protein with an in-frame deletion or duplication.
The impact on bestrophin-1 structure and function of these BEST1 mutations in ADVIRC 
and the MRCS syndrome is unclear. Several mechanisms may be possible. The shortened 
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or elongated protein may not be properly trafficked to the basolateral membrane of the 
RPE and remain intracellularly, where it may be degraded. On the other hand, should the 
protein be incorporated in the RPE plasma membrane, this affected protein may hinder 
wild-type bestrophin-1 function(s), for instance through either absent or abnormal 
oligomerization or abnormal protein binding. In addition to the disease-causing 
mechanism of haploinsufficiency, the abnormal bestrophin-1 protein could also exert a 
dominant negative effect on the wild-type protein or -if it is retained intracellularly and 
is not degraded- on intracellular processes. 
 In ARB, the RNA product of the homozygous p.Arg200X BEST1 nonsense mutation is 
probably subject to nonsense-mediated decay and these patients consequently may not 
express bestrophin-1 in the RPE plasma membrane. In vitro studies on the p.Arg141His 
and p.Pro152Ala mutations, that cause ARB in the compound heterozygous state, show 
that the mutant bestrophin-1 proteins are associated with a markedly reduced Cl- current 
when expressed without wild-type bestrophin-1.9 However, in contrast to many BVMD 
mutations,12,23 when these ARB mutants are expressed with wild-type bestrophin-1, Cl- 
conductance was not significantly different from that in the wild-type bestrophin-1 
situation.9 Bearing these findings in mind, it is intriguing that the p.Arg141His mutation 
has also been described in a heterozygous state in BVMD, although the clinical description 
of these patients was incomplete and did not mention EOG findings.3,74 In summary, 
contrary to BVMD, AFVD, ADVIRC, and the MRCS syndrome, the presence of homozygous 
or compound heterozygous BEST1 mutations is required to cause ARB. Thus, ARB can be 
considered the BEST1 null phenotype.
4.2. Genotype-phenotype correlations
Nearly all BEST1 mutations identified in BVMD and AFVD are missense mutations. Only 
one nonsense mutation and two frameshift mutations have been identified, mostly 
in poorly documented and/or sporadic cases. A remarkable clustering of missense 
mutations associated with the BVMD phenotype is seen in the amino acid regions 6-30, 
80-104, 221-243, and 293-312 of bestrophin-1 (Fig. 3.1). These four regions are all situated 
near or in the RPE plasma membrane, and may therefore be of particular importance for 
bestrophin-1 Cl- channel function and/or CaV channel modulation. 
 There is a clear genotype-phenotype correlation for BEST1 mutations that cause ADVIRC 
and MRCS syndrome. These mutations all affect splicing, leading to in-frame deletions or 
duplications. Although some of the BEST1 mutations found in BVMD lie very close to the 
missense mutations in ADVIRC and MRCS syndrome, they do not alter splicing.5 Finally, 
the null phenotype of ARB requires homozygous or compound heterozygous nonsense 
or missense BEST1 mutations.9
 In BVMD, a markedly variable penetrance and expressivity is observed, even in 
patients within one family.83,149,196 As mentioned previously, some patients never manifest 
fundus changes, and a number of patients with genetically confirmed BVMD even have 
a normal EOG.99,116 Late-onset symptoms are not uncommon and these individuals with 
BEST1 mutations may therefore be misdiagnosed as having AMD.2,67,84 Relatively mild 
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phenotypes may also be encountered in ADVIRC.5 
Little is known about the exact mechanisms of such reduced penetrance and variable 
expression, so that (a combination of) several explanations remain possible. 
In BVMD, some BEST1 mutations may be more likely to show reduced penetrance than 
others. In one study, the BVMD mutations p.Ile295del and p.Asn99Lys showed reduced 
penetrance, since they were found in asymptomatic carriers between 11 and 42 years 
of age.99 The impact of a BEST1 mutation may depend on the presence or absence of a 
dominant negative effect of the mutant protein on wild-type bestrophin-1. As bestrophin-1 
has been postulated to form oligomers,12,22,23 the pathologic effect of a bestrophin-1 mutant 
may also depend on the ratio of mutant protein subunits compared to wild-type protein 
subunits, at least in mutant proteins that do not have a dominant negative effect on wild-
type bestrophin-1. Even in such dominant negative mutations, the detrimental influence 
of the protein may be weakened, for instance through heteromeric oligomerization with 
wild-type bestrophin-2,20 which is also present in the RPE.13 Bestrophin-1 mutants such 
as p.Asp312Asn are unable to exert a dominant negative effect on wild-type bestrophin-2, 
so that upregulation of bestrophin-2 could be imagined to (partly) compensate for the 
deleterious effects of the bestrophin-1 mutant and its effect on the EOG.20 The severity 
of the phenotype in ADVIRC/MRCS syndrome may depend on the different functional 
consequences of the different isoforms, as well as the relative proportion of the two 
mutated isoforms.8
Another plausible explanation for the decreased penetrance and variable expressivity 
in BEST1-associated phenotypes is the dependency on other genetic and environmental 
modifiers.68,98 Such factors could influence for example the level of expression of the 
wild-type allele. Interestingly, recent studies suggests that the transcription factors 
OTX2, MITF, and possibly CRX, may play a role as modifiers of BEST1 expression.15-17 These 
transcription factors are able to bind to specific sites within the -154 to -104 base pair 
region of the BEST1 gene promoter.15-17 In mice, this region contains positive regulatory 
elements that may cause a broad variation in BEST1 promotor activity.15,17 
OTX and MITF play a central role in the differentiation of the RPE, photoreceptors, and 
bipolar cells, as well as lens and anterior segment formation.197-199 The CRX protein, 
which is found in the photoreceptors and RPE,17,200 is a target of OTX2 in photoreceptors 
and possibly also the RPE.201 Human OTX2, MITF, and CRX mutations are associated with a 
broad range of ocular abnormalities.202-204 Heterozygous Otx2(+/-) mice also display a wide 
spectrum of ocular abnormalities that partly overlap with those seen in ADVIRC, the MRCS 
syndrome, and ARB, including RPE and photoreceptor abnormalities, microphthalmia, 
and abnormalities of the lens, cornea, and iris.205 Homozygous Otx2 knockout mice die 
early in embryogenesis as a complete absence of Otx2 precludes normal formation of the 
brain.205,206 Homozygously mutated Mitf mice show microphthalmia, RPE abnormalities 
and other pigmentary abnormalities related to a loss of melanocytes.207,208
Therefore, as OTX2 and MITF are key players in the development and differentiation 
of various ocular tissues,197-199 variations in these genes may be of influence in the 
pathogenesis and the severity of the panretinal photoreceptor dysfunction and other 
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ocular developmental abnormalities in BEST1-related ADVIRC, the MRCS syndrome, 
and ARB. However, although there is a possible role for OTX2, MITF, and CRX as genetic 
modifiers of BEST1, it is currently unknown if these transcription factors actually provide 
an explanation for the broad clinical variability that is observed between individuals 
with identical BEST1 mutations.
4.3. Pathophysiology of ocular phenotypes caused by BEST1 mutations
It has been postulated that the accumulation of fluid and vitelliform material in BVMD 
is the result of the disruption of epithelial ionic transport and fluid homeostasis by the 
RPE.12,129 Such a disruption of epithelial transport could occur through the dysfunction of 
Cl- transport in bestrophin-1 channels and/or through the disruption of Ca2+ signaling.30 
Normal apposition and functional interaction between the photoreceptors/neuroretina 
and the RPE requires that the RPE maintains a normal ionic microenvironment, both 
intracellularly and extracellularly. In this way, intracellular processes are optimized, 
enabling for instance the proper phagocytosis and degradation of photoreceptor outer 
segments,209,210 as well as a net transport of fluid away from the photoreceptor-RPE 
interface towards the choroid.211-214 
 The accumulation of fluid between the neuroretina and photoreceptors in BVMD and 
AFVD separates the photoreceptors from their natural “housekeeper”, the RPE (Fig. 3.2J 
and K). As a consequence, normal retinoid transport between the photoreceptors and 
the RPE is hindered, as is the ability of the RPE cells to efficiently perform photoreceptor 
outer segment phagocytosis.215 These photoreceptor outer segments are then thought 
to accumulate on the outer neuroretina and are also shed into the abnormal space 
under the detached neuroretina.129 These shed photoreceptor outer segments contain 
toxic autofluorescent retinoid-derived lipofuscin precursors.137 The toxic precursors in 
the subretinal space may show an increased susceptibility to oxidative damage, due to 
a delay in RPE phagocytosis.136,140,216-218 The photoreceptors may subsequently be harmed, 
as they are not able to get rid of their outer segments in a normal fashion, with their 
unphagocytosed outer segments full of potentially toxic waste still nearby. This, in turn, 
may induce photoreceptor cell loss, possibly even before RPE atrophy, with consequent 
central visual loss. Although less efficiently, due to a lack of apposition to the RPE, the 
damaged photoreceptor outer segments may eventually be phagocytosed by the RPE cells. 
These RPE cells then gradually become overload with toxic autofluorescent lipofuscin 
constituents.135,219 This lipofuscin overload is thought to disturb normal RPE function, 
which could eventually lead to atrophy of the RPE. 
As mentioned above, bestrophin-1 Cl- channel activity and intracellular CaV channel 
activity, modulated by bestrophin-1, appear to be mutually dependent. As the numerous 
functions of the RPE, such as phagocytosis of photoreceptor outer segments and the 
secretion of paracrine factors such as vascular endothelial growth factor,46,51,215 depend 
on changes in intracellular Ca2+ concentrations, bestrophin-1 may be of considerable 
influence on these processes. A disruption of the normal anatomical relationships, in 
concert with altered levels of angiogenic factors such as vascular endothelial growth 
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factor, could predispose to CNV formation in BEST1-associated disease.
 The abnormal light response on the EOG in BVMD patients was originally thought 
to arise from bestrophin-1 Cl- channel dysfunction.12 However, in rare instances, 
patients with a vitelliform lesion and a BEST1 mutation (such as the p.Ala243Val 
and the p.Ile295del mutations) may display a normal EOG light response.3,81,99,116 
Nevertheless, these mutations were shown to cause a considerably decreased Cl- channel 
conductance in vitro.20,30 Part of the explanation could be that the EOG may (initially) 
not be sensitive enough to detect less pronounced Cl- conductance changes in the RPE. 
Another explanation, as proposed by Marmorstein and colleagues based on experiments 
in mice,39 may be that the EOG light response is not generated by bestrophin-1. Best1(-
/-) knockout mice were shown to have normal RPE-derived ERG light responses and a 
normal Ca2+-sensitive Cl- conductance.39 Such preservation of a normal Ca2+ activated Cl- 
current could find its explanation in the recent hypothesis that other channels, such 
as those from the anoctamin (ANO or TMEM16) family, rather than the bestrophins, are 
the classical Ca2+-dependent Cl- channels.220 The EOG light peak may therefore also be 
derived from ion channels other than the bestrophin-1 Cl- channels, with bestrophin-1 
possibly influencing the EOG only indirectly. Experiments in mice and rats suggest that 
bestrophin-1 mutants can have a gain-of-function, affecting the EOG through a disturbed 
regulation of CaV channels rather than through an effect on Cl- channel function.39-41 
Again, it is unclear to what extent studies of bestrophin-1 in in vitro and animal models 
relate to the human situation. 
 Histopathological studies in BVMD patients with confirmed BEST1 mutations parallel 
the clinical observations. A histopathological study in a 86-year-old patient with advanced 
BVMD,21 as well as in his previously described son,221 who both carried a p.Thr6Arg BEST1 
mutation, showed massive lipofuscin accumulation in the RPE, together with a more than 
4-fold increase of A2E compared to controls.21,132 Such large amounts of RPE lipofuscin 
and A2E are in agreement with the increased FAF that is seen in most BVMD lesions. 
An area of disciform scarring was observed in the macula, with adjacent degeneration 
of the RPE and outer nuclear layer. Bruch’s membrane was intact, and there was no 
evidence of CNV. The observed disciform scar in the macula may be the histopathological 
correlate of the scarring that is seen on ophthalmoscopy in many patients with advanced 
BVMD. Mullins and colleagues showed that the amount of bestrophin-1 was higher in 
the extramacular RPE than in the macular RPE.21 The authors hypothesized that BVMD, 
at least when caused by a p.Thr6Arg mutation, is the result of insufficient amounts of 
wild-type bestrophin-1 in the macula. The macular RPE would then be unable to support 
proper ion homeostasis. As a consequence, an accumulation of subretinal fluid between 
the photoreceptors and the RPE may arise, and possibly intracellular RPE changes that 
increase lipofuscin and A2E accumulation.
 Another histopathological study described the findings in a 93-year-old patient with 
a late-onset atypical form of BVMD, who carried a p.Tyr227Asn mutation in BEST1.82 This 
patient showed small multifocal vitelliform lesions on ophthalmoscopy at the age of 
77, that gradually became “gliotic” within the next decade. Again, Bruch’s membrane 
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was completely intact, and there was no evidence of CNV. This patient also displayed 
midperipheral drusen-like flecks at the level of the RPE, both on ophthalmoscopy and 
on histopathological examination. Surprisingly, the amount of RPE lipofuscin was not 
significantly different from that in age-matched controls. The authors speculated that a 
possible explanation for the apparently normal amount of RPE lipofuscin accumulation 
in this patient may be the exceptionally late age at onset of 75 years, suggesting a 
decreased level of expression of the allele with the p.Tyr227Asn mutation in this case. 
The resulting lipofuscin accumulation in the RPE would therefore also be more modest. 
A normal age-related increase of RPE lipofuscin,222,223 both in this aged BVMD patient 
and in an age-matched control group, may mask possible disease-related differences 
that might have been more evident earlier in life. Cystic changes in the outer nuclear 
layer have been observed both in BVMD and AFVD, and may provide an explanation for 
the apparent predisposition to macular hole formation in both conditions.115,126,224-226 In 
several cases, a generally intact RPE underlying the advanced macular BVMD lesions 
was seen on histopathology.82,132 This indicates that the loss of visual acuity due to 
photoreceptor degeneration is not necessarily secondary to RPE atrophy.
 Histopathological findings have also been described on the eyes of a homozygous 
p.Trp93Cys BEST1 mutation carrier, who suffered from BVMD, just like several affected 
family members who carried the mutation heterozygously. Increased levels of A2E were 
found in the RPE, together with a large serous retinal detachment in the macula.132 
These findings also reflect the clinical observations of increased FAF and hyperreflective 
material on OCT in the earlier stages of BVMD,123,126,144 corresponding to a dynamic process 
of accumulation of vitelliform material within the subretinal space. 
 Two earlier histopathological studies on ungenotyped BVMD cases have also found 
marked accumulation of lipofuscin and melanolipofuscin in the RPE, together with 
evidence of CNV.227,228 One of these studies analysed the contents of the subretinal space 
between the photoreceptors and the RPE. This subretinal space contained accumulations 
of photoreceptor outer segments, lipofuscin-like material, and melanin. In addition, 
phagocytic cells were seen in the subretinal space, possibly derived from RPE cells, which 
were packed with lipofuscin and melanin.228 Melanin-containing phagocytic cells were 
also found in the subretinal space in a genetically confirmed case of BVMD (p.Thr6Arg 
mutation).21 Again, these findings correlate with the clinical findings on FAF and OCT in 
BVMD patients. 
In summary, the available histopathological data on BVMD correspond to the clinical 
observations and lend further credence to the proposed pathophysiological mechanism, 
involving the accumulation of shed photoreceptor outer segments in the abnormal 
subretinal space between the photoreceptors and the RPE.
 The pathogenesis of BEST1-related AFVD is probably comparable to BVMD. Several 
histopathological studies on AFVD have been published, without information on the 
genetic background.85,87,224,229,230 A detachment of the neuroretina was observed in some 
cases, similar to the findings on OCT, with the subretinal vitelliform material derived 
from photoreceptor outer segments, as well as from lipofuscin-loaded pigmented cells. 
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Lipofuscin accumulation was also seen in the RPE, together with RPE clumping and 
atrophy. An attenuation of the overlying neuroretina with photoreceptor degeneration 
could precede RPE atrophy.224 
 The clinical characteristics of ADVIRC, the MRCS syndrome, and ARB, are quite 
distinct from those observed in BVMD and AFVD. The clinical features in ADVIRC, the 
MRCS syndrome, and ARB, are at least partially the result of an incomplete development 
of various ocular structures, including the RPE, photoreceptors, as well as the anterior 
segment of the eye. The observed clinical differences of these diseases with BVMD and 
AFVD may be explained by the differential functional and structural impact of BEST1 
mutations. In ADVIRC and the MRCS syndrome, the abnormally spliced BEST1 pre-mRNA 
causes an in-frame alteration of bestrophin-1 that has unknown functional consequences 
for the protein.5,8 In ARB, the BEST1 null phenotype, there is an absence of normal 
bestrophin-1 protein, which also probably affects its presumed influence on ocular 
development. As bestrophin-1 is proposed to play a role in ocular development, possibly 
in concert with OTX and MITF, BEST1 mutations in ADVIRC, the MRCS syndrome, and 
presumably ARB, may adversely affect normal ocular development through mechanisms 
that are currently unclear. The photoreceptor abnormalities on the ERG that are observed 
in ADVIRC, the MRCS syndrome, as well as in ARB, may be either due to a primary effect 
of the mutant bestrophin-1 on the photoreceptors, but may also occur secondary to 
abnormal RPE function and/or RPE degeneration.
ADVIRC, the MRCS syndrome, as well as ARB, may thus be considered to be part of an 
overlapping continuum of ocular developmental abnormalities due to bestrophin-1 
dysfunction. 
Two histopathological studies on ungenotyped ADVIRC have been published on the eyes 
of a 26-year-old and an 88-year-old patient. These studies showed disorganization of the 
peripheral retina, with intraretinal RPE migration, which may correspond to the retinal 
hyperpigmentation, as well as multifocal atrophy of the RPE and photoreceptors, which 
may correspond to the atrophic zones on ophthalmoscopy.231,232 A preretinal membrane was 
also observed, which consisted of condensed vitreous together with marked proliferation 
of Müller cells.232 These preretinal vitreous condensations are also observed clinically.
 The currently available mouse and rat models are indispensable to acquire further 
insight in the pathophysiology of BEST1-related diseases, as well as in the development of 
treatment strategies. However, these animals do not have a macula and do not develop 
retinal lesions as seen in humans, which is a drawback in their use as a model for 
human disease. The cmr dog model does show juvenile-onset lesions that resemble those 
seen in multifocal vitelliform dystrophy.83,233 The disease in this dog model is caused by 
naturally occurring autosomal recessive homozygous BEST1 mutations, and may serve as 
a model for the human null phenotype ARB. A small sample of heterozygous carrier dogs 
appeared unaffected, although further evaluation on these heterozygotes (for instance 
with EOG) is warranted.233 These animal models may aid in the development of future 
therapeutic strategies such as gene therapy in BEST1-related disease.
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5. Future perspectives
Therapeutic intervention in BVMD and AFVD may be primarily aimed at the restoration 
of normal contact between the photoreceptors and the RPE. However, merely restoring 
such anatomical contact will most likely not solve the problem, as BEST1 mutations may 
also affect intracellular processes in the RPE that could have damaging effects. Therefore, 
it seems preferable to eradicate the detrimental effect of the bestrophin-1 mutant, for 
instance by means of gene therapeutic strategies. Intervention with gene therapy in 
BVMD and AFVD caused by BEST1 mutations may have a large time span in which it could 
be successfully implemented, as progression is rather slow in most patients. 
 Gene delivery of wild-type BEST1 to the RPE may be efficient in the treatment of BVMD 
and AFVD haploinsufficiency phenotypes, caused by BEST1 mutations that exclusively 
result in a loss of sufficient wild-type protein.238,242 Such BEST1 gene delivery may be 
achieved through various methods, such as adeno-associated viral vectors and non-viral 
gene carriers such as DNA nanoparticles, administered for instance through subretinal 
injection.234-237 However, many BEST1 mutations cause disease through a dominant 
negative effect. In these cases, a destruction of mutant messenger RNA would be required 
for treatment to be effective, rather than an increased expression of wild-type BEST1 such 
as in haploinsufficiency phenotypes. Such a disruption of the dominant negative mutant 
gene is possible through RNA interference techniques and ribozymes.235,236,238-241 Among 
the many challenges in gene therapy are the achievement of sufficient transduction and 
transfection efficiency, a prolonged gene expression, as well as the safe administration of 
the therapeutic agent.238,242 Important issues in the application of gene therapy in BVMD 
and AFVD are the frequent occurrence of decreased penetrance and variable expressivity, 
as well as the sometimes relatively mild clinical symptoms. Such issues raise questions 
about who should be treated, and when treatment should be started. After all, gene 
therapy may have potentially serious side effects, especially when using viral vectors.243,244 
The development of stringent inclusion criteria is obviously required to perform gene 
therapy for BVMD and AFVD in the safest and most effective way. Fortunately, the eye is 
relatively easily accessible for the localized administration of a therapeutic agent and for 
the clinical evaluation of its effects.238,245 
 Retinal disease in ADVIRC, the MRCS syndrome, as well as ARB, could also respond 
to timely gene therapeutic intervention. However, treatment of these diseases would be 
more challenging, since the structural anterior segment abnormalities that predispose 
to angle-closure glaucoma are probably already present at birth. Furthermore, like in 
BVMD, variable expression and reduced penetrance of BEST1 mutations have also been 
noted in ADVIRC,5 complicating decisions on the necessity and timing of treatment. A 
more practical prophylactic approach, applying YAG laser iridotomies in patients with 
narrow anterior chamber angles at risk for angle-closure glaucoma, appears a rational 
and feasible alternative that is currently possible in these cases.184 Cataract extraction 
may be successfully performed in patients with disturbing lens opacities.5,184
 The broad clinical spectrum of ocular diseases caused by mutations in the BEST1 gene 
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clearly alludes to the multifunctional role of its protein product, bestrophin-1. Such 
functional and phenotypic diversity underscores the challenging need for differentiated 
therapeutic approaches, which may be further developed using the currently available 
animal models.
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3.2.  Clinical and molecular genetic analysis of Best 
vitelliform macular dystrophy
Abstract
Objectives: To describe the phenotype of Best vitelliform macular dystrophy (BVMD), and 
to evaluate genotype-phenotype and histopathological correlations. 
Methods: Retrospective analysis of patients with BVMD who underwent an extensive 
ophthalmic examination, including best-corrected Snellen visual acuity, fundus 
examination by indirect ophthalmoscopy, fundus photography, fundus autofluorescence 
(FAF), optical coherence tomography (OCT), fluorescein angiography, and electro-
oculography. In addition, molecular genetic analysis of the BEST1 gene was performed 
in all patients.
Results: We examined 40 eyes of 20 patients with BVMD. Sixteen eyes (40%) had a well-
defined BVMD stage, whereas 18 eyes displayed characteristics attributable to different 
stages. Six eyes had an atypical form of BVMD. FAF and OCT frequently detected 
abnormalities that were not visible on ophthalmoscopy and fluorescein angiography. All 
patients carried a mutation in the BEST1 gene. Molecular genetic analysis identified eight 
different BEST1 mutations in 15 families, including two novel mutations (p.Gly299Ala 
and p.Ile3Thr). Genotype-phenotype correlation was limited, as we observed a broad 
phenotypic range in association with a single BEST1 mutation. However, the p.Ala243Val 
appears to cause a mild and relatively invariable BVMD phenotype.
Conclusions: A broad phenotypic variability may be observed in BVMD, even with a 
single BEST1 mutation. FAF and OCT are valuable non-invasive imaging techniques for 
the phenotyping and follow-up of BVMD patients.
Introduction
Best vitelliform macular dystrophy (BVMD) is an autosomal dominant retinal disease 
with incomplete penetrance and a variable phenotypic expression.1-3 BVMD is associated 
with mutations in the BEST1 gene, formerly known as the VMD2 gene, which can be found 
in virtually all patients with a positive family history.4-6 The BEST1 gene encodes the 
bestrophin-1 protein, which oligomerizes and is assumed to be a Ca2+-activated Cl- channel, 
located at the basolateral plasma membrane of the RPE.7 Moreover, bestrophin-1 may 
also modulate the activity of voltage-gated L-type Ca2+ channels.7,8 In addition to BVMD, 
BEST1 mutations may also cause a spectrum of other eye diseases, including adult-onset 
foveomacular vitelliform dystrophy (AFVD),4 autosomal recessive bestrophinopathy,8 
autosomal dominant vitreoretinochoroidopathy, and the microcornea, retinal dystrophy, 
cataract, and posterior staphyloma (MRCS) syndrome.9 
Patients with BVMD typically show bilateral yellow macular lesions that resemble an 
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egg-yolk at a certain point in time, in combination with a subnormal electro-oculogram 
(EOG). The full-field electroretinogram is usually normal, whereas the multifocal 
electroretinogram may reveal abnormalities early in the course of the disease.10-13 Gass 
has classified BVMD into six phenotypic stages: the previtelliform or carrier stage, the 
vitelliform stage, the pseudohypopyon stage, the vitelliruptive or scrambled-egg stage, 
the atrophic stage, and the cicatricial and choroidal neovascular stage.1 Lesions may be 
multifocal.14 Controversy exists about the chronological order of these stages.15 
 The current classification of BVMD relies almost completely on the findings on 
ophthalmoscopy, despite emerging techniques such as optical coherence tomography 
(OCT) and short-wavelength fundus autofluorescence (FAF) imaging. OCT provides cross-
sectional images of the various layers of the neuroretina as well as the retinal pigment 
epithelium (RPE).16 FAF imaging, on the other hand, has emerged as an important 
non-invasive imaging technique to visualize retinal changes related to lipofuscin 
accumulation.17,18 This is important especially in BVMD, since histopathological reports 
indicate that the yellow material in BVMD lesions is lipofuscin.19-21 With FAF and OCT, the 
phenotypic characteristics of retinal dystrophies such as BVMD can be studied in greater 
detail, thereby improving the clinical characterization. Before these techniques can be 
used in such a manner, the specific pathological findings in OCT and FAF should be linked 
to the familiar ophthalmoscopic and fluorescein angiographic images. Analysis of the 
underlying genetic defect in the BEST1 gene may allow genotype-phenotype correlation. 
In this study, we describe in detail the FAF and OCT characteristics of the six phenotypic 
stages of BVMD. The clinical findings of these imaging modalities will be compared to 
the ophthalmoscopic and fluorescein angiographic features, and possible genotype-
phenotype correlations are analyzed.
Methods
Clinical studies
This study followed the tenets of the Declaration of Helsinki and informed consent was 
obtained from all subjects. We examined 40 eyes of 20 BVMD patients (10 males and 10 
females, aged 11-53 years) from 15 different families, who were referred to the Departments 
of Ophthalmology of the University Medical Centres in Nijmegen and Utrecht. The 
diagnosis BVMD was established based on the lesions visible on ophthalmoscopy, an 
autosomal dominant inheritance pattern, and an abnormal EOG. The EOG was recorded 
according to the International Society for Clinical Electrophysiology of Vision (ISCEV) 
standards and was considered abnormal if the Arden ratio was below 2.0. After the 
medical histories of the patients were obtained, an extensive clinical examination was 
performed, including best-corrected Snellen visual acuity and fundus examination by 
indirect ophthalmoscopy. Fundus photography and FAF imaging (Heidelberg Retina 
Angiograph (HRA) 2, Heidelberg Engineering, Dossenheim, Germany) were subsequently 
performed using a previously described protocol,22 as well as OCT (Stratus OCT, Carl Zeiss 
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Meditech, Inc., Dublin, CA, USA), using the “Macular Thickness Map” protocol provided 
by the manufacturer. Fundus photography, FAF, and OCT were repeated in 14 patients 
after a mean follow-up period of 11 months (range, 7 - 19 months). Finally, all patients 
underwent fundus fluorescein angiography (FFA).
Molecular genetic studies
Blood samples were collected from all patients. The genomic DNA was isolated according 
to a previously described protocol.23 Molecular genetic analysis of the 10 coding exons 
and splice junctions of the BEST1 gene was performed in all patients, according to a 
previously described protocol.24 Primers and PCR-conditions are available on request.
Results 
Molecular genetic findings
We identified eight different BEST1 mutations in 20 patients of 15 different families. 
Patients 1 and 2 belonged to the same family (family A), as did patients 4 and 5 (family C), 
patients 6 and 7 (family D), and patients 16, 17, and 18 (family M). Two novel mutations 
were identified: p.Gly299Ala (c.895G>C, in patients 19 and 20) and p.Ile3Thr (c.8T>C, 
in patient 15). These mutations were not identified in 100 control alleles, and both 
mutations are predicted to be pathogenic. Six previously described mutations were 
found: p.Thr6Pro (c.16A>C, in patients 1-9),4,6,14,25 p.Tyr227Asn (c.679T>A, in patients 
12 and 13),6,24-27 p.Lys194_Ala195insVal (c.583_584insTGG, in patient 10),14 p.Leu82Val 
(c.244C>G, in patient 11),25,28 p.Asp302_Asp304del (c.904-912del, in patients 16, 17, and 
18),14 and p.Ala243Val (c.728C>T, in patient 14).4,28 Three mutations were found in more 
than one family. The p.Thr6Pro mutation, which has been previously described in BVMD 
patients from the Netherlands,6 was found in eight patients of five different families 
(Table 3.2). The p.Gly299Ala mutation was found in two unrelated patients (patients 19 
and 20). The p.Tyr227Asn mutation was found in the unrelated patients 12 and 13.
Clinical findings
The clinical characteristics of the patients are summarized in Table 3.2. The Snellen visual 
acuity ranged from 20/200 to 20/16 (mean 20/35). During the mean follow-up period of 
11 months, this mean visual acuity remained stable. Of the 40 eyes that were examined, 
16 demonstrated lesions compatible with a typical stage as described by Gass: two eyes 
showed no macular abnormalities and thus were in the carrier stage (Fig. 3.5), one eye 
was in the vitelliform stage (Fig. 3.6A-E), two eyes showed a pseudohypopyon lesion 
(Fig. 3.6F-I), 5 eyes were in the vitelliruptive stage (Fig. 3.6J-M), 3 eyes had an atrophic 
lesion (Fig. 3.7A-D) and three eyes were in the cicatricial stage (Fig. 3.7E-H). 
 Eighteen of the 40 eyes showed macular lesions that were combinations of the BVMD 
stages as described by Gass. The following combinations were encountered: vitelliform/
vitelliruptive stage (2 eyes), vitelliruptive/pseudohypopyon stage (1 eye), vitelliruptive/
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atrophic stage (1 eye), vitelliruptive/cicatricial stage (9 eyes), vitelliruptive/pseudo hypopyon/
cicatricial stage (1 eye), cicatricial/atrophic stage (1 eye) and pseudohypopyon/cicatricial/
atrophic stage (3 eyes). Vitelliruptive/pseudohypopyon/cicatricial lesions were differentiated 
from pseudohypopyon/cicatricial/atrophic lesions, as the latter lesions clearly showed 
profound atrophy of the RPE on ophthalmoscopy, in addition to an area of scarring. In 6 
patients, the BVMD stage differed between both eyes. After a mean follow-up period of 11 
months in 14 patients, 12 patients showed no or only minor changes within the lesion. 
Two patients displayed clear changes of lesion characteristics. After a follow-up period of 8 
months in patient 7, the pseudohypopyon in the right eye evolved towards a vitelliruptive 
stage, whereas the left eye showed considerable enlargement of the pseudohypopyon 
(Fig. 3.6F-I). The lesion in the right eye of patient 3 developed a pseudohypopyon after a 
follow-up period of 7 months (Fig. 3.6A-E). 
 Six eyes of 3 patients demonstrated an atypical form of Best disease (patients 12, 14, 
and 20). Patient 14, who carried a p.Ala243Val mutation in BEST1, had macular lesions 
that simulated a pattern dystrophy (Fig. 3.8A-D). The EOG was mildly disturbed, with an 
Chapter 3
Figure 3.5.*     
Carrier stage. A. Fundus photograph of patient 4 (p.Thr6Pro mutation in BEST1), the 
41-year-old father of patient 5, does not show any abnormalities. B. Fluorescein angiography 
does not show any abnormalities of the macula. C. Fundus autof luorescence image, showing 
a normal autof luorescence pattern of the macula. D. Optical coherence tomography scan 
shows a normal aspect of the retinal layers.
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Figure 3.6.*      
Vitelliform stage. A. Fundus photograph of 
patient 3 (p.Thr6Pro mutation in BEST1), 
showing a yellowish lesion with some 
 fibrosis and pigmentation at the boundaries 
of the lesion. B. Fundus autof luorescence 
(FAF) of the yellowish parts of the lesion is 
significantly  increased, but becomes less 
intense towards the lesions margins. Zones 
of increased FAF are beginning to cluster 
within the lesion. C. Seven months later, the 
ophthalmoscopic and FAF picture evolved to 
a lesion with combined  characteristics of the 
scrambled-egg and pseudohypopyon stage. 
D. At this point in time, fundus f luorescein 
angiography (FFA) was performed, showing 
patchy hyperf luorescence in the superior 
part of the lesion, and a hyperf luorescent 
 pseudohypopyon. E. A vertical optical 
 coherence tomography (OCT) scan (arrow in 
panel A) shows a hyperref lective  subretinal 
lesion in the vitelliform stage.Pseudo-
hypopyon stage. F. Fundus  photograph of 
patient 7, who also carried a p.Thr6Pro 
mutation, showing yellowish material 
 inferiorly with transparent f luid in the 
 superior part of the lesion. G. The yellowish 
material of the pseudohypopyon shows 
 substantially increased FAF, with only some small spots of increased FAF in the  superior part of the 
lesion. H. The pseudohypopyon is intensely hyperf luorescent in the  mid-late phase of FFA.  
I. The pseudohypopyon corresponds to subretinal material of  increased ref lectivity on a vertical OCT 
 section (arrow in panel F). Additional hyperref lective material is attached to the outer retina and to 
the bottom of the subretinal space  (arrowhead). Vitelliruptive/Scrambled-egg stage. J. Fundus photo-
graph of patient 10 (p.Lys194_Ala195insVal mutation in the BEST1), showing a large lesion with 
scattered clusters of yellowish material within transparent f luid. K. In addition to the locations of 
clinically apparent yellowish material, increased FAF can be observed at the borders of the lesion 
where yellowish subretinal material cannot readily be visualized by ophthalmoscopy. L. On FFA, the 
lesion shows patchy hyperf luorescence. M. OCT scan taken vertically (arrow in panel J), showing 
 elevation of the retina by subretinal f luid that has no ref lectance. The clusters of yellow material 
that were seen on the fundus photograph appear as prominent hyperref lective structures (arrowheads).
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Arden ratio of 1.7 in the left eye and 1.8 in the right eye. Despite these atypical clinical 
characteristics, evidence of an autosomal dominant inheritance pattern and discrete 
vitelliform lesion aspects on ophthalmoscopy prompted a molecular genetic evaluation 
of the BEST1 gene. Patient 20, who carried a p.Gly299Ala mutation in BEST1, displayed the 
phenotype of multifocal vitelliform macular dystrophy with an absent light peak on EOG 
(Fig. 3.8E-H). Patient 12, a 35-year-old male, showed discrete RPE changes in the fovea that 
had not changed since the first examination at the age of 6 years, with no light rise on 
EOG (Arden ratio of 1.0) in both eyes. This phenotype is not described in the classification 
of Gass, but corresponds to stage I in the classification of Mohler and Fine.15 Analysis of 
the BEST1 gene in this patient, performed because of the absent light rise on the EOG, 
revealed a p.Tyr227Asn mutation. 
Spectrum of BEST1-associated phenotypes
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Figure 3.7.*       
Atrophic stage. A. Fundus photograph of 
patient 19 (p.Gly299Ala mutation in BEST1) 
showing an atrophic lesion. B. The fundus 
autof luorescence (FAF) image shows 
 markedly decreased FAF of the atrophic 
area, surrounded by a ring-shaped area of 
increased FAF. C. Fundus f luorescein 
 angiography (FFA) shows a well-circum-
scribed, hyperf luorescent window defect 
due to atrophy of the retinal pigment 
 epithelium. D. This atrophic area 
 corresponds with retinal thinning with 
underlying hyperref lectivity on the optical 
coherence tomography (OCT) scan (arrow in 
panel A). Small intraretinal cystoid changes 
can also be discerned. Cicatricial stage.  
E. The fundus photograph of patient 2  
(p.Thr6Pro mutation in BEST1) shows a 
 prominent yellow-white subretinal scar with pigmented borders, surrounded by a serous retinal 
detachment. The visual acuity (20/25) was remarkably preserved. F. FAF imaging reveals signifi-
cantly decreased FAF of the central scar, surrounded by small amounts of material of increased FAF 
intensity scattered throughout the rest of the lesion. This material is not evident on the fundus 
 photograph. G. In the late phase of FFA, the scar is intensely hyperf luorescent due to passive 
 leakage of f luorescein into the scar, whereas the surrounding part of the lesion shows more discrete, 
patchy hyperf luorescence. H. OCT (arrow in panel E) shows a prominent and hyperref lective 
 structure, in contact with the overlying retina. This structure is surrounded by elevated retina with 
underlying spots of increased ref lectivity.
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Fundus autofluorescence, optical coherence tomography, and fluorescein 
angiography
In the carrier stage, no abnormalities were detectable on FAF, OCT, and FFA (Fig. 3.5). In the 
vitelliform stage, however, the yellowish material of the “egg-yolk” lesion corresponded 
with an intense FAF signal. This material was hyperreflective on OCT (Fig. 3.6A-E). In 
the early phase of FFA, the vitelliform material blocked fluorescence and thus appeared 
hypofluorescent. The vitelliform material subsequently became hyperfluorescent, and in 
the late stages became hypofluorescent again. Increased FAF was seen inferiorly in the 
pseudohypopyon lesions, where a fluid level with relatively transparent fluid is formed 
in the superior part of the lesion (Fig. 3.6F-I). This fluid did not have an increased FAF 
Chapter 3
Figure 3.8.*        
Atypical forms of Best vitelliform macular 
dystrophy. A. Fundus photograph of 
patient 14 (p.Ala243Val mutation in 
BEST1). A small pseudohypopyon (arrow-
head) and some scattered yellow deposits 
are combined with a spoke-like pattern of 
subretinal yellowish changes, resembling a 
pattern dystrophy. B. The lesion shows 
increased fundus autof luorescence (FAF) of 
the small pseudohypopyon and a radial 
pattern of spoke-like extensions with 
 increased FAF on a background of 
 markedly decreased FAF. C. The spokes of 
increased FAF are hypof luorescent on 
 fundus f luorescein angiography (FFA), 
whereas the spokes of decreased FAF are 
hyperf luorescent. D. A horizontal optical 
coherence tomography (OCT) scan (arrow 
in panel A) shows an elevated retina with 
irref lective subretinal material. E. Fundus photograph of patient 20 (p.Gly299Ala mutation in 
BEST1), who presented with multifocal vitelliform lesions. The different lesions all have 
 characteristics of the vitelliruptive stage, with circular deposition of yellowish material along the 
edges of the lesions. The lesions show some degree of fibrosis and atrophy as well. F. FAF shows that 
the yellowish deposits are intensely autof luorescent, whereas areas with atrophy and fibrosis show 
absent FAF. G. On FFA, lesions are predominantly hyperf luorescent. H. A vertical OCT scan (arrow 
in panel E) through the central lesion reveals a serous retinal elevation with intraretinal cystoid 
changes. The underlying layer shows increased ref lectivity, probably corresponding with the fibrosis 
seen on ophthalmoscopy.
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signal and showed no reflectivity on OCT. On FFA, the lower part of the lesion, which 
contained vitelliform material, had a similar aspect as in vitelliform lesions. The upper 
part showed patchy hyperfluorescence, that sometimes increased in intensity towards the 
later phases of the angiogram (Fig. 3.6H). The vitelliruptive/scrambled-egg stage showed 
clusters of vitelliform material scattered throughout the lesion. These lesions showed 
increased FAF and increased reflectivity on OCT, and were generally hyperfluorescent 
on FFA (Fig. 3.6J-M). In the atrophic stage, lesions displayed a predominantly decreased 
FAF signal, corresponding with an irregular posterior thickening of the highly reflective 
external band on OCT, due to a deeper penetration of the light to the choroid through 
the atrophic retina (Fig. 3.7A-D). Areas of RPE atrophy showed well-circumscribed 
hyperfluorescence on the fluorescein angiogram. Finally, in the cicatricial stage, 
areas with discrete scarring showed slightly increased FAF, whereas FAF in areas with 
advanced cicatrization was decreased compared to normal FAF. These areas with sub- 
and intraretinal fibrosis generally appeared as prominent hyperreflective structures 
on OCT, and were intensely hyperfluorescent on the FFA (Fig. 3.7E-H). Nineteen of the 
40 eyes (47,5%) showed evidence of subretinal yellow-white fibrous tissue and scarring. 
Fourteen eyes (35%) showed adhesions between the retina and subretinal hyperreflective 
structures on OCT (Fig. 3H). In five eyes (12,5%) of four different patients, intraretinal 
cystoid changes overlying the lesion were observed (Fig. 3.7D and 3.8H). One patient 
(patient 3) had evidence of previous choroidal neovascularization in one eye on FFA. 
Discussion
Phenotype
Less than half (40%) of the BVMD patients in our study showed a typical lesion stage as 
originally described by Gass. A substantial number (45%) of the BVMD lesions simultaneously 
displayed abnormalities that were attributable to two or even more different BVMD 
stages. The remaining 15% of the eyes showed an atypical form of BVMD. Gass assumed 
a chronological order in the various stages, but the patients in our study show that this 
sequence is not always followed. In three eyes, a pseudohypopyon together with evidence 
of scarring and atrophy was observed, resulting in a visual acuity that did not exceed 
20/50. Gass placed the atrophic stage before the cicatricial stage, but many lesions in 
the present study showed signs of subretinal fibrous tissue before marked atrophy was 
evident on ophthalmoscopy, FAF and OCT. Our results indicate that a strict classification 
in stages is too rigid, since almost half of the BVMD lesions show aspects of different 
stages. Most BVMD lesions remain stationary after a considerable follow-up period,15,29 
but our study also illustrates that a minority of lesions may show notable stage changes 
within less than a year. The variable amount of vitelliform material and the sometimes 
alternating pseudohypopyon and vitelliruptive stages have been described previously.29 
This phenomenon may find its origin in variations in photoreceptor outer segment disc 
shedding, RPE phagocytotic activity, as well as variable physical activity of the patient.30  
Spectrum of BEST1-associated phenotypes
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 In accordance with previous studies on BVMD,15,29,31 our study indicates that 
choroidal neovascularization (CNV) is rare in this type of retinal dystrophy. In some 
BVMD patients, lesions with signs of scarring and/or discrete signs of fluorescein leakage 
on the fluorescein angiogram might suggest a mild form of CNV. However, Bruch’s 
membrane was completely intact in several histopathological studies,27,32,33 also in areas 
with overlying scars or atrophy. This shows that scars and atrophy are not necessarily 
indicative of previous CNV. Staining of these lesions in the late phases of FFA may be 
caused by passive leakage and subretinal accumulation of fluorescein due to abnormal 
RPE structure and function. CNV should still be suspected when subretinal hemorrhages 
and exudation are seen within the BVMD lesion, in combination with visual loss. In these 
cases, FFA and possibly indocyanine green angiography may be performed to confirm the 
presence of CNV. After all, identification of CNV may have therapeutic consequences, as 
treatment of CNV with a form of anti-angiogenic therapy may be effective.34,35 It should be 
emphasized, however, that the majority of BVMD patients with subretinal hemorrhage 
do not have evident signs of CNV on the fluorescein angiogram and generally show 
spontaneous and significant improvement of visual acuity.31 
Comparison of fundus autofluorescence, optical coherence tomography, 
and fluorescein angiography
We observed increased FAF in the earlier stages of BVMD (except for the carrier stage), 
corresponding with the yellowish vitelliform material on ophthalmoscopy. FAF imaging 
was also able to visualize small amounts of vitelliform material of increased FAF 
that were not seen on ophthalmoscopy, OCT, and FFA. In later stages, the amount of 
this material decreased in favor of relatively transparent subretinal fluid that lacked 
the increased FAF signal. Scars and atrophic regions in advanced BVMD lesions were 
characterized by decreased FAF. Often, FAF more clearly shows the extent of the lesion. 
As mentioned previously, it remains unclear why this yellowish material with increased 
FAF, which is initially abundant, may alternately disappear and reappear in some cases. 
It is also unknown how the transparent fluid without increased FAF appears. This fluid 
may possibly find its origin in the disturbed ion and fluid transport by the RPE in BVMD 
patients, associated with bestrophin-1 dysfunction.5,36 
 OCT imaging also provides further insight into the composition of BVMD lesions. 
Both the yellowish vitelliform and the subretinal fibrosis appeared hyperreflective 
with this technique. OCT was able to detect abnormalities that were not seen on 
ophthalmoscopy, FAF, and FFA, such as an adhesion between retinal tissue and subretinal 
hyperreflective structures, as well as hyporeflective intraretinal cystoid changes, a 
finding which has been described previously in BVMD.37 OCT is able to visualize the 
antero-posterior dimensions of a BVMD lesion and thus adds another dimension to the 
insight into the lesional constitution. In addition, OCT may better delineate the size 
and shape of a subretinal scar and its position relative to the overlying retina. Atrophic 
areas, accumulation of hyperreflective material, and the location and amount of sub- 
and intraretinal fluid may also be easily visualized with OCT. The OCT findings may 
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correlate well with findings with other imaging methods. For instance, the areas of 
accumulation of subretinal material of increased FAF seem to correspond largely with 
the hyperreflective material within BVMD lesions on OCT (Fig. 3.6G and I). The lack of 
apposition between the photoreceptors and the RPE, presumably caused by subretinal 
fluid accumulation due to bestrophin-1 dysfunction, results in inefficient phagocytosis 
of the photoreceptor outer segments by the RPE.30 The hyperreflective material adjacent 
to the outer surface of the neuroretina in BVMD on OCT (Fig. 3.6I) could therefore 
correspond to accumulations of shed photoreceptor outer segments, that are filled with 
A2E-precursor fluorophores responsible for high FAF.30 As these shed photoreceptor outer 
segments further accumulate, they may eventually be distributed throughout the lesion, 
corresponding with an egg-yolk appearance on ophthalmoscopy, high FAF of the entire 
lesion, and a completely hyperreflective lesion on OCT (Fig. 3.6A, B, and E). With time, 
this material gravitates to the inferior part of the lesion, causing a pseudohypopyon, 
with a displacement of high FAF and hyperreflectivity on OCT predominantly to this part 
of the lesion (Fig. 3.6C, F, G, H, and I). Our results show that the anatomical level of such 
accumulations (adjacent to the retina, the RPE, or both) is more readily identified with 
OCT as compared to ophthalmoscopy, FAF, and FFA. We used the Stratus OCT, but the use 
of higher resolution spectral domain OCT imaging techniques may further increase our 
insight in the composition and pathophysiology of BVMD lesions. 
The OCT and FAF findings in our study are in accordance with a previous study combining 
fundus camera-based FAF and OCT in nine BVMD patients, without information on the 
underlying molecular genetic defect.38 Our OCT observations also conform to a recent 
study in BVMD patients using high-definition OCT.39
Genotype-phenotype correlation
Many specific BEST1 mutations are associated with a striking range of BVMD disease 
expression. The p.Thr6Pro mutation, for instance, may cause a spectrum of phenotypes 
ranging from an abnormal EOG without ophthalmoscopic abnormalities to multifocal 
vitelliform dystrophy.14 Certain mutations in the BEST1 gene may lead to a more 
severely affected RPE, sometimes resulting in the formation of multifocal vitelliform 
lesions that extend beyond the macula.27,40,41 Presently unknown additional genetic and 
environmental modifying factors obviously exert their influence on the phenotypic 
outcome. The high phenotypic variability is not unique to BEST1-related disease and may 
also be seen in other autosomal dominantly inherited retinal diseases, such as those 
caused by peripherin/RDS mutations.42 
 There appears to be a certain degree of genotype-phenotype correlation in association 
with the p.Ala243Val mutation in BEST1. Patient 14, who carried this p.Ala243Val mutation, 
displayed an atypical phenotype of BVMD with a radial, spoke-like configuration of 
deposits on ophthalmoscopy and FAF, together with a near-normal EOG. This phenotype 
may be easily confused with pattern dystrophy of the retina. A small pseudohypopyon 
lesion in the centre of the lesion and the finding of a p.Ala243Val mutation in BEST1 
supported the diagnosis of BVMD. The p.Ala243Val mutation has been reported previously 
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in association with both BVMD and AFVD, but generally seems to cause a mild phenotype 
with a normal or near-normal EOG, just like in our study.4,13 A study by Yu and colleagues 
indicates that this mutation alters the Cl-- channel function of human bestrophin-1 and 
that the absence of a dominant negative effect of the mutation might be the cause of the 
milder symptoms, such as the normal or near-normal EOG.36 BVMD and AFVD may share 
clinical features, and in a number of AFVD cases, mutations in the BEST1 gene have been 
identified.4, 43,44 Compared to BVMD, AFVD shows smaller lesions, with a later age at onset 
and often a normal EOG. However, lesions in BVMD may also be small and the mean age 
at onset in BVMD is higher than initially described.13 An Arden ratio of the EOG below 
2.0 has been rather arbitrarily chosen as a cut-off point to consider the EOG abnormal. 
Therefore, we propose that BEST1-associated AFVD may be regarded as a mildly expressed 
form of BVMD, in which the RPE has preserved sufficient overall function to result in an 
EOG within the normal range. 
Histopathological correlations
The histopathological correlate of one of the most frequent BEST1 mutations in our 
study, p.Tyr227Asn (patients 12 and 13), has been described. This study described the 
findings in the eye of a patient with a late-onset atypical, multifocal form of BVMD, who 
carried a p.Tyr227Asn mutation in BEST1.27 Somewhat surprisingly, the amount of RPE 
lipofuscin was not significantly different from that in age-matched controls. Patients 
12 and 13 (both also carrying a p.Tyr227Asn mutation) in our study, however, clearly 
showed abnormally increased FAF, consistent with an abnormally high level of lipofuscin-
related fluorophores in the RPE and/or under the neuroretina. This difference with the 
published histopathological findings may be explained by differences in age and age at 
onset, due to possible modifying factors.
 In addition, histopathological studies have been carried out on two BVMD patients 
who carried a p.Thr6Arg mutation in BEST1, an amino acid substitution on the same site 
as in patients 1-9 in our study, who carried a p.Thr6Pro missense mutation. In a patient 
with advanced BVMD,33 as well as in his previously described son,21 massive lipofuscin 
accumulation was seen in the RPE, together with a more than 4-fold increase of A2E, 
the major fluorophore of lipofuscin, compared to normal controls.32,33 These markedly 
elevated amounts of RPE lipofuscin and A2E are in agreement with the finding of 
increased FAF in most BVMD stages in our study. In the case of the p.Thr6Arg mutation, 
the amount of bestrophin-1 was higher in the extramacular RPE than in the macular 
RPE.33 The authors hypothesized that BVMD, at least when caused by a p.Thr6Arg 
mutation, is a result of insufficient amounts of wild-type bestrophin-1 in the macula. As a 
consequence, the macular RPE is unable to support proper ion homeostasis, resulting in 
the accumulation of subretinal fluid, a detachment of the photoreceptors from the RPE, 
and possibly intracellular RPE changes that increase lipofuscin and A2E accumulation.
In a homozygous p.Trp93Cys BEST1 mutation carrier, who was known with BVMD just 
like several affected family members who carried the mutation heterozygously, increased 
A2E levels were also found in the RPE, together with a large serous retinal detachment 
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in the macula.32 Again, these findings parallel our clinical observations of increased FAF 
and hyperreflective material under the neuroretina on OCT in the earlier stages of BVMD, 
corresponding to a dynamic process of accumulation of vitelliform material within a 
subretinal space. In all of the histopathological cases mentioned above, gliotic scar tissue 
was found in the macula, which could correspond to our findings in the patients with 
lesions in the cicatricial stage (Fig. 3E-H). A central scar was observed in these lesions, 
that showed decreased FAF and a hyperreflective prominence on OCT.
 Two earlier histopathologic studies on ungenotyped BVMD cases, performed before 
the era of molecular genetic confirmation, have also found marked accumulation 
of lipofuscin and melanolipofuscin in the RPE, besides evidence of choroidal 
neovascularization.19,20 One of these studies analysed the contents of the subretinal 
space between the photoreceptors and the RPE. An accumulation of photoreceptor outer 
segments, lipofuscin-like material, and melanin was found. This again corresponds to 
our FAF and OCT findings and lends further credence to the proposed pathophysiological 
mechanism, involving the accumulation of shed photoreceptor outer segments between 
the detached neuroretina and the RPE. In addition, phagocytic cells were seen in the 
subretinal space, possibly derived from RPE cells, which were packed with lipofuscin and 
melanin.20 Such phagocytic cells containing melanin were also found in the subretinal 
space in a genetically confirmed case of BVMD (p.Thr6Arg mutation).33
Conclusion
Many BVMD patients simultaneously display characteristics of the different BVMD stages 
described by Gass. A broad phenotypic variability may be observed in association with 
a single BVMD mutation. The p.Ala243Val mutation, however, shows a considerable 
degree of genotype-phenotype correlation. FAF and OCT appear to be excellent imaging 
methods for phenotyping and follow-up of BVMD patients, and provide valuable insight 
into the pathogenesis of BVMD. Both FAF and OCT are non-invasive and relatively patient-
friendly. In our opinion, adequate phenotyping and follow-up of BVMD patients should 
therefore include OCT and FAF imaging, in addition to ophthalmoscopy and EOG. These 
techniques may be able to replace FFA as the imaging method of choice for further 
evaluation and follow-up of BVMD lesions, in addition to ophthalmoscopy. However, FFA 
remains indicated in BVMD cases where CNV is suspected. In every patient suspected of 
BVMD, a molecular genetic analysis of the BEST1 gene should be performed.
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3.3.  Clinical and genetic heterogeneity in multifocal 
vitelliform dystrophy
Abstract
Objective: To describe the clinical and genetic findings in 15 patients with multifocal 
vitelliform lesions.
Methods: All patients and, if possible, affected family members underwent an extensive 
ophthalmic examination. In addition, their genomic DNA was analyzed for mutations 
in the BEST1 gene. Patients who did not have a mutation in BEST1 were screened for 
mutations in the peripherin/RDS gene.
Results: The age at onset of the disease was highly variable, ranging from 5 to 59 years. 
The peripheral lesions varied in number, size and overall appearance, but showed similar 
characteristics on fundus autofluorescence imaging and optical coherence tomography, 
when compared to the central vitelliform lesion. Mutations in the BEST1 gene were 
identified in nine of the 15 patients. One patient without a BEST1 mutation carried a 
sequence variant in the 5’ untranslated region of the peripherin/RDS gene. 
Conclusions: Multifocal vitelliform dystrophy is a clinically and genetically heterogeneous 
retinal disease, which can be caused by mutations in the BEST1 gene. Other genes 
associated with this phenotype remain to be identified.
Introduction
Multifocal vitelliform lesions have been described in several reports.1-16 Lesions typically 
present as sharply demarcated yellowish cysts in the macula, near the retinal vascular 
arcades and around the optic disk. A variation in size and number (up to 20) of these 
lesions can be observed. The lesions may grow and merge with neighboring lesions. The 
evolution of the peripheral lesions may parallel the evolution of the central lesion, but 
their evolution may also show a different time course.1,7,9,10,12 The previously reported cases 
of multifocal vitelliform lesions were either familial or sporadic. The majority of lesions 
showed at least partial staining on fluorescein angiography.3,8,10 Although the electro-
oculogram (EOG) was often reduced, some patients displayed normal EOG responses.5,8 
Electroretinographic (ERG) results were normal in most patients with multifocal 
vitelliform lesions.8 Some authors consider this phenotype an atypical variant of Best 
vitelliform macular dystrophy (BVMD), especially in combination with an autosomal 
dominant mode of inheritance and a disturbed EOG. The BVMD phenotype is associated 
with mutations in the BEST1 gene, which can be found in virtually all patients with a 
positive family history, as well as in 28% to 69% of the sporadic cases.17-19 Typically, the 
EOG is moderately to severely disturbed, although normal EOGs have been reported in 
patients with BVMD who carry a mutation in BEST1.5,17,20,21 
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 In adult-onset foveomacular vitelliform dystrophy (AFVD), vitelliform lesions 
are generally unifocal and located in the macula, but on rare occasions a multifocal 
distribution may be encountered.22 Contrary to typical BVMD, the lesions in AFVD are 
usually one-third to one disk diameter in size, with a central pigmented spot, although 
lesions may also mimic those seen in BVMD.23 If symptomatic, the age at onset of visual 
disturbance in AFVD is usually between 30 and 50 years. The EOG results in AFVD are 
normal or only slightly reduced. AFVD shows genetic heterogeneity: mutations in the 
peripherin/RDS gene were found in up to 18% of AFVD patients, whereas in up to 25% of 
the cases mutations in the BEST1 gene were identified.17,24,25 
To date, two studies have been published describing a total of two patients with multifocal 
vitelliform lesions carrying mutations in the BEST1 gene.11,14 The purpose of this study is 
to clinically characterize 15 patients with multifocal vitelliform lesions and to investigate 
the possible role of the BEST1 gene and the peripherin/RDS gene in the pathogenesis of this 
peculiar phenotype.
Methods
Clinical studies
This study conformed to the tenets of the Declaration of Helsinki and was approved by the 
Committee on Research Involving Human Subjects at the Radboud University Nijmegen 
Medical Centre (Nijmegen). Informed consent was obtained from all participants. 
Fifteen probands who were diagnosed with multifocal vitelliform dystrophy, based on 
the ophthalmoscopic appearance, were examined. When possible, the affected family 
members and their parents were examined. Their medical histories were obtained, and 
subsequent clinical examination included best-corrected Snellen visual acuity, Amsler 
grid testing, fundus examination by indirect ophthalmoscopy, and fundus photography. 
In addition, fundus autofluorescence (FAF) imaging (Heidelberg Retina Angiograph, HRA 
2, Heidelberg Engineering, Dossenheim, Germany) and optical coherence tomography 
(Stratus OCT, OCT 3, Carl Zeiss Meditech, Inc., Dublin, CA, USA) were performed. 
Fluorescein angiography was performed previously in 11 of 15 patients. All patients 
underwent an EOG. Eight of these patients were tested according to the International 
Society for Clinical Electrophysiology of Vision (ISCEV) standards. In seven patients, 
the EOGs were recorded prior to ISCEV regulations, according to an older protocol 
described by Thijssen and colleagues.26 Six patients gave permission to perform full-field 
electroretinography (ERG), which was carried out following the ISCEV guidelines.
Molecular genetic studies
Blood samples were obtained from all probands and, when possible, their parents and 
other affected family members. The genomic DNA was isolated according to previously 
described protocols.27 Sequence analysis of the 10 coding exons and splice junctions of the 
BEST1 gene was performed in all patients.28 In the patients who did not have mutations in 
Chapter 3
175
BEST1, the three exons and splice junctions of the peripherin/RDS gene were amplified by 
the polymerase chain reaction (PCR) and analyzed by direct sequencing.29 
 
Results
Fifteen patients with multifocal vitelliform dystrophy were included in this study. Six 
patients were male and nine were female, ranging from 5 to 59 years of age (mean, 
40.6±18.1; median, 49.0) at the time of their first visit. Nine patients reported additional 
family members with comparable complaints of visual disturbances. All patients 
experienced a reduction of visual acuity as the initial symptom.
Analysis of the BEST1 and peripherin/RDS genes in patients with multifocal 
vitelliform dystrophy
Sequence analysis of the BEST1 gene revealed mutations in nine of the 15 patients 
(60%), whereas no mutations in BEST1 were detected in the remaining six patients. 
BEST1 mutations in these nine patients included five different missense mutations, one 
in-frame deletion and one in-frame insertion. Four mutations (p.Asn296Lys, p.Lys194_
Ala195insVal, p.Asp302_Asp304del, p.Ser16Tyr) are novel, whereas three mutations 
(p.Ala195Val, p.Thr6Pro, p.Phe298Ser) have been described previously in BVMD and 
AFVD.17-19,30,31 The four novel mutations were not identified in 185 control individuals. 
The missense mutation p.Ala195Val was found in two unrelated probands (patients 1 
and 8). Two other patients with multifocal vitelliform lesions (patients 3 and 9), who 
were not related, both carried the missense mutation p.Thr6Pro. In patient 1, two amino 
acid changes were detected: p.Ala195Val and p.Leu134Val. Segregation analysis in the 
patient’s family members indicated that both changes reside on the same allele. The 
p.Ala195Val mutation has been described previously in patients with BVMD,18,31 whereas 
the pathogenic nature of p.Leu134Val is unknown. This p.Leu134Val variant was not 
identified in 185 control individuals. Sequence analysis of the peripherin/RDS gene in the 
remaining six patients identified one sequence variant (c.-11A>C) in the 5’ untranslated 
region in patient 15. This change is not a known polymorphism, is not present in the SNP 
databases, and was not found in 92 control individuals. The variant is not predicted to 
affect regulatory elements or transcription factor binding sites. However, pathogenicity 
of this variant cannot be excluded. 
Clinical features of patients with multifocal vitelliform dystrophy and BEST1 
mutations
Three male and six female patients carried a mutation in the BEST1 gene. The age at onset 
was highly variable (mean 29.8±17.7, median 33), as was the visual acuity (Table 3.3). 
The visual acuity ranged from 20/20 to 20/800. The aspect of the central lesions varied 
from typical vitelliform round-to-oval lesions (Fig. 3.9B), to large and diffuse lesions with 
multiple yellowish deposits of vitelliform material (Fig. 3.10A). Peripheral lesions did 
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not only vary in number, but also in size and aspect, from small and well-circumscribed 
yellow-white spots to large and diffuse lesions with irregular yellow-white deposits, 
comparable to the central lesion. These eccentric lesions were located superior and nasal 
to the optic disc, and adjacent to the temporal vascular arcades. Like the central lesions, 
the lesions outside the macula varied in aspect, size and number during a follow-up 
period of several years (Fig. 3.9A and B).
On FAF imaging, areas of highly increased FAF within lesions corresponded with the 
yellow-white material as seen on ophthalmoscopy (Fig. 3.9C and 3.10B). Fluorescein 
angiographic characteristics were variable, but all lesions had a predominantly 
hyperfluorescent aspect in the early and late phases. OCT imaging of the central lesion 
showed hyporeflective material under the macula, which elevated the central retina 
to a variable degree. In a number of cases, areas of increased reflectivity could be seen 
within this hyporeflective space, corresponding with the yellowish material seen on 
ophthalmoscopy. Areas within the lesion with a cicatricial aspect on ophthalmoscopy 
were prominent and hyperreflective on OCT, and were often in contact with the overlying 
retina. The OCT characteristics of the larger extramacular lesions were similar to those 
of the central lesions (Fig. 3.9D and E). The size of the extramacular lesions ranged from 
smaller than one optic disc area (25 of 38 lesions) to larger than 5 optic disc areas (7 
of 38 lesions). The larger extramacular lesions were found superior to the optic disc. 
Demarcation of individual lesions was better possible with FAF imaging (Fig. 3.10) and 
OCT. 
The EOG was abnormal in all cases. ERG testing was done in three patients and revealed 
normal cone and rod responses. Eight patients reported family members with similar 
visual complaints. Mutation screening in nine of these family members revealed the 
same mutation in the BEST1 gene as the proband. Ophthalmic examination was 
performed in all of these nine family members, and revealed multifocal lesions in five 
cases and a unifocal lesion in four cases. Three of the four family members who had 
unifocal BVMD were 15 years of age or younger. The 44-year-old father of patient 4, who 
carried a p.Ala195_Trp196insVal mutation in the BEST1 gene like his daughter, displayed 
no abnormalities on elaborate eye examination, and had a normal EOG (Arden ratio OD 
2.0, OS 2.2).
Clinical features of patients with multifocal vitelliform lesions without BEST1 
mutations  
This group, consisting of two males and four females, also displayed a variable age at 
onset (mean 37.8±14.0, median 38.5) and visual acuity (Table 3.4). A decreased visual 
acuity was the presenting symptom in all patients. One patient had a positive family 
history for similar visual disturbances. Funduscopic, FAF and fluorescein angiographic 
characteristics in this group were comparable to those described in the group of 
patients who carried a mutation in the BEST1 gene (Fig. 3.11A and B and 3.12A and B). 
The extramacular lesions also had the same aspect on OCT as the central lesions, which 
resembled the OCT aspect of the lesions seen in the group of patients with multifocal 
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vitelliform dystrophy carrying BEST1 mutations (Fig. 3.11C and D). The number of lesions 
was higher in the group of patients without BEST1 mutations. All lesions in this group 
were smaller than one optic disc area, except for the lesions in patient 15. The EOG 
findings were abnormal in two of the six patients. The ERG, recorded in three patients, 
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Figure 3.9.*     
A. Fundus image of the left eye of patient 5 (p.Asp302_Asp304del mutation) at the age of  
18 years. Besides a central cicatricial lesion, a lesion superior to the optic disc with 
 characteristics of a pseudohypopyon is evident (arrowhead). At the age of 44, the lesion 
superior to the optic disc shows a “scrambled-egg” aspect (B). On the fundus 
 autof luorescence (FAF) image (C), the central lesion shows markedly decreased FAF of the 
area that corresponds with the scar on ophthalmoscopy, surrounded by a zone of mottled 
alterations of FAF intensity. The suprapapillary lesion shows spots of increased FAF at the 
edges of the lesion, which correspond with the remnants of vitelliform material on ophthal-
moscopy. D. A vertical optical coherence tomography (OCT) scan through the central lesion 
(white arrow in Fig. 3.9B) reveals a prominent hyperref lective structure, corresponding with 
the central scar seen on ophthalmoscopy. This structure is surrounded by a hyporef lective 
subretinal space, suggesting subretinal f luid. E. A vertical OCT section through the 
 suprapapillary lesion (black arrow in Fig. 3.9B) shows a dome-shaped structure with a 
 optically clear centre and a hyperref lective band above it, which possibly corresponds to the 
elevated photoreceptor layer.
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was normal. The father of patient 10 had multifocal pigmentary changes in both eyes 
in combination with a normal EOG, when he was examined at the age of 65 years. The 
64-year-old brother of patient 10 had nonspecific multifocal pigmentary changes in both 
eyes. His EOG findings were within the normal range. Patient 15 experienced a further 
loss of visual acuity at the age of 65, when she developed choroidal neovascularization 
in the fovea of both eyes.
Discussion
Multifocal vitelliform dystrophy shows characteristic lesions that are also seen in 
BVMD and AFVD. In multifocal vitelliform dystrophy, multiple yellow-white lesions are 
encountered, that are often located in the posterior pole and adjacent to the vascular 
arcades. This phenotype should be differentiated from several other disorders, including 
acute exudative polymorphous vitelliform maculopathy syndrome, central serous 
chorioretinopathy, white dot syndromes such as birdshot chorioretinopathy, multifocal 
serous detachments of the retinal pigment epithelium (RPE), and ocular presentations of 
large cell non-Hodgkin lymphoma.32,33 
 We identified seven different BEST1 mutations in nine out of 15 unrelated patients 
with multifocal vitelliform dystrophy.11,14 A comparison of the clinical data between the 
group of patients with and without confirmed mutations in the BEST1 gene revealed 
differences in the age at onset, visual acuity and electrophysiological findings. The age at 
onset was highly variable, but appears to be lower in the group of patients with a BEST1 
Spectrum of BEST1-associated phenotypes
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Figure 3.10.*     
Fundus photograph and autof luorescence image of the right eye of patient 4, carrying a  
p.Lys194_Ala195insVal mutation in the BEST1 gene (A and B, respectively). A. The fundus 
image shows extensive lesions with scattered yellow-white deposits. B. These deposits are 
intensely autof luorescent. The lesions show a generally increased autof luorescence signal, 
which enables a better appreciation of the size and extent of the lesions.
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Figure 3.11.*     
A. Fundus image of the left eye of patient 12, who did not carry a mutation in BEST1. 
Multiple vitelliform lesions are visible, which can be more clearly delineated with 
 autof luorescence imaging (B). Both the central and superior temporal lesion show a pseudo-
hypopyon-like distribution of the material of increased autof luorescence. Vertical optical 
coherence tomography images of the central lesion (C, white arrow in Fig. 3.11A) and the 
lesion temporal and superior to the central lesion (D, black arrow in Fig. 3.11A) are highly 
similar, although the central lesion shows more subfoveal material of increased ref lectivity.
Figure 3.12.*       
A. Fundus image of the right eye of patient 15 (no BEST1 mutation), showing a small central 
vitelliform lesion and a large arcuate lesion, below the superior temporal vascular arcade. 
B. A composition of fundus autof luorescence (FAF) images shows the large eccentric lesion 
with scattered areas of increased FAF. At the inferior edges of this lesion, pseudohypopyon-
like deposits of material of increased FAF can be observed (arrows).
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mutation, with a mean age at onset of 29.8 versus 37.8 in the group of patients without 
BEST1 mutations. The loss of visual acuity was more pronounced in the patients who 
carried mutations in BEST1. All patients with BEST1 mutations showed an abnormal EOG, 
compared to two of the six patients without BEST1 mutations. The widespread dysfunction 
of the RPE in patients with BEST1 mutations, as indicated by the abnormal EOG, is not 
unexpected since the bestrophin-1 protein encoded by the BEST1 gene is located in the 
basolateral membrane of the RPE, where it is assumed to function as a Ca2+-sensitive Cl- 
channel and a regulator of regulation of voltage-dependent Ca2+ channels.35 
The aspect of the extramacular lesions varied in both groups, ranging from small 
vitelliform spots to large and diffuse lesions. These extramacular lesions seemed to have 
the same characteristics as the central lesion on ophthalmoscopy, FAF, and OCT, although 
the stages between the lesions could differ.36 The aspect on fluorescein angiography 
varied, but lesions were usually hyperfluorescent in both the early and late stages, 
probably depending on the amount of vitelliform material and the degree of atrophy in 
the lesions. 
 BVMD generally causes central lesions in the posterior pole. However, on indocyanine 
green angiography, small peripheral hyperfluorescent spots may be observed.37 
Histopathological reports have also shown abnormalities of the RPE, Bruch’s membrane 
and the choroid throughout the fundus.11,38-40 It is possible that certain mutations in 
the BEST1 gene may lead to a more severely affected RPE, resulting in the formation of 
multifocal, extramacular vitelliform lesions. This is supported by the finding of five 
affected family members in our study who also had multifocal lesions. Four affected 
family members had a unifocal central lesion. Three of these four patients were younger 
than fifteen years of age. Possibly, extramacular lesions are more likely to develop with 
older age. Contradictory to this hypothesis is the finding that the father of patient 4 had 
the same mutation as his daughter, despite having a normal fundus appearance and 
even a normal EOG, which is a rare exception on the rule that heterozygous carriers of 
a BEST1 mutation have an abnormal EOG.17,20,41 Additional genetic and environmental 
factors may therefore also influence the development of multifocal vitelliform lesions in 
patients with mutations in the BEST1 gene.
 Analysis of the BEST1 and peripherin/RDS gene did not reveal a mutation in six patients. 
A disease-related alteration in these genes cannot be ruled out completely, since 
heterozygous deletions of one or more exons are missed by PCR-based mutation analysis, 
and the introns and promotor have not been analysed for mutations. An alternative 
explanation could be the involvement of a thus far unknown gene in the pathogenesis 
of the multifocal vitelliform phenotype in these patients. The EOG was normal in four 
of these six patients without a mutation in the BEST1 gene, indicating that there was no 
generalized disturbance of the electrical activity of the RPE in this subgroup. In patient 
15, an alteration in the 5’ untranslated region of the peripherin/RDS gene was found, of 
which the pathogenic nature is unclear. 
The clinical and genetic heterogeneity of retinal disorders with multifocal vitelliform 
lesions suggests that the clinical diagnosis is inaccurate and overlap between the 
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phenotypes may occur. In our opinion, a patient that presents with the combination of 
multifocal vitelliform lesions, an autosomal dominant inheritance pattern, an abnormal 
EOG and a mutation in the BEST1 gene, should receive the diagnosis of multifocal Best 
vitelliform macular dystrophy. 
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4.1.  The spectrum of retinal dystrophies caused by mutations 
in the peripherin/RDS gene
Abstract
Peripherin/rds is an integral membrane glycoprotein, mainly located in the rod and 
cone outer segments. The relevance of this protein to photoreceptor outer segment 
morphology was first demonstrated in retinal degeneration slow (rds) mice. Thus far, over 
90 human peripherin/RDS gene mutations have been identified. These mutations have 
been associated with a variety of retinal dystrophies, in which there is a remarkable 
inter- and intrafamilial variation of the retinal phenotype. In this paper, we discuss 
the characteristics of the peripherin/RDS gene and its protein product. An overview is 
presented of the broad spectrum of clinical phenotypes caused by human peripherin/
RDS gene mutations, ranging from various macular dystrophies to widespread forms of 
retinal dystrophy such as retinitis pigmentosa. Finally, we review the proposed genotype-
phenotype correlation and the pathophysiological mechanisms underlying this group 
of retinal dystrophies.
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Abbreviations: adRP, autosomal dominant retinitis pigmentosa; AFVD, adult-onset 
foveomacular vitelliform dystrophy; AMD, age-related macular degeneration; CACD, 
central areolar choroidal dystrophy; DGGE, denaturating gradient gel electrophoresis; 
EOG, electro-oculogram; ERG, electroretinography; FAF, fundus autofluorescence; OSs, 
outer segments; rds, rds, retinal degeneration slow; RP, retinitis pigmentosa; RPA, retinitis 
punctata albescens; RPE, retinal pigment epithelium; SSCA, single strand conformational 
analysis; STGD1, autosomal recessive Stargardt disease.
1. Introduction
The retinal degeneration slow (rds) mouse is one of the oldest animal models of retinal 
degeneration. The abnormal photoreceptor outer segment formation in the rds mouse 
is caused by mutations in the rds gene and results in a slowly progressive photoreceptor 
degeneration.1-4 
The role of mutations in the human homologue of rds, the peripherin/RDS gene, in human 
retinal dystrophies was first recognized in autosomal dominant retinitis pigmentosa 
in two simultaneous reports.5,6 Subsequent reports identified peripherin/RDS mutations 
not only in autosomal dominant retinitis pigmentosa, but also in a variety of macular 
dystrophies, such as adult-onset foveomacular vitelliform dystrophy and butterfly-
shaped pigment dystrophy of the fovea.7,8 Other retinal dystrophies that have been found 
in association with peripherin/RDS mutations are central areolar choroidal dystrophy,9,10 
retinitis punctata albescens,11 cone-rod dystrophy,12 multifocal pattern dystrophy 
simulating Stargardt disease (STGD1)/fundus flavimaculatus,13 age-related macular 
degeneration (AMD)-like late-onset maculopathy,14 and other unspecified autosomal 
dominant macular dystrophies.15,16 The combination of a specific mutation in peripherin/
RDS (p.Leu185Pro) and a mutation in the ROM1 gene causes a digenic form of retinitis 
pigmentosa.17,18 
 Several studies showed that a striking inter- and intrafamilial phenotypic variation 
may be observed in association with peripherin/RDS mutations.19-21 Mutations in this gene 
not only account for a broad spectrum of retinal disorders, but causative peripherin/RDS 
mutations are also relatively frequent in patients with retinal dystrophies. Peripherin/RDS 
mutations are present in up to 25% of the central retinal dystrophies, depending on the 
inclusion criteria, methods of mutation analysis, and ethnic background of the patient 
population.22-27 Furthermore, peripherin/RDS is one of the most frequently involved genes 
in patients with autosomal dominant retinitis pigmentosa.28,29 
 This paper aims to review the characteristics of the peripherin/RDS gene, as well as the 
broad spectrum of retinal dystrophies caused by mutations in this gene. In addition, in 
vitro studies and transgenic animal models are discussed, which add to the insight in 
the pathogenesis of peripherin/RDS-related retinal dystrophies and improve the genotype-
phenotype correlations. Finally, future therapeutic perspectives are discussed. 
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2. Molecular biology of the human peripherin/RDS gene
2.1. The peripherin/RDS gene
Two years prior to the identification of the human peripherin/RDS gene, the murine 
ortholog was found.4 Since abnormalities in this gene result in a slowly progressive 
degeneration of photoreceptors, the gene was named Retinal Degeneration Slow (rds).2 
The phenotype in rds mice is due to haploinsufficiency and is dose-dependent: retinal 
degeneration is faster and more pronounced in rds(-/-) mice compared to rds(+/-) mice.1,30 
 There has been some variation in nomenclature of the peripherin/RDS gene, as other 
authors have used RDS/peripherin, peripherin-2 and rd2 as the name of this gene. The 
official gene symbol approved by the Human Gene Nomenclature Committee is PRPH2 or 
peripherin-2. We will, however, maintain the name peripherin/RDS, as this name is widely 
used and accepted by the vision research community (the abbreviation RDS has been 
used for nearly 30 years). The peripherin/RDS gene localizes to chromosome 6p21.2, spans 
26 kilobases of genomic DNA and contains 3 exons. 
2.2. The peripherin/rds protein 
Rod and cone photoreceptor outer segments (OSs) contain hundreds of orderly arranged 
flat membranous structures, appropriately named discs (in rod OSs) and lamellae (in cone 
OSs), in which phototransduction is initiated. The human peripherin/RDS cDNA encodes 
the peripherin/rds protein, which plays a pivotal role in the formation, maintenance and 
renewal of these photoreceptor OSs.4,31-34 Peripherin/rds encompasses an open reading 
frame of 346 amino acids, with a polypeptide weight of 39.3 kilodalton.4 Most of the 
knowledge about the function of peripherin/rds originates from in vitro studies with 
murine and bovine peripherin/rds, as well as mouse models.35,36 
 Murine and bovine peripherin/rds polypeptides both are 91% identical to their human 
ortholog.4,37 Peripherin/rds is an integral membrane glycoprotein with four helical 
transmembrane domains,37,38 and is predominantly localized to the rim regions of rod 
and cone OS discs and lamellae.39,40 Its N- and C-termini are located in the extradiscal 
space (within the cytoplasm), whereas two extracellular loops (D1 and D2, also termed 
EC1 and EC2) are located in the intradiscal space (Fig. 4.1).37,38 A single N-glycosylation site 
is present at p.Asn229, which is not required for normal peripherin/rds biosynthesis or 
function.38,41
 Peripherin/rds functions as an oligomer, composed of dimer subunits that form 
strong noncovalently bound tetramers, mediated by the large D2 loop.42,43 Besides 
homotetramers, peripherin/rds also forms heterotetrameric complexes with the 
homologous protein rom1, through a specific region in the D2 loop.44-49 Rom1 is likely to 
function as a regulator of photoreceptor OS disc morphogenesis.50-52 The D2 loop contains 
7 cysteine residues (Fig. 4.1). Six of these cysteines are important for protein structure 
through the formation of intramolecular disulfide bonds, whereas one specific cysteine 
(p.Cys150) mediates polymerization of tetramers.48,53 Tetrameric assembly of peripherin/
rds dimers and peripherin/rds - rom1 dimers is required for proper targeting to and 
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incorporation into newly formed rod OS disc membranes.54 Tetramerization also enables 
interaction with intracellular and extracellular structures through disulfide-mediated 
polymerization.43,45,48,55-57 Furthermore, peripherin/rds may also be required for the 
proper interaction between cone OSs and the extracellular “cone matrix sheath”.31,58-60
 The C-terminus is a structurally flexible region that probably has multiple functional 
activities.32,61,62 A highly conserved region within the C-terminal domain of peripherin/
rds plays a critical role in membrane fusion, which is important for disc morphogenesis 
and disc shedding.35,56,63-68 The C-terminal region also functions as a signal sequence for 
the targeting and localization of peripherin/rds to the rod OS.69 Calcium-dependent 
association of calmodulin with the C-terminal domain modulates peripherin/rds 
function.70 An intramembrane glutamic acid residue (p.Glu276) also acts as an important 
regulator of peripherin/rds functional activity.51 Finally, peripherin/rds may also influence 
or even participate in the visual cycle.71
 The proposed functional properties of peripherin/rds, as described above, clearly 
indicate that peripherin/rds is a multifunctional protein, important in disc morphogenesis, 
maintenance of proper disc alignment and disc shedding.32,72 Interestingly, peripherin/
rds appears to play a different role in rod and cone OS morphogenesis. In mice, absence 
of peripherin/rds leads to rods without OSs that eventually undergo apoptosis.30,73-75 
The cones, on the other hand, develop atypical OSs that not completely preclude cone 
functionality.30,31,73-75 
2.3. Human peripherin/RDS gene mutations
2.3.1. Macular dystrophies
The involvement of the peripherin/RDS gene in macular dystrophies was first recognized 
in 1993, when different peripherin/RDS mutations were identified in a variety of 
macular phenotypes.7,8,20,76,77 Mutations in the peripherin/RDS gene are a frequent cause 
of autosomal dominant macular dystrophies. Prevalence numbers vary considerably, 
due to differences in mutation analysis, interpretation of the retinal phenotype as well 
as ethnic background. Kohl and colleagues analysed the peripherin/RDS gene in a group 
of patients from continental Europe, with a predominantly central retinal dystrophy 
and intrafamilial variability of disease expression.26 They also included patients with 
phenotypes similar to those previously reported with peripherin/RDS mutations. In this 
patient group, peripherin/RDS mutations were identified in approximately 11% of patients. 
Mutation detection in this study consisted of combined single strand conformational 
analysis (SSCA) and heteroduplex analysis under two different gel conditions. In a 
Spanish population of patients with autosomal dominant macular dystrophies, a 
peripherin/RDS mutation frequency of 23% was found with denaturating gradient gel 
electrophoresis (DGGE) and direct genomic sequencing.25 Peripherin/RDS mutations were 
identified in approximately 7% of British patients with various dominantly inherited 
macular dystrophies, using heteroduplex analysis and direct sequencing of polymerase 
chain reaction-amplified coding exons.78 A p.Arg172Trp mutation (located in the 
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important D2 loop of the protein) was found in a notably high frequency in this study, 
accounting for 50% of identified mutations, and was shown to be the result of a founder 
effect. Mutations in the peripherin/RDS gene appear to be rare in Japanese patients with 
macular dystrophies.22,24 In a specific form of macular pattern dystrophy, adult-onset 
foveomacular vitelliform dystrophy, the mutation detection rate is 2-18% in European 
and Caucasian-American patients.23,79,80 
 The majority of mutations in macular dystrophies such as central areolar choroidal 
dystrophy and pattern dystrophies are missense mutations and are located in the 
intradiscal D2 loop (Fig. 4.1), but mutations may also be found in other parts of the 
peripherin/rds protein.81-84 An exception is multifocal pattern dystrophy simulating 
STGD1/fundus flavimaculatus, which appears to be caused mainly by frameshift 
mutations.13,85 An overview of peripherin/RDS mutations and the associated phenotypes 
can be found on the Retina International website (http://www.retina-international.org/
sci-news/rdsmut.htm) and in the Human Gene Mutation Database (http://www.hgmd.
cf.ac.uk/ac/index.php).
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et al.53). The mutations associated with retinal dystrophies are indicated. Colored residue: missense 
mutation or in-frame deletion. Colored bar: nonsense or frameshift mutation. 
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2.3.2. Cone and cone-rod dystrophy
Six peripherin/RDS mutations have been reported in well-documented cases of cone 
and cone-rod dystrophy: p.Arg172Trp,86-88 p.Tyr184Ser,89 p.Lys197Glu,26 p.Val200Glu,90 
p.Asn244His,12,89 and likely p.Ser27Phe.91 The p.Tyr184Ser, p.Asn244His and p.Val200Glu 
mutations have all been reported in Japanese families. Except for p.Ser27Phe, which 
is associated with cone dystrophy, all of these mutations are located in the D2 loop of 
peripherin/rds. Peripherin/RDS mutations probably account for a small number of cone 
and cone-rod dystrophy cases, but firm data are lacking on this subject.24,28 
2.3.3. Retinitis pigmentosa
Retinitis pigmentosa (RP) shows extreme genetic heterogeneity. Over 45 genes have been 
identified, with autosomal dominantly inherited RP (adRP) accounting for 30-40% of the 
cases.92 Peripherin/RDS mutations were found in 3-9% of adRP patients of mostly European 
ancestry in extensive genetic surveys using SSCA,17,28,29 and in 8% of Swedish adRP cases 
using DGGE.93 These results indicate that mutations in the peripherin/RDS gene are among 
the most prevalent genetic causes of adRP in the United States of America and Northern 
Europe. Peripherin/RDS mutations appear to be rare in Southern European adRP patients 
(0-1.4%),94,95 as well as in Japanese RP patients (0-1.9%).22,24,96 
 To date, 34 different peripherin/RDS mutations have been implicated in adRP, including 
24 missense mutations, five frameshift mutations leading to premature termination, 
four in-frame deletions and one stop mutation. The majority of these mutations is located 
in the D2 loop, although mutations have also been described in parts of the peripherin/
rds that are predicted to be situated in transmembrane domains 2-4 and the cytoplasmic 
N- and C-terminal ends. 
2.3.4. Digenic retinitis pigmentosa
A specific peripherin/RDS missense mutation, p.Leu185Pro, causes RP only in patients 
who also carry a mutation in the ROM1 gene, which is located on chromosome 11.18 To 
date, two ROM1 mutations have been described to cause digenic RP when co-inherited 
with the p.Leu185Pro mutation in peripherin/RDS: a null mutation and a p.Gly113Glu 
missense mutation.17,18 This digenic inheritance of double heterozygous peripherin/RDS 
and ROM1 mutations is relatively rare, accounting for 0.5-3% of cases of presumed adRP 
in a population of predominantly European origin.17,29 The p.Leu185 residue is situated 
in the large D2 loop and is critical for tetramer formation.97 Two reports have described 
a heterozygous ROM1 variant without detectable mutations in the peripherin/RDS gene.98,99 
However, none of these variants has been shown to be conclusively pathogenic.17 
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3.  Ocular findings in patients with peripherin/RDS gene 
mutations
3.1. Introduction
The group of retinal dystrophies is genetically and phenotypically heterogeneous.100,101 
Clinical classifications encounter difficulties as there is an ongoing debate about the 
parameters that should be used for categorization. Both cone and rod photoreceptors are 
compromised in the majority of retinal dystrophies, although the extent to which each 
of the photoreceptor systems is affected varies greatly. Detection of electrophysiological 
abnormalities in retinal dystrophies depends on the sensitivity of the detection 
technique.31,100-102 In addition, electrophysiological results may vary over the course 
of the disorder. In peripherin/RDS-related retinal disease, as with many types of retinal 
dystrophies, phenotypes are encountered that are not easily classified in the current 
clinical classification system.13,19,84 An evolution from one clinical phenotype to another, 
for instance from a macular dystrophy towards a cone-rod or rod-cone dystrophy, is not 
uncommon.13,16,88 
The alternative, a classification based solely on underlying molecular genetic 
abnormalities, is not practical in view of the high clinical heterogeneity associated 
with mutations in genes such as peripherin/RDS and ABCA4.13,20,103-105 The next best option 
therefore remains a classification based on the clinical findings, supplemented by 
knowledge of the underlying molecular genetic defect.100,101,106,107
 To enable categorization of the phenotypes associated with peripherin/RDS mutations, 
it is inevitable to formulate convenient defining features, as incomplete as they 
might be. In this review, we classified the broad phenotypic range according to the 
ophthalmoscopically observed retinal abnormalities, in combination with full-field 
electroretinographic (ERG) findings. This pragmatic approach allows us to classify most 
peripherin/RDS-related phenotypes. 
 We define macular dystrophy broadly, as a retinal phenotype that is largely confined 
to the central fundus at ophthalmoscopy, with a generally normal photopic and scotopic 
full-field ERG earlier in the course of the disease. One must bear in mind, however, that 
many “macular” dystrophies may probably be considered panretinal disorders at the 
molecular level. This is illustrated by the observation that some phenotypes, though 
initially confined to the macula, eventually will extend beyond the retinal vascular 
arcades, with cone and/or rod dysfunction on the full-field ERG. This has been shown 
not only in peripherin/RDS-related dystrophies, but also in macular dystrophies associated 
with genes such as ABCA4, TIMP3 and BEST1.13,20,108,109 Patients with macular dystrophies 
often report central visual loss, and display fairly symmetrical macular abnormalities at 
ophthalmoscopy. The peripheral retina and peripheral visual fields are typically normal. 
In macular dystrophies with a normal cone and rod function on full-field ERG, the 
multifocal and pattern ERG often do show photoreceptor dysfunction.15,110
 The clinically and genetically heterogeneous group of progressive cone and cone-rod 
dystrophies is characterized by progressive visual loss, color vision abnormalities, visual 
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field loss, a variable degree of photophobia, and sometimes nystagmus.111 In cone-rod 
dystrophy, cones and rods both show panretinal abnormalities. However, cone function is 
affected earlier and more severely than rod function on the full-field ERG, and symptoms 
associated with cone dysfunction are generally more pronounced. 
 Patients with RP, also termed rod-cone dystrophy, a clinically variable and genetically 
heterogeneous retinal disorder, typically experience night blindness and constriction of 
the peripheral visual field early in the course of the disease.92,105,112 The rod-driven full-field 
ERG is predominantly affected in RP, which is in contrast to cone-rod dystrophy. In later 
stages of both RP and cone-rod dystrophy, however, photopic and scotopic responses on 
full-field ERG may become nonrecordable and the clinical characteristics may coalesce. 
3.2.  The clinical spectrum of retinal dystrophies associated with mutations in 
the peripherin/RDS gene 
3.2.1. Macular dystrophies
Mutations in the peripherin/RDS gene are associated with a broad spectrum of macular 
dystrophies: pattern dystrophies, such as butterfly-shaped pigment dystrophy and adult-
onset foveomacular vitelliform dystrophy, as well as central areolar choroidal dystrophy, 
and AMD-like late-onset macular dystrophy. 
 The pattern dystrophies constitute a group of retinal disorders characterized by a 
variety of deposits of yellow, orange or grey pigment, predominantly in the macular 
area.113-115 According to the classification of Gass, five main categories of pattern 
dystrophies are discriminated on the basis of the pattern of pigment distribution: adult-
onset foveomacular vitelliform dystrophy, butterfly-shaped pigment dystrophy, reticular 
dystrophy of the pigment epithelium, multifocal pattern dystrophy simulating fundus 
flavimaculatus, and fundus pulverulentus.113 Mutations in the peripherin/RDS gene appear 
to be a relatively frequent cause of pattern dystrophies, and have been described in adult-
onset foveomacular vitelliform dystrophy, butterfly-shaped pigment dystrophy, as well as 
multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus.7,13,23,26,82,101,103,116-118 
In 2-18% of patients with adult-onset foveomacular vitelliform dystrophy, peripherin/
RDS mutations are found.23,79,80 Thus far, the remaining two types of pattern dystrophy, 
reticular dystrophy of the pigment epithelium and fundus pulverulentus, have not been 
linked to mutations in the peripherin/RDS gene. The age at onset in pattern dystrophy is 
highly variable, but patients tend to remain asymptomatic until the 5th decade and some 
patients may remain asymptomatic. In general, mild disturbances of central vision are 
first noticed in midlife. The course of the disease is relatively benign, although it should 
be emphasized that severe vision loss occurs in up to 50% of the affected individuals 
after the age of 70, due to chorioretinal atrophy and/or the development of choroidal 
neovascularization.13,82,103,119,120 Fluorescein angiography and fundus autofluorescence (FAF) 
imaging may aid to discriminate between the different types of pattern dystrophy.13,121
 Adult-onset foveomacular vitelliform dystrophy (AFVD) is clinically and genetically 
heterogeneous.23,79,122 Besides the peripherin/RDS gene, AFVD is associated with mutations 
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in the BEST1 gene, which accounts for up to 25% of cases.122,123 The majority of underlying 
genetic causes remain to be identified.80 Ophthalmoscopy typically shows symmetrical, 
solitary, yellow-white, round to oval, slightly elevated subretinal lesions, often with a 
central pigmented spot.79,113 These lesions are usually one-third to one disc diameter 
in size, but may occasionally be larger and even multifocal, and may thus be confused 
with Best vitelliform macular dystrophy.23,113,124 Subretinal neovascularization seldomly 
occurs.79,120,125 Fluorescein angiography typically shows a central nonfluorescent 
spot, corresponding with the vitelliform lesion, surrounded by a small irregular 
hyperfluorescent ring. Most patients show increased FAF of the vitelliform lesion, which 
is in accordance with the histopathologic finding of increased lipofuscin quantities in 
AFVD lesions.126,127 Vitelliform lesions in AFVD can also be clearly delineated with optical 
coherence tomography.128,129 Contrary to Best vitelliform macular dystrophy, the electro-
oculogram (EOG) in AFVD is usually normal.23,79 In general, the full-field ERG in AFVD 
caused by peripherin/RDS mutations is also normal.80,84,128
 In butterfly-shaped pigment dystrophy of the fovea, a spoke-like pigment pattern 
resembling the shape of a butterfly is observed in the central macula, surrounded by a 
zone of depigmentation (Fig. 4.2A).130 Butterfly-shaped pigment dystrophy is genetically 
heterogeneous: apart from peripherin/RDS mutations,7,103 a locus on 5q21.2-q33.2 is also 
associated with autosomal dominant butterfly-shaped pigment dystrophy.131,132 On FAF, 
lesions in butterfly-shaped pigment dystrophy may show increased as well as decreased 
FAF, corresponding with changes in lipofuscin (Fig. 4.2B). On fluorescein angiography, 
pigmented regions within the lesion correspond with hypofluorescence, whereas 
depigmented zones corresponding with chorioretinal atrophy are hyperfluorescent (Fig. 
4.2C).81,103,121 Rarely, butterfly-shaped pigment dystrophy may be complicated by subretinal 
neovascularization.133 Full-field ERG and dark adaptometry are generally normal, but 
patients may exhibit abnormal color vision and EOG results.7,81,114,134
 Multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus is 
characterized by irregular yellow-white flecks scattered throughout the posterior pole, 
often extending beyond the retinal vascular arcades (Fig. 4.2D and G).13,113 Besides these 
remarkable changes, patients display macular abnormalities, ranging from various 
patterns of yellow or greyish deposits to well-demarcated lesions of marked chorioretinal 
atrophy.13 Visual loss is usually first experienced in the 5th decade, but patients may remain 
asymptomatic. The flecks seen in multifocal pattern dystrophy resemble those encountered 
in STGD1/fundus flavimaculatus, an autosomal recessive retinal dystrophy caused by 
mutations in the ABCA4 gene. The resemblance can be observed on ophthalmoscopy, as 
well as on FAF (Fig. 4.2E and H) and optical coherence tomography.13,135 Flecks are usually 
hyperfluorescent in the early and late phase of the fluorescein angiogram, sometimes 
with a central hypofluorescent spot (Fig. 4.2F and I). Contrary to most STGD1 cases,136 
the fluorescein angiogram in multifocal pattern dystrophy generally does not show a 
so-called “dark choroid”,13 although an atypical patient (carrying a 4-base pair insertion 
at codon 140 of peripherin/RDS) has been described with a multifocal pattern dystrophy 
phenotype in combination with a dark choroid and choroidal neovascularization.137 
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Figure 4.2.     
Pattern dystrophies caused by mutations in the peripherin/RDS gene. (A-C) Butterf ly-shaped 
pigment dystrophy of the fovea. A. Color fundus photograph of a 62-year-old patient 
 carrying a p.Arg220fsX34 mutation in peripherin/RDS. A butterf ly-shaped lesion is observed 
in the fovea, containing areas of increased and decreased pigmentation. On a fundus 
autof luorescence (FAF) image (B), some parts of the lesion display increased FAF, whereas 
FAF is decreased in other parts. C. Fluorescein angiogram of the same patient. Hyper-
f luorescent areas correspond with the depigmentated areas at ophthalmoscopy, whereas 
hypof luorescent parts largely coincide with the pigmented parts of the lesion. The visual 
acuity in this patient was 20/20. 
(D-I) Multifocal pattern dystrophy simulating STGD1/ fundus f lavimaculatus.  
D. Color  fundus photograph of a 57-year-old patient carrying a p.Pro147fsX4 mutation in 
the peripherin/RDS gene. An irregularly shaped yellow-white lesion is observed in the central 
macula, surrounded by irregular yellow-white STGD1-like f lecks scattered throughout the 
posterior pole. E. These lesions can be more clearly delineated on FAF. In general, lesions 
show markedly increased FAF, sometimes bordered by zones of decreased FAF.  
F. Fluorescein angiogram of the same patient, showing many hyper f luorescent lesions.  
Note the normal choroidal background f luorescence. This patient had a visual acuity of 
20/20. G. Color fundus photograph of advanced multifocal pattern  dystrophy simulating 
STGD1/ fundus f lavimaculatus. In this 56-year-old patient, who carried a p.Asn54fsX9 
 mutation in peripherin/RDS, numerous, conf luent, mildly atrophic lesions are seen in the 
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Central macular lesions may remain fairly discrete, thus causing little or no visual 
loss, but they may also evolve towards well-defined chorioretinal atrophy. The STGD1-
like flecks may show confluence with advancing age (Fig. 4.2G and H), and extensive 
atrophy of the posterior pole tends to occur in patients over 60 years of age.13 Contrary 
to the previously described pattern dystrophies, this phenotype frequently shows signs 
of panretinal degeneration, especially later in the course of the disease. In the majority 
of patients, a mild to marked constriction of the peripheral visual field is seen.13,16,20 
Night blindness in combination with RP-like pigmentary changes and chorioretinal 
atrophy in the (mid-)peripheral retina may also be observed. Most patients show an 
abnormal EOG.13 Full-field ERG findings are often normal in early multifocal pattern 
dystrophy simulating STGD1. With advancing disease, cone and rod function become 
compromised on the panretinal level, which is reflected by the appearance of full-field 
ERG abnormalities. In general, the decrease of cone and rod responses on the full-field 
ERG is relatively equal, but results may show a slight preponderance of either cone or 
rod dysfunction, probably depending on the type of mutation.13,13,16,19,21,85,138,139 Like many 
so-called macular dystrophies, multifocal pattern dystrophy simulating STGD1/fundus 
flavimaculatus should therefore be regarded as a disorder that involves the entire retina. 
However, the multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus 
phenotype may be preceded or even accompanied by butterfly-shaped lesions and adult-
onset foveomacular vitelliform lesions.13 Clinical findings that may aid to distinguish 
between multifocal pattern dystrophy and STGD1 are the autosomal dominant pattern 
of inheritance, the relatively late age at onset, the comparatively good and stable visual 
acuity and the absence of a “dark choroid” in most patients.13
 Different types of pattern dystrophy may be observed in a single family with 
individuals carrying an identical peripherin/RDS mutation. Occasionally, RP-like changes 
are seen in combination with these pattern dystrophies.13,19-21,140 An evolution from one 
type of pattern dystrophy to another may be observed within a single patient, and the 
type of pattern dystrophy may even be different between the two eyes of a patient.13,120,137 
Age-dependent progression of a phenotype may be seen, evolving from localized patterns 
of macular abnormalities to more widespread retinal disease and atrophy of the retinal 
pigment epithelium (RPE)-photoreceptor complex.13,82,141 
 Central areolar choroidal dystrophy (CACD) is a macular dystrophy that affects the 
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posterior pole. H. The FAF image shows a large, ring-shaped zone of increased FAF, 
 surrounding the macula and optic disc. Granular zones of decreased FAF may be observed 
within this area, corresponding with atrophy of the retinal pigment epithelium (RPE).  
The macula seems relatively unaffected on FAF, which is ref lected in the visual acuity of 
20/16. On the f luorescein angiogram (I), however, a markedly hyperf luorescent macular 
 lesion is observed, consistent with RPE atrophy. This macular lesion is surrounded by many 
irregular, predominantly hyperf luorescent lesions.
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retina, RPE, and choriocapillaris.142-144 To date, 5 peripherin/RDS mutations have been 
reported in CACD or CACD-like phenotypes: p.Arg142Trp,9,145 p.Arg172Trp,8,15,26,78,86-88,146-1
48 p.Arg172Gln,8,15,88 p.Arg195Leu,110,149 and p.Leu307fsX83, the last mutation causing a 
somewhat atypical late-onset CACD.150 Missense variants at codon 172 appear to be the 
most frequent peripherin/RDS mutations in macular dystrophy and have been reported to 
cause a relatively constant CACD phenotype.15,78,87 The p.Arg172Trp mutation, however, 
may be associated with incomplete penetrance, intrafamilial variability, cone-rod 
dystrophy and adRP.86,147 
 A CACD patient usually presents with mild central visual loss and metamorphopsia, 
sometimes accompanied by mild photophobia. Nyctalopia is reported rarely in CACD, and 
seems to be associated with pigmentary changes of the peripheral retina.86 The course 
of the disease is divided into four stages that can be observed on ophthalmoscopy.87,144 
In stage I, slight parafoveal pigmentary changes of the RPE are seen, usually in the 
adolescent patient (Fig. 4.3A). Stage II is characterized by a round to oval, mildly atrophic 
hypopigmented area of 1.5 to several disc diameters (Fig. 4.3B). In stage III, one or more 
areas of well-circumscribed atrophy of the RPE and choriocapillaris appear outside the 
fovea (Fig. 4.3C). When stage III evolves to stage IV, visual acuity often decreases severely. 
In this stage, an area of well-circumscribed chorioretinal atrophy affects the fovea (Fig. 
4.3D). End-stage CACD appears as a round to oval area of chorioretinal atrophy in the 
posterior pole, sometimes also surrounding the optic disc. The appearance of the macular 
lesions in peripherin/RDS-associated CACD is fairly constant, although with a variable age 
at onset and rate of progression.9,15,110,144 CACD has also been described in association with 
drusen-like changes and dominant drusen.10,87 Rarely, the macula in CACD may have a 
bull’s eye aspect.86 
 The mean age at onset of visual disturbances in CACD varies with the specific 
mutation, ranging from the 3rd to 4th decade in the phenotype caused by the p.Arg172Trp 
and p.Arg195Leu mutation, to the 5th to 6th decade in the phenotype associated with 
the p.Arg142Trp mutation. A severe decrease in visual acuity to 20/200 or less in one 
or both eyes generally occurs in the 5th to 8th decade, also depending on the type of 
mutation. Both fluorescein angiography and FAF imaging are excellent means to detect 
early macular changes that are difficult to discern with ophthalmoscopy alone.15,110,144 
 FAF imaging, which visualizes changes in RPE lipofuscin, appears to be a convenient 
non-invasive method aiding the diagnosis and follow-up of peripherin/RDS-related 
retinal dystrophies such as CACD.13,15,110,151,152 In early CACD, a speckled increase of FAF 
predominates, whereas sharply demarcated areas of severely decreased to absent FAF 
appear in stage III and IV CACD (Fig. 4.3E). 
The first fluorescein angiographic findings, in stage I CACD, are small parafoveal window 
defects.144 As the lesion enlarges towards a round-to-oval area of RPE atrophy, the area 
of hyperfluorescence also becomes progressively larger (Fig. 4.3F). Full-field ERG testing 
in CACD is often normal, but may display abnormalities in a cone or cone-rod pattern. 
Full-field ERG abnormalities tend to occur in the later stages and in association with the 
p.Arg172Trp mutation.15,26,86,110,144,146 Tests of the macular function, such as the pattern ERG 
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and multifocal ERG, as well as results from color vision testing, may be abnormal early in 
the course of the peripherin/RDS-related retinal dystrophies, such as CACD and the pattern 
dystrophies.15,86,88,110,128,144,153 The EOG is usually normal or slightly subnormal.15,87,144
 A peculiar macular dystrophy has been described in a single large family with 17 
affected family members.14 Bearing a striking resemblance to AMD, this macular 
dystrophy was termed AMD-like late-onset maculopathy. In this macular dystrophy, 
which is caused by a p.Tyr141Cys missense mutation in peripherin/RDS, vision loss usually 
manifests in the 5th to 7th decade and is relatively mild in the majority of patients. 
A wide spectrum of AMD-like exudative and non-exudative macular changes are observed 
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Figure 4.3.      
Central areolar choroidal 
 dystrophy (CACD) caused by a  
p.Arg142Trp mutation in the 
peripherin/RDS gene. (A-D) 
Color fundus photographs of 
CACD. A. Stage I CACD in a 
30-year-old patient, showing 
slight hypopigmentation in the 
temporal parafoveal area.  
The visual acuity was 20/20.  
In stage II CACD (B), an oval, 
mildly atrophic area is observed 
in the macula. Note the small 
yellow-white dots at the border 
of the lesion. This 55-year-old 
patient had a visual acuity of 
20/32. C. Stage III CACD, 
 showing a parafoveal area of 
well-circumscribed chorioretinal atrophy. This patient was 51 years of age, and the visual 
acuity was 20/20. D. In stage IV CACD, the well-circumscribed area of profound 
 chorioretinal atrophy affects the fovea, resulting in a visual acuity of 20/1000 in this 
59-year-old patient. E. Fundus autof luorescence (FAF) image of stage III CACD, of the same 
patient as in panel (C). The severely atrophic part of the lesion corresponds with a well-
demarcated absence of FAF, surrounded by speckled areas of decreased and increased FAF  
in the remaining part of the lesion. F. Fluorescein angiogram of stage III CACD. A well-
demarcated round patch with increased visibility of the underlying choroidal vessels is seen 
in the nasal part of the lesion, adjacent to the fovea, consistent with profound chorioretinal 
atrophy. The remaining parts of the lesion show mottled hyperf luorescence, corresponding 
with mild chorioretinal atrophy on ophthalmoscopy.
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on ophthalmoscopy, such as drusen-like deposits, pigmentary changes, geographic 
chorioretinal atrophy, choroidal neovascularization and disciform scars.14 On fluorescein 
angiography, leakage of fluorescein dye as a result of choriodal neovascularization may 
be seen, and a dark choroid may be present. Full-field ERG and EOG testing indicates that 
overall retinal function remains largely intact.14 
 Macular dystrophies caused by peripherin/RDS mutations may share several hallmark 
features of AMD, the most common cause of blindness at older age in the Western 
world.154 Peripherin/RDS phenotypes with a relatively late age at onset may therefore be 
confused with AMD. The presence of drusen and geographic atrophy may also falsely 
lead to the diagnosis of an atrophic form of AMD,10,13,14,21,82,87 whereas peripherin/RDS-related 
retinal dystrophies with choroidal neovascularization, exudative changes and disciform 
scars may be confused with neovascular AMD.14,26,120,125,137,155 The specific characteristics 
of the peripherin/RDS-related phenotypes, in combination with the autosomal dominant 
inheritance pattern, as well as molecular genetic analysis in selected cases, can assist the 
clinician in establishing the correct diagnosis. Contrary to other genes that are relatively 
frequent causes of macular dystrophies, such as ABCA4 and BEST1, the possible role of the 
peripherin/RDS gene in AMD has not been thoroughly evaluated to date.156,157
3.2.2. Cone and cone-rod dystrophy
In cone-rod dystrophy caused by peripherin/RDS mutations, loss of visual acuity starts 
in the 2nd to 4th decade, sometimes accompanied by mild photophobia and/or night 
blindness. Macular abnormalities are frequently observed on ophthalmoscopy and may 
appear similar to lesions in CACD, ranging from granular, mildly atrophic RPE changes to 
areas of profound, well-circumscribed chorioretinal atrophy. Some individuals may show 
bull’s eye maculopathy and/or (mid-)peripheral areas of RPE atrophy and pigmentary 
changes.86,89,90 Color vision testing is often severely abnormal, and the peripheral visual 
field may gradually become constricted. FAF imaging tends to show lesions with speckled 
areas of increased and decreased FAF, similar to the observations in CACD.15,86 The full-
field ERG shows a severely diminished to non-recordable cone response and variable 
abnormalities in the rod-derived responses.19,86,89,90,138,139 In asymptomatic mutation 
carriers, a reduced cone response on the photopic ERG may be the first detectable clinical 
feature.90 The pattern ERG, as a marker of macular dysfunction, is markedly abnormal. 
Interestingly, the p.Arg172Trp mutation may lead to CACD as well as cone-rod dystrophy, 
the latter apparently evolving from a localized, central cone dystrophy to a more 
generalized cone and/or cone-rod dystrophy.15,86-88 The p.Ser27Phe variant, presumably 
a pathologic mutation, has been described in a family with late-onset cone dystrophy.91 
This phenotype was characterized by photophobia and central visual loss, together with 
impaired color vision, mild non-specific foveal changes and subnormal macular and full-
field cone ERG responses.
3.2.3.Retinitis pigmentosa
In adRP caused by peripherin/RDS mutations, the onset and severity of the phenotype 
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depends on the type of mutation. A relatively early age at onset, between the 1st and 3rd 
decade, has been associated with the p.Asp173Val and p.Asn244Lys mutations, as well 
as a  three-base pair deletion of codon 118 or 119, residing in the 3rd transmembrane 
domain.5,89,158 The majority of adRP patients with other peripherin/RDS mutations have an 
age at onset in the 3rd to 5th decade.140,158-161 These patients usually first experience night 
blindness, followed by a progressive loss of the peripheral visual field. In most cases, a 
decrease in visual acuity does not occur before the age of 50. In general, an earlier age 
at onset leads to earlier and more profound visual impairment. On ophthalmoscopy, 
the classic features of RP are encountered: bone spicule pigmentation, retinal arteriolar 
attenuation and a waxy pale optic disc (Fig. 4.4). The full-field ERG reveals the absence of 
a rod response in the early teens, often accompanied by a mildly to severely decreased 
and delayed cone response. Dark adaptometry shows an abnormally delayed recovery of 
rod sensitivity, together with a rod threshold elevation of at least 1.0 log units compared 
to normal individuals.162,163 The EOG may also be abnormal.140 Color vision testing is 
normal, except in cases with macular involvement.160,163 Kinetic visual field examination 
shows a progressive constriction of the peripheral visual field.5,20,140,160,163 
 The adRP phenotype may be associated with macular dystrophy.140,164,165 The relatively 
severe adRP phenotype caused by a p.Asn244Lys mutation in peripherin/RDS, described in 
a Japanese family, is associated with bull’s eye maculopathy.163,166 These macular lesions 
may evolve towards profound chorioretinal atrophy, resulting in a low visual acuity of 
counting fingers or even hand movements after the 5th decade. In this family, both the 
scotopic and photopic ERG were often extinguished in the early 20s.
 A very typical form of autosomal dominant rod-cone dystrophy is retinitis punctata 
albescens (RPA). This retinal dystrophy is characterized by night blindness, innumerable 
round white deposits in the retina, progressive attenuation of the retinal arterioles, 
abnormal fundus pigmentation, progressive restriction of the visual fields, and non-
detectable or severely reduced full-field ERG responses.167 An autosomal dominant RPA-
like phenotype has also been described in families with peripherin/RDS mutations.11,19,85 
The full-field ERG in peripherin/RDS-related RPA shows a relatively equal loss of rod and 
cone function, which is in contrast to RPA related to mutations in the RLBP1 and rhodopsin 
genes, where the rod system is generally affected more severely.167-169 The RPA phenotype 
caused by peripherin/RDS mutations may be difficult to differentiate from multifocal 
pattern dystrophy simulating STGD1/fundus flavimaculatus. Both are characterized 
by multiple yellowish subretinal lesions and both may also be combined with night 
blindness and adRP-like changes such as bone spicule-like pigmentation.11,13,19 However, 
lesions in RPA appear to be less irregular, more punctate, higher in number, and 
distributed throughout the entire retina.
 The scarce clinical data on patients with digenic RP suggest that it has an onset of 
night blindness before the 4th decade and that it may be associated with a loss of visual 
acuity in the later stages.6,17,18,170 Other clinical features, such as the ophthalmoscopic 
picture and the preferential rod involvement on the full-field ERG, appear to be 
comparable to peripherin/RDS-related adRP. The peripherin/RDS and ROM1 genes are located 
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on different chromosomes. An affected individual from unrelated and unaffected parents 
has a 25% chance of transmitting both mutations to the offspring.17,18,105 This is the cause 
for the pseudodominant transmission of the phenotype in the case of digenic RP. The 
possibility of digenic RP should therefore be kept in mind in RP families with a specific 
segregation pattern, although most digenic RP patients are isolated cases.  
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Figure 4.4.       
Color fundus photograph of autosomal dominant retinitis pigmentosa in a 60-year-old patient, 
caused by a p.Pro147fsX4 mutation in peripherin/RDS. The typical features of retinitis pigmentosa 
are evident: bone spicule pigmentation, narrow retinal arterioles, and a waxy pale optic disc. 
Extensive chorioretinal atrophy is seen outside the macular area. The visual acuity was 20/100.  
He experienced night blindness since early childhood and was diagnosed with retinitis pigmentosa 
at the age of 12 years. A decrease in visual acuity and photophobia were first experienced around 
40 years of age. This patient was a cousin of the patient with multifocal pattern dystrophy 
 simulating STGD1/fundus f lavimaculatus, described in Fig. 4.2D-F, who carried the same mutation. 
Analysis of the ROM1 gene in these patients did not reveal any mutations, thus making ROM1 
 unlikely to be the modifying genetic factor in these family members.
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4. From gene mutation to disease
4.1. Peripherin/RDS mutations and protein structure
Phenotypes associated with peripherin/RDS mutations do not show a straightforward 
dependence on the position of the mutation in the primary protein sequence or the 
type of mutation.32 Moreover, a single mutation may cause a spectrum of phenotypes 
ranging from a number of different macular dystrophies to adRP.13,19,20,86,87,147 Clearly, this 
remarkable phenotypic heterogeneity makes the interpretation of animal models of 
human disease more complex. As with other retinal disorders, the obvious anatomical 
differences between human and mouse retina also complicate the interpretation of 
these animal models.32,33,171 Despite these reservations, in vitro and animal models have 
provided valuable insights into peripherin/rds function, because of the high degree of 
identity of peripherin/rds sequence between human, bovine and murine orthologs.36 
 The region between p.Cys165 and p.Asn182 in the D2 loop (Fig. 4.1) is required for 
peripherin/rds - rom1 interaction.45 Mutations within this region have been described in 
macular dystrophies as well as adRP. These mutations may lead to a disturbed peripherin/
rds - rom1 interaction, but different mutations in this region apparently affect rods 
and cones in a different way. The p.Arg172Trp mutation, located in the same region of 
peripherin/rds, may cause a spectrum of phenotypes, ranging from macular dystrophy 
to cone-rod dystrophy and adRP.86,87,93 Several functional studies, however, report a 
preferential cone involvement.86,88,138,139 The p.Arg172Trp mutation also causes cone 
and cone-rod dystrophy in a transgenic mouse model.172 In these mice, the p.Arg172Trp 
mutant protein localized properly to the rod and cone OSs and showed normal complex 
formation and association with rom1. A direct correlation was seen between transgene 
expression levels and the onset and severity of the phenotype. The results indicated that 
the p.Arg172Trp phenotype in mice is caused by a dose-dependent dominant negative 
effect that preferentially affects cones. In this mouse model, genetic supplementation 
of wild-type peripherin/rds provided partial, long-term rescue of rod function, but no 
permanent rescue of cone function.173
 A relatively large number of mutations associated with adRP have been found in a 
specific region within the large D2 loop, ranging from p.Lys193 to p.Glu226. This region 
contains two adjacent cysteine residues (p.Cys213 and p.Cys214), which form two of 
the three intramolecular disulfide bonds that are present in the D2 loop of peripherin/
rds (Fig. 4.1). These cysteines appear to be essential for peripherin/rds protein folding 
and subunit assembly.32 Most of the mutations in the p.Lys193 to p.Glu226 region are 
missense mutations, the majority leading to changes in peripherin/rds that may affect 
rods more than cones. However, some mutations in this region, including p.Cys213Arg, 
p.Cys213Tyr and p.Cys214Tyr, may also cause different types of macular dystrophy, as 
well as autosomal dominant cone-rod dystrophy.26,103,110,149 
Two adRP-causing mutations in the D2 loop have been studied in animal models and in 
vitro experiments: p.Cys214Ser and p.Pro216Leu.6,28,161 The p.Cys214Ser mutant protein, 
which causes a late-onset adRP phenotype in humans,161 is retained in the rod inner 
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segments, as this grossly misfolded protein does not pass certain quality control 
mechanisms in the rod photoreceptor cell.54,174 The resultant lack of wild-type peripherin/
rds and tetramers causes a haploinsufficiency/loss-of-function phenotype.54,72,175 In 
contrast, the adRP phenotype caused by the p.Pro216Leu mutation is probably due to a 
dominant negative effect on rod OS structure.54,72,176,177 The p.Pro216Leu mutant protein 
does not preclude tetramer formation, but the formed tetramers are dysfunctional, 
presumably as a result of hyperglycosylation of the protein.54,177 Another late-onset 
slowly progressive adRP is caused by a C-terminal 1 base pair deletion at codon 307 of 
peripherin/RDS, which is predicted to result in a completely altered and shorter C-terminal 
domain.19 This abnormal C-terminus may lead to an absent localization signal and other 
C-terminal dysfunction.32,56,62,63,65,69 A murine model of the same mutation indicates 
that the phenotype is caused by a dominant negative effect, in conjunction with 
haploinsufficiency.178  
 Digenic RP is caused by the p.Leu185Pro peripherin/RDS mutation, when it is 
co-inherited double heterozygously with a ROM1 mutation.18 In vitro studies on COS-1 
cells have found that these mutations prevent sufficient forming of homotetramers and 
higher order disulfide-linked oligomers,97,179 and suggested that functional asymmetry 
between peripherin/rds and rom1 plays a role in digenic RP.50 A transgenic mouse model, 
Xenopus immunofluorescence, as well as COS-1 cell studies pointed out that digenic RP 
is a haploinsufficiency phenotype.54,72,180 Like in the p.Cys214Ser mutation phenotype, 
insufficient amounts of tetramers are formed to allow proper OS disc morphogenesis. 
No photoreceptor degeneration was detected in rom1(+/-)/rds(+/+) mice, but rom1(-/-)/rds(+/+) 
mice showed a very mild photoreceptor degeneration.17,50,180  
 Six peripherin/RDS mutations lead to a change in cysteine residues. Cysteine residues are 
important for peripherin/rds protein structure through the formation of intramolecular 
disulfide bonds. The replacement of a cysteine by another amino acid, or the appearance 
of an extra cysteine may therefore alter protein structure. Three of the six peripherin/
RDS mutations that affect a cysteine residue have been described in adRP: p.Tyr141Cys,28 
p.Cys165Tyr,181 and p.Cys214Ser.161 The remaining three mutations (p.Cys213Arg, 
p.Cys213Tyr and p.Cys214Tyr), on the other hand, are associated with various macular 
dystrophies.78,103,145 Using a specific computer prediction programme of secondary protein 
structure, a significant correlation was found between the predicted molecular alteration 
and clinical severity.149,182 However, the computer-predicted changes in secondary structure 
were not able to predict the clinical subtype of retinal degeneration. 
 In summary, mouse models and in vitro experiments suggest that both 
haploinsufficiency and dominant negative mechanisms play a role in human retinal 
dystrophies caused by mutations in the peripherin/RDS gene.
 Rods and cones differ in several important aspects.183,184 Some studies in rds(+/-) mice 
indicate that haploinsufficiency has a greater impact on rods than on cones, and that the 
defect is more detrimental to L (“red”) and M (“green”) cones than to S (“blue”) cones.185,186 
Other mouse and human studies report that rds(+/-) haploinsufficiency phenotypes result 
in a relatively equal rod and cone cell loss.85,138,139,187,188
Chapter 4
207
4.2. Genotype-phenotype correlations
The phenotypic spectrum caused by a specific peripherin/RDS mutation, even in family 
members with identical mutations, may range from no visible abnormalities to various 
macular dystrophies, cone-rod dystrophy, as well as adRP.13,19,20,86 Incomplete penetrance 
of peripherin/RDS mutations has been described in several families.13,86,116,137 Differences in 
age and therefore disease progression alone are insufficient to explain the variability 
of the phenotypic outcomes. This makes it difficult to recognize consistent genotype-
phenotype correlations.32,117,182,189 
 Most missense mutations and in-frame deletions (75%) are located in the D2 loop 
(Fig. 4.1). More than half (52%) of the mutations in the group of macular dystrophies are 
nonsense or frameshift mutations, whereas missense mutations and in-frame deletions 
account for the majority (81%) of the mutations in adRP patients (Fig. 4.1). Some mutations 
lead to specific phenotypes with relative consistency. The p.Arg142Trp and p.Arg172Trp 
mutations, for instance, generally result in a localized macular dystrophy or in cone-rod 
dystrophy.9,15,87,144 Missense mutations in the p.Pro210 to p.Pro216 region of the D2 loop in 
the peripherin/rds protein, as well as the p.Asn244Lys mutation, are more likely to cause 
adRP, also with a fairly uniform phenotype.6,159,161,163 The p.Tyr141Cys mutation, on the 
other hand, is associated with AMD-like macular dystrophy,14 pattern dystrophies,120 and 
adRP.28 
 To date, no satisfactory explanation has been reported to explain this remarkable 
phenotypic variability and incomplete penetrance associated with peripherin/RDS 
mutations. Other factors, such as the genetic background, modifying genes and/or 
environmental factors, obviously exert their influence on the phenotypic outcome.190 The 
phenotype may depend on the amount of residual wild-type and mutant peripherin/rds 
protein, especially in haploinsufficiency phenotypes.54,180 In the case of the p.Arg172Trp 
mutation, mouse studies indicate that differences in expression level of the mutant 
protein may aid in explaining the differences in onset and severity of the disease in 
animals of the same age.172 
The phenotypic expression may also be influenced by the genetic background and 
by modifying genes.190 In the search for such factors, the ROM1 gene seemed a likely 
candidate. It has been shown, however, that variations in this gene do not constitute 
an important modulating factor.14,20,191 One of the many possible modifying genes may 
be RPE65, through the modulation of rhodopsin regeneration kinetics and light-damage 
susceptibility.192  Environmental factors may also influence phenotypes. Experimental 
evidence from animal models indicates that light exposure can modify the progression 
of several forms of retinal degeneration.193 In rds(-/-) and rds(+/-) mice, constant light 
exposure accelerates photoreceptor cell loss compared to normal mice. This retinal cell 
loss progresses from the central retina to the periphery and appears to affect rods earlier 
than cones.194 Other animals models in which retinal degeneration is accelerated by light 
exposure include animal models of adRP caused by rhodopsin mutations,138,195,196 animal 
models of Oguchi disease caused by rhodopsin kinase or arrestin mutations,197,198 and in the 
abca4(-/-) mouse model for STGD1.199,200 Dietary habits and nutritional components, such 
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as the intake of vitamin A, lutein, zeaxanthin, and omega-3 polyunsaturated fatty acids, 
may also be of influence on the clinical course of retinal degenerations.201-206 The role 
of smoking as a possible modifying factor in retinal dystrophies is unclear, although 
smoking is known to be strongly associated with AMD.207
4.3.  Pathophysiology of retinal dystrophies caused by peripherin/RDS gene 
mutations
A histopathological study in a donor eye of a patient with advanced butterfly-shaped 
pattern dystrophy, caused by a p.Cys213Tyr mutation in peripherin/RDS, revealed a central 
area of complete photoreceptor and RPE cell loss, with an intact choriocapillaris, and 
lipofuscin-containing cells in the subretinal space.103 In the surrounding region, RPE 
cells were distorted and greatly distended by lipofuscin, whereas the photoreceptors 
were partly atrophic. 
 The differential effect of peripherin/RDS mutations on cone and rod photoreceptors has 
been discussed in paragraph 4.1. Phenotypes dominated by rod photoreceptor loss may be 
caused by both a haploinsufficiency and/or a dominant negative effect. Phenotypes with 
predominantly cone dysfunction appear to be the result of a dose-dependent dominant 
negative effect.186 The multifocality of lesions in phenotypes related to peripherin/RDS 
mutations may be explained by local differences in retinal cell interactions, distribution, 
morphology and metabolism.208 
The exact mechanisms through which peripherin/RDS mutations cause photoreceptor 
and RPE cell death are as yet unclear. Animal studies indicate that photoreceptors 
containing mutant peripherin/rds may lead to a shortening of average OS length, 
whorls of OS membranes in the subretinal space, and alterations in the normal OS-RPE 
interface and disc phagocytosis.32,209 Changes secondary to peripherin/RDS mutations may 
lead to abnormalities in photoreceptor energy metabolism, physiology and intercellular 
interactions.183,210-212 These changes may lead to an accumulation of autofluorescent waste 
products like lipofuscin and toxic lipofuscin components like A2E in the photoreceptors 
and RPE.213-215 The rate of lipofuscin accumulation may be influenced by environmental 
factors such as light exposure and vitamin A intake.193,216-218 Finally, a mutation in 
peripherin/rds may initiate photoreceptor cell death through apoptosis.219,220 In peripherin/
RDS mutations that preferentially affect rods, cone cell loss at a later stage may be caused 
by a primary detrimental effect of the mutation on cone photoreceptors. An alternative 
or additional explanation may be that cone degeneration occurs secondary to rod loss, 
for instance due to a decrease in rod-derived cone viability factor.60,100,139,221-223 
5. Future perspectives
A better understanding of the underlying mechanisms of retinal dystrophies, such as the 
peripherin/RDS-related disorders in this review, is necessary for the future development 
of effective therapeutic strategies. Information from animal model research is 
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indispensable to demonstrate the efficacy and safety of such treatments.36,186,224 Detailed 
studies on retinal dystrophies caused by peripherin/RDS mutations are mandatory, not 
only to provide the patient with accurate information about his or her disease and its 
prognosis, but also to be able to obtain proper outcome parameters in future therapeutic 
trials.106,107,225,226 This may be facilitated by the employment of new functional and imaging 
techniques.129,227,228 
 The eye is a unique target organ for therapeutic intervention, as the therapeutic 
agents may be precisely administered at the required location. Equally important, the 
eye is readily accessible to evaluate the effects of this intervention in great detail.188,229,230 
Currently, gene therapy appears to be the most promising approach in peripherin/RDS-
related disease. In animal studies of haploinsufficiency phenotypes, a dose-dependent 
rescue effect on photoreceptors was observed through the gene delivery of wild-type 
rds.186,188,231 In mice homozygous for a rds null mutation, subretinal injection of adeno-
associated viral vectors carrying rds cDNA resulted in significant improvement on the 
ultrastructural and functional level.232-234 However, limited transduction efficiency was 
seen in these studies, and the effect was partial and of limited duration.229,233 Moreover, 
concerns remain about toxic side effects that may be caused by the AAV vector.235,236 
A promising and possibly safer alternative for the use of viral vectors in gene therapy is 
the use of DNA nanoparticles.237 Unfortunately, this approach may also be complicated 
by a low transfection efficiency, as well as a short duration of gene expression.186,237 In 
the case of dominant negative mutations, the phenotype may not only result from a lack 
of normal peripherin/rds, but also from a deleterious effect of the mutant protein on 
photoreceptors. Disruption of the mutant gene, for instance through RNA interference 
techniques and ribozymes, may be necessary in these cases besides an increased 
expression of wild-type peripherin/RDS.31,54,229,238-240 The delivery of trophic factors may also 
constitute a therapeutic approach.241-246 Delivery of ciliary neurotrophic factor (CNTF) via 
an AAV vector, in rds(+/-) mice carrying the dominant negative p.Pro216Leu mutation, 
resulted in a partial, dose-dependent, but long-term rescue of photoreceptors after 
subretinal administration.241,242,247 Prolonging rod survival may also promote survival of 
cones, for instance through the influence of rod-derived cone viability factor.221,231,248,249 
The use of rod-derived cone viability factor may therefore be an interesting approach to 
preserve cones in retinal dystrophies such as RP.244 
 The aforementioned studies also illustrate that, before the treatment of patients 
using these strategies may actually start, a considerable number of challenges have to 
be overcome. Despite all these promising experimental studies, there are currently no 
specific treatment options for retinal dystrophies caused by peripherin/RDS mutations. A 
reduction in light exposure may mildly influence the rate of disease progression through 
a reduction of A2E accumulation.170,193,218,250,251 Data on the impact of dietary influences 
on the outcome of retinal dystrophies are relatively scarce.201,206 It is likely that the nature 
of the disease-causing genes and mutation(s) may have a considerable influence on the 
effect of nutritional factors and supplements. The role of vitamin A supplementation 
is still subject for debate, but large studies indicate that at least a subset of RP patients 
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may benefit from this therapy, possibly in combination with docosahexaenoic acid, 
an omega-3 polyunsaturated fatty acid.202,216,217,252-254 However, these studies did not take 
information on the underlying genetic defects into account. Studies on abca4(-/-) mice 
showed that a reduction in serum vitamin A may reduce the accumulation of A2E and 
lipofuscin in the RPE.205 In AMD, a higher dietary intake of nutritional components such as 
lutein/zeaxanthin and omega-3 polyunsaturated fatty acids may promote photoreceptor 
survival through numerous mechanisms, including a decrease in oxidative stress.255-260 
In autosomal dominant Stargardt-like retinal dystrophy (STGD3), caused by mutations in 
the ELOVL4 gene, supplementation with specific omega-3 polyunsaturated fatty acids may 
reduce the severity of the macular phenotype.204,258 Patients with X-linked RP may also 
benefit from supplementation with docosahexaenoic acid.203 However, the effect of the 
aforementioned nutritional factors has, to the best of our knowledge, not been studied 
in retinal dystrophies associated with peripherin/RDS. Therefore, it seems reasonable to 
practice reservation with regard to the use of nutritional supplements in peripherin/RDS-
related disease. 
 Reports in single patients or small patient groups indicate that choroidal 
neovascularization in retinal dystrophies may respond to various treatments, such as 
photodynamic therapy,261,262 and intravitreal or systemic bevacizumab.263,264 In general, 
choroidal neovascularization is a rare event in inherited retinal dystrophies, and may 
have a relatively favorable prognosis compared to choroidal neovascularization in 
AMD.265 Cystoid macular edema in RP patients, although never reported in peripherin/
RDS-related adRP, may respond to topical treatment with dorzolamide.266
References
 1.  Hawkins RK, Jansen HG, Sanyal S. Development and degeneration of retina in rds mutant mice: 
photoreceptor abnormalities in the heterozygotes. Exp Eye Res 1985;41:701-720.
 2.  van Nie R, Ivanyi D, Demant P. A new H-2-linked mutation, rds, causing retinal degeneration in the 
mouse. Tissue Antigens 1978;12:106-108.
 3.  Connell G, Bascom R, Molday L, Reid D, McInnes RR, Molday RS. Photoreceptor peripherin is the 
normal product of the gene responsible for retinal degeneration in the rds mouse. Proc Natl Acad 
Sci U S A 1991;88:723-726.
 4.  Travis GH, Brennan MB, Danielson PE, Kozak CA, Sutcliffe JG. Identification of a photoreceptor-
specific mRNA encoded by the gene responsible for retinal degeneration slow (rds). Nature 
1989;338:70-73.
 5.  Farrar GJ, Kenna P, Jordan SA, Kumar-Singh R, Humphries MM, Sharp EM, Sheils DM, Humphries 
P. A three-base-pair deletion in the peripherin-RDS gene in one form of retinitis pigmentosa. Nature 
1991;354:478-480.
 6.  Kajiwara K, Hahn LB, Mukai S, Travis GH, Berson EL, Dryja TP. Mutations in the human retinal 
degeneration slow gene in autosomal dominant retinitis pigmentosa. Nature 1991;354:480-483.
 7.  Nichols BE, Sheffield VC, Vandenburgh K, Drack AV, Kimura AE, Stone EM. Butterfly-shaped 
Chapter 4
211
pigment dystrophy of the fovea caused by a point mutation in codon 167 of the RDS gene. Nat Genet 
1993;3:202-207.
 8.  Wells J, Wroblewski J, Keen J, Inglehearn C, Jubb C, Eckstein A, Jay M, Arden G, Bhattacharya S, 
Fitzke F, Bird AC. Mutations in the human retinal degeneration slow (RDS) gene can cause either 
retinitis pigmentosa or macular dystrophy. Nat Genet 1993;3:213-218.
 9.  Hoyng CB, Heutink P, Testers L, Pinckers A, Deutman AF, Oostra BA. Autosomal dominant central 
areolar choroidal dystrophy caused by a mutation in codon 142 in the peripherin/RDS gene. Am J 
Ophthalmol 1996;121:623-629.
 10.  Klevering BJ, van Driel M, van Hogerwou AJ, van de Pol DJ, Deutman AF, Pinckers AJ, Cremers FPM, 
Hoyng CB. Central areolar choroidal dystrophy associated with dominantly inherited drusen. Br J 
Ophthalmol 2002;86:91-96.
 11.  Kajiwara K, Sandberg MA, Berson EL, Dryja TP. A null mutation in the human peripherin/RDS gene in 
a family with autosomal dominant retinitis punctata albescens. Nat Genet 1993;3:208-212.
 12.  Nakazawa M, Kikawa E, Chida Y, Tamai M. Asn244His mutation of the peripherin/RDS gene causing 
autosomal dominant cone-rod degeneration. Hum Mol Genet 1994;3:1195-1196.
 13.  Boon CJF, van Schooneveld MJ, den Hollander AI, van Lith-Verhoeven JJC, Zonneveld-Vrieling 
MN, Theelen T, Cremers FPM, Hoyng CB, Klevering BJ. Mutations in the peripherin/RDS gene are an 
important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. Br J 
Ophthalmol 2007;91:1504-1511.
 14.  Khani SC, Karoukis AJ, Young JE, Ambasudhan R, Burch T, Stockton R, Lewis RA, Sullivan LS, 
Daiger SP, Reichel E, Ayyagari R. Late-onset autosomal dominant macular dystrophy with choroidal 
neovascularization and nonexudative maculopathy associated with mutation in the RDS gene. 
Invest Ophthalmol Vis Sci 2003;44:3570-3577.
 15.  Downes SM, Fitzke FW, Holder GE, Payne AM, Bessant DA, Bhattacharya SS, Bird AC. Clinical 
features of codon 172 RDS macular dystrophy: similar phenotype in 12 families. Arch Ophthalmol 
1999;117:1373-1383.
 16.  van Lith-Verhoeven JJC, van den Helm B, Deutman AF, Bergen AA, Cremers FPM, Hoyng CB, de Jong 
PTVM. A peculiar autosomal dominant macular dystrophy caused by an asparagine deletion at 
codon 169 in the peripherin/RDS gene. Arch Ophthalmol 2003;121:1452-1457.
 17.  Dryja TP, Hahn LB, Kajiwara K, Berson EL. Dominant and digenic mutations in the peripherin/RDS 
and ROM1 genes in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1997;38:1972-1982.
 18.  Kajiwara K, Berson EL, Dryja TP. Digenic retinitis pigmentosa due to mutations at the unlinked 
peripherin/RDS and ROM1 loci. Science 1994;264:1604-1608.
 19.  Apfelstedt-Sylla E, Theischen M, Ruther K, Wedemann H, Gal A, Zrenner E. Extensive intrafamilial 
and interfamilial phenotypic variation among patients with autosomal dominant retinal dystrophy 
and mutations in the human RDS/peripherin gene. Br J Ophthalmol 1995;79:28-34.
 20.  Weleber RG, Carr RE, Murphey WH, Sheffield VC, Stone EM. Phenotypic variation including retinitis 
pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of 
codon 153 or 154 of the peripherin/RDS gene. Arch Ophthalmol 1993;111:1531-1542.
 21.  Gorin MB, Jackson KE, Ferrell RE, Sheffield VC, Jacobson SG, Gass JD, Mitchell E, Stone EM. A 
peripherin/retinal degeneration slow mutation (Pro-210-Arg) associated with macular and peripheral 
retinal degeneration. Ophthalmology 1995;102:246-255.
Spectrum of peripherin/RDS-associated phenotypes
4
212
 22.  Budu, Hayasaka S, Matsumoto M, Yamada T, Zhang XY, Hayasaka Y. Peripherin/RDS gene mutation 
(Pro210Leu) and polymorphisms in Japanese patients with retinal dystrophies. Jpn J Ophthalmol 
2001;45:355-358.
 23.  Felbor U, Schilling H, Weber BH. Adult vitelliform macular dystrophy is frequently associated with 
mutations in the peripherin/RDS gene. Hum Mutat 1997;10:301-309.
 24.  Fujiki K, Hotta Y, Hayakawa M, Fujimaki T, Takeda M, Isashiki Y, Ohba N, Kanai A. Analysis of 
peripherin/RDS gene for Japanese retinal dystrophies. Jpn J Ophthalmol 1998;42:186-192.
 25.  Gamundi MJ, Hernan I, Muntanyola M, Trujillo MJ, Garcia-Sandoval B, Ayuso C, Baiget M, Carballo 
M. High prevalence of mutations in peripherin/RDS in autosomal dominant macular dystrophies in 
a Spanish population. Mol Vis 2007;13:1031-1037.
 26.  Kohl S, Christ-Adler M, Apfelstedt-Sylla E, Kellner U, Eckstein A, Zrenner E, Wissinger B. RDS/peripherin 
gene mutations are frequent causes of central retinal dystrophies. J Med Genet 1997;34:620-626.
 27.  Milla E, Heon E, Piguet B, Ducrey N, Butler N, Stone E, Schorderet DF, Munier F. [Mutational 
screening of peripherin/RDS genes, rhodopsin and ROM-1 in 69 index cases with retinitis pigmentosa 
and other retinal dystrophies]. Klin Monatsbl Augenheilkd 1998;212:305-308.
 28.  Sohocki MM, Daiger SP, Bowne SJ, Rodriquez JA, Northrup H, Heckenlively JR, Birch DG, Mintz-
Hittner H, Ruiz RS, Lewis RA, Saperstein DA, Sullivan LS. Prevalence of mutations causing retinitis 
pigmentosa and other inherited retinopathies. Hum Mutat 2001;17:42-51.
 29.  Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Lewis RA, Garcia CA, 
Ruiz RS, Blanton SH, Northrup H, Gire AI, Seaman R, Duzkale H, Spellicy CJ, Zhu J, Shankar SP, 
Daiger SP. Prevalence of disease-causing mutations in families with autosomal dominant retinitis 
pigmentosa: a screen of known genes in 200 families. Invest Ophthalmol Vis Sci 2006;47:3052-
3064.
 30.  Sanyal S, de Ruiter A, Hawkins RK. Development and degeneration of retina in rds mutant mice: 
light microscopy. J Comp Neurol 1980;194:193-207.
 31.  Farjo R, Skaggs JS, Nagel BA, Quiambao AB, Nash ZA, Fliesler SJ, Naash MI. Retention of function 
without normal disc morphogenesis occurs in cone but not rod photoreceptors. J Cell Biol 
2006;173:59-68.
 32.  Goldberg AF. Role of peripherin/rds in vertebrate photoreceptor architecture and inherited retinal 
degenerations. Int Rev Cytol 2006;253:131-175.
 33.  Molday RS. Photoreceptor membrane proteins, phototransduction, and retinal degenerative 
diseases. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 1998;39:2491-2513.
 34.  Wrigley JD, Ahmed T, Nevett CL, Findlay JB. Peripherin/rds influences membrane vesicle morphology. 
Implications for retinopathies. J Biol Chem 2000;275:13191-13194.
 35.  Boesze-Battaglia K, Goldberg AF. Photoreceptor renewal: a role for peripherin/rds. Int Rev Cytol 
2002;217:183-225.
 36.  Ding XQ, Naash MI. Transgenic animal studies of human retinal disease caused by mutations in 
peripherin/rds. Adv Exp Med Biol 2006;572:141-146.
 37.  Connell GJ, Molday RS. Molecular cloning, primary structure, and orientation of the vertebrate 
photoreceptor cell protein peripherin in the rod outer segment disk membrane. Biochemistry 
1990;29:4691-4698.
 38.  Travis GH, Sutcliffe JG, Bok D. The retinal degeneration slow (rds) gene product is a photoreceptor disc 
Chapter 4
213
membrane-associated glycoprotein. Neuron 1991;6:61-70.
 39.  Arikawa K, Molday LL, Molday RS, Williams DS. Localization of peripherin/rds in the disk 
membranes of cone and rod photoreceptors: relationship to disk membrane morphogenesis and 
retinal degeneration. J Cell Biol 1992;116:659-667.
 40.  Molday RS, Hicks D, Molday L. Peripherin. A rim-specific membrane protein of rod outer segment 
discs. Invest Ophthalmol Vis Sci 1987;28:50-61.
 41.  Kedzierski W, Bok D, Travis GH. Transgenic analysis of rds/peripherin N-glycosylation: effect 
on dimerization, interaction with rom1, and rescue of the rds null phenotype. J Neurochem 
1999;72:430-438.
 42.  Goldberg AF, Molday RS. Subunit composition of the peripherin/rds-rom-1 disk rim complex from 
rod photoreceptors: hydrodynamic evidence for a tetrameric quaternary structure. Biochemistry 
1996;35:6144-6149.
 43.  Goldberg AF, Fales LM, Hurley JB, Khattree N. Folding and subunit assembly of photoreceptor 
peripherin/rds is mediated by determinants within the extracellular/intradiskal EC2 domain: 
implications for heterogeneous molecular pathologies. J Biol Chem 2001;276:42700-42706.
 44.  Bascom RA, Schappert K, McInnes RR. Cloning of the human and murine ROM1 genes: genomic 
organization and sequence conservation. Hum Mol Genet 1993;2:385-391.
 45.  Ding XQ, Stricker HM, Naash MI. Role of the second intradiscal loop of peripherin/rds in homo and 
hetero associations. Biochemistry 2005;44:4897-4904.
 46.  Goldberg AF, Moritz OL, Molday RS. Heterologous expression of photoreceptor peripherin/rds 
and Rom-1 in COS-1 cells: assembly, interactions, and localization of multisubunit complexes. 
Biochemistry 1995;34:14213-14219.
 47.  Kedzierski W, Weng J, Travis GH. Analysis of the rds/peripherin.rom1 complex in transgenic 
photoreceptors that express a chimeric protein. J Biol Chem 1999;274:29181-29187.
 48.  Loewen CJ, Molday RS. Disulfide-mediated oligomerization of Peripherin/Rds and Rom-1 in 
photoreceptor disk membranes. Implications for photoreceptor outer segment morphogenesis and 
degeneration. J Biol Chem 2000;275:5370-5378.
 49.  Bascom RA, Manara S, Collins L, Molday RS, Kalnins VI, McInnes RR. Cloning of the cDNA for a novel 
photoreceptor membrane protein (rom-1) identifies a disk rim protein family implicated in human 
retinopathies. Neuron 1992;8:1171-1184.
 50.  Clarke G, Goldberg AF, Vidgen D, Collins L, Ploder L, Schwarz L, Molday LL, Rossant J, Szel A, Molday 
RS, Birch DG, McInnes RR. Rom-1 is required for rod photoreceptor viability and the regulation of 
disk morphogenesis. Nat Genet 2000;25:67-73.
 51.  Goldberg AF, Ritter LM, Khattree N, Peachey NS, Fariss RN, Dang L, Yu M, Bottrell AR. An 
intramembrane glutamic acid governs peripherin/rds function for photoreceptor disk 
morphogenesis. Invest Ophthalmol Vis Sci 2007;48:2975-2986.
 52.  Moritz OL, Molday RS. Molecular cloning, membrane topology, and localization of bovine rom-1 in 
rod and cone photoreceptor cells. Invest Ophthalmol Vis Sci 1996;37:352-362.
 53.  Goldberg AF, Loewen CJ, Molday RS. Cysteine residues of photoreceptor peripherin/rds: role in 
subunit assembly and autosomal dominant retinitis pigmentosa. Biochemistry 1998;37:680-685.
 54.  Loewen CJ, Moritz OL, Tam BM, Papermaster DS, Molday RS. The role of subunit assembly in 
peripherin-2 targeting to rod photoreceptor disk membranes and retinitis pigmentosa. Mol Biol 
Spectrum of peripherin/RDS-associated phenotypes
4
214
Cell 2003;14:3400-3413.
 55.  Boesze-Battaglia K. Fusion between retinal rod outer segment membranes and model membranes: 
functional assays and role for peripherin/rds. Methods Enzymol 2000;316:65-86.
 56.  Boesze-Battagliaa K, Stefano FP. Peripherin/rds fusogenic function correlates with subunit assembly. 
Exp Eye Res 2002;75:227-231.
 57.  Goldberg AF, Molday RS. Expression and characterization of peripherin/rds-rom-1 complexes and 
mutants implicated in retinal degenerative diseases. Methods Enzymol 2000;316:671-687.
 58.  Hageman GS, Marmor MF, Yao XY, Johnson LV. The interphotoreceptor matrix mediates primate 
retinal adhesion. Arch Ophthalmol 1995;113:655-660.
 59.  Hollyfield JG, Varner HH, Rayborn ME, Osterfeld AM. Retinal attachment to the pigment epithelium. 
Linkage through an extracellular sheath surrounding cone photoreceptors. Retina 1989;9:59-68.
 60.  Johnson LV, Blanks JC, Hageman GS. Effects of retinal degenerations on the cone matrix sheath. 
Prog Clin Biol Res 1989;314:217-232.
 61.  Poetsch A, Molday LL, Molday RS. The cGMP-gated channel and related glutamic acid-rich proteins 
interact with peripherin-2 at the rim region of rod photoreceptor disc membranes. J Biol Chem 
2001;276:48009-48016.
 62.  Ritter LM, Arakawa T, Goldberg AF. Predicted and measured disorder in peripherin/rds, a retinal 
tetraspanin. Protein Pept Lett 2005;12:677-686.
 63.  Boesze-Battaglia K, Lamba OP, Napoli AA, Jr., Sinha S, Guo Y. Fusion between retinal rod outer 
segment membranes and model membranes: a role for photoreceptor peripherin/rds. Biochemistry 
1998;37:9477-9487.
 64.  Damek-Poprawa M, Krouse J, Gretzula C, Boesze-Battaglia K. A novel tetraspanin fusion protein, 
peripherin-2, requires a region upstream of the fusion domain for activity. J Biol Chem 
2005;280:9217-9224.
 65.  Ritter LM, Boesze-Battaglia K, Tam BM, Moritz OL, Khattree N, Chen SC, Goldberg AF. Uncoupling 
of photoreceptor peripherin/rds fusogenic activity from biosynthesis, subunit assembly, and 
targeting: a potential mechanism for pathogenic effects. J Biol Chem 2004;279:39958-39967.
 66.  Boesze-Battaglia K, Goldberg AF, Dispoto J, Katragadda M, Cesarone G, Albert AD. A soluble 
peripherin/Rds C-terminal polypeptide promotes membrane fusion and changes conformation 
upon membrane association. Exp Eye Res 2003;77:505-514.
 67.  Boesze-Battaglia K, Song H, Sokolov M, Lillo C, Pankoski-Walker L, Gretzula C, Gallagher B, Rachel 
RA, Jenkins NA, Copeland NG, Morris F, Jacob J, Yeagle P, Williams DS, Damek-Poprawa M. The 
tetraspanin protein peripherin-2 forms a complex with melanoregulin, a putative membrane 
fusion regulator. Biochemistry 2007;46:1256-1272.
 68.  Boesze-Battaglia K, Stefano FP, Fitzgerald C, Muller-Weeks S. ROM-1 potentiates photoreceptor 
specific membrane fusion processes. Exp Eye Res 2007;84:22-31.
 69.  Tam BM, Moritz OL, Papermaster DS. The C terminus of peripherin/rds participates in rod outer 
segment targeting and alignment of disk incisures. Mol Biol Cell 2004;15:2027-2037.
 70.  Edrington TC, Yeagle PL, Gretzula CL, Boesze-Battaglia K. Calcium-dependent association of 
calmodulin with the C-terminal domain of the tetraspanin protein peripherin/rds. Biochemistry 
2007;46:3862-3871.
 71.  Kemp CM, Jacobson SG, Cideciyan AV, Kimura AE, Sheffield VC, Stone EM. RDS gene mutations 
Chapter 4
215
causing retinitis pigmentosa or macular degeneration lead to the same abnormality in 
photoreceptor function. Invest Ophthalmol Vis Sci 1994;35:3154-3162.
 72.  Molday RS, Molday LL, Loewen CJ. Role of subunit assembly in autosomal dominant retinitis 
pigmentosa linked to mutations in peripherin 2. Novartis Found Symp 2004;255:95-112.
 73.  Nir I, Papermaster DS. Immunocytochemical localization of opsin in the inner segment and ciliary 
plasma membrane of photoreceptors in retinas of rds mutant mice. Invest Ophthalmol Vis Sci 
1986;27:836-840.
 74.  Reuter JH, Sanyal S. Development and degeneration of retina in rds mutant mice: the 
electroretinogram. Neurosci Lett 1984;48:231-237.
 75.  Sanyal S, Jansen HG. Absence of receptor outer segments in the retina of rds mutant mice. Neurosci 
Lett 1981;21:23-26.
 76.  Nichols BE, Drack AV, Vandenburgh K, Kimura AE, Sheffield VC, Stone EM. A 2 base pair deletion 
in the RDS gene associated with butterfly-shaped pigment dystrophy of the fovea. Hum Mol Genet 
1993;2:601-603.
 77.  Travis GH, Hepler JE. A medley of retinal dystrophies. Nat Genet 1993;3:191-192.
 78.  Payne AM, Downes SM, Bessant DA, Bird AC, Bhattacharya SS. Founder effect, seen in the British 
population, of the 172 peripherin/RDS mutation-and further refinement of genetic positioning of the 
peripherin/RDS gene. Am J Hum Genet 1998;62:192-195.
 79.  Renner AB, Tillack H, Kraus H, Kohl S, Wissinger B, Mohr N, Weber BH, Kellner U, Foerster MH. 
Morphology and functional characteristics in adult vitelliform macular dystrophy. Retina 
2004;24:929-939.
 80.  Zhuk SA, Edwards AO. Peripherin/RDS and VMD2 mutations in macular dystrophies with adult-onset 
vitelliform lesion. Mol Vis 2006;12:811-815.
 81.  Fossarello M, Bertini C, Galantuomo MS, Cao A, Serra A, Pirastu M. Deletion in the peripherin/RDS 
gene in two unrelated Sardinian families with autosomal dominant butterfly-shaped macular 
dystrophy. Arch Ophthalmol 1996;114:448-456.
 82.  Francis PJ, Schultz DW, Gregory AM, Schain MB, Barra R, Majewski J, Ott J, Acott T, Weleber RG, Klein 
ML. Genetic and phenotypic heterogeneity in pattern dystrophy. Br J Ophthalmol 2005;89:1115-
1119.
 83.  Pajic B, Weigell-Weber M, Schipper I, Kryenbuhl C, Buchi ER, Spiegel R, Hergersberg M. A novel 
complex mutation event in the peripherin/RDS gene in a family with retinal pattern dystrophy. 
Retina 2006;26:947-953.
 84.  Sears JE, Aaberg TA, Sr., Daiger SP, Moshfeghi DM. Splice site mutation in the peripherin/RDS gene 
associated with pattern dystrophy of the retina. Am J Ophthalmol 2001;132:693-699.
 85.  Jacobson SG, Cideciyan AV, Kemp CM, Sheffield VC, Stone EM. Photoreceptor function in 
heterozygotes with insertion or deletion mutations in the RDS gene. Invest Ophthalmol Vis Sci 
1996;37:1662-1674.
 86.  Michaelides M, Holder GE, Bradshaw K, Hunt DM, Moore AT. Cone-rod dystrophy, intrafamilial 
variability, and incomplete penetrance associated with the R172W mutation in the peripherin/RDS 
gene. Ophthalmology 2005;112:1592-1598.
 87.  Piguet B, Heon E, Munier FL, Grounauer PA, Niemeyer G, Butler N, Schorderet DF, Sheffield VC, 
Stone EM. Full characterization of the maculopathy associated with an Arg-172-Trp mutation in the 
Spectrum of peripherin/RDS-associated phenotypes
4
216
RDS/peripherin gene. Ophthalmic Genet 1996;17:175-186.
 88.  Wroblewski JJ, Wells JA, III, Eckstein A, Fitzke F, Jubb C, Keen TJ, Inglehearn C, Bhattacharya S, 
Arden GB, Jay M, Bird AC. Macular dystrophy associated with mutations at codon 172 in the human 
retinal degeneration slow gene. Ophthalmology 1994;101:12-22.
 89.  Nakazawa M, Kikawa E, Chida Y, Wada Y, Shiono T, Tamai M. Autosomal dominant cone-rod 
dystrophy associated with mutations in codon 244 (Asn244His) and codon 184 (Tyr184Ser) of the 
peripherin/RDS gene. Arch Ophthalmol 1996;114:72-78.
 90.  Nakazawa M, Naoi N, Wada Y, Nakazaki S, Maruiwa F, Sawada A, Tamai M. Autosomal dominant 
cone-rod dystrophy associated with a Val200Glu mutation of the peripherin/RDS gene. Retina 
1996;16:405-410.
 91.  Fishman GA, Stone EM, Alexander KR, Gilbert LD, Derlacki DJ, Butler NS. Serine-27-phenylalanine 
mutation within the peripherin/RDS gene in a family with cone dystrophy. Ophthalmology 
1997;104:299-306.
 92.  Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795-1809.
 93.  Ekstrom U, Ponjavic V, Andreasson S, Ehinger B, Nilsson-Ehle P, Abrahamson M. Detection of 
alterations in all three exons of the peripherin/RDS gene in Swedish patients with retinitis pigmentosa 
using an efficient DGGE system. Mol Pathol 1998;51:287-291.
 94.  Milla E, Maseras M, Martinez-Gimeno M, Gamundi MJ, Assaf H, Esmerado C, Carballo M. [Genetic 
and molecular characterization of 148 patients with autosomal dominant retinitis pigmentosa 
(ADRP)]. Arch Soc Esp Oftalmol 2002;77:481-484.
 95.  Ziviello C, Simonelli F, Testa F, Anastasi M, Marzoli SB, Falsini B, Ghiglione D, Macaluso C, Manitto 
MP, Garre C, Ciccodicola A, Rinaldi E, Banfi S. Molecular genetics of autosomal dominant retinitis 
pigmentosa (ADRP): a comprehensive study of 43 Italian families. J Med Genet 2005;42:e47.
 96.  Nakazawa M. [A molecular biological study on retinitis pigmentosa]. Nippon Ganka Gakkai Zasshi 
1993;97:1394-1405.
 97.  Loewen CJ, Moritz OL, Molday RS. Molecular characterization of peripherin-2 and rom-1 mutants 
responsible for digenic retinitis pigmentosa. J Biol Chem 2001;276:22388-22396.
 98.  Bascom RA, Liu L, Heckenlively JR, Stone EM, McInnes RR. Mutation analysis of the ROM1 gene in 
retinitis pigmentosa. Hum Mol Genet 1995;4:1895-1902.
 99.  Sakuma H, Inana G, Murakami A, Yajima T, Weleber RG, Murphey WH, Gass JD, Hotta Y, Hayakawa 
M, Fujiki K, Gae YQ, Danciger M, Farber D, Cideciyan AV, Jacobson SG. A heterozygous putative 
null mutation in ROM1 without a mutation in peripherin/RDS in a family with retinitis pigmentosa. 
Genomics 1995;27:384-386.
 100.  Bird AC. Retinal photoreceptor dystrophies LI. Edward Jackson Memorial Lecture. Am J Ophthalmol 
1995;119:543-562.
 101.  Michaelides M, Hunt DM, Moore AT. The genetics of inherited macular dystrophies. J Med Genet 
2003;40:641-650.
 102.  Scullica L, Falsini B. Diagnosis and classification of macular degenerations: an approach based on 
retinal function testing. Doc Ophthalmol 2001;102:237-250.
 103.  Zhang K, Garibaldi DC, Li Y, Green WR, Zack DJ. Butterfly-shaped pattern dystrophy: a genetic, 
clinical, and histopathological report. Arch Ophthalmol 2002;120:485-490.
 104.  Klevering BJ, Blankenagel A, Maugeri A, Cremers FPM, Hoyng CB, Rohrschneider K. Phenotypic 
Chapter 4
217
spectrum of autosomal recessive cone-rod dystrophies caused by mutations in the ABCA4 (ABCR) 
gene. Invest Ophthalmol Vis Sci 2002;43:1980-1985.
 105.  van Soest S, Westerveld A, de Jong PTVM, Bleeker-Wagemakers EM, Bergen AA. Retinitis pigmentosa: 
defined from a molecular point of view. Surv Ophthalmol 1999;43:321-334.
 106.  Sieving PA, Collins FS. Genetic ophthalmology and the era of clinical care. JAMA 2007;297:733-
736.
 107.  Stone EM. Genetic testing for inherited eye disease. Arch Ophthalmol 2007;125:205-212.
 108.  Felbor U, Benkwitz C, Klein ML, Greenberg J, Gregory CY, Weber BH. Sorsby fundus dystrophy: 
reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation. Arch 
Ophthalmol 1997;115:1569-1571.
 109.  Klevering BJ, Deutman AF, Maugeri A, Cremers FPM, Hoyng CB. The spectrum of retinal phenotypes 
caused by mutations in the ABCA4 gene. Graefe’s Arch Clin Exp Ophthalmol 2005;243:90-100.
 110.  Keilhauer CN, Meigen T, Weber BH. Clinical findings in a multigeneration family with autosomal 
dominant central areolar choroidal dystrophy associated with an Arg195Leu mutation in the 
peripherin/RDS gene. Arch Ophthalmol 2006;124:1020-1027.
 111.  Michaelides M, Hardcastle AJ, Hunt DM, Moore AT. Progressive cone and cone-rod dystrophies: 
phenotypes and underlying molecular genetic basis. Surv Ophthalmol 2006;51:232-258.
 112.  Shastry BS. Retinitis pigmentosa and related disorders: phenotypes of rhodopsin and peripherin/RDS 
mutations. Am J Med Genet 1994;52:467-474.
 113.  Gass JD. Heredodystrophic disorders affecting the pigment epithelium and retina. In: Stereoscopic 
atlas of macular diseases: diagnosis and treatment. 4th Ed. Vol. 1. St. Louis: C.V. Mosby, 1997: 314-
325.
 114.  Pinckers A. Patterned dystrophies of the retinal pigment epithelium. A review. Ophthalmic Paediatr 
Genet 1988;9:77-114.
 115.  Marmor MF, Byers B. Pattern dystrophy of the pigment epithelium. Am J Ophthalmol 1977;84:32-
44.
 116.  Grover S, Fishman GA, Stone EM. Atypical presentation of pattern dystrophy in two families with 
peripherin/RDS mutations. Ophthalmology 2002;109:1110-1117.
 117.  Keen TJ, Inglehearn CF. Mutations and polymorphisms in the human peripherin-RDS gene and their 
involvement in inherited retinal degeneration. Hum Mutat 1996;8:297-303.
 118.  Weigell-Weber M, Kryenbuhl C, Buchi ER, Spiegel R. Genetic heterogeneity in autosomal dominant 
pattern dystrophy of the retina. Mol Vis 1996;2:6.
 119.  Marmor MF, McNamara JA. Pattern dystrophy of the retinal pigment epithelium and geographic 
atrophy of the macula. Am J Ophthalmol 1996;122:382-392.
 120.  Yang Z, Li Y, Jiang L, Karan G, Moshfeghi D, O’Connor S, Li X, Yu Z, Lewis H, Zack D, Jacobson 
S, Zhang K. A novel RDS/peripherin gene mutation associated with diverse macular phenotypes. 
Ophthalmic Genet 2004;25:133-145.
 121.  Tuppurainen K, Mantyjarvi M. The importance of fluorescein angiography in diagnosing pattern 
dystrophies of the retinal pigment epithelium. Doc Ophthalmol 1994;87:233-243.
 122.  Kramer F, White K, Pauleikhoff D, Gehrig A, Passmore L, Rivera A, Rudolph G, Kellner U, Andrassi 
M, Lorenz B, Rohrschneider K, Blankenagel A, Jurklies B, Schilling H, Schutt F, Holz FG, Weber BH. 
Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best 
Spectrum of peripherin/RDS-associated phenotypes
4
218
disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J 
Hum Genet 2000;8:286-292.
 123.  Seddon JM, Afshari MA, Sharma S, Bernstein PS, Chong S, Hutchinson A, Petrukhin K, Allikmets 
R. Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-
onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull’s-eye maculopathy. 
Ophthalmology 2001;108:2060-2067.
 124.  Boon CJF, Klevering BJ, den Hollander AI, Zonneveld MN, Theelen T, Cremers FPM, Hoyng CB. Clinical 
and genetic heterogeneity in multifocal vitelliform dystrophy. Arch Ophthalmol 2007;125:1100-
1106.
 125.  Feist RM, White MF, Jr., Skalka H, Stone EM. Choroidal neovascularization in a patient with adult 
foveomacular dystrophy and a mutation in the retinal degeneration slow gene (Pro 210 Arg). Am J 
Ophthalmol 1994;118:259-260.
 126.  Dubovy SR, Hairston RJ, Schatz H, Schachat AP, Bressler NM, Finkelstein D, Green WR. Adult-onset 
foveomacular pigment epithelial dystrophy: clinicopathologic correlation of three cases. Retina 
2000;20:638-649.
 127.  Patrinely JR, Lewis RA, Font RL. Foveomacular vitelliform dystrophy, adult type. A clinicopathologic 
study including electron microscopic observations. Ophthalmology 1985;92:1712-1718.
 128.  Schatz P, Abrahamson M, Eksandh L, Ponjavic V, Andreasson S. Macular appearance by means 
of OCT and electrophysiology in members of two families with different mutations in RDS (the 
peripherin/RDS gene). Acta Ophthalmol Scand 2003;81:500-507.
 129.  Wirtitsch MG, Ergun E, Hermann B, Unterhuber A, Stur M, Scholda C, Sattmann H, Ko TH, Fujimoto 
JG, Drexler W. Ultrahigh resolution optical coherence tomography in macular dystrophy. Am J 
Ophthalmol 2005;140:976-983.
 130.  Deutman AF, van Blommestein JD, Henkes HE, Waardenburg PJ, Solleveld-van Driest E. Butterfly-
shaped pigment dystrophy of the fovea. Arch Ophthalmol 1970;83:558-569.
 131.  den Hollander AI, van Lith-Verhoeven JJC, Kersten FF, Heister JG, de Kovel CG, Deutman AF, Hoyng 
CB, Cremers FPM. Identification of novel locus for autosomal dominant butterfly shaped macular 
dystrophy on 5q21.2-q33.2. J Med Genet 2004;41:699-702.
 132.  van Lith-Verhoeven JJC, Cremers FPM, van den Helm B, Hoyng CB, Deutman AF. Genetic heterogeneity 
of butterfly-shaped pigment dystrophy of the fovea. Mol Vis 2003;9:138-143.
 133.  Marano F, Deutman AF, Aandekerk AL. Butterfly-shaped pigment dystrophy of the fovea associated 
with subretinal neovascularization. Graefe’s Arch Clin Exp Ophthalmol 1996;234:270-274.
 134.  Prensky JG, Bresnick GH. Butterfly-shaped macular dystrophy in four generations. Arch Ophthalmol 
1983;101:1198-1203.
 135.  Allikmets R. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in 
recessive Stargardt macular dystrophy. Nat Genet 1997;17:122.
 136.  Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL, Hockey RR. Variation of clinical expression 
in patients with Stargardt dystrophy and sequence variations in the ABCR gene. Arch Ophthalmol 
1999;117:504-510.
 137.  Kim RY, Dollfus H, Keen TJ, Fitzke FW, Arden GB, Bhattacharya SS, Bird AC. Autosomal dominant 
pattern dystrophy of the retina associated with a 4-base pair insertion at codon 140 in the peripherin/
RDS gene. Arch Ophthalmol 1995;113:451-455.
Chapter 4
219
 138.  Cideciyan AV. In vivo assessment of photoreceptor function in human diseases caused by 
photoreceptor-specific gene mutations. Methods Enzymol 2000;316:611-626.
 139.  Jacobson SG, Cideciyan AV, Maguire AM, Bennett J, Sheffield VC, Stone EM. Preferential rod and 
cone photoreceptor abnormalities in heterozygotes with point mutations in the RDS gene. Exp Eye 
Res 1996;63:603-608.
 140.  Richards SC, Creel DJ. Pattern dystrophy and retinitis pigmentosa caused by a peripherin/RDS 
mutation. Retina 1995;15:68-72.
 141.  Thomann U, Buchi ER, Suppiger M, Kryenbuhl C, Schipper I, Spiegel R. Age-dependent phenotypic 
expression of a pattern dystrophy of the retina. Eur J Ophthalmol 1995;5:107-112.
 142.  Ferry AP, Llovera I, Shafer DM. Central areolar choroidal dystrophy. Arch Ophthalmol 1972;88:39-
43.
 143.  Hoyng CB, Pinckers AJ, Deutman AF. Early findings in central areolar choroidal dystrophy. Acta 
Ophthalmol (Copenh) 1990;68:356-360.
 144.  Hoyng CB, Deutman AF. The development of central areolar choroidal dystrophy. Graefe’s Arch Clin 
Exp Ophthalmol 1996;234:87-93.
 145.  Trujillo MJ, Martinez-Gimeno M, Gimenez A, Lorda I, Bueno J, Garcia-Sandoval B, Ramos C, Carballo 
M, Ayuso C. Two novel mutations (Y141H; C214Y) and previously published mutation (R142W) in the 
RDS-peripherin gene in autosomal dominant macular dystrophies in Spanish families. Hum Mutat 
2001;17:80.
 146.  Nakazawa M, Wada Y, Tamai M. Macular dystrophy associated with monogenic Arg172Trp mutation 
of the peripherin/RDS gene in a Japanese family. Retina 1995;15:518-523.
 147.  Ekstrom U, Andreasson S, Ponjavic V, Abrahamson M, Sandgren O, Nilsson-Ehle P, Ehinger B. A 
Swedish family with a mutation in the peripherin/RDS gene (Arg-172-Trp) associated with a progressive 
retinal degeneration. Ophthalmic Genet 1998;19:149-156.
 148.  Reig C, Serra A, Gean E, Vidal M, Arumi J, De lC, Antich J, Carballo M. A point mutation in the RDS-
peripherin gene in a Spanish family with central areolar choroidal dystrophy. Ophthalmic Genet 
1995;16:39-44.
 149.  Yanagihashi S, Nakazawa M, Kurotaki J, Sato M, Miyagawa Y, Ohguro H. Autosomal dominant 
central areolar choroidal dystrophy and a novel Arg195Leu mutation in the peripherin/RDS gene. 
Arch Ophthalmol 2003;121:1458-1461.
 150.  Keilhauer CN, Meigen T, Stohr H, Weber BH. Late-onset central areolar choroidal dystrophy caused 
by a heterozygous frame-shift mutation affecting codon 307 of the peripherin/RDS gene. Ophthalmic 
Genet 2006;27:139-144.
 151.  Wabbels B, Demmler A, Paunescu K, Wegscheider E, Preising MN, Lorenz B. Fundus autofluorescence 
in children and teenagers with hereditary retinal diseases. Graefe’s Arch Clin Exp Ophthalmol 
2006;244:36-45.
 152.  Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular 
fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 
1995;36:718-729.
 153.  Holder GE, Robson AG, Hogg CR, Kurz-Levin M, Lois N, Bird AC. Pattern ERG: clinical overview, and 
some observations on associated fundus autofluorescence imaging in inherited maculopathy. Doc 
Ophthalmol 2003;106:17-23.
Spectrum of peripherin/RDS-associated phenotypes
4
220
 154.  de Jong PTVM. Age-related macular degeneration. N Engl J Med 2006;355:1474-1485.
 155.  Moshfeghi DM, Yang Z, Faulkner ND, Karan G, Thirumalaichary S, Pearson E, Zhao Y, Tsai T, Zhang 
K. Choroidal neovascularization in patients with adult-onset foveomacular dystrophy caused by 
mutations in the RDS/peripherin gene. Adv Exp Med Biol 2006;572:35-40.
 156.  Klaver CC, Allikmets R. Genetics of macular dystrophies and implications for age-related macular 
degeneration. Dev Ophthalmol 2003;37:155-169.
 157.  Shastry BS, Trese MT. Evaluation of the peripherin/RDS gene as a candidate gene in families with age-
related macular degeneration. Ophthalmologica 1999;213:165-170.
 158.  Gruning G, Millan JM, Meins M, Beneyto M, Caballero M, pfelstedt-Sylla E, Bosch R, Zrenner E, Prieto 
F, Gal A. Mutations in the human peripherin/RDS gene associated with autosomal dominant retinitis 
pigmentosa. Hum Mutat 1994;3:321-323.
 159.  Farrar GJ, Kenna P, Jordan SA, Kumar-Singh R, Humphries MM, Sharp EM, Sheils D, Humphries 
P. Autosomal dominant retinitis pigmentosa: a novel mutation at the peripherin/RDS locus in the 
original 6p-linked pedigree. Genomics 1992;14:805-807.
 160.  Lam BL, Vandenburgh K, Sheffield VC, Stone EM. Retinitis pigmentosa associated with a dominant 
mutation in codon 46 of the peripherin/RDS gene (arginine-46-stop). Am J Ophthalmol 1995;119:65-
71.
 161.  Saga M, Mashima Y, Akeo K, Oguchi Y, Kudoh J, Shimizu N. A novel Cys-214-Ser mutation in the 
peripherin/RDS gene in a Japanese family with autosomal dominant retinitis pigmentosa. Hum 
Genet 1993;92:519-521.
 162.  Kemp CM, Jacobson SG, Cideciyan AV, Kimura AE, Sheffield VC, Stone EM. RDS gene mutations 
causing retinitis pigmentosa or macular degeneration lead to the same abnormality in 
photoreceptor function. Invest Ophthalmol Vis Sci 1994;35:3154-3162.
 163.  Nakazawa M, Kikawa E, Kamio K, Chida Y, Shiono T, Tamai M. Ocular findings in patients with 
autosomal dominant retinitis pigmentosa and transversion mutation in codon 244 (Asn244Lys) of 
the peripherin/RDS gene. Arch Ophthalmol 1994;112:1567-1573.
 164.  Bareil C, Hamel C, Arnaud B, Demaille J, Claustres M. A complex allele (1064delTC and IVS2 + 
22ins7) in the peripherin/RDS gene in retinitis pigmentosa with macular dystrophy. Ophthalmic 
Genet 1997;18:129-138.
 165.  Bareil C, Delague V, Arnaud B, Demaille J, Hamel C, Claustres M. W179R: a novel missense mutation 
in the peripherin/RDS gene in a family with autosomal dominant retinitis pigmentosa. Hum Mutat 
2000;15:583-584.
 166.  Kikawa E, Nakazawa M, Chida Y, Shiono T, Tamai M. A novel mutation (Asn244Lys) in the peripherin/
RDS gene causing autosomal dominant retinitis pigmentosa associated with bull’s-eye maculopathy 
detected by nonradioisotopic SSCP. Genomics 1994;20:137-139.
 167.  Fishman GA, Roberts MF, Derlacki DJ, Grimsby JL, Yamamoto H, Sharon D, Nishiguchi KM, Dryja 
TP. Novel mutations in the cellular retinaldehyde-binding protein gene (RLBP1) associated with 
retinitis punctata albescens: evidence of interfamilial genetic heterogeneity and fundus changes in 
heterozygotes. Arch Ophthalmol 2004;122:70-75.
 168.  Humbert G, Delettre C, Senechal A, Bazalgette C, Barakat A, Bazalgette C, Arnaud B, Lenaers G, 
Hamel CP. Homozygous deletion related to Alu repeats in RLBP1 causes retinitis punctata albescens. 
Invest Ophthalmol Vis Sci 2006;47:4719-4724.
Chapter 4
221
 169.  Souied E, Soubrane G, Benlian P, Coscas GJ, Gerber S, Munnich A, Kaplan J. Retinitis punctata 
albescens associated with the Arg135Trp mutation in the rhodopsin gene. Am J Ophthalmol 
1996;121:19-25.
 170.  Berson EL. Light deprivation and retinitis pigmentosa. Vision Res 1980;20:1179-1184.
 171.  Wistow G. The NEIBank project for ocular genomics: data-mining gene expression in human and 
rodent eye tissues. Prog Retin Eye Res 2006;25:43-77.
 172.  Ding XQ, Nour M, Ritter LM, Goldberg AF, Fliesler SJ, Naash MI. The R172W mutation in peripherin/
rds causes a cone-rod dystrophy in transgenic mice. Hum Mol Genet 2004;13:2075-2087.
 173.  Conley S, Nour M, Fliesler SJ, Naash MI. Late-onset cone photoreceptor degeneration induced by 
R172W mutation in Rds and partial rescue by gene supplementation. Invest Ophthalmol Vis Sci 
2007;48:5397-5407.
 174.  Saliba RS, Munro PM, Luthert PJ, Cheetham ME. The cellular fate of mutant rhodopsin: quality 
control, degradation and aggresome formation. J Cell Sci 2002;115:2907-2918.
 175.  Stricker HM, Ding XQ, Quiambao A, Fliesler SJ, Naash MI. The Cys214-->Ser mutation in peripherin/
rds causes a loss-of-function phenotype in transgenic mice. Biochem J 2005;388:605-613.
 176.  Kedzierski W, Lloyd M, Birch DG, Bok D, Travis GH. Generation and analysis of transgenic mice 
expressing P216L-substituted rds/peripherin in rod photoreceptors. Invest Ophthalmol Vis Sci 
1997;38:498-509.
 177.  Wrigley JD, Nevett CL, Findlay JB. Topological analysis of peripherin/rds and abnormal glycosylation 
of the pathogenic Pro216-->Leu mutation. Biochem J 2002;368:649-655.
 178.  McNally N, Kenna PF, Rancourt D, Ahmed T, Stitt A, Colledge WH, Lloyd DG, Palfi A, O’Neill B, 
Humphries MM, Humphries P, Farrar GJ. Murine model of autosomal dominant retinitis pigmentosa 
generated by targeted deletion at codon 307 of the rds-peripherin gene. Hum Mol Genet 2002;11:1005-
1016.
 179.  Goldberg AF, Molday RS. Defective subunit assembly underlies a digenic form of retinitis pigmentosa 
linked to mutations in peripherin/rds and rom-1. Proc Natl Acad Sci U S A 1996;93:13726-13730.
 180.  Kedzierski W, Nusinowitz S, Birch D, Clarke G, McInnes RR, Bok D, Travis GH. Deficiency of rds/
peripherin causes photoreceptor death in mouse models of digenic and dominant retinitis 
pigmentosa. Proc Natl Acad Sci U S A 2001;98:7718-7723.
 181.  Souied EH, Rozet JM, Gerber S, Dufier JL, Soubrane G, Coscas G, Munnich A, Kaplan J. Two novel 
missense mutations in the peripherin/RDS gene in two unrelated French patients with autosomal 
dominant retinitis pigmentosa. Eur J Ophthalmol 1998;8:98-101.
 182.  Nakazawa M, Wada Y, Chida Y, Tamai M. A correlation between computer-predicted changes in 
secondary structure and the phenotype of retinal degeneration associated with mutations in 
peripherin/RDS. Curr Eye Res 1997;16:1134-1141.
 183.  Eckmiller MS. Defective cone photoreceptor cytoskeleton, alignment, feedback, and energetics can 
lead to energy depletion in macular degeneration. Prog Retin Eye Res 2004;23:495-522.
 184.  Mata NL, Radu RA, Clemmons RC, Travis GH. Isomerization and oxidation of vitamin a in cone-
dominant retinas: a novel pathway for visual-pigment regeneration in daylight. Neuron 2002;36:69-
80.
 185.  Cheng T, Peachey NS, Li S, Goto Y, Cao Y, Naash MI. The effect of peripherin/rds haploinsufficiency 
on rod and cone photoreceptors. J Neurosci 1997;17:8118-8128.
Spectrum of peripherin/RDS-associated phenotypes
4
222
 186.  Farjo R, Naash MI. The role of Rds in outer segment morphogenesis and human retinal disease. 
Ophthalmic Genet 2006;27:117-122.
 187.  Ma J, Norton JC, Allen AC, Burns JB, Hasel KW, Burns JL, Sutcliffe JG, Travis GH. Retinal degeneration 
slow (rds) in mouse results from simple insertion of a t haplotype-specific element into protein-
coding exon II. Genomics 1995;28:212-219.
 188.  Travis GH, Groshan KR, Lloyd M, Bok D. Complete rescue of photoreceptor dysplasia and 
degeneration in transgenic retinal degeneration slow (rds) mice. Neuron 1992;9:113-119.
 189.  Kohl S, Giddings I, Besch D, Apfelstedt-Sylla E, Zrenner E, Wissinger B. The role of the peripherin/RDS 
gene in retinal dystrophies. Acta Anat (Basel) 1998;162:75-84.
 190.  Scheetz TE, Kim KY, Swiderski RE, Philp AR, Braun TA, Knudtson KL, Dorrance AM, DiBona GF, 
Huang J, Casavant TL, Sheffield VC, Stone EM. Regulation of gene expression in the mammalian eye 
and its relevance to eye disease. Proc Natl Acad Sci U S A 2006;103:14429-14434.
 191.  Leroy BP, Kailasanathan A, De Laey JJ, Black GC, Manson FD. Intrafamilial phenotypic variability 
in families with RDS mutations: exclusion of ROM1 as a genetic modifier for those with retinitis 
pigmentosa. Br J Ophthalmol 2007;91:89-93.
 192.  Samardzija M, Wenzel A, Naash M, Reme CE, Grimm C. Rpe65 as a modifier gene for inherited 
retinal degeneration. Eur J Neurosci 2006;23:1028-1034.
 193.  Paskowitz DM, Lavail MM, Duncan JL. Light and inherited retinal degeneration. Br J Ophthalmol 
2006;90:1060-1066.
 194.  Sanyal S, Hawkins RK. Development and degeneration of retina in rds mutant mice: effects of light 
on the rate of degeneration in albino and pigmented homozygous and heterozygous mutant and 
normal mice. Vision Res 1986;26:1177-1185.
 195.  Naash ML, Peachey NS, Li ZY, Gryczan CC, Goto Y, Blanks J, Milam AH, Ripps H. Light-induced 
acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. 
Invest Ophthalmol Vis Sci 1996;37:775-782.
 196.  Organisciak DT, Darrow RM, Barsalou L, Kutty RK, Wiggert B. Susceptibility to retinal light damage 
in transgenic rats with rhodopsin mutations. Invest Ophthalmol Vis Sci 2003;44:486-492.
 197.  Chen CK, Burns ME, Spencer M, Niemi GA, Chen J, Hurley JB, Baylor DA, Simon MI. Abnormal 
photoresponses and light-induced apoptosis in rods lacking rhodopsin kinase. Proc Natl Acad Sci U 
S A 1999;96:3718-3722.
 198.  Chen J, Simon MI, Matthes MT, Yasumura D, Lavail MM. Increased susceptibility to light damage in 
an arrestin knockout mouse model of Oguchi disease (stationary night blindness). Invest Ophthalmol 
Vis Sci 1999;40:2978-2982.
 199.  Mata NL, Weng J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice and humans 
with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci U S A 2000;97:7154-
7159.
 200.  Radu RA, Mata NL, Bagla A, Travis GH. Light exposure stimulates formation of A2E oxiranes in a 
mouse model of Stargardt’s macular degeneration. Proc Natl Acad Sci U S A 2004;101:5928-5933.
 201.  Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000;40:93-111.
 202.  Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson 
CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Further evaluation of docosahexaenoic acid 
in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch 
Chapter 4
223
Ophthalmol 2004;122:1306-1314.
 203.  Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-
controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. 
Am J Ophthalmol 2004;137:704-718.
 204.  Hubbard AF, Askew EW, Singh N, Leppert M, Bernstein PS. Association of adipose and red blood 
cell lipids with severity of dominant Stargardt macular dystrophy (STGD3) secondary to an ELOVL4 
mutation. Arch Ophthalmol 2006;124:257-263.
 205.  Radu RA, Han Y, Bui TV, Nusinowitz S, Bok D, Lichter J, Widder K, Travis GH, Mata NL. Reductions 
in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for 
treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393-4401.
 206.  Weleber RG, Kurz DE, Trzupek KM. Treatment of retinal and choroidal degenerations and 
dystrophies: current status and prospects for gene-based therapy. Ophthalmol Clin North Am 
2003;16:583-93, vii.
 207.  Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related 
macular degeneration: a review of association. Eye 2005;19:935-944.
 208.  Besch D, Jagle H, Scholl HP, Seeliger MW, Zrenner E. Inherited multifocal RPE-diseases: mechanisms 
for local dysfunction in global retinoid cycle gene defects. Vision Res 2003;43:3095-3108.
 209.  Usukura J, Bok D. Changes in the localization and content of opsin during retinal development in 
the rds mutant mouse: immunocytochemistry and immunoassay. Exp Eye Res 1987;45:501-515.
 210.  Gregory-Evans K, Fariss RN, Possin DE, Gregory-Evans CY, Milam AH. Abnormal cone synapses in 
human cone-rod dystrophy. Ophthalmology 1998;105:2306-2312.
 211.  Papermaster DS. The birth and death of photoreceptors: the Friedenwald Lecture. Invest Ophthalmol 
Vis Sci 2002;43:1300-1309.
 212.  Pierce EA. Pathways to photoreceptor cell death in inherited retinal degenerations. Bioessays 
2001;23:605-618.
 213.  Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular 
fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 
1995;36:718-729.
 214.  Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced 
damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci 2000;41:1981-1989.
 215.  Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595-
606.
 216.  Katz ML, Drea CM, Robison WG, Jr. Relationship between dietary retinol and lipofuscin in the 
retinal pigment epithelium. Mech Ageing Dev 1986;35:291-305.
 217.  Katz ML, Gao CL, Rice LM. Long-term variations in cyclic light intensity and dietary vitamin A 
intake modulate lipofuscin content of the retinal pigment epithelium. J Neurosci Res 1999;57:106-
116.
 218.  Wu J, Seregard S, Algvere PV. Photochemical damage of the retina. Surv Ophthalmol 2006;51:461-
481.
 219.  Travis GH. Mechanisms of cell death in the inherited retinal degenerations. Am J Hum Genet 
1998;62:503-508.
 220.  Chang GQ, Hao Y, Wong F. Apoptosis: final common pathway of photoreceptor death in rd, rds, and 
Spectrum of peripherin/RDS-associated phenotypes
4
224
rhodopsin mutant mice. Neuron 1993;11:595-605.
 221.  Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, Simonutti M, Forster V, 
Cavusoglu N, Chalmel F, Dolle P, Poch O, Lambrou G, Sahel JA. Identification and characterization 
of rod-derived cone viability factor. Nat Genet 2004;36:755-759.
 222.  McCall MA, Gregg RG, Merriman K, Goto Y, Peachey NS, Stanford LR. Morphological and physiological 
consequences of the selective elimination of rod photoreceptors in transgenic mice. Exp Eye Res 
1996;63:35-50.
 223.  Mohand-Said S, Hicks D, Leveillard T, Picaud S, Porto F, Sahel JA. Rod-cone interactions: 
developmental and clinical significance. Prog Retin Eye Res 2001;20:451-467.
 224.  Chader GJ. Animal models in research on retinal degenerations: past progress and future hope. 
Vision Res 2002;42:393-399.
 225.  Fishman GA, Jacobson SG, Alexander KR, Cideciyan AV, Birch DG, Weleber RG, Hood DC. Outcome 
measures and their application in clinical trials for retinal degenerative diseases: outline, review, 
and perspective. Retina 2005;25:772-777.
 226.  Koenekoop RK, Lopez I, den Hollander AI, Allikmets R, Cremers FP. Genetic testing for retinal 
dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin Experiment Ophthalmol 
2007;35:473-485.
 227.  Duncan JL, Zhang Y, Gandhi J, Nakanishi C, Othman M, Branham KE, Swaroop A, Roorda A. High-
resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest 
Ophthalmol Vis Sci 2007;48:3283-3291.
 228.  Ergun E, Hermann B, Wirtitsch M, Unterhuber A, Ko TH, Sattmann H, Scholda C, Fujimoto JG, Stur 
M, Drexler W. Assessment of central visual function in Stargardt’s disease/fundus flavimaculatus 
with ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci 2005;46:310-
316.
 229.  Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: the eye. Gene Ther 
2006;13:1191-1197.
 230.  Chader GJ. Beyond basic research for inherited and orphan retinal diseases: successes and 
challenges. Retina 2005;25:S15-S17.
 231.  Nour M, Ding XQ, Stricker H, Fliesler SJ, Naash MI. Modulating expression of peripherin/rds in 
transgenic mice: critical levels and the effect of overexpression. Invest Ophthalmol Vis Sci 
2004;45:2514-2521.
 232.  Ali RR, Sarra GM, Stephens C, de Alwis M, Bainbridge JW, Munro PM, Fauser S, Reichel MB, Kinnon C, 
Hunt DM, Bhattacharya SS, Thrasher AJ. Restoration of photoreceptor ultrastructure and function 
in retinal degeneration slow mice by gene therapy. Nat Genet 2000;25:306-310.
 233.  Sarra GM, Stephens C, de Alwis M, Bainbridge JW, Smith AJ, Thrasher AJ, Ali RR. Gene replacement 
therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following 
partial transduction of the retina. Hum Mol Genet 2001;10:2353-2361.
 234.  Schlichtenbrede FC, da Costa L, Stephens C, Smith AJ, Georgiadis A, Thrasher AJ, Bainbridge JW, 
Seeliger MW, Ali RR. Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-
mediated gene replacement therapy. J Gene Med 2003;5:757-764.
 235.  Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal 
insertion of gene transfer vectors. Hum Gene Ther 2006;17:253-263.
Chapter 4
225
 236.  Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene 
therapy. Nat Rev Genet 2003;4:346-358.
 237.  Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res 2007.
 238.  Bonapace G, Waheed A, Shah GN, Sly WS. Chemical chaperones protect from effects of apoptosis-
inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc Natl Acad 
Sci U S A 2004;101:12300-12305.
 239.  Farrar GJ, Kenna PF, Humphries P. On the genetics of retinitis pigmentosa and on mutation-
independent approaches to therapeutic intervention. EMBO J 2002;21:857-864.
 240.  Palfi A, Ader M, Kiang AS, Millington-Ward S, Clark G, O’Reilly M, McMahon HP, Kenna PF, 
Humphries P, Farrar GJ. RNAi-based suppression and replacement of rds-peripherin in retinal 
organotypic culture. Hum Mutat 2006;27:260-268.
 241.  Bok D, Yasumura D, Matthes MT, Ruiz A, Duncan JL, Chappelow AV, Zolutukhin S, Hauswirth W, 
Lavail MM. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure 
and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002;74:719-735.
 242.  Bok D. Ciliary neurotrophic factor therapy for inherited retinal diseases: pros and cons. Retina 
2005;25:S27-S28.
 243.  Hauswirth WW, Li Q, Raisler B, Timmers AM, Berns KI, Flannery JG, Lavail MM, Lewin AS. Range 
of retinal diseases potentially treatable by AAV-vectored gene therapy. Novartis Found Symp 
2004;255:179-188.
 244.  Sahel JA. Saving cone cells in hereditary rod diseases: a possible role for rod-derived cone viability 
factor (RdCVF) therapy. Retina 2005;25:S38-S39.
 245.  Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic 
factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell 
intraocular implants. Proc Natl Acad Sci U S A 2006;103:3896-3901.
 246.  Lavail MM. Survival factors for treatment of retinal degenerative disorders: preclinical gains and 
issues for translation into clinical studies. Retina 2005;25:S25-S26.
 247.  Lavail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung CH, Steinberg RH. Protection 
of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 
1998;39:592-602.
 248.  Mohand-Said S, Hicks D, Simonutti M, Tran-Minh D, Deudon-Combe A, Dreyfus H, Silverman MS, 
Ogilvie JM, Tenkova T, Sahel J. Photoreceptor transplants increase host cone survival in the retinal 
degeneration (rd) mouse. Ophthalmic Res 1997;29:290-297.
 249.  Mohand-Said S, Hicks D, Dreyfus H, Sahel JA. Selective transplantation of rods delays cone loss in a 
retinitis pigmentosa model. Arch Ophthalmol 2000;118:807-811.
 250.  Enoch JM, Birch DG, Birch EE, Benedetto MD. Alteration in directional sensitivity of the retina by 
monocular occlusion. Vision Res 1980;20:1185-1189.
 251.  Lavail MM. Interaction of environmental light and eye pigmentation with inherited retinal 
degenerations. Vision Res 1980;20:1173-1177.
 252.  Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. A 
randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch 
Ophthalmol 1993;111:761-772.
 253.  Berson EL. Retinal photoreceptor dystrophies: LI. Edward Jackson Memorial Lecture. Am J 
Spectrum of peripherin/RDS-associated phenotypes
4
226
Ophthalmol 1995;120:683-684.
 254.  Lamb TD, Pugh EN, Jr. Dark adaptation and the retinoid cycle of vision. Prog Retin Eye Res 
2004;23:307-380.
 255.  Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention 
of age related macular degeneration: systematic review and meta-analysis. BMJ 2007;335:755.
 256.  Chucair AJ, Rotstein NP, SanGiovanni JP, During A, Chew EY, Politi LE. Lutein and zeaxanthin 
protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic 
acid. Invest Ophthalmol Vis Sci 2007;48:5168-5177.
 257.  Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, 
Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N, Jr., Serhan CN, Smith LE. Increased 
dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. 
Nat Med 2007;13:868-873.
 258.  Macdonald IM, Hebert M, Yau RJ, Flynn S, Jumpsen J, Suh M, Clandinin MT. Effect of docosahexaenoic 
acid supplementation on retinal function in a patient with autosomal dominant Stargardt-like 
retinal dystrophy. Br J Ophthalmol 2004;88:305-306.
 259.  SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and 
disease of the retina. Prog Retin Eye Res 2005;24:87-138.
 260.  SanGiovanni JP, Chew EY, Clemons TE, Ferris FL, III, Gensler G, Lindblad AS, Milton RC, Seddon 
JM, Sperduto RD. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-
related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 
2007;125:1225-1232.
 261.  Parodi MB, Liberali T, Pedio M, Francis PJ, Piccolino FC, Fiotti N, Romano M, Ravalico G. Photodynamic 
therapy of subfoveal choroidal neovascularization secondary to reticular pattern dystrophy: three-
year results of an uncontrolled, prospective case series. Am J Ophthalmol 2006;141:1152-1154.
 262.  Wong SC, Fong KC, Lee N, Gregory-Evans K, Gregory-Evans CY. Successful photodynamic therapy for 
subretinal neovascularisation due to Sorsby’s fundus dystrophy: 1 year follow up. Br J Ophthalmol 
2003;87:796-797.
 263.  Leu J, Schrage NF, Degenring RF. Choroidal neovascularisation secondary to Best’s disease 
in a 13-year-old boy treated by intravitreal bevacizumab. Graefe’s Arch Clin Exp Ophthalmol 
2007;245:1723-1725.
 264.  Prager F, Michels S, Geitzenauer W, Schmidt-Erfurth U. Choroidal neovascularization secondary to 
Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin(R)). Acta Ophthalmol Scand 
2007;85:904-906.
 265.  Marano F, Deutman AF, Leys A, Aandekerk AL. Hereditary retinal dystrophies and choroidal 
neovascularization. Graefe’s Arch Clin Exp Ophthalmol 2000;238:760-764.
 266.  Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular 
oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2007;91:743-745.
Chapter 4
227
4.2. Central areolar choroidal dystrophy
Abstract
Objectives: To describe the clinical characteristics, follow-up data and molecular genetic 
background in a large group of patients with central areolar choroidal dystrophy 
(CACD).
Methods: One hundred and three patients with CACD from the Netherlands. 
Ophthalmological examination, including color vision testing, fundus photography, 
fluorescein angiography, fundus autofluorescence (FAF) imaging, optical coherence 
tomography, full-field electroretinography (ERG), multifocal ERG, and electro-oculography 
(EOG). Blood samples were obtained for DNA extraction and subsequent analysis of the 
peripherin/RDS gene, as well as haplotype analysis.
Results: The mean age at onset of visual loss was 46 years, with a subsequent gradual 
deterioration in visual acuity. Ninety-eight patients carried a p.Arg142Trp mutation in 
peripherin/RDS, whereas five affected members of a CACD family carried a p.Arg172Gln 
peripherin/RDS mutation. A remarkable variation in disease severity was observed, and 
non-penetrance was seen up to the age of 64 years, in up to 21% of mutation carriers. 
However, the great majority of macular lesions in mutation carriers conformed to 
a typical stage of CACD. Substantial changes were seen on FAF imaging after a mean 
follow-up period of 11 months. Electrophysiological data were consistent with a central 
cone dystrophy. The age at onset and phenotypic characteristics of CACD show a 
considerable overlap with atrophic age-related macular degeneration (AMD). The great 
majority of p.Arg142Trp-carrying CACD patients originated from the southeast region of 
the Netherlands. Haplotype analysis strongly suggested a common founder mutation in 
these patients.
Conclusions: CACD caused by a p.Arg142Trp mutation in the peripherin/RDS gene is a 
central cone dystrophy phenotype. This mutation, which most likely originates from 
a common founder in most patients, is associated with a significant degree of non-
penetrance. In the elderly patient, CACD may be confused with atrophic AMD, especially 
in cases with decreased penetrance.
Introduction
Central areolar choroidal dystrophy (CACD) is a hereditary retinal disorder that 
principally affects the macula, often resulting in a well-defined area of atrophy of the 
retinal pigment epithelium (RPE) and choriocapillaris in the centre of the macula.1-4 A 
dysfunction of the macular photoreceptors usually leads to a decrease in visual acuity, 
which generally occurs between the age of 30 and 60 years.4-6
In most cases, CACD is inherited as an autosomal dominant trait,7 although autosomal 
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recessive cases have been reported.8 Autosomal dominant CACD is genetically 
heterogeneous,9,10 but mutations in the peripherin/RDS gene (official Human Gene 
Nomenclature Committee gene symbol: PRPH2 or peripherin-2) appear to be the most 
frequent cause.11,12 To date, five different mutations in peripherin/RDS have been described 
in autosomal dominant CACD: p.Arg142Trp,9 p.Arg172Trp,5,13,14 p.Arg172Gln,5,15 
p.Arg195Leu16 and p.Leu307fsX83.17 The latter mutation causes an atypical variant of 
CACD. In the case of the mutations at codon 172, full penetrance and uniform symptoms 
and signs were reported initially,5,14,15 but a more recent study described a marked 
intrafamilial variation and non-penetrance associated with the p.Arg172Trp mutation.18 
Another study indicated that the higher frequency of the p.Arg172Trp mutation in the 
British population was the result of a founder effect.12 
Full penetrance and a highly uniform age-related clinical presentation have also been 
reported in patients with CACD caused by the p.Arg142Trp mutation in peripherin/
RDS, which is mainly found in CACD patients originating from a specific region in 
the south-eastern part of the Netherlands.4,9 We report the clinical characteristics and 
follow-up data of a group of 103 patients with CACD caused by two specific peripherin/
RDS mutations, and compare them to CACD phenotypes caused by other mutations 
in the peripherin/RDS gene. We describe three large families that show evidence of non-
penetrance of the p.Arg142Trp mutation. In addition, we provide evidence showing that 
the frequent finding of the p.Arg142Trp mutation in Dutch CACD patients is the result of 
a founder effect. We propose a pathophysiological disease sequence of CACD. Finally, the 
close resemblance and differential diagnosis of CACD with atrophic age-related macular 
degeneration (AMD) is discussed. 
Methods
Clinical studies
We included 103 patients (204 eyes, excluding one amblyopic eye and one eye with 
previous trauma) with CACD, who were all examined at the Institute of Ophthalmology 
of the Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands), 
between June 1972 and December 2007. This department of ophthalmology serves as 
a tertiary referral centre for patients from the north-east, middle-east, and south-east 
regions of the Netherlands.
 Patients received the diagnosis of CACD based on the aspect of the lesions on 
ophthalmoscopy, as described by Hoyng et al.4 In selected cases, the results of peripherin/
RDS mutation analysis helped in differentiating CACD from other macular disorders. 
Four stages were discerned, according to a previously described classification.4,14 In stage 
I, slight parafoveal pigmentary changes of the RPE are seen, usually in the adolescent 
patient. Stage II is characterized by a round to oval, mildly atrophic hypopigmented 
area of 1.5 to several disc diameters. In stage III, one or more areas of well-circumscribed 
atrophy of the RPE and choriocapillaris appear outside the fovea. In stage IV, this area 
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of well-defined chorioretinal atrophy affects the fovea. When the area of profound 
chorioretinal atrophy has reached the centre of the macula and is about to involve 
central foveal function, with a still fairly good visual acuity, lesions were categorized as 
stage III-IV. The diagnosis of CACD was supported by mutation analysis of the peripherin/
RDS gene: 98 of the 103 patients carried a p.Arg142Trp mutation in peripherin/RDS, which 
has been previously described as a common finding in CACD patients that originate from 
the south-east of the Netherlands.9 The remaining five patients were found to carry a 
p.Arg172Gln mutation in peripherin/RDS, which has also been implicated in the CACD 
phenotype.19
 After the medical histories of the patients were obtained, an extensive clinical 
examination was performed, including best-corrected Snellen visual acuity testing, 
Amsler grid testing, fundus examination by indirect ophthalmoscopy, and fundus 
photography. 
Fundus autofluorescence (FAF) imaging (Heidelberg Retina Angiograph (HRA) 2, 
Heidelberg Engineering, Heidelberg, Germany) was performed in 58 patients using a 
previously described protocol.20 FAF was used to detect RPE atrophy (dark macular 
regions) and lipofuscin increase (bright macular spots). Follow-up FAF images were 
available in 11 patients and were analysed using a standard protocol, based on previously 
published methods.21-23 These methods of FAF analysis are published online (see online 
supplemental material on http://aaojournal.org).
Optical coherence tomography (Stratus OCT, Carl Zeiss Meditech, Inc., Dublin, CA, 
USA) was done in 58 patients, using the “Macular Thickness Map” protocol provided 
by the manufacturer. 
Full-field electroretinography (ERG) was performed in 55 patients. Twenty-three of 
these patients underwent full-field ERG according to the standards of the International 
Society for Clinical Electrophysiology of Vision (ISCEV).24 In 32 patients, a full-field ERG 
was recorded prior to the introduction of ISCEV standards, according to a previously 
described protocol.25 In 17 patients, multifocal ERG testing was performed according 
to the ISCEV guidelines, using 103 hexagons.26 Electro-oculography (EOG) was done in 
49 patients: 16 of these patients underwent EOG according to the ISCEV standards,27 
whereas the EOG in the other 33 patients was performed prior to ISCEV regulations, 
according to a protocol by Thijssen et al.25 
Color vision testing was performed in 36 patients, using a standard protocol. The Tokyo 
Medical College (TMC) test was used as a screening test for color vision. When the TMC 
testing result was normal, the Ishihara test (1970 edition) was performed. When a patient 
failed the TMC test, the Hardy Rand and Rittler (HRR) test (second edition) was used. After 
this test, the Standard Pseudoisochromatic Plates test was performed, followed by the 
New Color Test (NCT, box 4/8). After these tests, the patients underwent a desaturated 
Panel D-15 test and, if possible, the Farnsworth-Munsell 100 Hue test. 
This study adhered to the tenets of the Declaration of Helsinki and was approved by the 
Committee on Research Involving Human Subjects at the Radboud University Nijmegen 
Medical Centre (Nijmegen). Informed consent was received from all subjects.
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Figure 4.5.*    
Clinical stages of central areolar choroidal dystrophy (CACD). A. Color fundus photograph of stage 
I CACD, showing slight parafoveal hypopigmentation. B. This area of hypopigmentation on 
 ophthalmoscopy corresponds with an area increased fundus autof luorescence (FAF). C. Fluorescein 
angiography shows hyperf luorescent parafoveal changes in stage I CACD. D. In stage II CACD, a 
round to oval area of hypopigmentation is seen in the macula. E. FAF in stage II shows a 
 corresponding area of speckled changes of increased and decreased FAF. Initially, increased FAF 
may predominate, but with time, as the lesion enlarges and atrophy of the retinal pigment 
 epithelium (RPE) progresses, decreased FAF may become more prominent. F. The f luorescein 
 angiogram in stage II displays a speckled hyperf luorescence of the lesion, corresponding with 
 partial atrophy of the RPE. G. Stage III CACD shows one or more patches of well-circumscribed 
chorioretinal atrophy, appearing outside the central fovea, within the area of slight 
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Mutation screening and haplotype analysis
Peripheral venous blood samples were obtained from all patients for analysis of the 
peripherin/RDS gene. The genomic DNA was isolated as described elsewhere.28 The three 
coding exons and splice junctions of the peripherin/RDS gene were amplified by the 
polymerase chain reaction (PCR), and these fragments were then subjected to sequence 
analysis to detect mutations as described previously.29 Subsequently, in three patients 
carrying the p.Arg142Trp mutation who were members of large families, the p.Arg142Trp 
mutation was also screened in a total of 28 clinically affected and unaffected family 
members. Likewise, 15 additional family members of a patient carrying a p.Arg172Gln 
mutation were also screened for this mutation in codon 172. Family members who were 
found to carry the p.Arg142Trp or the p.Arg172Gln mutation underwent an ophthalmic 
examination as described above. 
 Haplotype analysis was performed with microsatellite markers and single nucleotide 
polymorphisms (SNPs) surrounding the peripherin/RDS gene. Microsatellites D6S1552 
and D6S1582 were amplified with primers containing a M13-forward or -reverse tail. 
A second PCR was performed with a fluorescently labelled M13-forward primer and an 
unlabelled M13-reverse primer. PCR products were mixed with a fluorescent size marker 
(Applied Biosystems), and samples were analyzed on a 3100 or 3730 DNA Analyzer 
(Applied Biosystems). Fragment lengths were analyzed with GeneMapper software 
(Applied Biosystems). SNPs with a high heterozygote frequency in European descendents 
were selected from the International HapMap Project. Selected SNPs (rs2281462, 
rs9349227, rs9471874, rs373341, rs3846893, rs9381218, rs6941837) were analyzed by PCR 
amplification and direct sequencing. 
Control Group
The p.Arg142Trp variant has been previously screened in 200 chromosomes from 100 
normal individuals from the Netherlands, and was found in none of these patients.9 
In addition, we screened a group of 57 persons originating from the same region in the 
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 hypopigmentation. H. These areas of chorioretinal atrophy correspond to severely decreased to 
absent FAF. I. Fluorescein angiography in stage III CACD clearly visualizes the remaining choroidal 
vessels in the area of chorioretinal atrophy. In the later phase of the angiogram, discrete leakage  
of f luorescein could be observed at the edge of the lesion, corresponding with incomplete atrophy  
of the choriocapillaris. J. In stage IV CACD, the well-defined area of chorioretinal atrophy involves 
the fovea, with a corresponding severe decrease in visual acuity. K. This area corresponds with  
a round to oval zone of absent FAF involving the fovea in late stage IV CACD, bordered by a small 
residual band of increased FAF. L. End-stage CACD also shows a well-demarcated area of 
 chorioretinal atrophy on the f luorescein angiogram, with enhanced visibility of the residual 
 underlying choroidal vessels. 
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south-east of the Netherlands for the p.Arg142Trp variant. These 57 control subjects were 
over 70 years of age, did not experience visual disturbances, and did not have a family 
history of macular disease. The p.Arg172Gln mutation has also been previously tested in 
a control group.5
Results
Clinical characteristics
The 103 CACD patients originated from 46 different families. Of the 98 patients with a 
p.Arg142Trp mutation, 96 patients (98%) originated from the south-east region of the 
Netherlands, despite the considerably wider area of tertiary referral. Three patients with 
CACD caused by a p.Arg142Trp mutation were identified after analysis of the peripherin/
RDS gene in a group of 21 patients of whom blood was sent to the Human Genetics 
department with the diagnosis of “early-onset AMD” (age < 55 years). Information about 
the age at onset of visual loss was available in 88 patients. The mean age at onset of 
visual loss was 46 years (range, 12-63 years) in a group of 59 CACD patients with the 
p.Arg142Trp mutation. Twenty-nine of the 88 CACD patients (33%) did not experience 
visual loss. In these patients, the phenotype was discovered by coincidence or as a result 
of ophthalmological screening because of a positive family history. Twenty-one patients 
(20%) did not have a family history of visual loss compatible with macular disease. 
The visual acuity varied widely, generally depending on the disease stage. Table 4.1 shows 
the mean age, the mean lesion size, and the visual acuities differentiated by CACD stage, 
as well as the number of patients with visual disturbances in each CACD stage. 
Follow-up data were available in 86 eyes of 43 patients, and are depicted in Table 4.2. 
In the group of patients with a follow-up time of more than five years, 36 of 64 eyes (56%) 
showed progression to another stage. 
 Of the 103 CACD patients, 99 (96%) patients showed a CACD stage on ophthalmoscopy 
that largely corresponded to the typical stages as described by Hoyng and colleagues 
(Fig. 4.5).4 The four patients with an atypical phenotype showed either atypical parafoveal 
pigmentary changes (3 patients), or lesions resembling pattern dystrophy in a butterfly-
shaped configuration (1 patient). Asymmetry of stages between both eyes was observed 
in 26 patients (25%). When comparing the observed CACD phenotypes in our study to 
the stages described by Hoyng and co-workers, mild variation of the CACD phenotype 
was common. For instance, in 20 patients (19%), the macular lesion was not confined 
to the central macula but reached the retina adjacent to the temporal part of the optic 
disc or completely surrounded the optic disc (Fig 4.6A and B). In one patient, the lesions 
extended beyond the temporal retinal vascular arcades. Small drusen-like lesions at 
the edge of the macular lesion were seen in 11 patients (11%), whereas two patients 
belonging to the same family had larger drusen in the centre of the lesion. One patient 
had extensive macular and peripheral basal laminar drusen in combination with the 
macular CACD lesion. Macular lesions had a “bull’s eye” aspect in 4 patients (4%) from 3 
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different families. Two of the patients with a bull’s eye appearance of the CACD lesion 
on ophthalmoscopy, who received a full-field ERG evaluation, had normal photopic and 
scotopic full-field ERGs. Relative foveal sparing in advanced CACD, with a correspondingly 
good visual acuity, was seen in four patients. One patient with high myopia developed 
choroidal neovascularization.
 The characteristics on fluorescein angiography are depicted in Figure 4.5. Discrete 
abnormalities in stage I CACD could be easily visualized with fluorescein angiography. 
Except in some cases of early stage I CACD, CACD lesions were easily identified with 
FAF imaging (Fig. 4.5). Fluorescein angiography appeared most sensitive to identify some 
cases of early stage I CACD, as it was able to visualize even minuscule areas of discrete 
RPE atrophy that were not readily detected on ophthalmoscopy or FAF. The analysis of 
follow-up FAF images is depicted in Table 4.3. Individual examples of increasing lesion 
size and progression of chorioretinal atrophy on FAF are given in Figure 4.6, and are 
shown in online videos 1 and 2 (available at http://aaojournal.org).
On optical coherence tomography, increased reflectivity of the “outer red line” could be 
observed,30 which was proportional to the degree of chorioretinal atrophy observed on 
ophthalmoscopy and FAF.
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Figure 4.6.      
Follow-up of patients with 
 fundus autof luorescence (FAF, 
also see Table 4.3 and online 
supplemental movies). A and B. 
After 19 months of follow-up in 
this patient with stage III 
 central areolar choroidal 
 dystrophy (CACD), the total area 
of FAF abnormalities changed 
from 22.95 mm2 to 24.20 mm2 
(an increase of 1.25 mm2).  
The area of absent FAF, 
 corresponding with atrophy of 
the retinal pigment epithelium, 
increased from 7.61 mm2 to  
9.27 mm2. C and D. In this example of another patient with stage III CACD, the total area  
of FAF changes increased from 9.46 mm2 to 10.14 mm2, an increase of 0.68 mm2 after a  
follow-up period of 30 months. The area of absent FAF increased from 2.18 mm2 to 3.24 mm2 
(a 1.06 mm2 increase).
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Change of CACD stage Number of eyes* Mean time (years) between
  change of CACD stage
  (range)
Stage I → Stage II 5 18.2 (13 - 20)
Stage I → Stage III 1 13
Stage II → Stage III 12 11.8 (5 - 17)
Stage II → Stage IV 7 19.6 (13 - 31)
Stage III → Stage IV 16 6.4 (2 - 16) 
*From a total of 86 eyes on which follow-up information was available.
 Initial visit Follow-up*
Mean surface area of FAF changes 10.6 11.2
(in mm2, n = 22 eyes) (range, 0.3 – 23.0) (range, 0.7 – 24.2) 
Mean area of absent FAF†  1.69 2.11
(in mm2, n = 22 eyes) (range, 0 – 7.61) (range, 0 – 9.27)
Mean area of absent FAF in  2.48  3.09
patients with area of absent FAF  (range, 0.05 – 7.61) (range, 0.12 – 9.27)
at initial visit 
(in mm2, n = 15 eyes)                                                           
*Mean follow-up time: 18 months (range, 11 – 30 months).
†The area of absent FAF corresponds to profound chorioretinal atrophy on ophthalmoscopy.
  Normal Abnormal
ISCEV Full-field ERG (n = 23) Photopic 20 3*
 Scotopic 23 0 
Non-ISCEV Full-field ERG   Photopic 29 3
 Scotopic 31 1
Table 4.2. 
 Follow-up data in central areolar choroidal dystrophy (CACD).
Table 4.3. 
Follow-up of fundus autofluorescence (FAF) imaging in central areolar choroidal  
dystrophy patients.
Table 4.4. 
Results from psychophysical testing in patients with central areolar choroidal 
 dystrophy (CACD).
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The results from full-field ERG, multifocal ERG, EOG and color vision testing are 
summarized in Table 4.4. 
Mutation screening, clinical examination and haplotype analysis in four large 
families of CACD patients 
We examined three large families with CACD patients with the p.Arg142Trp mutation 
(Families A-C). In addition, we examined the family of a patient carrying a p.Arg172Gln 
mutation (Family D), which has been previously described in patients with CACD-like 
macular dystrophy.5,15,31 Two of these four families did not have a positive family history 
for visual symptoms attributable to macular disease. The pedigrees of families A-D are 
depicted in Figure 4.7A and C. A summary of the clinical characteristics of the affected 
family members is given in Tables 4.5 and 4.6. 
A striking variability of disease severity was observed (Fig. 4.8). The frequent occurrence 
of the p.Arg142Trp mutation in the patient cohort of this study, and the finding that 
the great majority of mutations carriers (96 of 98 patients, 98%) originated from the south-
Chapter 4
Multifocal ERG (n = 17)  2† 15‡ 
ISCEV EOG (n = 16)  15 1§
Non-ISCEV EOG (n = 33)  25 8" 
Color vision testing (n = 36)  9 27# (75%)
ISCEV = International Society for Clinical Electrophysiology of Vision; ERG = electroretinography;  
EOG = electro-oculography.
*One patient with bilateral stage II CACD had an abnormal photopic ERG (defined as a response below 
1% of the normal range: < 69 μV). Two patients, one with bilateral stage II CACD and one with bilateral 
stage III, had a unilaterally abnormal photopic full-field ERG. Of the remaining majority of patients 
with a normal photopic ERG, 22 eyes were in stage III or IV CACD.
† Patients with stage I and early stage II CACD. 
‡  Six patients were in stage II CACD. Severely decreased multifocal ERG responses were observed, 
especially in the parafoveal area. The most prominent decrease in central retinal response amplitude 
was seen in stage III and IV CACD. Three patients showed relative foveal sparing of the response 
amplitude.
§ An abnormal ISCEV EOG is defined as having an Arden ratio below 2.0 in at least one eye.
"  An abnormal non-ISCEV EOG is defined as having an Arden ratio below 1.8 in at least one eye.  
Six of these patients showed stage IV CACD and 2 patients showed stage III CACD.
#  In this group, 14 patients showed a blue-yellow defect, 4 patients showed a red-green defect,  
and 9 patients showed a combined red-green/blue-yellow defect. All patients with a combined  
red-green/blue-yellow defect had stage III or IV CACD, whereas either a blue-yellow or a red-green 
defect could be observed in stage II, III, or IV.
Abbreviations: ISCEV, International Society for Clinical Electrophysiology of Vision; ERG,  
electroretinography; EOG, electro-oculography.
Table 4.4. continued
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Figure 4.7.    
Molecular genetic analysis of the peripherin/RDS gene in four large families. A. Pedigrees of three 
families with the p.Arg142Trp mutation. B. Haplotype surrounding the p.Arg142Trp mutation in 
families A, B and C. The distance of each marker to the p.Arg142Gln mutation is shown in kilobases 
(kb). C. Pedigree of a family with the p.Arg172Gln mutation. Black symbols denote individuals with 
central areolar choroidal dystrophy (CACD) who noted visual disturbances. Grey symbols denote 
 individuals who did not note visual disturbances, but showed macular abnormalities compatible with 
CACD on ophthalmic examination. Mutation carriers who did not note visual disturbances, and did 
not show macular abnormalities, are denoted with white symbols.  
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eastern part of the Netherlands, suggest that it is a founder mutation. Employing selected 
CA markers and SNPs near peripherin/RDS, we analysed several individuals of families A, 
B, and C (data not shown). The deduced at-risk haplotypes of three mutation carriers are 
depicted in Figure 4.7B. All three families share the same chromosomal segment of 519 
kilobases encompassing the peripherin/RDS gene, which is highly suggestive of a common 
founder mutation.
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Figure 4.8.      
Illustration of the phenotypic 
variability associated with the 
p.Arg142Trp mutation in the 
peripherin/RDS gene; A. Fundus 
autof luorescence (FAF) image of 
stage IV (end-stage) central  
areolar choroidal dystrophy 
(CACD) in patient A-II.1. Note 
the well-defined central absence 
of FAF, due to atrophy of the 
retinal pigment epithelium.  
B. In patient A-II.3, FAF 
 imaging showed signs of early 
stage II CACD. C. FAF image of 
the 64-year-old patient B-II.5, 
who was found to carry the p.Arg142Trp mutation, showing an entirely normal macular 
area. D. Patient C-II.3 had small atypical parafoveal lesions in both eyes.
Figure 4.9.      
Fundus autof luorescence image showing 
stage II central areolar choroidal dystrophy 
in an asymptomatic 76-year-old person who 
was recruited for the control group. He was 
the only person in the control group in 
whom the p.Arg142Trp mutation was found.
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The carrier frequency of the p.Arg142Trp mutation in this population was analyzed in 57 
asymptomatic control individuals (of at least 70 years of age) from the same south-eastern 
region of the Netherlands. The mutation was identified in 1 of 57 (1.8 %) controls. This 
mutation carrier was a 76-year-old male, who did not have any visual disturbances, and 
neither did his parents nor his 11 siblings. Ophthalmoscopy and FAF imaging, however, 
clearly demonstrated early stage II CACD (Fig. 4.9).
Discussion
Phenotype
In CACD caused by an p.Arg142Trp mutation in the peripherin/RDS gene, our study 
found a mean age at onset of 46 years, which is consistent with previous studies on this 
mutation.4,9 The course of CACD caused by this mutation is variable: some patients never 
reach stage IV, III or even stage II CACD. In most CACD patients in our study, it takes 
more than a decade to progress from stage II to stage III (Table 4.2). The progression from 
stage III to stage IV lesions - when severe visual loss occurs - is somewhat faster, with a 
mean of 6.4 years (Table 4.2). The multifocal ERG shows abnormalities that are consistent 
with central cone dysfunction, especially in the parafoveal area. Such abnormalities 
on the multifocal ERG have also been noted in CACD caused by other peripherin/RDS 
mutations.6 Even in patients with advanced (stage IV) disease caused by the p.Arg142Trp 
mutation, the photopic and scotopic full-field ERG generally remain within the limits of 
normality. In contrast with p.Arg172Trp-related CACD (see below), the CACD phenotype 
associated with the p.Arg142Trp mutation appears to be largely confined to the macula, 
both ophthalmoscopically and electrophysiologically. This type of CACD may therefore 
be categorized as a central cone dystrophy. FAF imaging appears to be a useful tool in 
the diagnosis and follow-up of CACD. Small, subclinical lesions may be easily identified 
on FAF, and enlargement of the lesions and progression of chorioretinal atrophy can be 
closely monitored. Substantial changes within the same CACD stage may be noted on FAF 
imaging within 11 months of follow-up. In lesions with an area of profound chorioretinal 
atrophy (geographic atrophy), the mean enlargement of this area after a mean follow-up 
time of 18 months was 0.61 mm2. 
Genotype
The great majority of CACD patients with a p.Arg142Trp mutation in peripherin/RDS 
originated from the same southeastern region of the Netherlands. Analysis of CA 
markers and SNPs near the peripherin/RDS gene in three families carrying the p.Arg142Trp 
mutation revealed a shared chromosomal segment of at least 519 kb, strongly suggesting 
that this mutation represents a founder mutation. A founder effect was also found in a 
study on the p.Arg172Trp mutation, the most frequent peripherin/RDS mutation in British 
patients with autosomal dominant macular dystrophies.12 
 In our study, a striking variation in severity of the phenotype, as well as non-
penetrance, were observed in several families in association with both the p.Arg142Trp 
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and p.Arg172Gln peripherin/RDS mutations. These variations could not be explained 
solely by the age of the patient and the stage of the macular dystrophy. Non-penetrance, 
defined as an absence of macular abnormalities on ophthalmoscopy, FAF, as well as 
on fluorescein angiography, in mutation carriers was observed up to 64 years of age, 
and this non-penetrance was seen in up to 21% of patients (4 out of 19 patients in 
Families A-C). Our study indicates that a considerable number of p.Arg142Trp mutation 
carriers may remain asymptomatic up to 76 years of age. Due to this non-penetrance 
and variable expression of mutations such as p.Arg142Trp, cases may appear sporadic 
or the inheritance pattern of CACD may appear autosomal recessive in some families. 
Molecular genetic analysis of the peripherin/RDS gene may facilitate genetic counseling 
in these cases. The p.Arg142Trp variant was found in one individual out of a group of 57 
control persons beyond 70 years of age from the south-eastern region of the Netherlands. 
This 76-year-old asymptomatic person was shown to have early stage II CACD. This 
indicates that carriership of p.Arg142Trp may be quite frequent in this region, and that 
non-penetrance and/or a decreased penetrance of this mutation is even more frequent 
than the 21% estimated above.
Genotype-phenotype correlation
There are insufficient data to explain the broad phenotypic variation that is encountered 
in association with identical mutations in the peripherin/RDS gene.32-34 A study by Samardzija 
and colleagues indicates that sequence variants in the RPE65 gene may act as a modifier 
of light-damage susceptibility in mice with retinal degeneration.35 An environmental 
influence on the phenotype may also be possible, but is probably of limited importance, 
as most patients in our study originated from the same geographic area and did not 
show notable differences in lifestyle.
 The large majority of macular lesions encountered in carriers of the p.Arg142Trp 
mutation had the typical aspect of a certain stage of CACD, although the age at onset and 
the rate of progression were variable. In CACD, the mean age at onset of visual loss as well 
as the degree of photoreceptor dysfunction on full-field ERG is strongly influenced by the 
type of peripherin/RDS mutation. The onset of visual disturbances is usually before the age 
of 40 in CACD caused by the p.Arg172Trp or p.Arg195Leu mutation in peripherin/RDS. In 
p.Arg142Trp-related CACD, visual symptoms usually become manifest in the middle of 
the fifth decade.5,6,14,16 The p.Arg142Trp mutation is associated with a CACD phenotype 
without progression to panretinal cone(-rod) dystrophy. The p.Arg172Trp mutation was 
initially reported to cause a fairly constant phenotype resembling p.Arg142Trp-related 
CACD, but p.Arg172Trp was subsequently shown to be associated with a more widespread 
cone or cone-rod dystrophy.18 The p.Arg195Leu mutation also appears to cause panretinal 
cone or cone-rod dysfunction, in contrast to the p.Arg142Trp mutation in our study.6,16 
Pathophysiology 
Several histopathological studies on CACD have been published.1,3,36 All studies showed 
an absence of photoreceptors, RPE and choriocapillaris in the area of atrophy, which is 
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in keeping with the clinical findings in CACD. In none of the aforementioned studies, 
information of the underlying genetic defect was available. The clinical observations 
and experimental studies suggest that choriocapillaris atrophy ensues from primary RPE 
atrophy.37,38 A histopathological study on a donor eye of a patient with advanced butterfly-
shaped pattern dystrophy caused by a p.Cys213Tyr mutation in peripherin/RDS found a 
central area of complete photoreceptor and RPE cell loss, with lipofuscin-containing cells 
in the subretinal space, and an intact choriocapillaris.39 In the area surrounding this 
zone of profound atrophy, RPE cells were distorted and greatly distended by lipofuscin, 
with the overlying photoreceptors being partly atrophic. 
 Experimental studies on transgenic mice carrying the p.Arg172Trp mutation indicate 
that this mutation exerts a dominant negative effect on photoreceptors, especially 
cones, and that the severity of the phenotype depends on the degree of expression of the 
mutant allele.40,41 In this mouse model, genetic supplementation of wild-type peripherin/
rds provided a partial, long-term rescue of rod function, but no permanent rescue of 
cone function.42 It is tempting to speculate that the p.Arg142Trp mutation exerts its 
detrimental effect through the same dominant-negative mechanism as the p.Arg172Trp 
mutation. A slightly less pathogenic effect might explain why this mutation primarily 
affects the dense, central cone population, with relative sparing of the more peripherally 
located photoreceptor elements. 
 We propose the following pathophysiological sequence of CACD associated with 
the p.Arg142Trp mutation in the peripherin/RDS gene. The amino acid substitution of 
a relatively large, positively charged, arginine residue to a nonpolar and hydrophobic 
tryptophan residue probably has a disturbing effect on peripherin/rds protein structure, 
resulting in dysmorphic cone and rod outer segments. The disturbance of normal 
photoreceptor function and extracellular matrix interaction leads to alterations in the 
normal photoreceptor outer segment - RPE interface and results in an increase in the 
phagocytosis of these abnormal outer segments by RPE cells.41,43,44 This in turn raises the 
level of lipofuscin and toxic by-products in the RPE, which is reflected in the findings on 
FAF, resulting in RPE and photoreceptor cell death through apoptosis.45,46 Finally, when 
atrophy of the choriocapillaris occurs,37,38 the typical ‘punched-out’ CACD lesion arises.
Central areolar choroidal dystrophy versus atrophic age-related macular 
degeneration 
CACD and other peripherin/RDS-related macular dystrophies share clinical characteristics 
with atrophic AMD, such as geographic atrophy and drusen-like deposits.17,31,47,48 Our 
study also indicates that there may be an overlap in the age at onset of CACD and 
atrophic AMD. CACD in the elderly patient may be confused with AMD, especially in 
cases with low penetrance. This is illustrated by mutation analysis of peripherin/RDS in a 
group of 21 patients in our hospital that were categorized as having “early-onset AMD”. 
Three of these patients carried the p.Arg142Trp mutation in peripherin/RDS, and were 
subsequently re-diagnosed as having CACD. On the other hand, familial cases of AMD are 
not uncommon, and may mimic an autosomal dominant pattern of inheritance. 
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 Several features may help to distinguish CACD from atrophic AMD. In the early 
stages of CACD, an oval area of hypopigmentation is observed in the macula. In contrast, 
early age-related maculopathy usually displays either dispersed hard and/or soft 
drusen clustered in the macula, or a parafoveal band of reticular hyperpigmentation. 
Geographic atrophy in AMD usually emanates from large, confluent atrophic drusen 
or from the parafoveal band of hyperpigmentation.47 The area of geographic atrophy 
is often surrounded by residual drusen or smaller satellite geographic lesions in these 
cases. Unlike CACD, the geographic atrophy in end-stage atrophic AMD is often bordered 
by a band of hyperpigmentation. On FAF, geographic atrophy in atrophic AMD shows a 
median enlargement of 1.52 mm2 per year.49 This is significantly higher than the 0.61 
mm2 enlargement per 18 months in the CACD patients in our study. Drusen-like changes 
that may be observed especially at the edge of CACD lesions show intense FAF, whereas 
basal laminar drusen caused by CFH gene mutations and drusen in AMD generally 
do not display intense FAF.50,51 This probably reflects a difference in the pathogenesis 
and composition of these drusen-like lesions, despite the superficial similarity on 
ophthalmoscopy. Choroidal neovascularisation is rare in CACD, as it was observed in 
only one highly myopic patient in the present study. 
 Peripherin/RDS mutations probably do not play an important role in AMD, but studies 
on the prevalence of peripherin/RDS mutations in patients with atrophic AMD are sparse.52 
The finding of a p.Arg142Trp peripherin/RDS mutation in 1 out of 57 asymptomatic 
control persons over the age of 75 years, originating from the south-eastern region of 
the Netherlands, also indicates that the carrier frequency of the mutation in this region 
may be quite high. Future studies may be directed towards investigating the incidence of 
peripherin/RDS mutations in patients with (CACD-like) atrophic AMD. 
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4.3.  Mutations in the peripherin/RDS gene are an important 
cause of multifocal pattern dystrophy simulating 
STGD1/fundus flavimaculatus
Abstract
Objectives: To describe the phenotype and to analyse the peripherin/RDS gene in 10 
unrelated families with multifocal pattern dystrophy simulating Stargardt disease 
(STGD1).
Methods: The probands of 10 families and 20 affected family members underwent an 
ophthalmic examination, including dilated fundus examination, fundus autofluorescence 
imaging and optical coherence tomography (OCT). In all probands and in selected family 
members, fluorescein angiography, electrophysiological testing and visual field analysis 
were performed. Blood samples were obtained from affected and unaffected family 
members for analysis of the peripherin/RDS gene.
Results: All 10 probands carried mutations in the peripherin/RDS gene. Nine different 
mutations were identified, including six mutations that were not described previously. 
All probands showed a pattern dystrophy with yellow-white flecks in the posterior pole 
that strongly resembled the flecks seen in STGD1, on ophthalmoscopy as well as on 
autofluorescence and OCT. Clinical findings in the family members carrying the same 
mutation as the proband were highly variable, ranging from no visible abnormalities to 
early-onset retinitis pigmentosa.
Conclusions: Mutations in the peripherin/RDS gene are the major cause of multifocal 
pattern dystrophy simulating STGD1/fundus flavimaculatus. This autosomal dominant 
disorder should be distinguished from autosomal recessive STGD1, in view of the different 
inheritance pattern and the overall better visual prognosis. 
Introduction
The autosomal dominant pattern dystrophies constitute a group of disorders 
characterized by deposits of yellow, orange or grey pigment, predominantly in the 
macular area. In general, these disorders are relatively benign, manifesting usually 
in midlife with mild to moderate disturbance of central vision.1-4 Nevertheless, severe 
vision loss may occur in up to 50% of the affected individuals after the age of 70, due 
to atrophy of the retinal pigment epithelium (RPE)-photoreceptor complex and/or the 
development of choroidal neovascularization.5-9 In addition, progression to a more 
widespread retinal dystrophy with characteristics of retinitis pigmentosa may develop, 
depending on the underlying genotype.10,11 In the classification according to Gass, five 
main categories of pattern dystrophy are discriminated, based on the pattern of pigment 
distribution: adult-onset foveomacular vitelliform dystrophy, butterfly-shaped pigment 
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dystrophy, reticular dystrophy of the retinal pigment epithelium, multifocal pattern 
dystrophy simulating fundus flavimaculatus, and fundus pulverulentus.11 A striking 
inter- and intrafamilial phenotypic variability has been described by several authors, 
and different subtypes of pattern dystrophy have even been reported in the individual 
patient.4-7,10,12-22,22-24 Pattern dystrophy is genetically heterogeneous, but mutations in the 
peripherin/RDS gene are frequently encountered.5,11,23,25-28 Weleber and co-workers reported 
pattern dystrophy, retinitis pigmentosa and fundus flavimaculatus in a single family 
with family members carrying the same peripherin/RDS mutation.29 Besides pattern 
dystrophy and autosomal dominant retinitis pigmentosa, peripherin/RDS mutations have 
been associated with central areolar choroidal dystrophy, cone-rod dystrophy, as well 
as digenic retinitis pigmentosa.11,25-27 The gene product of peripherin/RDS is the integral 
membrane protein peripherin/rds, which plays an important role in photoreceptor 
outer segment morphogenesis.30-32 In this study, we describe the clinical findings and the 
underlying genetic defects of patients in 10 unrelated families with multifocal pattern 
dystrophy resembling Stargardt disease (STGD1)/fundus flavimaculatus.
Methods
The research described in this study conformed to the tenets of the Declaration of 
Helsinki and was approved by the Committee on Research Involving Human Subjects 
at the Radboud University Nijmegen Medical Centre (Nijmegen). Informed consent was 
obtained from all participants before enrolling them in the clinical and molecular 
genetic studies.
Molecular genetic studies
Peripheral venous blood samples were obtained from the 10 probands and from 39 family 
members. Their genomic DNA was isolated as described elsewhere.33 The three coding 
exons and splice junctions of the peripherin/RDS gene were amplified by the polymerase 
chain reaction (PCR), and these fragments were then subjected to sequence analysis to 
detect mutations.23
Clinical studies
We examined 10 probands from 10 different families with multifocal pattern dystrophy 
simulating STGD1/fundus flavimaculatus (Fig. 4.10). Seven of these patients had received 
the diagnosis multifocal pattern dystrophy in the past. Three of the 10 probands (E, G 
and H) were identified retrospectively when a group of 15 presumed STGD1 patients 
without ABCA4 mutations were analysed for peripherin/RDS mutations. The medical 
histories of the 10 probands were obtained. Subsequent clinical examination included 
best-corrected Snellen visual acuity, indirect ophthalmoscopy and fundus photography. 
In addition, fundus autofluorescence (FAF) imaging (Heidelberg Retina Angiograph (HRA) 
2, Heidelberg Engineering, Dossenheim, Germany) was performed in all probands using 
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Figure 4.10.    
Pedigrees of the examined families. The probands with multifocal pattern dystrophy are indicated with 
an arrow. The specific mutations have been put between brackets and are indicated by an “M” within 
the pedigree. Mutation carriers who showed only mild foveal abnormalities, without signs of multifocal 
pattern dystrophy, are indicated with a black dot. The pedigree of proband A (p.Asp157Asn) is not 
shown, as he was the only person of his family who was clinically affected and who was  examined.  
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Figure 4.11.*       
The development of lesions in multifocal pattern dystrophy simulating STGD1/fundus 
 f lavimaculatus. A. Fundus autof luorescence (FAF) image of the 37-year-old daughter (E-IV:2,  
p.Pro146fsX4) of proband E, demonstrating small dots of increased FAF, in the absence of  
foveal lesions. This picture may represent an early stage of  multifocal pattern dystrophy.  
B. Composition of FAF images of individual H-II:2 (p.Arg203fsX8), showing two irregular  
lesions with increased FAF in the  macular area and small irregular f lecks around the  retinal 
vessels. Note that most of these f lecks show adjacent zones of decreased FAF. C. Fundus photo-
graph of proband B (p.Asp145fsX30) taken at the age of 35, demonstrating three pigmented 
spots with a depigmented border in the macula. D. These lesions display a “dot-and-halo” 
aspect on the f luorescein angiogram, which was made before we had the  possibility to  
perform FAF imaging. E. Six years later, the phenotype had evolved to a  picture mimicking 
STGD1, with irregular yellow-white f lecks around the vascular arcades, which showed  
predominantly increased FAF on the composition of FAF images (F). The macular lesion had  
a butterly-shaped configuration both on ophthalmoscopy and on the FAF image (E, F).
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a previously described protocol,34 as well as optical coherence tomography (Stratus OCT, 
Carl Zeiss Meditech, Inc., Dublin, CA, USA), using the “Macular Thickness Map” protocol. 
The probands also underwent fluorescein angiography and visual field analysis, by means 
of Goldmann perimetry (stimuli V4e-III4e-I4e-I3e-I2e-I1e) and Humphrey 10-2 Swedish 
Interactive Thresholding Algorithm (SITA)-Fast visual field analysis of the central 10º of 
the visual field, except for patient 8 and 10 who were unavailable for visual field analysis. 
Full-field electroretinography (ERG) and an electro-oculography (EOG) were performed 
in all probands according to the guidelines of the International Society for Clinical 
Electrophysiology of Vision (ISCEV), except for proband H, in whom the ERG and EOG 
were recorded according to the protocol by Thijssen et al.35 Additionally, we examined 
the 20 family members who carried the same mutation as the proband of that family. 
The medical history was obtained in all of these 20 family members, and a clinical 
examination was performed including fundus photography, FAF imaging, and optical 
coherence tomography. Six affected family members underwent full-field ERG and EOG 
according to the ISCEV standards, whereas one patient underwent these examinations 
according to the previously mentioned protocol.35
Results
Molecular genetic findings
All 10 probands carried mutations in the peripherin/RDS gene. Nine different mutations 
were identified, including five different frameshift mutations, two missense mutations 
and one nonsense mutation (Table 4.7). Six of these mutations (p.Asp145fsX30, 
p.Asn54fsX9, p.Arg220fsX34, c.581+4dupA, p.Arg203fsX8, and p.Trp21X) have not been 
described previously. The splice site mutation c.581+4dupA was detected in proband G. 
This mutation is predicted to completely abolish splicing.36 The six novel mutations were 
not found in 92 control individuals. The frameshift mutation p.Pro147fsX4 was identified 
in two unrelated probands (probands D and E). Of the 39 additional family members that 
were screened for the peripherin/RDS mutation that was found in the proband, 20 family 
members were shown to also carry the same mutation as the proband (Table 4.8). 
Clinical findings
The clinical characteristics of the probands are summarized in Table 4.7. The mean 
age at onset was 45 (range: 34-55 years). The initial symptoms were metamorphopsia 
(6 patients), loss of visual acuity (4 patients), central scotomata (3 patients), and night 
blindness (5 patients). Seven probands reported additional family members with similar 
visual complaints. All probands retained reading vision in at least one eye, except for 
proband G, a 73-year-old male (c.581+4dupA). This patient experienced visual loss with 
metamorphopsia at age 45, in combination with night blindness. He lost the ability to 
read approximately 21 years later, at the age of 66 years. 
 All patients showed irregular yellowish flecks in the posterior pole at a certain point 
in time, resembling the flecks seen in STGD1. These flecks were also found in variable 
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size, shape and number in several asymptomatic family members who carried the same 
mutation as the proband of their family (Fig. 4.11). The flecks were mostly situated 
around the retinal vascular arcades, nasal and superior to the optic disc and in the 
macular area, where flecks were usually largest (Fig. 4.11 and 4.12). Probands A, C, D, 
G, I and J showed a variable degree of confluence and atrophy of the STGD1-like flecks 
over a period of probably more than 5 years, based on the comparison of consecutive 
fluorescein angiograms (Fig. 4.12 and 4.13). Besides these flecks, all patients displayed 
macular changes, ranging from a variety of patterns of yellow or greyish deposits in the 
foveomacular area, to atrophic lesions in proband F (p.Arg220fsX34) (Fig. 4.12 and 4.13). 
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Figure 4.12.*       
Advanced multifocal pattern dystrophy. A. Fundus photograph of proband F  
(p.Arg220fsX54), showing numerous yellowish f lecks that are scattered throughout the 
 posterior pole, with the larger f lecks situated around a central area of well-circumscribed 
 chorioretinal atrophy. B. A fundus autof luorescence (FAF) image shows increased FAF, 
 corresponding to the yellow lesions on ophthalmoscopy, together with a complete absence of 
FAF in the central atrophic area. C. A composition of fundus photographs of proband A  
(p.Asp157Asn) demonstrated a central lesion typical for pattern dystrophy. A large ring-
shaped, atrophic-appearing area can be seen, surrounding the macular area and optic disc. 
D. These lesions could be delineated with more detail on a composition of FAF images.  
The ring-shaped zone showed conf luence of the f lecks. Granular zones of decreased FAF were 
seen within this area of increased FAF, which ref lects the  beginning atrophy of the retinal 
pigment epithelium. Towards the periphery, the f lecks  became less conf luent and could be 
identified individually.
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Typical “dot-and-halo” lesions were observed in patient B (p.Asp145fsX30) (Fig. 4.11). The 
central “dot-and-halo” lesions in the left eye gradually developed into a butterly-shaped 
pattern dystrophy of the macula (Fig. 4.11). None of the patients in this study developed 
subretinal neovascularization. Four patients (probands C, D, E and G) demonstrated 
pigmentary changes in the peripheral retina. All four patients suffered from a variable 
degree of night blindness. Typical retinitis pigmentosa characteristics were observed 
only in proband D (Table 4.7). 
 On fluorescein angiography, the flecks were hyperfluorescent in the early and late 
phase of the examination, sometimes with a central hypofluorescent spot. None of the 
patients displayed a so-called “dark choroid” on fluorescein angiography. On FAF imaging, 
the flecks showed a highly increased FAF, often with small adjacent zones of decreased 
FAF (Fig. 4.11 and 4.12). Lesions that were yellowish and seemed to contain a lipofuscin-
like substance on ophthalmoscopy, mostly corresponded with an increased FAF signal. 
On OCT, some of the STGD1-like flecks appeared as a highly reflective focal thickening 
of the hyperreflective “outer red line” (ORL), which corresponds to the photoreceptor/
retinal pigment epithelium complex.37 Macular lesions showed thickening of the ORL, 
with a variable increase in underlying reflectivity.
 Full-field ERG results varied from normal to nonrecordable (Table 4.7). The photopic 
ERG was abnormal to nonrecordable in all patients with confluence of the yellowish 
flecks. The EOG also varied largely, from a normal to absent light rise, and was abnormal 
in 11 of 20 eyes. Humphrey 10-2 SITA-Fast analysis of the central 10º of the visual field 
showed normal to near-normal results in 4 cases (probands A, B, C and E), whereas 
proband D, F and G displayed a severely decreased sensitivity in both eyes. Proband I 
showed a decrease in sensitivity at the inferior and temporal edges of the central visual 
field of both eyes. Goldmann perimetry was normal only in proband F, whereas the other 
patients showed a mild to marked constriction of the peripheral visual field.
 Twenty family members in whom the same mutation as in the proband was found, 
were examined (Table 4.8). Nine of these individuals experienced visual disturbances. 
The genetically affected family members of probands C, D, H, G and I all showed the 
phenotype of multifocal pattern dystrophy, except for patient C-IV:1, who was 34 years 
of age. Other phenotypes were observed in families B, E, F and J (Table 4.8), although 
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Fundus photograph of patient 
E-III:14 (p.Pro147fsX4 mutation), 
showing a characteristic retinitis 
pigmentosa phenotype.
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these individuals carried the same mutation as the proband with multifocal pattern 
dystrophy. Three family members showed no retinal abnormalities despite carrying a 
pathologic peripherin/RDS mutation.
Discussion
The phenotype of the multifocal pattern dystrophy described in this report is caused by 
autosomal dominant inheritance of mutations in the peripherin/RDS gene, with a variable 
expressivity and decreased penetrance. The type and distribution of the flecks in this 
pattern dystrophy strongly resembled the flecks observed in the fundus flavimaculatus 
phenotype of STGD1, an autosomal recessive retinal dystrophy caused by mutations in 
the ABCA4 gene.41 This resemblance was evident on ophthalmoscopy as well as on FAF 
and OCT.42-46  
All probands demonstrated a variable number of irregularly shaped yellow-white 
flecks scattered throughout the posterior pole and around the retinal vascular arcades. 
These yellowish flecks were preceded either by typical macular pattern dystrophy or 
by non-specific pigmentary changes in the fovea. The lesions were best defined by FAF 
imaging. Discrete retinal abnormalities were also easily identified with this technique 
in several asymptomatic family members carrying the same peripherin/RDS mutation 
as the proband. Extensive atrophy of the central retina tends to occur with increasing 
age, as demonstrated by the four probands who were over 60 years of age. The fact that 
multifocal pattern dystrophy, like many other ‘macular’ dystrophies, may involve the 
peripheral retina is demonstrated by the abnormal photopic and scotopic ERGs in almost 
half of the probands and an abnormal EOG in the majority of the probands.
 Of the nine different mutations that were identified, there were five different 
frameshift mutations and one nonsense mutation, which led to a premature termination 
by a stop codon. This may lead to either a shorter protein product or it may induce 
degradation of the mRNA by nonsense-mediated decay. The mechanism of pathogenicity 
of the mutation may be haploinsufficiency in case of the frameshift mutations, the 
nonsense mutation and the splice site mutation. In case of the two missense mutations 
that were found, a dominant negative effect may also be possible, although there is 
plausible evidence that these mutations may also lead to haploinsufficiency.47,48 
The frameshift mutation p.Pro147fsX4 has been previously described in patients with 
central areolar choroidal dystrophy.39 This p.Pro147fsX4 mutation was found in two 
unrelated probands, patients D and E. Both patients had multifocal pattern dystrophy 
simulating STGD1, but in patient D the phenotype progressed to a panretinal dystrophy 
resembling retinitis pigmentosa, with widespread involvement of both the rod and cone 
system. The missense mutation p.Asp157Asn has been reported previously in patients 
with pattern dystrophy,38 whereas the p.Pro210Arg missense mutation was found in 
patients with adult-onset foveomacular vitelliform dystrophy.27,40
 In our study, a genotype-phenotype correlation could not be established. The present 
study again demonstrates the highly divergent phenotypes in family members who 
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carry identical peripherin/RDS mutations. The retinal abnormalities range from minor 
foveal abnormalities to multifocal pattern dystrophy simulating STGD1 and even 
retinitis pigmentosa. This remarkable clinical heterogeneity precludes a straightforward 
genotype-phenotype correlation even with larger patient series.5,8,10,12,16,18,20,29,49 Obviously, 
modifying factors besides the specific mutation in the peripherin/RDS gene exert an 
important influence on the resulting phenotype. 
 Zhang and co-workers reported the histopathological findings in a patient with 
butterfly-shaped pigment dystrophy with Stargardt-like flecks caused by a p.Cys213Tyr 
substitution in peripherin/RDS.8,21 Adjacent to a central area of atrophy, the RPE cells were 
greatly distended by lipofuscin. This is in accordance with the predominantly increased 
FAF signal of the lesions described in the present study. The same accumulation 
of lipofuscin in RPE cells has been demonstrated for STGD1.50-52 It is likely that the 
lipofuscin accumulation in multifocal pattern dystrophy is less pronounced, in view 
of the better visual prognosis as well as the absence of choroidal blockage on the 
fluorescein angiogram. The small adjacent zones with a decreased FAF signal, that were 
seen in association with the majority of the STGD1-like flecks, are probably caused by 
RPE atrophy. This is reflected in the predominant hyperfluorescence of the flecks on 
the fluorescein angiogram. As the disease progresses, the flecks tend to evolve towards 
a confluent atrophic area which shows larger zones of decreased FAF intensity. The 
multifocal nature of this pattern dystrophy may be explained by local differences in cell 
interactions, distribution, morphology and metabolism.53
 Autosomal dominant multifocal pattern dystrophy should not be confused with 
autosomal recessive STGD1, as well as infrequent autosomal dominant retinal disorders 
such as STGD3 (ELOVL4 gene) and STGD4.54-56 Clinical findings that may help to distinguish 
this pattern dystrophy from STGD1 are the autosomal dominant pattern of inheritance, 
the relatively late age at onset (fifth decade), the comparatively good and stable visual 
acuity and the absence of a “dark choroid”. However, the incomplete penetrance (10% 
in this study) and the variable expression may mask the dominant inheritance pattern. 
Conversely, due to the high carrier frequency of ABCA4 mutations, STGD1 patients may 
have relatives with some form of retinal dystrophy.57 Three of the probands in this study 
received the proper diagnosis only after analysis of the peripherin/RDS gene in a group 
of 15 patients with presumed STGD1, but without detectable mutations in the ABCA4 
gene. Therefore, an analysis of the peripherin/RDS gene should be considered in absence of 
ABCA4 mutations, especially when confronted with the aforementioned phenotype.
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5.1.  The spectrum of phenotypes associated with variants in 
the CFH gene
Abstract
Complement factor H (CFH) is a complement inhibitor, which is present as a soluble protein 
and attached to cell surfaces throughout the human body. As such, CFH is a key player 
in complement homeostasis, inhibiting excessive activation of the complement cascade, 
with an emphasis on the alternative pathway. The significance of CFH is demonstrated by 
the broad range of phenotypes associated with specific CFH gene variants. This phenotypic 
spectrum includes renal phenotypes, such as membranoproliferative glomerulonephritis 
and atypical hemolytic uremic syndrome, as well as ocular phenotypes, such as basal 
laminar drusen and age-related macular degeneration. In addition, several overlapping 
phenotypes have been described in association with CFH gene variants. The phenotypic 
outcome of these CFH variants depends on their differential impact on plasma- and 
surface-bound CFH function. Consequently, distinct genotype-phenotype correlations 
may be observed. 
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Abbreviations: aHUS, atypical hemolytic uremic syndrome; AMD, age-related macular 
degeneration; AP, alternative pathway; BLD, basal laminar drusen; CCP, complement 
control protein; CFH, Complement Factor H; CFI, Complement Factor I; CRP, C-reactive 
protein; CR1, complement receptor 1; DAF, decay accelerating factor; FHL-1, Factor H-like 
protein 1; GAG, glycosaminoglycan; GBM, glomerular basal membrane; HUS, hemolytic 
uremic syndrome; MCP, membrane co-factor protein; MPGN, membranoproliferative 
glomerulonephritis; RPE, retinal pigment epithelium; SCR, short consensus repeat; 
STEC, Shiga toxin-producing Escherichia coli.
1. Introduction
The complement system is a key component of innate immunity and constitutes one of 
the main effector mechanisms of antibody-mediated immunity.1 The human complement 
system consists of nearly 40 molecules, distributed as soluble plasma proteins, as 
integral membrane proteins, or both. The complement system has several physiologic 
activities. Amongst others, it is able to eliminate microbes and damaged self cells, it 
forms activation products which initiate inflammation, it enhances adaptive immune 
reactions, and it is able to clear immune complexes (Table 5.1). 
 Complement is a cascade system of successive steps in three different pathways: the 
classical pathway, the lectin pathway, and the alternative pathway (Fig. 5.1). The classical 
pathway can be activated by antibodies bound to antigens on a bacterial surface. The 
lectin pathway is initiated either by binding of mannose-binding lectin to mannose 
groups on bacterial surfaces or altered self-surfaces, or by ficolins recognizing specific 
carbohydrate structures.2 The alternative pathway (AP) is antibody-independent and 
involves binding of C3b (complement component 3b) to hydroxyl groups on (bacterial or 
host) cell-surface carbohydrates and proteins. Properdin may be directly involved in the 
initiation of the alternative pathway.3,4 
The three pathways ultimately converge, after the cleavage of C3 to form C3b. Once 
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sufficient C3b is generated, the common terminal complement pathway is activated, 
leading to the assembly of the membrane attack complex (C5b-9), which effectuates, 
amongst others, lysis of bacteria and modified cells. Upon triggering, the complement 
system is rapidly and abundantly activated and targeted onto foreign surfaces, but at 
the same time must be inhibited on normal host cells. There are several regulatory 
mechanisms and factors of the complement cascade. A delicate balance between 
stimulating and inhibiting factors ensures that activation of complement is focused 
on the elimination of invading microorganisms and unwanted cells, while limiting 
unwanted complement activation in normal tissues. 
 Complement Factor H (CFH) is the central regulator of the complement AP in the 
fluid phase and on cell surfaces, where it achieves complement homeostasis through 
the restriction of excessive AP activation. In addition, CFH also limits complement 
pathway amplification by C3b, through the inactivation of deposited C3b on self-cells 
after complement activation through any of the three initiation pathways.5 Through 
both these mechanisms, CFH exerts a potent inhibitory influence on the activity of the 
common complement pathway. 
Mutations and variants in the CFH gene have been found to be associated with a broad range 
of human pathological conditions. This clinical spectrum of diseases includes for instance 
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Activity Complement protein responsible for activity
Host defense against infection
-Opsonisation Covalently bound fragments of C3 and C4
-Chemotaxis and activation of leukocytes Anaphylatoxins (C5a, C3a, C4a); anaphylatoxin
 receptors on leukocytes
-Lysis of bacteria and cells  Membrane-attack complex (C5b-9)
Interface between innate and 
adaptive immunity
-Augmentation of antibody responses C3b and C4b bound to immune complexes 
 and to antigen; C3 receptors on B cells and 
 antigen-presenting cells
-Enhancement of immunologic memory C3b and C4b bound to immune complexes 
 and to antigen; C3 receptors on follicular
 dendritic cells 
Disposal of waste
-Clearance of immune complexes from tissues C1q; covalently bound fragments of C3 and C4
-Clearance of apoptotic cells  C1q; covalently bound fragments of C3 and C4 
Table 5.1. 
The three main physiologic activities of the complement system (after Walport1).
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the predominantly renal phenotypes membranoproliferative glomerulonephritis (MPGN) 
and atypical hemolytic uremic syndrome (aHUS). However, the spectrum also comprises 
basal laminar drusen (BLD) and age-related macular degeneration (AMD), pathological 
conditions that appear to be limited to the retina. In addition, several intermediate 
phenotypes may be observed in association with CFH variants, such as glomerulonephritis 
with isolated C3 deposits and late-onset MPGN with AMD. The hallmark retinal lesions 
in AMD and BLD are drusen, which may also be observed in MPGN patients. Conversely, 
AMD may also be associated with plasma complement AP activation, suggesting common 
pathogenetic mechanisms. When studying these phenotypes and the corresponding 
variants in the CFH gene, a considerable degree of genotype-phenotype correlation may 
be discerned. In this review, we discuss the characteristics of the CFH gene and its protein 
product CFH. Also, the remarkably broad spectrum of CFH-associated phenotypes and the 
available information on their pathophysiology are reviewed. Finally, possible genotype-
phenotype correlations are analysed, and a genotype-phenotype correlation model is 
proposed.
2. Molecular biology of CFH
2.1. The alternative complement pathway
The alternative complement pathway is the most ancient complement pathway, 
identifying, recognizing, attacking, and eliminating microorganisms and modified 
tissue cells. The AP is activated spontaneously in the organism by the C3 convertase that 
cleaves C3, resulting in C3a and C3b. C3, the central component of the complement 
system, is present in blood and body fluids, and can consequently act at almost every 
location in the body.1,6 Spontaneous hydrolysis of the thioester bond in C3 facilitates 
binding of Factor B and cleavage of Factor B by Factor D, to form the initial C3 convertase 
C3(H2O),Bb.7 This relatively slow initial phase leads to the cleavage of C3 to C3a and C3b 
(Fig. 5.1). The C3b molecules subsequently bind Bb (after cleavage of Factor B by Factor D), 
forming the more potent C3 convertase C3b,Bb. 
 The formation of C3b,Bb leads to an amplification of the reaction, resulting in an 
exponential increase in C3a and C3b molecules. C3a is an anaphylatoxin, which triggers 
degranulation of mast cells and is chemotactic for leucocytes (such as macrophages). In 
addition, C3a shows antimicrobial activity. C3b is able to adhere to and coat the bacterial 
cell surface (opsonisation), which is then better recognized by phagocytic cells that 
possess C3b receptors. These phagocytic neutrophils and monocytes/macrophages then 
internalize and degrade the pathogen. Binding of C3b to C3 convertase (C3b,Bb) forms the 
C5 convertase, that splits C5 into C5a (a strong anaphylatoxin) and C5b. C5b initiates the 
assembly of the terminal complement membrane attack complex C5b-9. This membrane 
attack complex is able to form a pore in the bacterial cell membrane, causing cell death. 
The initial enzymatic components of the AP do not differentiate between activator and 
non-activator surfaces. 
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Figure 5.1.    
The three pathways of complement activation (see also paragraph 1 and 2.1. in the text). Dotted 
arrow: inhibition. Bold, continuous arrow: stimulation. Abbreviations: CFH, Complement Factor 
H; CFI, Complement Factor I; CRP, C-reactive protein; DAF, Decay-Accelerating Factor; MASP(-1/-2), 
Mannose-Associated Serine Protease; MBL, Mannose-Binding Lectin; MCP, Membrane Cofactor 
Protein.
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 To prevent adverse effects on the host organism itself, a tight control of the formation 
and activity of the AP amplification C3 convertase C3b,Bb is essential. This is effectuated 
by inhibiting regulators that are present both in the plasma and on the surface of host 
cells. CFH and Complement Factor I (CFI) are the major down-regulators of the AP in the 
fluid phase. In addition, CFH also plays an important role in complement deactivation on 
self-surfaces such as retinal pigment epithelium (RPE) cells, erythrocytes and platelets.8-11 
Deactivation of complement on self-surfaces is also accomplished by the host cell 
surface complement regulators complement receptor 1 (CR1 or CD35), membrane 
co-factor protein (MCP or CD46), decay accelerating factor (DAF or CD55), and CD59. 
Properdin, a protein that works optimally after binding on bacterial surfaces, is able 
to bind C3b, C3b,B, as well as C3b,Bb, and protects these factors from catalytic cleavage 
by CFH and CFI.4
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Figure 5.2.   
The CFH region of the regulator of complement activation (RCA) gene cluster on chromosome 
1q32. A. Genomic organization of the CFH and CFHR1-5 genes. The region contains four haplotype 
blocks (orange). Three large duplicated regions are present in the cluster (A and A’, B and B’, C 
and C’). B. Non-homologous recombination between the 3’ ends of the duplicated regions A and A’ 
leads to a deletion of the CFHR1 and CFHR3 genes. This rearrangement is relatively common in 
African and European populations, and decreases the risk of AMD. C. Non-homologous recombi-
nation between the 5’ends of the duplicated regions A and A’ leads to a deletion of the CFHR1 and 
CFHR3 genes, and to the generation of a CFH-CFHR1 fusion gene. The fusion gene consists of the 
first 21 exons of CFH and the last two exons of CFHR1. This rearrangment has been found to be 
associated with aHUS.
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2.2. The CFH gene 
The CFH gene comprises 23 exons and spans more than 94 kb of genomic DNA.12,13 An 
alternative splice product of CFH RNA, containing exon 10, results in the synthesis of 
Factor H-like protein 1 (FHL-1).14 More than 550 SNPs in the human CFH gene region 
are known, that may sometimes lead to an amino acid substitution in CFH (www.ncbi.
nih.gov/SNP).15 Some of these polymorphisms, for instance the Tyrosine-402-Histidine 
(p.Tyr402His) variant, which is associated with an increased risk for AMD, may have 
discrete functional consequences that will be discussed further on in this chapter. Five 
other genes, CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5, encode proteins that are related to 
CFH. The CFH genomic region is organized in four SNP-haplotype blocks spanning the 
CFH and CFHR1-5 genes (Fig. 5.2).15,16 In some cases, genetic rearrangements in the CFH-
CFHR1-5 region may result in the deletion of the CFHR1 and CFHR3 genes.16,17 In addition, 
CFH-CFHR1 hybrid genes may be formed.18 Interestingly, the isolated deletion of CFHR1 and 
CFHR3 is a common polymorphism that is associated with a decreased risk of AMD,16,19 as 
well as an increased risk to develop aHUS.17 The presence of both the deletion of CFHR1 
and CFHR3 and a CFH-CFHR1 hybrid gene may predispose to aHUS.18 
CFH belongs to a superfamily of structurally and functionally related proteins, named 
the Regulators of Complement Activation (RCA), that are encoded by a gene cluster on 
chromosome 1q32 (Fig. 5.2).13,20,21 
The RCA family also includes the previously mentioned CR1, DAF, and MCP, which are 
expressed on the surface of host cells. In addition, the RCA family contains several CFH-
related proteins such as FHL-1, which is expressed in the fluid phase together with CFH 
itself.14,22-24 These proteins have overlapping and redundant activities, which may possibly 
explain why the absence or dysfunction of a single regulator has rather narrow tissue 
specifity and may not always cause clinical disease.11,25
2.3. The CFH protein
2.3.1. CFH structure
The CFH protein was first described in 1965,26 and plays a central role in the down-
regulation of activation of the complement AP.1,27 CFH is a 155 kDa glycoprotein, which is 
composed of 1213 amino acid residues.28 These amino acids are clustered in 20 repetitive 
units of approximately 60 amino acids, named short consensus repeats (SCRs).27,29 Each 
SCR is encoded by a single CFH exon, except for SCR 2, which is encoded by exons 3 and 4.15 
These SCRs all show four invariant cysteine residues and an almost invariant tryptophan 
residue at identical positions.27 Due to these compositional similarities, these 20 SCRs 
fold into 20 structurally similar three-dimensional structures called complement control 
protein (CCP) modules (Fig. 5.3).15,27 CFH contains several N-linked carbohydrates (glycans), 
that do not appear to be essential for its complement regulatory function.30
 The CFH protein is mainly synthesized by the liver.31,32 CFH is found in human plasma 
at highly variable concentrations, ranging from 116 to 711 μg/ml.33,34 These variable 
concentrations appear to be the result of both genetic and environmental influences.33 
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For instance, plasma CFH levels increase with age and are decreased in smokers.33 It has 
been estimated that roughly 60% of CFH plasma variation is due to genetic variations, 
for example as a result of low expression of CFH alleles.15,33 Extrahepatic synthesis of CFH 
is also seen in a broad range of cell types, such as RPE cells, glomerular mesangial cells, 
podocytes, erythrocytes, platelets, neurones, glia cells, myoblasts, and peripheral blood 
lymphocytes.8,15,35-38 
This extrahepatic synthesis, which increases local CFH concentrations, is presumed 
to locally protect specific host tissues against exaggerated complement activation and 
inflammation, for instance in the case of a local infection.15 CFH production by the RPE 
may be especially important to control local inflammation in this microenvironment. 
Interestingly, oxidative stress, an important pathogenetic factor in AMD, decreases CFH 
expression by the RPE.38
2.3.2. CFH function
The principal function of CFH, the down-regulation of complement AP activation, is 
effectuated in three ways.11,27,39 First, CFH inhibits the assembly of an active C3 convertase, 
by binding to C3b and therefore inhibiting interaction with Factor B. Second, CFH is able 
to destroy an existing C3b,Bb convertase, by accelerating the decay of this complement 
activator. In the third mechanism, CFH is an essential cofactor in the cleavage and 
inactivation of C3b by the serine protease CFI. In addition to the down-regulation of 
the complement AP, CFH accelerates the breakdown of cell surface-bound C3b to iC3b 
after activation of any of the three initiation pathways.5 In mice, classical complement 
pathway activation by immune complexes can recruit the AP, if the AP is not effectively 
regulated by CFH.40
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Figure 5.3.   
Functional domains of the CFH protein. The CFH protein consists of 20 short consensus repeats 
(SCRs) or Complement Control Protein (CCP) modules that show a certain degree of compositional 
similarity. However, different (clusters of) SCRs have different functional properties that are 
depicted in the figure. For additional discussion of these protein properties see also section 2.3. in 
the text. Abbreviations: CRP, C-reactive protein; GAG, Glycosaminoglycan.
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 CFH and CFH related proteins bind to bacterial and host cell surfaces through the 
interaction with sialic acid-rich polyanions, which is essential for its ability to effectively 
regulate complement AP activation on these surfaces.9,41-43 In addition, such cellular 
binding of CFH and/or its related proteins to B lymphocytes may be able to influence 
migration of these cells, and could influence their role in adaptive immunity.44-47 
However, some bacteria are able to take advantage of this mechanism, by binding CFH on 
their sialic acid-covered surface and consequently evading activation of the complement 
AP.25,48,49 In addition, CFH has the capacity to bind glycosaminoglycans (GAGs) such as 
heparin.27,50 CFH may also bind fibromodulin,51 as well as adrenomedullin. 
An important binding partner of CFH is C-reactive protein (CRP).52 Ligand-bound CRP 
recruited from the fluid phase activates the classical complement pathway, especially 
the initial stage involving C1-C4, through a concentration-dependent interaction with 
C1q, thus stimulating the opsonisation and elimination of microbes and damaged self 
cells.53,54 Surface-bound CRP, however, interacts with CFH via SCR 7.52,55-58 This interaction 
leads to an inhibition of the complement C3 and C5 convertases, reducing the generation 
and deposition of the membrane attack complex, C5b-9, in the common terminal 
pathway. It has been proposed that the function of CRP, in the latter mechanism, is to 
target CFH to injured self-tissues.57      
 Alterations in the function of complement regulators or induction of complement 
activation, for instance by altered self-surfaces or immune complexes, may lead to 
reduction in the levels of complement components and their function. As described above, 
there are three pathways for complement activation, and the level of activity of each of 
these pathways can be analyzed by hemolytic complement filtrations. More recently, an 
ELISA-based assay for the assessment of each of the three pathways was established and 
standardized.59 Such assays are performed on serum samples that have to be directly 
processed and stored at -80°C. Consumption of complement or complement deficiencies 
are detected relatively easy with these complement pathway ELISA assays. CH50 is such an 
assay of the complete complement pathway. A low CH50 indicates depletion of complement 
factors, without being able to distinguish between individual complement factors. 
Similarly, AP50 reflects the degree of consumption of the AP. Once a defect is observed, a 
more detailed analysis may be performed, such as the evaluation of specific components of 
the early classical pathway, the AP, or the lectin pathway. Each of the components of the 
terminal sequence can also be assessed. In general, it is important to determine whether 
levels of C3 or its breakdown products are within normal limits. For analysis of subtle 
turnover of complement, one should especially pay attention to the assessment of C5a or 
C5b-9, next to antigenic determination of specific complement components. In addition, 
antigenic analysis of specific complement components may assess whether an abnormality 
can be explained by loss of functional activity or by a gain of function.
2.3.3. Structure-function correlations in CFH
A schematic overview of the functional domains of CFH is depicted in Fig. 5.3. CFH has 
at least two distinct C3b-binding sites: the N-terminal SCRs 1-4 and the C-terminal SCRs 
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19 and 20, and possibly other sites, such as SCRs 12-14.23,60-63 The C-terminal C3b-binding 
site is unique in having specific high affinity for cell surface-bound C3b, whereas SCRs 
1-4 have only modest affinity for C3b, once C3b is attached to a surface. C3b,Bb decay 
accelerating activity as well as cofactor activity also reside in SCRs 1-4.23,61,64,65 Binding to 
GAGs and polyanions such as heparin is effectuated by SCR 7 and SCR 19-20, and possibly 
regions 9 and 13.66-70 SCR 7, which includes the site of the p.Tyr402His variant,71 does 
not only bind heparin and other GAGs, but also CRP,56,72 fibromodulin, DNA, and several 
bacteria-associated proteins.73 SCRs 19-20 have multiple binding properties, as they are 
able to bind to C3b/C3d,62,63 to heparin/heparan sulphate-containing surfaces,67 as well 
as to endothelial surfaces.10 A functional test of CFH on sheep erythrocytes uses these 
binding properties of SCRs 19-20 to look for mutations in this region of CFH. Binding of 
CFH to surface-associated C3b may be enhanced by CFH oligomerization.74 
3.  The spectrum of diseases associated with CFH gene 
variants
3.1. Membranoproliferative glomerulonephritis
3.1.1. Clinical characteristics of membranoproliferative glomerulonephritis
 The term MPGN, also known as mesangiocapillary glomerulonephritis, refers to the 
morphologic appearance of the typical glomerular lesions on light microscopy. Lesions 
are characterized by a thickening of the glomerular capillary wall, in association with 
mesangial cell proliferation. MPGN usually manifests in children and young adults 
between 5 and 30 years of age, and may present with hematuria and/or proteinuria, 
acute nephritic syndrome, or nephrotic syndrome. MPGN is generally associated with 
a chronic deterioration of renal function, leading to end-stage renal failure within 10 
years of the diagnosis in approximately half of the patients.75-77 Some patients experience 
episodes of acute renal deterioration together with strong fluctuations in proteinuria, 
without obvious triggering factors. In others, the disease may remain stable for many 
years despite persistent proteinuria.75 
 Three forms are discerned histologically, based on electron microscopic ultrastructural 
analysis of the glomerulus, together with immunofluorescent analysis of the presence of 
immunoglobulin and complement components. MPGN type I (MPGN-I) is characterized 
by subendothelial electron-dense deposits along the glomerular basal membrane (GBM), 
together with the presence of both complement and immunoglobulin within the 
glomerulus. Dense deposit disease, also known as MPGN type II (MPGN-II), is characterized 
by the dense deposition of C3 in the GBM, without the presence of immunoglobulin (as 
opposed to MPGN type I and III).39,75 Although MPGN-II is widely used as a synonym for 
dense deposit disease, the latter is considered a more accurate descriptive term.39,75 After 
all, the dense deposits are pathognomonic, whereas the condition is associated with 
capillary wall thickening and hypercellularity in only a minority of cases.78 Differentiation 
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between MPGN-I and -II may be difficult as both conditions may have largely overlapping 
microscopic and immunofluorescence characteristics,11 and CFH mutations have been 
described in both conditions.79,80 In MPGN type III, subepithelial and subendothelial 
deposits are present, as well as a variable amount of immunoglobulin and complement 
component C1q.     
MPGN is a relatively rare cause of glomerulonephritis and accounts for approximately 4 to 
7% of primary renal causes of nephrotic syndrome in children and adults, respectively.81,82 
A higher incidence of bacterial infection (such as Neisseria meningitidis meningitis) may 
be observed in MPGN patients, as a consequence of severe CFH deficiency and secondary 
depletion of C3, the central component in the complement defense mechanism,.39 
Patients with MPGN related to homozygous or compound heterozygous CFH mutations 
show an absence of CFH in the plasma, corresponding with continuous activation of 
the complement AP, high C3 turnover, and hypocomplementemia. In general, low 
plasma C3, high C3d, low Factor B, as well as low CH50 and AP50 are indicative of this 
condition.11,79 Several studies indicate that persistent hypocomplementemia is associated 
with a poorer prognosis,83-85 whereas other studies did not find a correlation between C3 
levels and the clinical course.86,87 MPGN-II may also be associated with acquired partial 
lipodystrophy, a condition with loss of subcutaneous fat in the upper half of the body, 
which usually precedes clinically apparent renal disease.88,89 However, this association 
has only been found in patients with MPGN-II related to the presence of C3 Nephritic 
Factor auto-antibodies, not in MPGN patients with CFH mutations.75 
 Patients with MPGN-II/dense deposit disease may develop drusen, yellow-white 
deposits in Bruch’s membrane that underlie the RPE (Fig. 5.4A).90 Drusen contain, 
amongst others, inflammation-associated proteins (including complement factors).90 As 
will be discussed further on in this review, drusen are the hallmark lesions in AMD.91 In 
MPGN-II, however, these drusen are often already detectable in the first decades of life, 
and they are usually smaller and more numerously spread throughout the retina, in 
that respect resembling the drusen observed in BLD.92,93 Like in BLD and AMD, drusen 
in MPGN-II are identified most readily on fluorescein angiography (Fig. 5.4A).92,94 In most 
cases, the retinal condition remains fairly stationary for a prolonged period of time.95,96 
Nevertheless, with time, these drusen may enlarge and merge, sometimes evolving to 
macular and peripheral chorioretinal atrophy and/or subretinal neovascular membranes 
in the macula, resulting in severe visual loss in up to 25% of patients.97-99 In long-standing 
cases, electro-oculography (reflecting the function of the entire RPE) may become 
abnormal due to widespread RPE atrophy.100,101 In these advanced stages, color vision, 
dark adaptation, as well as the dark-adapted electroretinogram (reflecting photoreceptor 
function) may also become mildly abnormal.100 Of note, drusen-like deposits have also 
been described in a case of partial lipodystrophy without MPGN.102
 An atypical case of late-onset MPGN and AMD was described in a patient with a single 
p.Cys431Tyr missense mutation in CFH (located in SCR 7, like p.Tyr402His).103 This patient 
developed both neovascular AMD with BLD-like deposits and MPGN in his late 50s. Plasma 
analysis showed a low C3 level, a CFH level in the lower part of the normal range, and 
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traces of C3 Nephritic Factor. Functional analyses indicated that the mutant CFH  protein 
was not present in the plasma. In addition to this heterozygous missense mutation, the 
patient carried numerous risk alleles for both AMD and MPGN. In addition, this patient 
was a heavy smoker, which is well-known as a major environmental risk factor for the 
development of AMD.104  
 There is no universally effective treatment for MPGN. Plasmapheresis and plasma 
exchange may be efficient in replacing deficient CFH with normal CFH, thus temporarily 
correcting the complement defect.75,77,80 Renal transplantation in MPGN ends in disease 
recurrence in most cases, and 5-year allograft failure is approximately 50%.77,105 This 
number is significantly higher than in the general population of renal transplant 
patients. Graft loss in MPGN typically occurs within 2.5 years after transplantation.77 Non-
specific therapeutic measures, such as optimal control of blood pressure and reduction 
of proteinuria, are beneficial to both MPGN and aHUS patients.75
 Glomerulonephritis with isolated C3 deposits, shortly named glomerulonephritis C3, 
is another renal disease that has recently been added to the expanding spectrum of CFH-
related diseases. Glomerulonephritis C3 is a phenotype that appears to be intermediate 
between MPGN and aHUS.106,107 Two subtypes are discerned: glomerulonephritis C3 with 
histological features of MPGN and glomerulonephritis C3 without MPGN.107 Like aHUS, 
glomerulonephritis C3 may be caused by heterozygous mutations in the CFH gene.107 
Interestingly, glomerulonephritis C3 with MPGN has been described secondary to 
aHUS.108 Conversely, MPGN followed by aHUS may also be observed.109 Apparently, CFH-
related glomerulonephritis C3 is situated in a transition area between MPGN and aHUS. 
The pathophysiological background for such an intermediate phenotype is unclear.
Chapter 5
Figure 5.4. 
Fluorescein angiography photographs displaying similar small and larger drusen in the  
posterior pole of the eye in patients with different CFH-related diseases. A. Excessive basal 
laminar drusen in a 32-year-old patient with membranoproliferative glomerulonephritis 
type II. B. Extensive drusen that enlarge and show conf luence towards the macula in a 
47-year-old patient with early-onset basal laminar drusen. C. Numerous small drusen that 
are indistinguishable from basal laminar drusen in an 86-year-old patient with age-related 
macular degeneration.
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3.1.2. CFH gene variants in membranoproliferative glomerulonephritis
Mutations in CFH account for a small minority of MPGN cases.11,75 To date, 9 patients and 
a total of 7 CFH mutations have been described in association with MPGN (Fig. 5.5). In four 
of these cases, homozygous mutations have been found: p.Arg127Leu (located in SCR 2),79 
p.Cys431Ser (in SCR 4),79 p.Cys673Ser (in SCR 11),79 and p.Lys224del (a deletion of lysine 
in SCR 4).80 Another patient carried the compound heterozygous mutations p.Cys518Arg 
and p.Cys941Tyr.110 More recently, a patient with late-onset MPGN was described, who 
carried a heterozygous p.Cys431Tyr missense mutation in CFH, and he carried the 
p.Tyr402His AMD and MPGN risk variant homozygously.103 In addition, he carried most 
of the other known AMD risk variants in several other complement genes, including 
C3, CFB, he was heterozygous for an AMD risk allele in ARMS2/LOC387715,111 and he lacked 
the protective deletion of the CFHR1/CFHR3 genes. Although most MPGN patients do not 
have disease-causing mutations in CFH, some polymorphisms in CFH (and also CFHR5) are 
significantly more frequent in MPGN patients compared to controls.112 Interestingly, the 
p.Tyr402His variant, which is also associated with AMD and BLD, is one of these MPGN 
risk variants.112 Besides CFH mutations, found in only a small number of patients, MPGN 
may also be caused by auto-antibodies, which are monoclonal immunoglobulin lambda 
light chain dimers, that inactivate the regulatory function of CFH in the plasma.113,114 
Another frequent finding in MPGN is the presence of the auto-antibody C3 Nephritic 
Factor in plasma, which stabilizes the C3b,Bb AP convertase.76,115 This C3 Nephritic Factor 
may also be found concurrently with CFH mutations in MPGN.80,107,116,117
3.1.3. Pathophysiology of membranoproliferative glomerulonephritis
Relatively little is known about the exact pathogenesis of CFH-related MPGN. In MPGN 
patients with homozygous or compound heterozygous CFH mutations, a lack of plasma 
CFH causes uncontrolled plasma complement AP activation, resulting in ubiquitous C3 
deposition. The characteristic finding in MPGN-II/dense deposit disease is an intense 
deposition of C3 cleavage products along the glomerular capillary walls, together with 
electron-dense deposits in the central part of the GBM.39,75 In MPGN-I, a glomerular 
deposition of immunoglobulin is seen in addition to complement deposition, as well 
as subendothelial dense deposits. As the disease progresses, mesangial hypercellularity 
and matrix interposition occur.39,75,118,119 As GBM damage progresses, podocytes detach, 
undergo hypertrophy and ultimately die.75,120,121 In this stage, the final barrier to protein 
loss is disrupted, resulting in marked proteinuria.121-123 
 Interestingly, deposits similar to the glomerular dense deposits in MPGN-II are seen in 
Bruch’s membrane of the eye (drusen), as well as in the sinusoidal basement membrane 
of the spleen.75,124,125 Histopathological studies on drusen in MPGN-II showed both linear 
and focal depositions throughout the extent of the inner collagenous layer of Bruch’s 
membrane.124,126 In this regard, several studies have drawn attention to the fact that the 
choriocapillaris-Bruch’s membrane-RPE complex shows a remarkable resemblance to the 
capillary tuft-GBM-glomerular epithelial interface.75,126,127 
 Disease severity in MPGN may be modified for instance by the additional presence 
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of C3 Nephritic Factor, which increases the damaging potential of unrestricted 
complement AP activation.80,103,115 Of note, complete CFH deficiency, with a corresponding 
C3 depletion, has also been found in an individual with systemic lupus erythematosus 
who also had a partial deficiency of C2.128 In addition, systemic lupus erythematosus and 
recurrent infections (including recurrent meningococcal disease) was also described in 
two families with complete CFH deficiency, which, in one of those families, was caused 
by a homozygous p.Glu171X nonsense mutation and concurrent absence of FHL-1 and 
CFH.129,130 Systemic lupus erythematosus is usually associated with deficiencies in the 
classical complement pathway (especially C1q deficiency).131 However, the classical and 
alternative complement pathways interact and converge downstream at the level of 
C3,40,132-134 making an overlap in pathogenesis biologically plausible.
 The aforementioned observations in human MPGN are mirrored by findings in 
a mouse and pig model. In these models, homozygous Cfh-deficient animals (Cfh -/-) 
had an absence of plasma CFH and a depletion of plasma C3. They developed MPGN 
as a result of uncontrolled complement activation and C3 deposition, whereas the 
heterozygous animals (Cfh +/-) did not develop a MPGN phenotype.39,40,135-138 In this mouse 
model of MPGN, an uncontrolled activation of C3 in plasma leads to MPGN.138 The renal 
depositions in this mouse MPGN consist of proteolytic cleavage products derived from 
C3b, that are generated by CFI.139 Such a massive C3 accumulation in the retina could 
also lead to retinal disorganization. When a transgenic CFH molecule that lacked SCR 
16-20, mimicking a human aHUS mutation, was introduced in Cfh -/- mice, plasma CFH 
and C3 levels and complement AP activity were largely restored.140 Instead, these animals 
developed a clinical picture resembling human aHUS.
3.2. Atypical hemolytic uremic syndrome 
3.2.1. Clinical characteristics of atypical hemolytic uremic syndrome
Hemolytic uremic syndrome (HUS) is characterized by the triad of microangiopathic 
hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in 
the renal microcirculation. Several etiologies have been described. Most patients with 
HUS are seen in childhood, in which the disease is often caused a Shiga toxin-producing 
Escherichia coli (STEC) infection.141,142 This STEC-associated or typical HUS manifests 
with watery or bloody diarrhea and has a fairly good prognosis. Non-STEC-associated 
or atypical HUS (aHUS) is rare and comprises a heterogeneous group of patients in 
whom a STEC infection can be excluded. Compared to STEC-associated HUS, aHUS has 
a more unfavorable outcome: a high mortality (up to 25%) and morbidity rate is seen in 
aHUS patients during the acute phase and the survivors frequently have recurrences, 
whereas 80-90% of typical HUS patients completely recover without recurrences.141,143 
Approximately 80% of aHUS cases have an undefined or sporadic inheritance pattern, 
the remainder roughly corresponding to familial cases (www.fh-hus.org). aHUS may 
be elicited by factors such as infection, drugs, and pregnancy, although no provocative 
factors are identified in many cases of aHUS.144 In the last decade, it has become clear 
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that a dysregulation of complement activation plays a major role in the pathogenesis of 
aHUS. So far, mutations in complement AP regulatory proteins are found in 50-60% of 
aHUS patients. The majority (20-30%) of these patients carry mutations in CFH, followed 
by mutations in MCP (10-13%), CFHR1-CFHR3 (10%), and CFI (5-10%).
 CFH-related aHUS usually presents earlier in childhood as compared to aHUS caused 
by mutations in MCP and CFI, although an adult onset may be seen in 30% of cases.145,146 
Plasma levels of CFH and C3 are often normal, as well as CH50 and AP50 levels, except in 
more severe cases caused by homozygous or compound heterozygous CFH mutations.147 
In these cases, the age at onset is earlier, often within the first two years of life.145,147-151 On 
histopathology, the predominant abnormality in aHUS is found in the renal arterioles 
and interlobular arteries.144 These structures show endothelial swelling with retraction, 
resulting in exposure of the GBM. The vessel lumina are clogged up with erythrocytes 
and platelet fibrinic thrombi.
 Compared to aHUS caused by mutations in other complement AP genes, patients 
with CFH-related aHUS have the worst prognosis, with regard to the incidence of end-
stage renal disease and death.145,146 Up to 60% of aHUS patients with CFH mutations reach 
end-stage renal disease or die within a year.145,146 Patients with CFH mutations show a less 
favorable response to plasmapheresis and plasma infusion, although these treatments 
may nevertheless may be able to achieve remission in 67% of the cases.145,146,150 Recurrence 
of aHUS in CFH-related aHUS patients who underwent kidney transplantation is seen in 
78-100%, often ending in graft rejection and graft failure.145,152,153 
Contrary to CFH-related MPGN, no drusen or other AMD-like changes have been described 
in CFH-related aHUS to date, although vitreous and choroidal hemorrhage, as well as 
retinal ischemia, may be noted.154
3.2.2. CFH gene variants in atypical hemolytic uremic syndrome
Most cases of aHUS are sporadic, but autosomal dominant and autosomal recessive 
familial cases have also been described.79,145,148,155,156 Mutations in CFH are found in 14-30% 
of aHUS patients145,156,157. To date, more than 70 CFH mutations have been described in 
aHUS (for a comprehensive overview, see www.fh-hus.org).158 Contrary to MPGN, aHUS is 
usually caused by heterozygous CFH mutations. Most of these mutations are located in the 
C-terminal region of CFH: approximately 65% is found in SCR 15-20, and 27% is situated 
in SCR 20 (Fig. 5.5).147,148,159 Missense mutations account for the majority (approximately 
55%) of CFH mutations in aHUS, followed by deletions (11%), and nonsense mutations 
(7%). aHUS-associated mutations in the C-terminal region of CFH may also be the result 
of gene conversion. Gene conversion between CFH and CFHR1, for instance, results in 
the replacement of CFH SCR 20 by CFHR1 SCR 5.160 Another example is a hybrid gene, 
in which exons 1-21 are derived from CFH, whereas exons 22-23 originate from CFHR1, 
resulting in a heterozygous disease-causing hybrid CFH-CFHR1 mutant.18 As mentioned 
previously, a deletion of CFH-related genes CFHR1 and CFHR3, sometimes in combination 
with CFH auto-antibodies, is also associated with aHUS.17,161
 Despite the predominance of heterozygous missense mutations in aHUS, homozygous 
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CFH mutations,79,145,148 as well as compound heterozygous mutations have also been 
reported in early-onset aHUS.147,149-151,157,159 As expected, homozygous mutations are often 
found in offspring from consanguineous parents. The p.Tyr899X nonsense mutation 
was found homozygously in several young patients with aHUS.79,145,150 Again, these 
mutations generally affect the most C-terminal SCRs, with a predilection for SCR 20. 
Another study has found a heterozygous CFH mutation together with a CFI mutation in 
glomerulonephritis C3.106 This renal phenotype may show overlapping features with both 
aHUS and MPGN.106,107 Heterozygous CFH mutations in aHUS show a high degree of non-
penetrance, indicating that additional genetic and/or environmental factors are required 
to develop the phenotype.162 In this regard, several aHUS risk polymorphisms have been 
identified in CFH and other complement-associated genes.17,155,157,162-164 In addition to CFH 
mutations, aHUS is also associated with variants in several other genes involved in the 
complement AP, including CFI,165-167 MCP,168,169 C3,15,170 as well as CFB.171 Like MPGN, aHUS 
may also be caused by auto-antibodies, which are directed against CFH in these cases.172 
These antibodies block the same C-terminal part of CFH that is often affected in aHUS 
caused by mutations in the CFH gene, and thus have a similar effect.173
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Figure 5.5.   
Overview of the disease-associated mutations in the CFH gene. Only the mutations in the 
 protein-coding sequence are depicted, excluding splice site mutations. In BLD, the depicted 
 mutations are found in combination with the p.Tyr402His variant on the other allele. Black dot: 
missense mutation. Grey dot: deletion or duplication. White dot: nonsense mutation. 
Abbreviations: aHUS, atypical hemolytic uremic syndrome; BLD, basal laminar drusen; MPGN, 
membranoproliferative glomerulonephritis; SCR, short consensus repeat.
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 HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets), a complication 
of pregnancy-related hypertension, has recently been shown to be associated with 
mutations in complement AP genes, including one p.Arg303Gln mutation in SCR 5 
of the CFH gene.174 Like aHUS, HELLP syndrome is associated with hemolytic anemia, 
thrombocytopenia, and acute renal dysfunction (in up to 50% of patients). However, liver 
involvement is uncommon in aHUS, whereas it is a hallmark feature in HELLP syndrome. 
HELLP syndrome and aHUS are therefore two distinct but related disease entities, and 
HELLP syndrome may be considered another member of the family of disorders related 
to dysregulation of the complement AP.
3.2.3. Pathophysiology of atypical hemolytic uremic syndrome
In aHUS, heterozygous (often missense) mutations that generally cluster in SCR 15-20 
generally do not preclude normal secretion of CFH into plasma and normal plasma 
regulatory activity of CFH.148,159 This corresponds to the often normal plasma C3 
levels and AP activity in these patients, although some patients appear to require an 
additional decrease in plasma CFH to develop aHUS.147,175 Instead, CFH mutations in aHUS 
compromise cell surface-associated protective functions of CFH.42 Normally, prevention 
of the propagation of the complement AP amplification loop on cellular surfaces of the 
host is effectuated by inactivation of C3b on endothelial cells through the interaction 
of CFH with sialic acids and heparin-like glycosaminoglycan polyanions on self-surface, 
and through membrane-bound complement regulators such as MCP, and CFI.68,74 This 
mechanism is compromised in aHUS through the dysfunction of the C3b-binding SCRs 
19-20 of CFH and/or a lack of recognition of polyanionic markers that identify host 
surfaces.68,74 
 In early-onset aHUS caused by homozygous or compound heterozygous CFH mutations, 
plasma CFH and C3 may be severely diminished, contrary to later-onset aHUS caused 
by single heterozygous CFH mutations.79,148,176 The interaction with specific self-surface 
polyanions appears necessary for CFH to adopt a configuration that allows the inhibition 
of C3b activation.68,177 Endothelial cell damage may result in an additional procoagulant 
situation.178 A disruption of these mechanisms may therefore lead to the attack of 
erythrocytes, platelets, and (especially renal) endothelial cells by the complement AP. 
As a result, the clinical triad of hemolytic anemia, thrombocytopenia, and renal failure 
is observed. In the cases of plasma CFH-deficient aHUS, there was no evidence of dense 
deposits in the GBM such as in MPGN.39
 Two especially interesting cases of aHUS with low plasma CFH and C3 have been 
described, in which one 11-month-old patient carried a homozygous p.Tyr899X 
nonsense mutation in CFH, whereas the other 16-month-old patient carried a compound 
heterozygous p.Asn767LysfsX7 CFH mutation together with a p.His183Arg missense 
mutation in the CFI gene.106 Several months to years after they underwent a renal 
transplantation, these patients developed glomerulonephritis C3 in the allograft. These 
results indicate that glomerulonephritis C3 and aHUS are different expressions of the 
same condition.
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3.3. Basal laminar drusen
3.3.1. Clinical characteristics of basal laminar drusen
The phenotype of BLD is also referred to as “cuticular drusen” or “early adult onset, 
grouped drusen”. The mean age at onset in BLD is 50 years, but ranges from 35 to 70 years, 
and patients may remain asymptomatic for a long period.179 In BLD caused by CFH variants, 
the age at onset appears to be even later, with a mean of 57 years, making the differential 
diagnosis with AMD even more challenging.179 BLD is characterized by a pattern of small 
(25 to 75 μm), slightly raised, yellow subretinal drusen with slightly pigmented borders, 
randomly scattered throughout the macula and peripheral retina.179,180 Drusen in CFH-
related BLD are usually smaller and more numerous than in “typical” AMD. Although 
these small drusen may be identified on ophthalmoscopy, additional investigations, 
such as fluorescein angiography, fundus autofluorescence, and infrared reflectance 
photography may assist in showing the true extent of the lesions.179-181 On fluorescein 
angiography, BLD displays a typical “stars-in-the-sky” picture (Fig. 5.4B).180 
 The drusen in BLD may remain relatively stationary and may be compatible with a 
fairly good visual acuity. In later stages, the drusen may become more numerously 
scattered throughout the retina, often clustered in groups. Both in the macula 
and peripheral retina, these drusen may show confluence and evolve to patches of 
chorioretinal atrophy.179 In the macula, these confluent drusen may lead to a serous, 
“pseudovitelliform” RPE detachment, which may compromise visual acuity. Such an 
RPE detachment may show spontaneous resolution with retention of a relatively good 
visual acuity, but may also become atrophic and/or end up in the formation of subretinal 
neovascularization.179,180 In this stage, the resulting visual loss is often severe. As 
mentioned previously, extensive small hard drusen like in BLD may not only be observed 
as an isolated BLD phenotype, but highly similar structures are also regularly observed 
in MPGN and AMD patients (Fig. 5.4).
 Different clinical subtypes of drusen are discerned, based mainly on ophthalmoscopic 
characteristics.182-184 Histopathological data show that BLD are ultrastructurally and 
compositionally similar to other types of drusen, which are also located between the 
RPE and Bruch’s membrane, suggesting a similar pathway for drusen biogenesis.185 In 
this respect, the term “basal laminar” drusen is not entirely correct, as the deposits do 
not seem to correspond to nodular or diffuse thickenings of Bruch’s membrane.185 On 
histopathology, drusen in BLD show a high degree of confluence, whereas they often 
appear as numerous small but separate lesions on ophthalmoscopy. This apparent 
discrepancy is less pronounced on fluorescein angiography, on which the number, 
extent, and degree of confluence of the hyperfluorescent lesions outnumber the lesions 
visible on ophthalmoscopy. 
 Routine laboratory testing of blood and urine in CFH-related BLD patients does not 
show obvious renal dysfunction.185 To date, no reports on complement concentrations in 
BLD caused by CFH variants have been published. Of note, preliminary data in CFH-related 
BLD caused by a p.Gln408X nonsense mutation in conjunction with the p.Tyr402His 
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variant in CFH indicate that this phenotype is also associated with mild systemic 
complement AP activation (personal observation, C.J.F. Boon and M.R. Daha). There are 
currently no data on the treatment outcome of choroidal neovascularization in BLD.
3.3.2. CFH gene variants in basal laminar drusen
Most cases of BLD are sporadic, but familial cases have also been described.179 Roughly 
17% of BLD patients appear to carry CFH mutations, and these patients often have a 
positive family history for macular degeneration.179 Like in AMD, the p.Tyr402His variant 
also appears to play a prominent role in BLD. The allele frequency of p.Tyr402His in 
BLD patients is up to 70%,179,186,187 compared to approximately 55% in “typical” AMD 
patients and 34% in healthy white control subjects.36,188,189 In a subset of BLD patients, 
the combination of at least one p.Tyr402His variant together with a specific CFH variant 
leads to an early-onset BLD phenotype.179 To date, four CFH variants have been described 
that may cause BLD when expressed together with the p.Tyr402His variant (Fig. 5.5): a 
p.Gln408X nonsense mutation, a p.Arg1078Ser missense variant (located in SCR18), a 
p.Arg567Gly missense variant (located in the interdomain hinge region between SCR9 
and SCR10), and a c.350+6TG splice site variant.179 Of note, one study indicates that 
missense variants in the fibulin 5 gene may also be involved in BLD.190
3.3.3. Pathophysiology of basal laminar drusen
The specific CFH variants that are found in some BLD patients, together with the CFH 
p.Tyr402His variant, apparently have specific pathological consequences for the retina. 
To date, there are no histopathological studies on drusen in BLD caused by such CFH gene 
variants. As mentioned previously, histopathological studies indicate that drusen in AMD, 
BLD (without genotyping), and MPGN are quite similar on the level of ultrastructure 
and molecular composition.124,185 Drusen in MPGN, as well as in BLD and AMD, contain 
complement factors and other inflammatory components.36,124,185,191-193 The comparable 
clinical and histopathological findings indicate that drusen in MPGN, BLD and AMD 
are a highly similar expression of a common underlying local inflammatory reaction. 
This leads to a complement deposition between the RPE and Bruch’s membrane, with 
or without a variable degree of systemic inflammation and complement activation (Fig. 
5.4). It remains to be unravelled if the exact composition of drusen in AMD, BLD, and 
MPGN is different, or if their constitution is identical and there is merely a difference in 
the time of appearance of these drusen. 
3.4. Age-related macular degeneration
3.4.1. Clinical characteristics of age-related macular degeneration
Drusen are also the hallmark lesions in AMD, the most common cause of legal blindness 
above the age of 60 in the Western world.91 The mean age at onset of visual loss in AMD 
is in the 8th decade. In persons over 80 years of age, the prevalence of legal blindness due 
to AMD may rise to more than 10%.194 Several clinical classifications have been developed 
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for AMD, based mainly on the findings on ophthalmoscopy.182,195-198 In the later stages 
of AMD, when visual loss becomes manifest, a distinction is made between atrophic or 
“dry” AMD, and neovascular or “wet” AMD. Atrophic AMD is characterized by patches 
of profound, chorioretinal (“geographic”) atrophy. Neovascular AMD, on the other 
hand, is caused by aberrant choroidal neovascular vessels that grow under or into the 
retina. These vessels form a neovascular membrane that leaks fluid, which compromises 
normal photoreceptor architecture and thus retinal function. Distortion of the normal 
photoreceptor arrangement leads to metamorphopsia, a symptom that is often the 
first manifestation of AMD. When photoreceptor function is further compromised and 
involves the fovea, visual acuity may decrease dramatically. Hemorrhages may occur 
within these lesions, and the neovascular complex may evolve to a scar. Contrary to 
atrophic AMD, which may take years to cause severe visual loss, neovascular AMD may 
end up in legal blindness within months.199 Both the atrophic and neovascular forms 
may be found in the same patients in random sequence.91 
 The diagnosis of AMD is generally established with ophthalmoscopy, but fluorescein 
angiography and/or optical coherence tomography (OCT) are often used to determine 
the exact location, size, and type of neovascularisation.200 Like in MPGN- and BLD-related 
drusen, fluorescein angiography is particularly suitable to determine the size and extent 
of drusen in AMD (Fig. 5.4C). Relatively recent imaging techniques, such as fundus 
autofluorescence and high-resolution spectral domain-OCT, are able to provide further 
insight into AMD lesions and may help to determine and evaluate the clinical outcome 
and therapeutic options.201-204 
AMD patients show increased plasma levels of complement AP activation products 
compared to control subjects.34 Most AP activation determinants are elevated, but this is 
especially true for C3d and Ba, which reflect chronic complement AP activation. Contrary 
to for instance MPGN and some subtypes of aHUS, the levels of CFH and C3 are comparable 
in AMD patients and controls.34 Factor D, an essential protein in the activation of the 
complement AP, also appears to be significantly elevated. Preliminary studies indicate 
that systemic complement AP activation in AMD is associated with the presence of 
specific AMD risk alleles in complement genes, including the p.Tyr402His risk variant in 
CFH.34 In addition, the presence of p.Tyr402His and another CFH risk polymorphism may 
be associated with a reduction in the glomerular filtration rate.205,206
 Current treatment modalities in AMD are aimed at the prevention of geographic 
atrophy and neovascular AMD, and the arresting or reversal of choroidal neovascularization 
once it has occurred.207 In addition, advice and support to stop smoking may be effective 
in significantly reducing the risk of AMD.104 Results from the Age-Related Eye Disease 
Study (AREDS) suggest that increased dietary intake or supplementation with vitamin 
C, vitamin E, zinc, and beta carotene, in patients with moderate to advanced AMD in 
one (the most affected) eye, may reduce the risk of advanced AMD in the fellow eye.207-
209 Recent data also suggest a protective role for omega-3-polyunsaturated fatty acids in 
the prevention of neovascular AMD.210-213 However, the current body of evidence does 
not support the use of antioxidant vitamin or mineral supplements in the general 
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population.214 Anti-angiogenic therapy, for instance through the intravitreal injection of 
an anti-vascular endothelial growth factor (anti-VEGF) such as ranibizumab, reduces the 
risk of visual loss and may even reverse visual loss in patients with neovascular AMD.215
3.4.2. CFH gene variants in age-related macular degeneration
The p.Tyr402His amino acid substitution, located in SCR 7, was the first CFH variant shown 
to be strongly associated with AMD in the Caucasian population.36,188,216,217 Estimates of 
the relative risk of AMD amongst carriers of this polymorphism, as compared to non-
carriers, range from 2.45 in heterozygotes to 7.4 (in homozygous carriers).36,188,216,217 
This relative risk of late AMD increases to 34.0 when homozygous carriers are current 
smokers.218 The p.Tyr402His variant appears to be much more frequent in people from 
Caucasian and African descent (allele frequency of approximately 35%) than in Hispanics 
and Asians (allele frequencies of approximately 17% and 7%, respectively).189,218,219 The 
p.Tyr402His variant shows no or only marginal association with AMD in the Chinese,220-223 
Japanese,224,225 and Korean populations.226 Apart from p.Tyr402His, several other CFH 
polymorphisms and haplotypes have been reported to confer an increased risk of AMD, 
both in Caucasians and Asians.36,188,223,226-228 Several other haplotypes of CFH and adjacent 
regions, one of them containing the previously mentioned deletion of CFHR1 and CFHR3,16 
lower the risk of AMD.19,36,228 One of these haplotypes (CFH haplotype H2), which carries a 
p.Val62Ile variant in the N-terminal region, lowers the risk not only of AMD, but also of 
aHUS and MPGN.15,17,140 
Variants in other genes involved in the complement system also alter the risk of AMD and 
its progression, including C3 (encoding complement component 3),229-231 CFB (encoding 
Factor B), and C2 (encoding complement component 2).232-235 Recent evidence also suggests 
a role for the classical pathway of complement activation in AMD, as genetic variants in 
the SERPING1 gene, which encodes the C1 inhibitor, alter the risk of AMD.236-238 However, 
these findings could not be replicated by another large study.239
3.4.3. Pathophysiology of age-related macular degeneration
In AMD, the CFH p.Tyr402His variant shows decreased affinity for GAGs and CRP. GAGs, 
present in the retina and Bruch’s membrane,240 may be used as markers of self-surface 
by CFH. With age, relative levels of GAGs change in Bruch’s membrane and the RPE.241,242 
The ability of the p.His402 and p.Tyr402 CFH variants to recognize and protect Bruch’s 
membrane may therefore fluctuate and differ with age.243 In addition, an age-related 
increase of oxidative influences, such as lipofuscin and its pro-oxidative constituents, 
may lead to a decrease of CFH expression by the RPE, and may trigger changes that 
eventually lead to AMD.38,244-246 Therefore, the p.Tyr402His variant may decrease the 
ability of CFH to locally protect the RPE. CRP, an acute phase reactant that has both 
pro- and anti-inflammatory properties, plays an important role in the down-regulation 
of the complement AP through the interaction with CFH.52,58,71,247 Such an interaction of 
CRP with CFH appears to be impaired by the p.Tyr402His change.71,243,248 Patients with 
AMD that carry the p.Tyr402His variant homozygously have elevated levels of CRP both 
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in serum and choroid.218,249-252 In addition, individuals carrying both CFH p.Tyr402His and 
specific CRP haplotypes, resulting in elevated serum CRP levels, have an increased risk of 
AMD,218 although results are somewhat conflicting on this matter.253 This suggests that 
elevated levels of CRP in AMD are associated with normal pro-inflammatory and reduced 
anti-inflammatory characteristics, possibly due to the p.Tyr402His variant in CFH.71 This 
could lead to the observed local and systemic chronic inflammation and complement 
AP activation,34,218,249,252 which predisposes to the deposition of inflammatory debris and 
drusen formation in the macula, as will be discussed further on in this review.90 
The aforementioned findings illustrate the pathophysiological consequences of the CFH 
p.Tyr402His variant that may lie at the basis of the development of AMD. However, these 
findings should be seen against the background of other genetic and environmental 
modifying factors, as the p.Tyr402His variant is neither sufficient nor necessary to 
develop AMD. 
 Various animal models of AMD have been developed, though none of these animal 
models exactly copy AMD.254 One of the major problems is that a macula is only found 
in humans and primates. However, since rod photoreceptor degeneration occurs prior 
to cone photoreceptor death in human AMD,255 the rod-dominated mouse retina may, 
to a certain extent, be a suitable model for the study of photoreceptor loss in AMD. One 
must bear in mind, however, that the enormous metabolic rate that is characteristic of 
the human macula, is not reflected in the mouse retina. To date, seven mouse models 
are available that display features of both atrophic and neovascular AMD: the Ccl-2/Ccr-2 
knockout mouse,256 the ApoE mouse,257 the Sod1 knockout mouse,258 the Ccl2/Cx3cr1 double 
knockout mouse,259,260 the Ceruloplasmin/Hephaestin double knockout mouse,261 and the 
Efemp1 p.Arg345Trp knock-in mouse.262,263 In mice immunized with carboxyethylpyrrole-
modified mouse serum albumin, in order to mimic oxidative damage in AMD,264,265 auto-
antibodies were formed against this hapten.245 As a result, the complement system was 
activated, and early AMD-like sub-RPE lesions appeared.245 These mouse models may show 
drusen, complement deposition, lipofuscin accumulation, Bruch’s membrane disruption, 
RPE atrophy, as well as choroidal neovascularization. These mouse models also confirm 
findings in humans that indicate that pro-inflammatory lifestyle characteristics, such 
as obesity, a high fat diet, lower antioxidant intake, as well as elevation of inflammatory 
biomarkers such as CRP, increase the risk of the development of AMD and the evolution 
towards advanced AMD.218,252,254,266
 AMD and BLD appear to be associated with systemic complement AP activation, like 
MPGN and some cases of aHUS, albeit in a more low-grade, chronic fashion.34 This could 
indicate that AMD (and possibly BLD), too, is a systemic disease that becomes clinically 
apparent only in the macula, which appears to be especially sensitive to this kind of 
damage. An interesting finding in this regard is that the estimated glomerular filtration 
rate is reduced in individuals with the p.Tyr402His AMD and MPGN risk variant, and 
several other CFH polymorphisms.205 Although speculative, these findings could suggest 
discrete subclinical CFH-related renal alterations in p.Tyr402His carriers. In cases of 
complement activation in the plasma, tissue surfaces that have a specific predisposing 
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anatomical structure (such as the eye and kidney) are probably particularly sensitive 
to complement deposition and damage. An additional explanation for this anatomical 
predisposition may be a relative lack of membrane-bound complement regulators on the 
GBM and, possibly, ocular structures such as the RPE basement membrane and Bruch’s 
membrane.74 
 A significant association of the p.Tyr402His CFH risk variant, as well as a lack of 
protective CFH alleles, was also found in multifocal choroiditis.267 Multifocal choroiditis is 
a retinal phenotype that typically affects persons younger than 50 years, and is presumed 
to have an autoimmune inflammatory pathogenesis.268,269 Like in AMD, choroidal 
neovascularization is often seen in multifocal choroiditis. The common genetic risk 
factors therefore suggest some shared disease mechanism between these diseases. 
3.5. Cardiovascular disease and Alzheimer’s disease
Some studies indicate that the CFH p.Tyr402His allele increases the risk of coronary 
heart disease, myocardial infarction, ischemic stroke, cardiovascular mortality, as well as 
mortality at old age in general.251,270-274 The cardiovascular risk may possibly be modified by 
the degree of hypertension.274 However, this association of p.Tyr402His and cardiovascular 
disease is refuted by several other studies, that either find no association,275,276 or even an 
inverse association.277
The same applies to Alzheimer’s disease. In one large study, the CFH p.Tyr402His variant 
conferred an increased risk of Alzheimer’s disease, an association that was only evident 
when individuals also carried the ApoE ε4 allele.278,279 Plasma CFH levels also appear to 
be increased in patients with Alzheimer’s disease, when compared to control subjects.280 
Interestingly, the ApoE ε4 allele decreases the risk of AMD.281-284 Other studies, however, 
did not find any association of p.Tyr402His and Alzheimer’s disease.285,286
Because of these contradictory study results, the possible association of cardiovascular 
disease and Alzheimer’s disease with the p.Tyr402His CFH variant will not be further 
discussed in this review.
4.  Pathophysiology of drusen and drusen-associated 
complications
Histopathologically, drusen may arise from so-called basal laminar and basal linear 
deposits, which are located between the basal membrane and the basement membrane 
of the RPE.287,288 One of the major components of drusen is lipofuscin,179,201,289 an 
autofluorescent mixture of fluorophores that contains toxic waste products of the visual 
cycle.246,289 This lipofuscin may find its origin in the overlying RPE, through the exocytosis 
of residual phagocytic material at the RPE basolateral membrane.290 In addition, drusen 
contain a broad range of components that are often related to inflammation.90,291 
Of special interest to this review is the finding of numerous complement components 
in drusen, including CFH, C3, C5 and the membrane attack complex C5b-9.90,291 
The accumulation of complement factors in drusen, especially C5b-9, could be precipitated 
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by the decreased interaction between the CFH p.Tyr402His variant and CRP, as discussed 
previously.52,71,243,248 The choroid is a source of many of the complement factors, whereas 
the RPE appears to have a more defensive function, as it produces CFH and carries several 
membrane-bound downregulators of the complement AP.35,90,292 Blue-light induced A2E, 
the major toxic fluorophore of lipofuscin in RPE and drusen, as well as other sources of 
oxidative stress, are able to initiate activation of the complement AP, possibly through 
the suppression of CFH expression by RPE cells.38,245,266 
 When present at increased concentrations, CFH may self-associate into oligomers 
that might facilitate the formation of protein precipitates within drusen.293 In this 
respect, it is worth noting that the CFH p.Tyr402His variant shows a higher propensity 
to oligomerise.294 Lipid components such as apolipoprotein E and amyloid P are also 
found in drusen, as well as proteins such as TIMP3 and amyloid-beta. In addition, HLA-DR 
has been identified in drusen, together with a core of dendritic cells, which are antigen-
presenting cells that may participate in the induction of immune responses.90 As such, 
drusen are the first clinical manifestation of a web of molecular and cellular activities 
that result from a complex interplay of multiple genetic and environmental factors, 
including chronic inflammation and complement AP activity. As a result of inflammation, 
oxidative damage and accumulation of a mixture of degradative and inflammatory 
debris, RPE cells and photoreceptors are damaged and die through apoptosis.207,245,295-297 
Photoreceptors overlying and adjacent to drusen show a decreased density and display 
morphologic and molecular signs of degeneration.298 
 Drusen are the precursors of geographic atrophy in MPGN, BLD, and AMD.299 The 
evolution of drusen takes place over many years, in which large amounts of small hard 
drusen may further increase in number and show confluence, to form larger, soft 
drusen.299,300 These soft drusen, which are actually small detachments of the RPE, may 
then further enlarge and evolve to larger RPE detachments with hyperpigmentation. 
Ultimately, these drusenoid RPE detachments result in profound atrophy of the 
overlying RPE and photoreceptors,298,301 resulting in the appearance of geographic 
atrophy. Therefore, geographic atrophy is viewed upon as the end stage of the process 
of drusen formation and progression. It should be noted that this end stage is reached 
in only a minority of patients with drusen.299,300 Geographic atrophy often appears first 
in the parafoveal area and may spare the fovea for a prolonged period of time.302 On 
histopathology, an absence of the RPE is seen, with secondary loss of photoreceptors and 
a variable degree of atrophy of the choriocapillaris.303 
 In some patients, the aforementioned process of drusen evolution is complicated 
by the formation of choroidal neovascularization (neovascular AMD). It is unknown 
why some individuals develop such choroidal neovascularization along the way, while 
others do not. Such a difference may find its origin in interindividual differences in 
the balance of pro- and anti-angiogenic factors, as well as discrete differences in the 
anatomical microenvironment of the retina. Local production of vascular endothelial 
growth factors (VEGFs) stimulates the formation and growth of aberrant neovascular 
vessels,304,305 a mechanism that is attacked in the case of anti-VEGF therapy in neovascular 
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AMD. Choroidal neovascularization may also be promoted by complement components 
C3a and C5a, which are present in drusen and are able to induce VEGF expression.306,307 
Early choroidal neovascularization in AMD is characterized by diffuse membranous 
deposits under the RPE, together with an infiltration of macrophages.308 In addition, 
ingrowth of vessels, surrounded by enlarged pericytes, into and through the damaged 
Bruch’s membrane and in the sub-RPE space is observed.295,308 The tips of these vessels are 
not covered by pericytes, allowing to leak fluid, erythrocytes and fibrin into this sub-RPE 
space.308 This results in the characteristic sub- and/or intraretinal fluid, hemorrhage, and 
scar formation. 
5.  Disease-associated CFH variants, their consequences for 
protein structure and function, and genotype-phenotype 
correlations
 
Most homozygous or compound heterozygous CFH mutations in MPGN, as well as the 
single heterozygous p.Cys431Tyr mutation in late-onset MPGN, are missense mutations 
that lead to the loss of a cysteine residue (Fig. 5.5).79,103,110 All four cysteines of each SCR in 
CFH form structurally important disulfide bonds.309 Mutations involving these residues 
may therefore lead to a considerable change in the secondary structure of CFH. Such 
a structurally altered protein is presumed to be retained and degraded intracellularly, 
without being secreted into the plasma.110,309 Contrary to the aforementioned mutations, 
the homozygous p.Lys224del mutation in SCR 4 does not preclude secretion of this 
mutated CFH into the plasma.80 Lysine residues are important determinants of the 
binding capacity of CFH for C3b.30 In the case of this specific p.Lys224del mutation in 
MPGN, the circulating mutant CFH proteins are unable to bind C3b and regulate plasma 
complement AP activation.80 Thus, the pathogenetic mechanisms leading to MPGN 
are different between the non-secreted CFH proteins and the secreted but functionally 
deficient p.Lys224del mutation. The consequence - uncontrolled plasma AP activation - 
is the same in both cases. However, because circulating mutant CFH has some residual 
function in the case of the homozygous p.Lys224del mutation, the age at onset is 
somewhat later (6 to 11 years, versus below 2 years of age in most cases of absent plasma 
CFH).79,80 Contrary to aHUS, the p.Lys224del mutation does not affect the binding of CFH 
to cell surfaces and its recognition of other ligands.
 More than 90% of CFH mutations in aHUS are located in the C-terminal region, the 
majority clustering in SCR 20 (Fig. 5.5).147,148 Firm evidence suggests that the two last 
C-terminal domains, SCRs 19-20, contain a C3b binding site and a heparin/polyanion 
binding site, which appear essential for the association of CFH with host endothelial and 
other surface cells, as well as surface-bound cofactor activity of CFH.10,67,69,74,147,148,175,310,311 
A loss of SCRs 19-20 deprives CFH of the capability to degrade endothelial cell-bound 
C3b.310 In this area of CFH, amino acids 1183, 1191, 1197, and 1210 correspond to 
mutational “hot spots”, and appear to be involved in binding of CFH to surface-bound 
Spectrum of CFH-associated phenotypes
5
294
C3b, to heparin, as well as to endothelial cells.10,175,312
 In glomerulonephritis C3 without MPGN, two CFH mutations have been described. 
The first mutation, a heterozygous p.Arg1210Cys missense mutation situated in SCR 
20, presumably reduces binding of CFH to C3b as well as to endothelial cells.10,107,312 
This mutation has also been identified in aHUS patients.10,312 The other mutation, 
a heterozygous p.Pro76X CFH nonsense mutation, leads to a truncated protein that 
is not secreted in the plasma, causing a decreased plasma CFH concentration due to 
haploinsufficiency.107 This mutation has also been reported repeatedly in aHUS (www.
fh-hus.org). In a case of glomerulonephritis C3 with MPGN, a heterozygous p.Gly650Val 
mutation was found, situated in SCR 11 close to a C3b-binding domain. Again, several 
mutations nearby this domain have also been found in aHUS.79,107,156
 In BLD, the heterozygous p.Gln408X nonsense mutation causes an early-onset drusen 
phenotype.179 The p.Gln408X mutation may lead to nonsense-mediated decay, preventing 
the expression of the protein. Alternatively, should the protein be translated, it is 
probably not secreted in the plasma or, if it is secreted, it will probably be degraded 
rapidly. The p.Arg1078Ser and p.Arg567Gly CFH  missense variants in BLD have, on the 
basis of homology models, been hypothesized to alter the affinity for several binding 
partners of CFH, such as C3b and CRP.179 The c.350+6TG CFH splice site mutation in 
BLD is predicted to severely affect splicing.179 The aforementioned mutations most likely 
cause early-onset BLD only when they are inherited in association with the p.Tyr402His 
variant.179 
 The p.Tyr402His risk variant is situated in SCR 7 (Fig. 5.5), which binds heparin and 
polyanions, as well as it interacts with CRP and group A streptococcal M protein.56,57,66,72 
The p.Tyr402His amino acid change results in little structural alterations.71,243 However, 
the p.Tyr402His variant does decrease the interaction of CFH with CRP,71,177,243,248 GAGs, 
and possibly heparin.71,177,243,313 A decreased ability of CFH to bind GAGs on self-surfaces and 
microbial surfaces could compromise its ability to regulate complement AP activation 
on such surfaces. An impaired interaction between CFH and CRP, the latter aiding C3 and 
C5 convertase inhibition, could lead to an increased production and deposition of C5b-
9, the membrane attack complex. In addition, the p.Tyr402His variant shows increased 
self-association to oligomers.294
 The aforementioned findings illustrate that the severity of disease roughly corresponds 
to the underlying defect(s) in the CFH gene. As a result, we propose a genotype-phenotype 
correlation model for CFH-related disease, which is summarized in Figure 5.6. In this 
model, early-onset MPGN and early-onset aHUS result from specific homozygous or 
compound heterozygous CFH mutations, that result in excessive plasma complement AP 
activation and - in the case of aHUS – a decreased cell surface activity of CFH leading to an 
attack of self-surfaces. Later-onset aHUS and MPGN are caused by single heterozygous CFH 
mutations, in addition to modifying genetic and environmental factors. Intermediate 
phenotypes, such as glomerulonephritis C3 with or without MPGN, may also be caused 
by specific single heterozygous CFH mutations. Early-onset BLD is caused by a specific 
CFH mutation together with a heterozygous or homozygous p.Tyr402His variant. An 
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increased risk of AMD with or without small drusen that resemble (late-onset) BLD is 
associated with the p.Tyr402His variant or other specific CFH variants or haplotypes. 
In this genotype-phenotype model, the degree of systemic complement AP dysregulation, 
as well as the consequences for renal function, decreases towards AMD, whereas additional 
genetic and environmental modifying factors may become more important. 
 As in most diseases with a genetic background, it should be noted that a 
straightforward genotype-phenotype correlation is not consistently seen in CFH-related 
disease. For instance, abnormally low plasma levels of CFH and C3 are not invariably 
caused by homozygous CFH nonsense mutations, but may also be seen in patients with 
(compound or isolated) heterozygous missense mutations in the CFH gene.103,149 Patients 
with BLD do not have renal disease on routine laboratory screening, despite carrying one 
allele with a presumably severe CFH mutation. Apparently, a single wild-type CFH allele 
and its protein product are sufficient to prevent excessive complement AP activation on 
blood and kidney cells. It is also sufficient to prevent the excessive plasma complement 
AP activation and C3 deposition in the glomeruli that cause MPGN, despite harboring 
the p.Tyr402His variant, that not only increases the risk of AMD and BLD, but also of 
MPGN. The CFH variants in BLD appear to have more specifically damaging consequences 
for the retina, without clinically affecting the kidneys. 
The aforementioned considerations thus provide only part of the explanation of the 
phenotypic differentiation of CFH-related disease. Obviously, genetic and environmental 
modifying factors, as well as for instance interindividual differences in cell surface 
characteristics, may be an important additional player in these cases. The proposed 
genotype-phenotype model and its graphic representation in Figure 5.6 therefore merely 
aims to serve as an overview, highlighting and categorizing the broad range of CFH-
related disorders.
6.  Phenotypic variability, variable expression, and non-
penetrance
The issue why some individuals that carry a heterozygous CFH variant remain disease-free 
is largely unresolved. It is also unclear why some patients with homozygous CFH variants 
that result in complete CFH deficiency develop MPGN, whereas others experience an 
early-onset aHUS. Interestingly, the morphological appearance of MPGN - a non-specific, 
histologically defined glomerular lesion - may develop into a picture of chronic aHUS.39 
 As indicated previously, several factors in addition to the type of CFH mutation could 
influence the resultant phenotype in CFH-related diseases like aHUS, such as the degree 
of CFH expression, the residual function of the affected and unaffected CFH domains, 
the presence of CFH splice variants, as well as the presence of auto-antibodies such as 
C3 Nephritic Factor.107,115,116 Different CFH risk alleles may differentially increase the 
susceptibility to MPGN, aHUS, as well as AMD.314 The p.Tyr402His variant, for instance, 
is associated with an increased risk of AMD and MPGN, but does not alter the risk of 
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Figure 5.6.    
Genotype-phenotype correlation model for diseases associated with variants in the CFH gene. 
In this model, the degree of systemic complement alternative pathway (AP)  dysregulation,  
as well as the consequences for renal function, decreases towards age-related macular 
 degeneration (AMD), whereas additional genetic and environmental modifying factors may 
become more important. Although atypical hemolytic uremic syndrome (aHUS) is placed 
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below membranoproliferative glomerulonephritis (MPGN), this does not implicate that this  
is a milder phenotype. It merely indicates that the disease is usually associated with  
heterozygous CFH mutations, and that it usually does not severely impact plasma CFH and 
C3 levels, contrary to MPGN. Additional abbreviations and symbols: nl, normal; C3 Ne F, C3 
Nephritic Factor; ↓, decreased; ↓↓, markedly decreased.
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aHUS.112,315 A deletion of CFHR1 and CFHR3 decreases the risk of AMD,16,19 whereas it 
increases the risk of aHUS.17 It has been estimated that approximately 60% of the 
phenotypic variance of CFH levels in aHUS is due to additional genetic modifiers.157,163 
 As for environmental factors, CFH plasma levels show an age-dependent increase, 
and are decreased in smokers.33 Oxidative insults such as blue-light induced damage 
by toxic fluorophores have been shown to decrease CFH expression by the RPE.35,38 
On the other hand, expression of Factor B by the RPE increases with advancing age, 
promoting complement AP activation.316 These findings indicate that, in the aging 
retina, the RPE and Bruch’s membrane are subjected to increasing levels of complement 
activation and its pro-inflammatory consequences. aHUS may be triggered for instance 
by infection, which may precede aHUS in up to 70% of cases,145 immunosuppressive 
agents, oral contraceptives, as well as pregnancy.145,148 In BLD, the p.Tyr402His variant 
appears to be required to develop an early-onset BLD phenotype.179 AMD is the example 
par excellence of complex multifactorial disease related to CFH. After all, carrying the 
p.Tyr402His variant and/or other CFH risk haplotypes significantly increases the risk 
of AMD, but the presence of these factors is not strictly required to develop AMD. The 
risk of AMD is modified by numerous additional genetic factors, both in complement 
and non-complement genes,91,315 as well as by environmental modifying factors, such as 
smoking and possibly Chlamydia pneumoniae infection.104,317,318 A predictive model based 
on 5 common polymorphisms in the CFH, ARMS2/LOC387715, and C2/CFB genes estimates 
that persons who carry all risk genotypes have a 14-fold higher AMD risk compared to the 
general population, and a 285-fold greater risk than the lowest risk group.228,319 
 Another striking illustration of the influence of genetic modifiers and environmental 
factors on the phenotypic outcome is the previously mentioned case of a patient with 
AMD with BLD-like deposits and late-onset MPGN.103 This patient carried only one 
missense mutation in CFH, which would normally not be expected to cause MPGN on 
itself. However, in addition to this mutation, this patient carried several AMD and MPGN 
risk variants, the plasma showed traces of C3 Nephritic Factor, and he was a heavy 
smoker. All these additional genetic and environmental “hits” may eventually lead to 
clinical disease, although with a later-than-usual onset.  
7. Future perspectives 
Especially in aHUS and AMD, which may be considered prototypes of multifactorial 
disease, the classical concepts of causality are challenged. In AMD, for instance, gene 
therapy does not seem an attractive option, as too many variables influence the 
pathogenesis and outcome of the disease.320 In such a scenario, the short- and long-term 
risks of gene therapy may outweigh the potential benefit. In this regard, it should be 
carefully considered that the complement AP has important physiological functions in 
the human body, such as protection against infection.1 The modification of exogenous 
factors such as smoking appears a more feasible and effective goal in this stage. In CFH-
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related diseases that follow a more straightforward causal relationship, such as early-
onset MPGN due to homozygous CFH nonsense mutations, gene therapy may prove to be 
a promising future treatment. In the case of AMD, on the other hand, it seems rational to 
apply more direct therapeutic approaches aimed at preserving and/or restoring central 
retinal function.
 Faster and more effective treatments in MPGN, aHUS, as well as in AMD and BLD, are 
urgently needed. The outcome of current treatments in aHUS and MPGN is generally 
poor, whereas morbidity and mortality are high, especially aHUS and MPGN caused 
by CFH mutations.145,146,152 As patients with CFH-related aHUS often display a rapid 
evolution towards end-stage renal disease, and have a high risk of mortality within a few 
years, effective treatment should be initiated as soon as possible particularly in these 
patients.145,146 Therefore, the rapid identification of the underlying genetic or functional 
defect, for instance using hemolytic assays, is of the utmost importance. Not only do these 
results have prognostic implications, they may also expedite the start of the appropriate 
therapy, such as plasma supplementation with normal CFH.175,321,322 
There are currently no gene therapeutic options to restore CFH deficiency due to CFH 
mutations in aHUS and in MPGN. In Cfh -/- mice, the MPGN phenotype may be corrected 
when mice are concurrently knocked out for Factor B (Cfb -/-), as the absence of Factor 
B prevents the formation of C3b,Bb.138 Knocking out C5 in Cfh -/- mice also resulted in 
a reduction in glomerular cellularity, serum creatinine levels and mortality,323 as C5 
activation appears to be a particularly important component of renal injury during 
acute inflammatory episodes.39,119 Consequently, treatment with an anti-C5a antibody 
such as eculizumab may prove to be effective.77,324 
 In AMD, the impact of the genetic background also becomes more and more apparent. 
Determining an individual’s genetic risk profile,228,319 together with behavioural risk 
factors,104,318 and possibly serological complement activation markers,34 may provide 
valuable insight in AMD risk assessment. The CFH p.Tyr402His variant may predispose 
to certain subtypes of AMD,325,326 and it influences the risk of progression in AMD.327 An 
individual’s response to treatment with nutritional supplements such as antioxidants 
and zinc,328,329 as well as the response to anti-angiogenic therapy,330-332 may also depend 
on the underlying CFH genotype. Especially in multifactorial diseases such as AMD and 
aHUS, the underlying palette of genetic (and environmental) factors may turn out to 
be essential in ones likelihood to respond to a specific therapeutic intervention. The 
development of agents that combat local complement overactivation could mean a huge 
step forward towards a marked risk reduction in for instance AMD. An important issue 
in this respect is to maintain a basal complement activation, to prevent for instance 
infectious complications that could result from excessive complement inhibition.  
 The aforementioned studies are the first steps in CFH-related pharmacogenetics. 
Current and future studies face the challenging task to further unravel the complex 
network of contributing genetic and environmental factors. In this perspective, knowledge 
about the underlying genotype may exert a considerable influence on the prognosis, as 
well as the choice and efficacy of specific preventive measures and treatments.
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5.2.  Basal laminar drusen caused by compound 
heterozygous variants in the CFH gene
Abstract
Objective: To evaluate the role of the CFH gene in 30 probands with early-onset basal 
laminar drusen. 
Methods: Thirty probands were diagnosed with basal laminar drusen, based on 
ophthalmoscopic and fluorescein angiographic findings. In addition to an extensive 
ophthalmologic evaluation, blood samples were obtained for analysis of the coding 
region of the CFH gene. The effect of amino acid variants were evaluated by molecular 
modeling.
Results: We identified heterozygous nonsense, missense and splice variants in CFH in five 
families. The affected individuals all carried the p.Tyr402His AMD risk variant on the 
other CFH allele. This supports an autosomal recessive disease model, where individuals 
who carry a CFH mutation on one allele and the p.Tyr402His variant on the other 
allele, develop drusen. Patients with these CFH variants show confluent macular drusen 
and many small drusen in the (mid-)peripheral retina, that may show an evolution to 
extensive chorioretinal atrophy. 
Conclusion: Our findings strongly suggest that monogenic inheritance of CFH variants 
can result in basal laminar drusen in young adults, which can progress to maculopathy 
and severe vision loss later in life. 
Introduction
Age-related macular degeneration (AMD) is the most common cause of blindness in the 
Western world, with a prevalence of 12% after 80 years of age.1 The presence of macular 
and/or extramacular drusen is an important risk factor for the development of advanced 
AMD.2 Different clinical subtypes of drusen have been described, but all drusen appear 
to be similar on the level of ultrastructural and molecular composition.3 AMD is a 
multifactorial disorder and variants in several genes have shown to be associated with 
the disease.1,4 Strong association is seen with the p.Tyr402His variant and several non-
coding variants in the CFH gene.5-9 The CFH protein has been detected in drusen and acts 
as an inhibitor of the alternative complement cascade.10   
 “Basal laminar drusen” (also termed “cuticular drusen” or “early adult onset, 
grouped drusen”) refers to an early-onset drusen phenotype, which shows a pattern of 
uniform small (25 to 75 μm), slightly raised, yellow subretinal nodules that are randomly 
scattered in the macula. The term “basal laminar drusen” is widely used, but may be 
considered a misnomer, as these deposits do not appear to correspond with nodular 
or diffuse thickenings of the Bruch’s membrane.3  In later stages, these drusen often 
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become more numerous, with clustered groups of drusen scattered throughout the 
retina. On fluorescein angiography, a typical “stars-in-the-sky” picture may be observed 
(Fig. 5.7).11 In time, these small basal laminar drusen may expand and ultimately lead 
to a serous pigment epithelial detachment of the macula, which may result in visual 
loss.11 The basal laminar drusen phenotype has an even stronger association with the 
p.Tyr402His variant than AMD, with an allele frequency of 70%, compared to 55% in a 
cohort of typical AMD patients and 34% in controls.12 Basal laminar drusen are also seen 
in patients with membranoproliferative glomerulonephritis type II (MPGN-II), a severe 
early-onset renal disease caused by an uncontrolled systemic activation of the alternative 
pathway of the complement cascade, which can be caused by highly penetrant recessive 
mutations in the CFH gene.13,14 MPGN-II associated drusen appear to be morphologically 
and compositionally similar to drusen in AMD.15  Mutations in CFH have been also 
associated with atypical hemolytic uremic syndrome (aHUS), a severe disease frequently 
leading to end-stage renal failure.16,17 
Methods
Clinical studies
In this study, we evaluated 30 probands diagnosed with basal laminar drusen 
maculopathy. At early stages the diagnosis was based on the biomicroscopic observation 
of small yellow-white deposits (“basal laminar drusen” or “cuticular drusen”) in the 
macula, sometimes extending towards the (mid-)peripheral retina, in combination with 
a “stars-in-the-sky” appearance on fluorescein angiography (Fig. 5.7). The occurrence of 
confluent (“soft”) drusen of variable size in the central macular region and subsequent 
development of a serous detachment of the retina and/or retinal pigment epithelium 
(RPE) were considered typical for the later stages of this disorder. A final feature in 
the later stages is geographic atrophy of the RPE that is frequently observed following 
resolution of the RPE detachment. An informed consent was obtained from all probands 
and participating family members. The study adhered to the tenets of the Declaration of 
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Figure 5.7.       
Typical f luorescein angiogram of  
a patient with advanced drusen 
maculopathy resembling basal  
laminar drusen (patient 9).  
Note the typical “stars-in-the-sky” 
appearance, with central conf luence 
of drusen and the small pseudo-
vitelliform pigment epithelial 
detachment.
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Helsinki and was approved by the Committee on Research Involving Human Subjects at 
the Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands).
Molecular genetic studies 
Peripheral venous blood samples were obtained from the 30 probands, as well as from 
18 family members from families A, B, and C. After isolation of their genomic DNA, we 
evaluated the role of CFH in the 30 probands by sequence analysis of the 22 coding exons 
and splice junctions. 
Results
Clinical findings
An overview of the clinical characteristics of these patients is given in Tables 5.2 and 5.3. 
Four patients did not experience visual complaints prior to the diagnosis (the finding 
of retinal abnormalities was coincidental), whereas 26 patients had noticed a decrease 
in visual acuity, with an age at onset ranging from 35 to 70 years (mean, 50 years). 
Eight patients reported family members with macular disease or visual disturbances 
compatible with macular disease. In 12 patients (40%), many small drusen were also seen 
in the (mid-)peripheral retina. In 28 patients (93%), the development of large, soft drusen 
could be observed in the central macular area. A pseudovitelliform yellow serous retinal 
or RPE detachment of the central macula with associated loss of visual acuity, was seen 
in 8 patients (27%). Ten patients (33%) showed chorioretinal atrophy of the macula. On 
fluorescein angiography, individual drusen as well as the larger exudative drusen were 
hyperfluorescent. Choroidal neovascularization was seen in 8 eyes of 5 patients (13% of 
60 eyes). 
Molecular genetic findings
The p.Tyr402His variant was present in 50% of CFH alleles (Tables 5.2 and 5.3), which is 
lower than the 70% reported elsewhere in patients with basal laminar drusen,12 but higher 
than in healthy control subjects (34%). More importantly, we found that 7 patients in two 
families (A and B) were compound heterozygous for the nonsense mutation p.Gln408X 
and the AMD risk allele p.Tyr402His (Fig. 5.8). The CFH variants in the deceased individual 
A-II.3 were deduced upon CA-marker analysis in the right branch of family A. The clinical 
characteristics of the affected family members are shown in Figure 5.9 and Table 5.3. Two 
family members (A-IV.1 and A-IV.2) carrying only the p.Gln408X allele did not develop 
drusen. In a third family (C), we identified three individuals with drusen who carried a 
heterozygous variant (p.Arg1078Ser) on one allele, and the p.Tyr402His variant on the 
other    CFH allele (Fig. 5.8). The p.Arg1078Ser variant occurs in the 18th short consensus 
repeat (SCR 18) of CFH. To predict the effect of this variant, we constructed a homology 
model for SCR 18 (Fig. 5.10). As SCR 18 shares 40% homology with SCR 19, model building 
was straightforward using the SCR 19-20 structure as a template.18 The model shows 
that the amino acid p.Arg1078 is solvent exposed, and the change to serine at this 
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position is not expected to have a large structural effect on SCR 18 itself. However, SCR 
18 neighbors the C-terminal SCR domains 19 and 20, which were shown to have many 
different interaction partners, including the major opsonin C3b, glycosaminoglycans 
and endothelial cells. The p.Arg1078Ser variant introduces a smaller side chain in SCR 18, 
and abolishes the negative charge at this position. This change might interfere with the 
different interactions in which CFH participates. Notably, mutation of a nearby residue 
(p.Gln1076Glu) was identified in a patient with aHUS (FH aHUS mutation database).  
 In patient D, we identified the p.Tyr402His variant homozygously, and a heterozygous 
variant in the splice donor site of exon 3 (c.350+6T>G) of CFH (Fig. 5.8). This variant is 
predicted to severely affect splicing, since the splice prediction score is reduced from 
0.97 to 0.59 (NNSPLICE version 0.9).19 Moreover, this residue is completely conserved 
between human and all species for which the genomic sequence of CFH is available 
(rhesus macaque, mouse, rat, dog, horse, opossum, platypus and elephant). The deceased 
mother of patient D was diagnosed with macular and peripheral drusen by a local 
ophthalmologist at the age of 43. 
A patient in a fifth family (E) carried a heterozygous amino acid variant (p.Arg567Gly), 
and was heterozygous for the p.Tyr402His variant (Fig. 5.8). Other family members were 
unavailable for examination or segregation analysis. The p.Arg567Gly variant occurs in 
the interdomain hinge region between the short consensus repeats SCR 9 and SCR 10. 
As no experimental structure of SCR 9-10 is known, we built a homology model of this 
hinge region and the two surrounding domains, using the crystal structure of the CFH 
SCR domains 19-20 as a template.18 
In our model, p.Arg567 is located on the protein surface and hydrogen bonds from 
the hinge region to the backbone of SCR 10 (Fig. 5.10). As such, p.Arg567 could play a 
structural role in defining the orientation of SCR 9 with respect to SCR 10. This hypothesis 
is supported by p.Glu566 and p.Glu568, which both hydrogen bond to a tyrosine residue 
in SCR 9 and SCR 10, respectively. As the charged p.Arg567 in our model also appears to 
be partially exposed to the surface, it could play a role in one of the many interactions 
in which CFH can engage. For example, CFH has been shown to bind complement factor 
C3b via interaction sites in SCR domains 1-4, 9, 12-14 and 19-20.20,21 Furthermore, CFH can 
bind C-reactive protein (CRP) via SCR 7, but also in the region spanning SCR 8-11.22 This 
would place p.Arg567 close to a C3b binding site and in a CRP-binding region. p.Arg567Gly 
removes a positive charge in the interdomain hinge region between SCR 9 and SCR 10, 
and is likely to result in an increased mobility of the linker between these repeats. Based 
on these findings, we speculate that p.Arg567Gly might result in an altered affinity of 
CFH for C3b and possibly also CRP.
The new CFH variants identified in these families were not identified in 92 ethnically 
matched control subjects, nor in 90 controls between 65 and 85 years of age who did 
not have any signs of maculopathy. In two other patients, we identified p.Asn1050Tyr 
and p.Glu936Asp heterozygously in CFH. The p.Asn1050Tyr variant was previously found 
in 4% of control alleles16, and the p.Glu936Asp variant was found in 18% of controls.23 
Although proband 24 in our study was compound heterozygous for the p.Asn1050Tyr 
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and p.Tyr402His alleles, his affected father carried the p.Asn1050Tyr variant without 
p.Tyr402His, indicating that compound heterozygosity of CFH variants does not cause 
the disease in this family. 
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Figure 5.8.   
Molecular genetic analysis of the CFH gene in families affected with drusen maculopathy.  
A and B. Seven affected individuals in two families are compound heterozygous for the nonsense  
mutation p.Gln408X and the AMD risk allele p.Tyr402His. Brackets f lanking the CFH variants of 
A-I.3 indicate that they were deduced through CA-marker analysis. C. Three affected individuals 
in a third family are compound heterozygous for the missense variant p.Arg1078Ser and p.
Tyr402His. D. Patient D is homozygous for the p.Tyr402His variant, and in addition carries a 
heterozygous variant in the splice donor site of exon 3 (c.350+6T>G). E. A patient in a fifth family 
carries a heterozygous amino acid variant (p.Arg567Gly), and is heterozygous for the p.Tyr402His 
variant. Segregation analysis could not be performed. The grey pedigree symbols in panels A-E 
denote patients with basal laminar drusen. The black symbols denote two females affected with 
AMD. Numbers in the pedigree symbols ref lect current age. F. Sequences of heterozygous variants 
detected in the CFH gene.
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Discussion
Previous studies have shown that the p.Tyr402His variant in CFH is strongly associated 
with AMD and basal laminar drusen.5-7,12 Our findings strongly support a recessive 
disease model in a subgroup of patients with basal laminar drusen. In these families, 
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Figure 5.9.*         
Retinal phenotypes of drusen patients 
carrying the combination of a  
p.Gln408X mutation and the  
p.Tyr402His AMD risk variant. (A-D) 
Retinal phenotype of patient A-III.5. 
A. Fundus photograph of the right 
eye, showing extensive chorioretinal 
atrophy of the posterior pole. At the 
first examination, 17 years earlier, 
these areas corresponded with large 
conf luent drusen with incipient 
atrophy. B. The short-wavelength 
fundus autof luorescence (FAF) image 
shows an absence of FAF correspon-
ding with the patches of chorioretinal 
atrophy, not only in the macular 
area, but also in the midperipheral 
retina. Moreover, diffuse changes in 
FAF intensity can be observed.  
C. Fundus photograph of the left eye, showing large conf luent drusen and mild chorioretinal  
atrophy. D. An infrared ref lectance photograph clearly visualizes small, round midperipheral  
drusen scattered between the patches of chorioretinal atrophy. The drusen on infrared ref lectance 
corresponded with discrete, round, yellow-white drusen with a slightly pigmented border on  
ophthalmoscopy. (E-H) Retinal phenotype of patient B-II.1. E. Fundus photograph showing  
conf luent macular drusen. F. The macular drusen can be more easily detected on the f luorescein 
angiogram. G. Optical coherence tomography (OCT, oblique section) showing small dome-shaped  
elevations of the “outer red line”, corresponding with visible drusen on ophthalmoscopy (arrow).  
H. Like in patient A-III.5, small midperipheral drusen were also seen in this patient, which had a 
similar aspect on OCT as the macular drusen. (I-J) Patient B-III.2, the 22-year-old asymptomatic son 
of patient B-II.1 showed tiny hyperf luorescent drusen in the parafoveal area (I) and in the (mid-)
peripheral retina (J) on f luorescein angiography, which were difficult to discern on ophthalmoscopy. 
His 25-year-old brother (B-III.1) had similar midperipheral lesions, but to a lesser extent.
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individuals develop drusen when they carry a CFH mutation on one allele and the 
p.Tyr402His variant on the other allele. The presence of a CFH mutation in the absence of 
the p.Tyr402His variant, however, might contribute to the development of AMD at later 
age (e.g. in individual B-I.2). Compound heterozygosity was confirmed in four families 
(A, B, C and D), whereas in one family (E) segregation analysis could not be performed. 
Affected individuals of families A, B, C and D presented with many small drusen with 
a slightly pigmented border peripheral to the vascular arcades. These peculiar drusen 
were most readily observed on ophthalmoscopy, fluorescein angiography and infrared 
reflectance photography (Fig. 5.9C,D,J). On optical coherence tomography (OCT), the 
appearance of the drusen peripheral to the vascular arcades was similar to the drusen 
located in the macula. 
 Mutations in the CFH gene can cause severe renal failure in patients with MPGN-II 
and aHUS. We did not observe signs of a renal disorder on routine laboratory testing 
of blood and urine in the drusen patients with compound heterozygous CFH variants. 
It is possible that in these patients, the residual complement factor H activity sustains 
sufficient complement regulatory activity for normal renal function, while the ocular 
environment may be more sensitive to deposition and damage. Subclinical renal 
abnormalities, however, remain possible.24  
 There are a few examples where heterozygosity for a mutation implicated in a 
Mendelian disorder appeared to result in an increased risk for a complex disease.25 In this 
study we show that monogenic inheritance of CFH variants can result in basal laminar 
Spectrum of CFH-associated phenotypes
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Figure 5.10.       
Molecular modeling of missense  
variants detected in CFH. A and B. 
Model of the SCR 18 domain, 
depicting the effect of the  
p.Arg1078Ser variant. Model of A, 
the wildtype sequence (p.Arg1078) 
and B, the p.Arg1078Ser variant.  
C and D. Model of the SCR 9 and 
SCR 10 domains, depicting the effect 
of the p.Arg567Gly variant. Model of 
C, the wildtype sequence (p.Arg567) 
and D, the p.Arg567Gly variant.  
The SCR 9 domain is shown in  
yellow, SCR 10 in orange, and  
the linker region between the two 
domain is shown in blue  
(see  original article for color version of the figure). Hydrogen bonding partners for the residues 
in the linker region are indicated with dotted lines. All figures were made using Yasara.
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drusen in young adults, which can progress to maculopathy and severe vision loss later 
in life. Our findings indicate that basal laminar drusen and AMD belong to a spectrum of 
diseases, associated with either monogenic or multifactorial inheritance of variants in 
the CFH gene.  
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Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih.gov/Omim
FH aHUS mutation database; http://www.fh-hus.org/
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1.  Ocular phenotypes caused by mutations in the BEST1 
gene
This thesis illustrates that Best vitelliform macular dystrophy (BVMD), which is caused 
by mutations in the BEST1 gene (formerly known as VMD2),1,2 is a highly variable 
phenotype. Even within a single family, the phenotype may range from absence of 
retinal abnormalities to classical BVMD, as well as multifocal vitelliform dystrophy. 
The phenotypic differences in and between BVMD and BEST1-associated multifocal 
vitelliform dystrophy are most likely due to additional unknown genetic modifiers and/
or environmental modifiers. Possible genetic modifiers will be discussed in paragraph 
1.4 of this discussion, whereas possible variation in anatomical and environmental 
influences is discussed in paragraph 4. 
1.1.  Fundus autofluorescence and optical coherence tomography in Best 
vitelliform macular dystrophy 
The use of fundus autofluorescence (FAF) and optical coherence tomography (OCT) was 
shown to be very helpful in obtaining additional information about the shape and 
composition of BVMD lesions. The subretinal space in BVMD lesions contains auto- 
fluorescent material. This autofluorescent material most likely includes the fluorophores 
A2-PE-H2 and its oxidated form, A2-PE. These bisretinoid molecules are fluorescent 
associations of two all-trans-retinal molecules (A2) and phosphatidylethanolamine (PE), that 
originate in the shed photoreceptor outer segment (OS) discs.3-5 In addition, histopathologic 
studies on the eyes of BVMD patients have shown that a significant accumulation of 
lipofuscin and A2E occurs in the retinal pigment epithelium (RPE) cells,6-10 despite the 
lack of apposition to the photoreceptor OS discs.6,8,10,11 Like in peripherin/RDS-associated 
retinal dystrophies and Stargardt disease (STGD1), this correlates with the highly increased 
FAF signal that is observed in many BVMD patients (Chapter 3). The studies in this thesis 
show that FAF is able to visualize even small amounts of vitelliform material that are not 
readily detected on ophthalmoscopy. With FAF, the dynamic process of accumulation and 
apparent resorption of autofluorescent vitelliform material can be monitored easily and 
non-invasively. Additional information can be obtained with OCT, giving insight into the 
characteristics of the lesion in the anteroposterior dimension. OCT is able to visualize for 
instance the site of accumulation of vitelliform subretinal material, the morphology of a 
scar, as well as its position relative to the neuroretinal detachment. FAF and OCT, especially 
when used in combination, also appear to give information about BVMD lesions beyond 
the information obtained with fluorescein angiography. 
 FAF and OCT appear useful in the clinical assessment and follow-up of BVMD, giving 
additional insight in the disease process and its course. When therapy for BVMD becomes 
available, these imaging modalities may prove to be useful parameters in the evaluation 
of the treatment effect. It should be noted, however, that FAF and time domain (Stratus) 
OCT are of limited value in the differential diagnosis of other diseases that may present 
with vitelliform lesions. In chronic detachment of the neuroretina in central serous 
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chorioretinopathy, a picture of increased FAF may be observed that is quite similar to 
BVMD, and OCT findings are also quite comparable.4,12,13 The same holds true for the 
other phenotypes that need to be differentiated from BVMD. Adult-onset foveomacular 
vitelliform dystrophy (AFVD),14-19 drusen-derived “pseudovitelliform” lesions,20-22 and 
acute exudative polymorphous vitelliform maculopathy may all display FAF and OCT 
characteristics that are sometimes hard to distinguish from BVMD and/or multifocal 
vitelliform dystrophy.23,24 The degree of FAF in the vitelliform-appearing lesions in these 
diseases probably depends on the amount of accumulated subretinal material, as well as 
the relative proportion of autofluorescent components within this material. 
In these cases, a similar clinical appearance obviously does not automatically reflect 
an identical pathogenesis. These findings rather indicate that the retina may have a 
limited set of responses to genetic defects and environmental influences. The clinical 
expression of a genetic background, whether or not modified by environmental factors, 
may converge in common final pathways.25 High resolution imaging techniques such as 
high resolution OCT may be able to reveal more subtle differences between apparently 
similar conditions, that are not seen on the time domain OCT, which has a lower 
resolution. In drusenoid pseudovitelliform RPE detachments, for instance, the RPE is 
included in the pseudovitelliform detachment, contrary to for instance BVMD lesions. 
Such differences can be more clearly shown on high-resolution OCT (Fig. 6.1). Contrary to 
BVMD lesions, the yellowish material in these drusen-derived pseudovitelliform lesions 
is not primarily derived from shed photoreceptor OSs under the neuroretina, but likely 
consists of heterogeneous inflammation-associated material, which will be discussed in 
Section 3.6.
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Figure 6.1.   
Ultrastructural differences between lesions that both appear vitelliform on ophthalmoscopy. 
A. High-resolution OCT image of a lesion in Best vitelliform macular dystrophy (BVMD, 
 combined cicatricial/vitelliruptive stage). A prominent scar is seen, with its tip in contact with 
the fovea. This scar appears to originate from the retinal pigment epithelium (RPE) cell layer 
(white arrowhead). Hyperref lective accretions under the photoreceptor layer (black arrowhead) 
 probably correspond to accumulations of photoreceptor outer segments that fail to be 
 phagocytosed by the distant RPE. B. Drusenoid pseudovitelliform RPE detachment in a patient 
with age-related macular degeneration. Contrary to the BVMD lesion in panel A, the RPE is 
included in the elevated retinal lesion (white arrowheads). Within the retina, hyperref lective 
spots are visible (white arrow), that probably correspond to the intraretinal hyperpigmented 
spots that are often observed on ophthalmoscopy in such drusenoid RPE detachments.
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1.2.  Genetic and pathophysiologic characteristics of Best vitelliform macular 
dystrophy and other BEST1-associated diseases
Best vitelliform macular dystrophy
The bestrophin-1 protein is situated in the basolateral plasma membrane of the RPE 
and probably functions as a volume-sensitive Ca2+-dependent Cl- channel that modulates 
ion flow across the RPE.1,26,27 In addition, it is involved in the regulation of intracellular 
voltage-dependent Ca2+ channels.28-31 Most mutations in BEST1-associated AFVD, BVMD, 
and multifocal BVMD are heterozygous missense mutations, although other mutations 
including homozygous missense mutations have also been described.6,19 Some of these 
mutations (such as the p.Ala243Val missense mutation) are deleterious, for example, 
through a haploinsufficiency mechanism. These mutations generally cause a milder 
phenotypes including AFVD.32 Most mutations, however, exert a dominant negative effect 
on wild-type bestrophin-1.33 In the case of a dominant negative mechanism, a markedly 
reduced to absent Cl- channel function is observed in animal and in vitro studies.34-36 
On the other hand, haploinsufficiency mechanisms often preserve the Cl- current to a 
larger extent,33,36 which possibly accounts for the milder phenotype. Another proposed 
mechanism is a “gain of function”, possibly affecting intracellular Ca2+ concentrations 
through voltage-dependent Ca2+ channels.28,31 
 The propensity of lesions in BVMD (as well as in BEST1-associated AFVD) to develop in 
the macula may be explained by topographic differences in bestrophin-1 protein.8 The 
finding that mutant and wild-type bestrophin-1 are more abundant in the peripheral 
retina suggests that BVMD results from a relative insufficiency of wild-type bestrophin-1 
in the macula.8 The macula has unique anatomical and functional features that differ 
from the peripheral retina. Not only does the macula have the highest photoreceptor 
and RPE cell density of the entire retina, with a corresponding high metabolic rate, but 
the choroidal blood flow also reaches a maximum in the macula. Bruch’s membrane 
is thinnest in the macula, compared to more peripherally located retina. These 
characteristics could make the macular region more vulnerable to this lack of wild-type 
bestrophin-1. The defective RPE ion conductance would then result in the accumulation 
of subretinal fluid and a lack of apposition between the photoreceptors and the RPE. 
The enormous metabolic demand of the densely packed photoreceptors poses a heavy 
burden on the macula, and requires a highly effective interaction between the different 
retinal layers and the underlying choroid. These normal interactions are obviously 
compromised by the separation of the neuroretina from the RPE.
 However, the visual acuity in BVMD patients may be unexpectedly high for many 
years,37-39 despite the fact that the photoreceptors are separated from the underlying RPE. 
There are several possible explanations for this phenomenon. Photoreceptor OS turnover 
appears to be slower in cones than in rods,40 and the shed OS are able to accumulate on 
the outer neuroretinal surface and in the subretinal space. Part of these OS may still 
reach the RPE, where they are phagocytosed, albeit in an inefficient way. The lack of 
photoreceptor apposition would also complicate 11-cis-retinal recovery via the RPE. This 
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problem may be at least partially bypassed, as the cones have an alternative route for 
visual pigment regeneration via the Müller cells.41,42 In addition, intact surrounding 
rods are able to secrete rod-derived cone viability factor, which can also promote cone 
survival.43,44
 Although this relative sparing of visual acuity in BVMD may be observed especially 
in the earlier stages, visual acuity tends to show a slowly progressive decline in BVMD 
patients over a period of several decades.38 In other cases, visual acuity can show a sharp 
decline in visual acuity within a few years. Apart from possible detrimental influences 
of mutant bestrophin-1 on RPE cell function, a progressive build-up of toxic fluorophores 
in the subretinal space and the RPE, as seen on FAF and in histopathological studies, 
may cause damage to the photoreceptors and RPE.6,8 Toxic properties of oxidized A2E 
precursors can damage the adjacent photoreceptors,45,46 and A2E derivatives are known 
to have a wide range of damaging effects on the RPE,47-52 including an inhibition of 
normal photoreceptor OS phagocytosis.53,54 Histopathological studies have shown that a 
degeneration of the photoreceptors and other elements of the neuroretina may precede 
RPE atrophy.6,8,11 Damage to the RPE can ultimately lead to fibrous metaplasia, scarring, 
initiation of apoptosis, and RPE atrophy.4,5,55,56 In rare instances, BVMD is complicated by 
choroidal neovascularization, resulting in more rapid visual loss.57
 The fact that the bestrophin-1 protein is located in the RPE and influences RPE ion 
conductance is mirrored by the hallmark electrophysiological abnormality in BVMD: a 
severely decreased or absent light rise on the electro-oculogram (EOG).58 However, the EOG 
response appears to be only indirectly dependent on bestrophin-1 function,27,28 and some 
Best1 mutations are associated with a normal EOG.33,59,60 Bestrophin-1 may still influence 
the EOG, for instance through the influence on other ion channels in the RPE.28,29,61
Autosomal recessive bestrophinopathy, autosomal dominant vitreoretinochoroidopathy, and 
the microcornea, rod-cone dystrophy, cataract, posterior staphyloma (MRCS) syndrome
Autosomal recessive bestrophinopathy (ARB) is caused by homozygous or compound 
heterozygous missense or nonsense mutations in BEST1.62 ARB is not limited to the 
macula, unlike AFVD and BVMD, but shows panretinal abnormalities, with retinal 
edema and subretinal fluid. FAF imaging in ARB shows widespread abnormalities. 
Contrary to AFVD and BVMD, an abnormal full-field electroretinogram (ERG) is seen, 
reflecting photoreceptor dysfunction in the entire retina, in addition to an abnormal 
EOG. Moreover, this condition does not only affect the retina and RPE, but also appears 
to be associated with hyperopia and an increased risk of acute angle-closure glaucoma.62 
Specific homozygous or compound heterozygous missense or nonsense mutations in 
ARB preclude normal whole-cell Cl- conductance and normal activation of L-type voltage-
dependent Ca2+ channels, as there is no wild-type BEST1.62 In addition, the compound 
heterozygous missense mutations that have been found in patients with ARB are often 
located more C-terminally in bestrophin-1 than most BEST1 missense mutations in BVMD, 
suggesting that these C-terminal mutations might affect a specific function encoded by 
this region.62
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 In autosomal dominant vitreoretinochoroidopathy (ADVIRC), vitreoretinal 
abnormalities are also accompanied by a certain degree of additional ocular 
developmental abnormalities, including nanophthalmos, microcornea, and congenital 
cataract.63,64 This anterior segment dysgenesis accounts for the high incidence of angle-
closure glaucoma in ADVIRC patients. Like ARB, the full-field ERG is often abnormal, as 
well as the EOG.63,64 In one family, rod-cone dystrophy and posterior staphyloma were 
additionally observed, corresponding with microcornea, rod-cone dystrophy, cataract, 
posterior staphyloma (MRCS) syndrome.64,65 ADVIRC and the MRCS syndrome are also 
caused by heterozygous missense mutations, like BVMD. However, contrary to BVMD-
associated missense mutations, the ADVIRC/MRCS syndrome-associated missense 
mutations, situated between c.704 and c.709 in BEST1 (except for p.Val86Met), alter the 
regulation of normal exon splicing.64,66 This abnormal splicing regulation results in 
functionally abnormal protein isoforms. 
 The ocular developmental abnormalities in ARB, ADVIRC, and the MRCS 
syndrome indicate that bestrophin-1 is much more than just a regulator of the ionic 
microenvironment of the RPE. In addition, some region(s) within bestrophin-1 apparently 
have an important role in ocular development. These data also suggest that the distinction 
between “developmental” and “late-onset” genes may sometimes be rather artificial.64 In 
this respect, it is important to recall that the RPE appears to fulfill a critical role in the 
regulation of growth signals to both the choroid and the sclera.67 Therefore, bestrophin-1 
could also take part in the web of events in ocular development.
1.3. Genotype-phenotype correlations in BEST1-associated disease
BEST1-associated ocular disease obeys to a genotype-phenotype correlation model. In this 
model, AFVD is caused by mild heterozygous missense mutations that affect the RPE 
to such an extent that the EOG remains relatively unaffected. In BVMD and multifocal 
vitelliform dystrophy, moderately severe heterozygous mutations, mostly missense 
mutations, diffusely affect the RPE to an extent that the EOG is severely disturbed. In ARB, 
specific compound heterozygous missense or nonsense mutations cause a phenotype 
that not only affects the entire RPE and neuroretina, but may also be associated with 
additional ocular developmental abnormalities that also affect the anterior segment of 
the eye. Finally, some of the heterozygous missense mutations in BEST1 that severely 
affect splicing may not only adversely affect the neuroretina and RPE, but also normal 
development of the entire eye, including the anterior segment, the crystalline lens, 
vitreous, choroid and sclera. These mutations result in ADVIRC or the MRCS syndrome, 
two phenotypes that appear to form a continuum.
1.4.  Phenotypic variability, non-penetrance, and possible genetic modifiers 
associated with BEST1-associated disease
The findings in Chapter 3 demonstrate that family members with an identical BEST1 
mutation, for instance the p.Lys194_Ala195insVal mutation, can have either extensive 
multifocal vitelliform dystrophy or unifocal BVMD, but may also remain completely 
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disease-free, even with a normal EOG. Such variation can not be solely explained by 
environmental or age differences. On the contrary, the asymptomatic individual with 
a normal EOG in the case of the p.Lys194_Ala195insVal mutation was the 44-year-old 
father of a daughter with early-onset multifocal vitelliform dystrophy. His son had a 
large BVMD lesion at the time of diagnosis, at age 5. These children both had a markedly 
abnormal EOG.
 Variations in other genes in addition to the BEST1 variant are probably responsible for 
this apparently illogical phenotypic variation. The identification of such modifier genes 
is challenging, as the effect of those genes may be very complex and indirect, and several 
genetic factors may be simultaneously involved.68 Before starting an expensive and 
time-consuming search for genetic modifiers, one must ascertain that the phenotypic 
variability is not entirely due to environmental influences and other mechanisms such 
as genetic heterogeneity.68 Several strategies for modifier gene identification are possible, 
such as linkage analysis, association studies, genome-wide screening, and candidate gene 
testing. For many genetic disorders, this quest for genetic modifiers is complicated by the 
rarity of the disease, and the correspondingly small size of the study population.
 Experiments in transgenic mice and in vitro studies indicate that the level of BEST1 
expression is controlled by the OTX gene,69 the MITF gene,69-71 and possibly the CRX 
gene.69 These genes encode essential transcription factors that orchestrate ocular 
development,72-74 and these factors bind to the BEST1 promotor region.69-71 Variations in 
these genes and their protein products may alter their influence on BEST1 promotor 
activity and therefore the level of BEST1 expression. Genetic variations in the interacting 
BEST1 promotor region itself may also contribute to this variable expressivity. OTX, MITF, 
and CRX are also of paramount importance in the development and differentiation of 
the photoreceptors, RPE and numerous other ocular tissues (such as the anterior segment 
structures). A disturbed interaction of these factors with BEST1 could therefore also be 
involved in the pathogenesis of ADVIRC, the MRCS syndrome, and ARB.
1.5. Gene therapy prospects in phenotypes caused by BEST1 mutations
In BVMD and AFVD phenotypes caused by haploinsufficiency, the delivery of wild-type 
BEST1 gene may prove to be sufficient. The null phenotype ARB also appears a suitable 
candidate for wild-type gene supplementation, and the cmr dog model -the canine 
counterpart of ARB- could be of great help in the development of such a strategy.62,75 
In gain-of-function BEST1 mutations, that have a dominant-negative effect on wild-type 
bestrophin-1, additional methods are required to abolish this effect. These methods 
could include RNA interference techniques that destroy the mutant messenger RNA.76,77 
The optimal choice of gene therapeutic approach in ADVIRC and the MRCS syndrome is 
unclear, as the functional consequences of the mutant protein are not known. In this 
regard, the prevention of ocular developmental abnormalities in ADVIRC, the MRCS 
syndrome, but also in ARB, with gene therapy would probably require treatment in the 
first years of life. This would further complicate decision making on this matter, given 
the fact that variable expressivity is also seen in for instance ADVIRC.66
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 When effective and as safe as possible gene therapeutic strategies have been 
developed for BVMD and BEST1-related AFVD, these should be reserved for patients that 
are beyond the carrier stage, as many carriers never develop symptomatic disease. Once 
the cicatricial and/or atrophic stage with photoreceptor and RPE cell death is reached, 
with a corresponding drop in visual acuity, gene therapeutic intervention will probably 
be of no or limited benefit. The results of this thesis illustrate that the staging and proper 
phenotypic evaluation of BVMD is complex and should not rely on ophthalmoscopy alone. 
Numerous parameters may prove to be essential in decision making about the usefulness 
of gene therapy in BVMD and BEST1-related AFVD, such as visual acuity, (high resolution) 
OCT, FAF, and retinal function tests such as multifocal ERG. After all, a combination of 
these parameters will provide the most reliable and detailed information on the viability 
of the macular photoreceptors and RPE.
2.  Retinal dystrophies caused by mutations in the peripherin/
RDS gene 
The peripherin/RDS protein is a structural photoreceptor protein, that is essential 
for the formation of normally shaped photoreceptor outer segment (OS) discs and 
lamellae. Mutations in the peripherin/RDS gene are associated with extreme phenotypic 
heterogeneity (Chapter 4). Phenotypes may range from central, predominantly macular 
dystrophies, such as central areolar choroidal dystrophy (CACD), to multifocal pattern 
dystrophy simulating STGD1, cone-rod dystrophy, as well as typical retinitis pigmentosa 
(RP). Even within the subgroup of central peripherin/RDS-related phenotypes, a broad 
phenotypic range can be observed, sometimes mimicking atrophic age-related macular 
degeneration (AMD) and/or neovascular AMD to a large extent. This predominantly 
macular phenotypes include CACD, MPD, butterfly-shaped pigment dystrophy, AFVD, 
and AMD-like late-onset maculopathy. Another puzzling observation is the broad range 
of phenotypes within a single family, and even a different phenotype between the two 
eyes of a single patient, associated with an identical peripherin/RDS mutation. These 
fascinating phenomena have to be explained by additional modifying genetic, anatomic, 
and environmental factors, that will be discussed in the following sections.
2.1.  Fundus autofluorescence and lipofuscin accumulation in peripherin/RDS-
associated retinal dystrophies
All of the aforementioned peripherin/RDS-associated phenotypes initially show a certain 
degree of increased FAF, which implicates the accumulation of lipofuscin. Chapters 2 
and 4 show that FAF may be a useful tool in the clinical evaluation of CACD and the 
follow-up of its progression, as well as in the diagnosis (and possibly the follow-up) of 
multifocal pattern dystrophy simulating STGD1. Lipofuscin accumulation was directly 
shown to be present in the only histopathological study on peripherin/RDS-associated 
disease that has been published to date, in a patient with butterfly-shaped pigment 
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dystrophy.78 The light-dependent formation of lipofuscin and its toxic constituents such 
as A2E may compromise RPE cell function in many ways, as discussed in Chapters 1 and 
2 of this thesis. These mechanisms may eventually lead to cell death through apoptosis, 
resulting in the chorioretinal atrophy that is seen in many advanced retinal dystrophies. 
Absent FAF in profound chorioretinal atrophy, for instance in stage IV CACD, is a direct 
consequence of RPE cell death.
 If peripherin/RDS is chiefly a structural protein, why is it that its mutations are 
associated with lipofuscin accumulation and increased FAF? The answer probably 
lies in the fact that an optimal photoreceptor OS structure is mandatory for efficient 
phototransduction and a normal lifespan of these OSs. Mouse models indicate that, 
whether the detrimental effect of a peripherin/RDS mutation is due to a haploinsufficiency 
or dominant-negative mechanism, the result of this mutant allele is a disorganization 
of the photoreceptor OSs.79,80 These malformed photoreceptors in mutant rds mice are 
more vulnerable to light, and have reduced phototransduction efficiency. 80-83 Contrary to 
Stargardt disease/STGD1, mutant peripherin/Rds does not appear to exert a strong direct 
influence on the visual cycle and all-trans-retinal accumulation. In the rds mouse model, 
heterozygously affected mice have irregularly shaped photoreceptor OSs, that are shed 
earlier and at a higher rate than in wild-type mice.84-86 Correspondingly, an increased 
formation rate and a higher load of phagosomes is observed in the RPE.82,83 These effects 
are more pronounced after prolonged light exposure and in sparsely pigmented eyes.82,83 
This is not surprising, as light exposure accelerates photoreceptor OS shedding,87 and 
melanin is photoprotective as well as anti-oxidative.88,89
As it is well-established that lipofuscin and A2E primarily originate from photoreceptor 
OS degradation products,51,90 the increased accumulation of lipofuscin and A2E in the RPE 
in autosomal dominant peripherin/RDS phenotypes appears to be secondary to abnormal 
photoreceptor OS structure and shedding. Provided that these mouse experiments could 
be extrapolated to the human situation, which is currently unclear, the aforementioned 
results also indicate that peripherin/RDS mutation-carrying patients that are frequently 
exposed to high levels of light are more likely to accumulate larger amounts of lipofuscin. 
The same could hold true for patients with lightly pigmented eyes. As a consequence, 
these patients could have earlier disease progression, given the fact that RPE lipofuscin 
accumulation may be an important factor in peripherin/RDS-related disease pathogenesis. 
2.2.  Central areolar choroidal dystrophy versus atrophic age-related 
macular degeneration 
Similarities between central areolar choroidal dystrophy and atrophic age-related 
macular degeneration
CACD and atrophic AMD show clinical similarities that can make the differential 
diagnosis between these disorders challenging. Peripherin/RDS-associated CACD may show 
a markedly decreased penetrance, which can mask the autosomal dominant pattern of 
inheritance. Conversely, familial cases of AMD may simulate an autosomal dominant 
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inheritance pattern, especially when the disorder manifests at a relatively early age. 
Some peripherin/RDS mutations associated with CACD, such as the p.Arg142Trp mutation 
described in Chapter 4, show a decreased expressivity. In these patients, the age at onset 
of visual loss may be well over the age of 55. The age at onset of visual loss may therefore 
overlap with that of atrophic AMD. Some CACD lesions even remain asymptomatic. 
A minority of CACD lesions may be associated with drusen-like abnormalities on 
ophthalmoscopy, which further complicates the distinction between CACD and AMD. In 
addition, geographic chorioretinal atrophy may be observed in stage III and IV CACD. 
Chorioretinal atrophy in both CACD and AMD shows a tendency to spare the fovea until 
relatively late in the course of the disease.91 Such initial foveal sparing may also be observed 
for instance in STGD1 and retinal dystrophy related to maternally inherited diabetes and 
deafness.92-94 There are several possible explanations for this intriguing phenomenon 
of foveal sparing, such as the observed increased vulnerability of parafoveal rods and 
S (“blue”) cones compared to the central M and L cones,95-98 as well as the presence of 
photoprotective macular pigment in the central fovea.94,99,100 Unlike rods, cones do not 
exclusively depend on the RPE for the regeneration of 11-cis-retinal, which could also 
contribute to their extended survival.41,101 In addition, cone outer segment turnover 
appears to be slower than rod outer segment turnover.40
Differences between central areolar choroidal dystrophy and atrophic age-related 
macular degeneration
Several differences between CACD and atrophic AMD may help to discriminate 
between these two conditions. In typical CACD cases, the age at onset is before the age 
of 55, and an autosomal dominant pattern of inheritance is observed. Early stages of 
atrophic AMD often show typical and numerous drusen or hyperpigmentation in the 
centre of the macula. Stage I and II CACD, on the other hand, are almost invariably 
characterized by an area of hypopigmentation. In contrast to CACD, areas of well-
demarcated chorioretinal (geographic) atrophy in atrophic AMD are usually bordered by 
drusen and/or hyperpigmentation, whilst lying in a round to oval zone of more discrete 
hypopigmentation in CACD. On FAF, CACD shows intensely increased FAF outside 
the areas of chorioretinal atrophy, whereas these areas often show less intense FAF in 
atrophic AMD. 
 In addition, the rate of progression of geographic atrophy (corresponding to absent 
FAF) appears to be more than double as high in atrophic AMD compared with CACD.102 
This is somewhat surprising, as one would intuitively expect early-onset hereditary 
macular dystrophies to progress at a higher rate. In AMD, large, soft, indistinct drusen 
with focal hyperpigmentation and/or a large RPE detachment, due to confluence of such 
soft drusen, highly increase the risk of development of geographic atrophy.103-105 The 
development of such advanced large drusenoid lesions generally requires a time span 
of several decades. Once these lesions have formed and have had the time to adversely 
influence the overlying RPE and photoreceptors, the “breaking point” of viability to 
irreversible apoptosis may be rapidly reached in this large area.106,107 Possibly, the RPE 
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is more resistant to the accumulation of A2E and its detrimental consequences in 
peripherin/RDS-related CACD, as compared to a sub-RPE accumulation of drusenoid toxic 
and inflammatory substances, which will be discussed in section 3 of this discussion. 
Still, this may at best be only part of the explanation of the observed differences in 
geographic atrophy progression between CACD and AMD.
2.3.  Multifocal pattern dystrophy simulating Stargardt disease/fundus 
flavimaculatus versus Stargardt disease/fundus flavimaculatus
Similarities between multifocal pattern dystrophy simulating Stargardt disease (STGD1)/
fundus flavimaculatus and Stargardt disease/fundus flavimaculatus
Stargardt disease (STGD1) is among the most common hereditary retinal dystrophies.108 
It has an autosomal recessive inheritance pattern, and is caused by mutations in the 
ABCA4 gene.109 Depending on the precise combination of genetic abnormalities in the 
ABCA4 gene, other retinal disorders may emerge, such as cone-rod dystrophy or retinitis 
pigmentosa.110 A conspicuous retinal abnormality in the fundus flavimaculatus subtype 
of STGD1 is the presence of irregularly shaped (“fish-tail” or “pisciform”) yellow-white 
flecks at the level of the RPE of the posterior pole, in the macula but also along and 
beyond the retinal vascular arcades.92,111 In time, these flecks may extend towards the 
equator, eventually merge, and become atrophic. 
 In peripherin/RDS-associated multifocal pattern dystrophy simulating STGD1 (MPD), 
similar flecks are observed that may show a similar evolution (Chapter 4). As shown in this 
thesis, these flecks in STGD1 and MPD have the same aspect on FAF. In both conditions, 
these lesions initially have a highly increased FAF signal.112 As mentioned previously, 
the photopic and scotopic full-field ERG eventually become affected in advanced MPD. 
Many STGD1 patients initially also have normal full-field ERGs,113-115 but may eventually 
develop generalized cone dysfunction,92,114,116-118 together with a more discrete panretinal 
rod dysfunction.114,116,119,120 Like in MPD, the presence or absence as well as the onset of 
full-field ERG abnormalities in STGD1 probably depends on the specific underlying 
mutations. Abnormalities of the EOG, indicative of generalized RPE dysfunction, have 
also been observed in significant numbers of MPD and STGD1 patients.92,111,115,121 
Differences between multifocal pattern dystrophy simulating Stargardt disease (STGD1)/
fundus flavimaculatus and Stargardt disease/fundus flavimaculatus
Even though there are striking similarities between MPD and STGD1, there are also obvious 
differences. First of all, MPD is caused by autosomal dominantly inherited peripherin/RDS 
mutations, whereas STGD1 follows the autosomal recessive inheritance pattern of ABCA4 
mutations. STGD1 patients, especially when affected with the fundus flavimaculatus 
subtype, often experience a severe decrease in visual acuity between the first and third 
decade.92,93,122-124 In MPD patients, on the other hand, the age at onset is generally in the 5th 
decade, and these patients generally retain a fairly good visual acuity for several decades. 
This corresponds well with the findings on FAF. After an early period of increased central 
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FAF in STGD1 lesions, these central lesions soon show largely decreased FAF, due to RPE 
atrophy. Central macular FAF changes in MPD, on the other hand, are often more discrete 
at first and are dominated by an increased FAF signal for a more prolonged period. This 
is compatible with increased RPE lipofuscin content without marked RPE atrophy in the 
earlier stages.51,125 The fluorescein angiogram in STGD1 often shows markedly reduced 
choroidal background fluorescence, the so-called “dark choroid”, whereas the choroidal 
background fluorescence appears normal in MPD.
 These differences between STGD1 and MPD may be explained by the essentially 
different pathogenetic processes in these two retinal dystrophies. Peripherin/RDS mainly 
has a structural function, whereas the ABCR protein functions as a retinoid transporter, 
which transports all-trans-retinal from the intradiscal to the extradiscal space, which 
is essential for proper visual pigment regeneration.126 This function is compromised in 
STGD1, and the resultant accumulation of all-trans-retinal in the photoreceptor outer 
segments leads to the formation of A2-PE in the photoreceptor outer segments. The 
overload of toxic substances in the photoreceptors probably compromises photoreceptor 
function more directly and quickly. After being phagocytosed by the RPE, this A2-PE is 
transformed to A2E and other toxic derivatives. Consequently, RPE levels of lipofuscin 
and A2E in STGD1 patients are 6 to 12 times higher than in normal control subjects,127-130 
corresponding with increased FAF in early STGD1.112,128 Changes in the size and 
distribution, and probably the total amount of RPE lipofuscin throughout the retina, may 
also account for the previously mentioned dark choroid on fluorescence angiography 
in STGD1.114,128-130 In STGD1, photoreceptors may degenerate secondary to atrophy of the 
lipofuscin-laden RPE, although primary toxic effects on photoreceptor function and 
viability, for instance inflicted by a high load of toxic A2-PE or A2-rhodopsin, are also 
plausible.48,131-133 The absence of a dark choroid on fluorescein angiography in MPD may 
be an indirect reflection of the difference in the level of RPE lipofuscin accumulation. 
As a result, the RPE may be able to cope with this stress and support the photoreceptors 
for a more prolonged period of time in MPD than in STGD1. The generally later onset 
of primary and/or secondary dysfunction of the central cones in MPD therefore likely 
accounts for the comparatively better visual acuity and prognosis of MPD. 
 Thus, although MPD and STGD1 share several characteristics, STGD1 often leads to 
marked visual loss earlier in life, due to different disease pathways. Quantitative FAF 
measurements, together with histopathological studies, may prove to be a useful non-
invasive imaging method to further differentiate these conditions. The finding of specific 
FAF patterns may also have prognostic implications, especially when combined with 
other functional information such as the full-field and multifocal ERG.112,118,134 In addition, 
FAF may prove to be valuable as an outcome parameter in future treatment trials in 
MPD and STGD1, as it is able to provide both morphological and functional information. 
At present, however, the quantitative measurements and quantative comparison of FAF 
encounters several difficulties. Factors that currently complicate FAF quantification are 
for instance the variability in the settings of the imaging camera, changes in the relative 
positioning of the patient and the camera, instability of the laser power over time, 
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interindividual variability of for instance refractive errors and optic media opacification, 
as well as variability in the dynamic metabolic processes influencing RPE lipofuscin.
2.4.  Phenotypic variability, non-penetrance, and possible genetic modifiers 
associated with peripherin/RDS-associated disease
Differential role of peripherin/RDS in cones versus rods
Although the peripherin/RDS protein is essential for normal photoreceptor OS formation 
in both cones and rods, peripherin/RDS appears to have distinct functions in cones 
versus rods.80,135 Consequently, peripherin/RDS mutations may also affect the phenotype 
differentially, ranging from preferential rod involvement (in RP), roughly equal cone 
and rod damage (in cone-rod dystrophy and MPD), to predominant cone involvement 
(in CACD). For example, rods are less able to cope with a lack of wild-type peripherin/
RDS than cones.84,86,136 In turn, peripherin/RDS intermolecular disulfide bonding appears 
more important in cones than in rods.135 This is most likely due to the differential 
structural requirements of the closed rod OS discs, that are covered by plasma membrane, 
compared to the open cone OS lamellae. Interaction of peripherin/RDS with ROM1 seems 
to be more important for cone lamellae maintenance.135 In addition, peripherin/RDS 
trafficking to the cone OSs is different from that in rods, and seems to be coupled to 
proper cone opsin localization.135 This is in contrast to rhodopsin trafficking in rods, that 
is independent of peripherin/RDS transport. Apart from its important structural role in 
photoreceptor OS formation, there are indications that peripherin/RDS could also be 
involved in signalling pathways, possibly even in the phototransduction cascade.137-140 
These functions may also be differentially affected in cones and rods. In the light of these 
substantial differences, the variable phenotypic consequences of different peripherin/RDS 
mutations makes perfect sense.
 In this perspective, the preferential involvement of central cones in CACD caused 
by the p.Arg142Trp peripherin/RDS mutation in this thesis is fascinating, especially 
when considering the fact that the great majority of peripherin/RDS mutations also 
cause significant rod and peripheral cone dysfunction, as reflected by full-field ERG 
measurements. The cause for such central cone involvement in p.Arg142Trp-related 
CACD may be extrapolated from experiments in the mouse models.
The amino acid change of a basic, polar, large arginine residue to the neutral tryptophan 
with its very different aromatic side chain could significantly affect peripherin/
RDS structure. The p.Arg142Trp change occurs near the cysteine residue on position 
150 (p.Cys150), which is essential for proper intermolecular disulfide bonding and 
subsequent higher-order peripherin/Rds oligomer formation in cones but not rods. 
In addition, its enables the interaction of peripherin/Rds with Rom1 in cones, which 
seems less important in rods.135 In cones, such biochemical interactions enable the 
normal formation of OS rim structures and lamellae, which is a prerequisite for normal 
photoreceptor function and phototransduction. A logical consequence is that the 
p.Cys150Ser mutation causes early-onset cone dystrophy in mice through a dominant-
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negative mechanism.135 The p.Arg142Trp mutation could therefore be envisioned to 
affect cone function in a dominant-negative manner by hindering the normal disulfide 
interactions of the nearby p.Cys150. The dominant-negative effect of p.Arg142Trp may 
depend on the degree of expression of the mutant allele, just like it was shown for the 
p.Arg172Trp mutation, that also predominantly affects the cones.141 The propensity 
for central cone involvement in p.Arg142Trp-associated CACD may be at least partially 
explained by the huge metabolic demand posed on these specific cones, which would 
make an optimal configuration of cone OS lamellae essential. The fact that cones do not 
rely as heavily on normal peripherin/RDS function compared to rods may account for the 
relatively late onset of visual loss in peripherin/RDS-related CACD and MPD, as compared 
to for instance STGD1.80,141
Genetic modifiers of peripherin/RDS-related disease
Still, the aforementioned findings do not explain the extreme intrafamilial variability that 
is observed with many peripherin/RDS mutations. Such observed phenotypic variablility 
also can not be explained simply by age differences. Therefore, largely unidentified 
genetic and environmental factors must exert an additional influence on the resultant 
phenotypic outcome. At present, this makes it difficult to establish genotype-phenotype 
correlations, even in supposedly monogenic retinal dystrophies. Apart from possible 
differences in dietary and smoking habits, as well as variations in light exposure,142 
which all probably contribute only marginally, genes that modify the expression and 
severity of peripherin/RDS mutations have to be implicated.
 A plausible candidate modifying gene is the ROM1 gene, which encodes the direct 
binding partner of peripherin/RDS in the assembly of heterotetramers that promote 
photoreceptor OS formation. However, our findings and other studies indicate that ROM1 
does not play an important role as a modifier of peripherin/RDS expression,143-145 besides its 
role in digenic RP.146,147 
Another possible genetic modifier is the RPE65 gene, for instance through the 
modulation of the susceptibility to light-induced retinal degeneration and rhodopsin 
regeneration.148-150 
Finally, another candidate modifier is the NR2E3 gene, which is a transcription factor that 
plays a role in photoreceptor (especially rod) differentiation and maintenance. This gene, 
which -when mutated- can cause enhanced S cone syndrome or autosomal dominant RP 
in humans,151-153 directly regulates peripherin/Rds expression in mice.154 Interestingly, NR2E3 
itself acts downstream and depends on the presence of the CRX and NRL gene, which are 
also key transcription factors involved in photoreceptor gene expression.72 Human CRX 
mutations are associated with autosomal dominant cone-rod dystrophy,155,156 autosomal 
dominant RP,156,157 as well as Leber congenital amaurosis.158 Autosomal dominant and 
autosomal recessive NRL mutations may also cause photoreceptor dystrophies with 
predominant rod degeneration.159,160 Therefore, peripherin/RDS expression may not only 
rely on a single genetic modifier, but may also be the result of the expression of several 
transcription factors.
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2.5.  Gene therapy perspectives in phenotypes caused by peripherin/RDS 
mutations
First of all, the delivery of the gene in gene therapy must be feasible in a safe and effective 
manner, with long-term results, for instance through a viral vector or via nanoparticles. 
After this is accomplished, the choice of a gene therapeutic approach depends on the 
type of peripherin/RDS mutation. 
In haploinsufficiency phenotypes, such as autosomal dominant RP caused by the 
p.Cys214Ser peripherin/RDS mutation,161 merely supplying enough wild-type peripherin/
RDS to the retina will probably be effective in rescuing the phenotype.162,163 
In dominant-negative peripherin/RDS mutations, such as the p.Arg172Trp and presumably 
p.Arg142Trp that mainly affect cones, the effect of the dominant mutant peripherin/
RDS protein needs to be eliminated. This could be accomplished with for instance 
ribozymes or small interfering/small hairpin RNA techniques.76,79,141,164 These methods 
may be especially effective in the dystrophies that are dominated by cone dysfunction, 
such as CACD, as cone photoreceptors do not rely as heavily on the amount of wild-type 
peripherin/RDS as rods do.80,86
In dominant-negative peripherin/RDS mutations that are most harmful to rods, such as 
p.Pro216Leu in autosomal dominant RP,165-167 the same RNA interference method can 
prevent the mutant protein from being formed, thus eliminating the dominant-negative 
component. However, as rods are more vulnerable to the remaining haploinsufficiency 
state, such phenotypes would probably also require gene replacement with wild-type 
peripherin/RDS.79
Besides gene therapy, the delivery of trophic factors such as ciliary neurotrophic factor 
or rod-derived cone viability factor may also prove to be beneficial.43,44,168-171 
Currently, the marked phenotypic variability of a single peripherin/RDS mutation and the 
lack of insight in its cause(s) would complicate decision making in which patients should 
be treated with gene therapy and when this treatment should commence.
3. Drusen and phenotypes characterized by drusen
Drusen are focal deposits of extracellular debris located between the basal lamina of the 
RPE and the inner collagenous layer of Bruch’s membrane.172-174 Although they are the 
characteristic lesions of age-related maculopathy and AMD,175 they are not specific for 
AMD. Drusen may be found in several other retinal phenotypes, as well as in association 
with systemic disease such as membranoproliferative glomerulonephritis (MPGN). 
Phenotypes displaying drusen(-like) lesions are associated with variants in a broad range 
of known genes (Table 7.1), and other thus far unidentified genes. Drusen in basal laminar 
drusen (BLD), AMD, and in MPGN type II have been reported to be quite similar on the 
level of ultrastructure and molecular composition.174,176,177 This is not surprising, as these 
three conditions are all associated with variants in the CFH gene.178 Different subtypes 
of drusen, such as hard and soft drusen, in for example AMD, may also show regional 
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differences in morphology, composition and physical properties.179 Drusen in conditions 
like Sorsby fundus dystrophy and malattia leventinese are probably compositionally 
different from drusen in CFH-related phenotypes, being dominated by accumulation of 
the specifically mutated proteins (TIMP-3 and EFEMP1, respectively).180,181
3.1. Age-related macular degeneration
AMD is the most frequently encountered retinal disease associated with drusen. The 
formation and evolution of drusen is a continuum: hard drusen may gradually become 
more numerous, merging and enlarging to soft indistinct drusen, which may further 
enlarge to form a large, “pseudovitelliform” drusenoid RPE detachment, which is 
often accompanied by pigmentary changes.103,104 Eventually, the latter lesions are 
often incompatible with normal retinal function, and generally lead to the death of 
photoreceptors and RPE cells, resulting in visual loss. Geographic atrophy is considered 
the end stage of drusen evolution.91,103 Drusen evolution and geographic atrophy 
formation may be complicated by choroidal neovascularization, which then further 
accelerates the process of visual loss. 
However, only a minority of persons with drusen actually develop late AMD, which is 
defined as geographic atrophy and/or neovascular AMD. It is estimated that individuals 
with hard drusen have a 1-3% chance to develop late AMD within a follow-up period of 
30 years.104 In contrast, patients with soft, indistinct drusen, have a 15-year cumulative 
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Table 6.1. 
 Retinal diseases other than AMD associated with drusen or drusen-like lesions.
Disease OMIM  Mode of  Associated  Reference(s) 
 phenotype inheritance gene
 number 
basal laminar drusen  126700 AR CFH this thesis
Doyne honeycomb   126600 AD EFEMP1 182 
retinal dystrophy     (fibulin-3) 
(malattia leventinese)
Sorsby fundus dystrophy 136900 AD TIMP3 183  
central areolar choroidal    215500 AD peripherin/RDS this thesis
dystrophy    
AMD-like late-onset     - AD peripherin/RDS 143
maculopathy
North Carolina macular    136550 AD unknown 184 
dystrophy   (MCDR1 locus)
AD, autosomal dominant; AMD, age-related macular degeneration; AR, autosomal 
 recessive; OMIM, Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/sites/
entrez?db=omim).
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incidence of late AMD of at least 18%.104,185,186 However, the interindividual period of time 
needed for such an evolution is widely variable, sometimes even between both eyes of 
the same individual.103          
 Apart from the CFH p.Tyr402His variant, several other CFH polymorphisms and 
haplotypes are associated with an increased risk of AMD.187-192 Several other haplotypes 
of CFH and adjacent regions, one of them containing a deletion of CFHR1 and CFHR3,193 
lower the risk of AMD.188,191,194 Interestingly, one of these haplotypes (CFH haplotype H2), 
which may carry a p.Val62Ile variant in the N-terminal region, lowers the risk not only 
of AMD, but also of atypical hemolytic uremic syndrome (aHUS) and MPGN.195-197 Many 
other genes, including several other complement-associated genes, have been found to 
be associated with AMD. A summary of these genes is given in Table 1.2 of the General 
Introduction. This broad range of genetic associations already alludes to the interesting, 
complex, and incompletely understood pathogenesis of AMD, which will be discussed in 
section 3.6 of this general discussion. 
It would be very relevant to reliably identify the small subgroup of patients with hard 
drusen that are at a high risk to progress to late AMD. After all, such information could 
give direction to the employment of therapeutic and, more importantly, preventive 
strategies. Despite the complex and multifactorial etiology of AMD, predictive models 
based on genetic risk factors, plasma inflammatory parameters, and/or environmental 
factors, may be very helpful in the assessment of an individual’s risk to develop AMD. A 
predictive model based on 5 common polymorphisms in the CFH, ARMS2/LOC387715, and 
C2/CFB genes estimated that persons who carry all risk genotypes have a 14-fold higher 
AMD risk compared to the general population, and a 285-fold greater risk than the lowest 
risk group.191,198 Alternatively or, more likely, in addition to such genetic prediction 
models, systemic levels of for instance complement factors, CRP, and interleukin-6 
may improve the risk assessment in AMD.199-202 Finally, the inclusion of environmental 
influences such as cigarette smoking and dietary habits may further enhance this 
predictive accuracy.199,203-205 
3.2. Basal laminar drusen 
Basal laminar drusen (BLD), also known as cuticular drusen or early adult onset, grouped 
drusen, is characterized by the presence of numerous small, “hard” drusen in the macula 
and often also in the (mid-) peripheral retina (Fig. 5.7). The diagnosis is often established 
at an earlier age than AMD, although the condition is not infrequently encountered by 
coincidence during a routine ophthalmological examination. BLD shows a characteristic 
“stars-in-the-sky” appearance on the fluorescein angiogram. Both the macular and 
peripheral drusen often show an abnormal FAF pattern, and the peripheral drusen 
resemble those in the macula on OCT. In our study, 32% of BLD patients had a positive 
family history for macular disease.
 As discussed in Chapter 5, BLD is also a genetically heterogeneous disorder. We 
demonstrate that BLD may be sporadic, without a clearly identifiable inheritance pattern 
and without mutations in the CFH gene. However, our findings also strongly suggest that 
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the BLD phenotype may be caused by autosomal recessive inheritance of a specific CFH 
variant together with the p.Tyr402His AMD risk variant. These specific BLD-associated 
CFH variants include p.Gln408X, p.Arg1078Ser, c.350+6TG, and p.Arg567Gly.21
3.3. Basal laminar drusen versus age-related macular degeneration
Similarities between basal laminar drusen and age-related macular degeneration
Drusen in BLD are highly similar to the small hard drusen that are seen in AMD (Fig. 5.4), 
also on the ultrastructural level.175,177 Hard drusen in AMD and BLD may both display a 
slightly pigmented border.206 Like in AMD, the small drusen in BLD may also merge and 
enlarge to soft drusen in the macula. With time, these soft drusen may coalesce to form 
a larger pigment epithelial detachment. Such an RPE detachment sometimes closely 
mimics vitelliform lesions that are seen in BVMD and AFVD both on ophthalmoscopy 
and on FAF, where it displays increased FAF intensity. The surrounding drusen on 
funduscopy and fluorescein angiography are important in the differentiation of this 
pseudovitelliform lesion from the aforementioned vitelliform lesions, as well as the 
normal EOG in contrast to BVMD. Like in AMD, BLD patients may eventually develop 
geographic chorioretinal atrophy or choroidal neovascularization, leading to significant 
visual loss. 
 The overlapping range in age at onset as well as the phenotypic similarities can 
complicate the differential diagnosis between BLD and AMD. This is not surprising, 
as we and others have shown that BLD and AMD may have a similar genetic and 
pathophysiological background. Not only is BLD associated with specific CFH mutations, 
it is also strongly associated to the p.Tyr402His AMD risk variant. The allele frequency 
of p.Tyr402His in BLD is 50-70%, compared to 55% in typical AMD, and 34% in normal 
controls.207 It can be difficult to recognize the postulated autosomal recessive pattern 
of inheritance in CFH-related BLD. This may be especially difficult in small families, but 
also in large families, as there may a pseudo-dominant inheritance pattern. This is due 
to the high carrier frequency of p.Tyr402His in the general population: 30-36% in the 
Northern European Caucasian population.199 In Asian populations, the p.Tyr402His 
carrier frequency is much lower, with 8% in Chinese,208 and 6% in Koreans.209 
Besides these similarities between BLD and AMD, there are several clinical differences 
that may aid in the differentiation of these two retinal diseases.
Differences between basal laminar drusen and age-related macular degeneration
A number of differences help to distinguish between the CFH-associated BLD phenotype 
and typical AMD. One should realize that “typical AMD” is a somewhat artificial term, 
as AMD itself shows considerable clinical heterogeneity. Nevertheless, the age at onset 
appears to be earlier in BLD compared to AMD. In atrophic AMD, the age at onset of 
visual loss is generally beyond 60 years, and often after the age of 70 years.210,211 Patients 
with neovascular AMD often are beyond 70 years of age when first experiencing visual 
loss.210,212,213 In BLD, we have found a mean age at onset of 50 years in the general group. 
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In the group of symptomatic patients with CFH mutations, the age at onset was 57 years. 
However, it should be noted that the range of the age at onset in BLD was broad, ranging 
from 35 to 70 years of age, and some patients did not experience visual loss at all. 
 A striking feature in BLD is the large number of “uniform small (25 to 75 μm), slightly 
raised, yellow subretinal nodules randomly scattered in the macula”, as described by 
Gass, that may extend to the (mid-)peripheral retina.214 The small drusen in BLD have 
been described to appear translucent on ophthalmoscopy with retroillumination,206 but 
this is a feature that may be easily overlooked. It is mainly the large number of macular 
and often peripheral drusen, as well as the clustering of densely packed drusen at a 
relatively young age that makes BLD a recognizable and separate clinical entity. In the 
patients with CFH-related BLD, these large amounts of BLD in the peripheral retina could 
be associated with numerous patches of profound chorioretinal atrophy (Fig. 5.9). This a 
feature that is not typically observed in AMD. When these peripheral changes in BLD are 
pronounced, they are easily identified on ophthalmoscopy. The affected sons (B-III.1 and 
B-III.2) of patient B-II.1 in Section 5.2 of Chapter 5 also illustrate, however, that early BLD 
changes may be overlooked on ophthalmoscopy, because they are more discrete and may 
mainly be located in the (mid-)peripheral retina. In these cases, fluorescein angiography 
with peripheral photographs is very useful, as these basal laminar drusen are clearly 
hyperfluorescent (Figs. 5.4 and 5.9I,J). 
 Interestingly, some patients with AMD may also show numerous small peripheral 
drusen, as illustrated in Figure 5.4 of Chapter 5. Apart from the later age at onset, 
such an AMD phenotype is actually hard to distinguish from BLD. These BLD-like AMD 
phenotypes appear to be situated in the grey zone that overlaps with BLD. Although at 
present speculative, this subgroup of AMD patients may also have specific underlying 
genetic determinants that overlap with BLD.
3.4.  Fundus autofluorescence in basal laminar drusen and age-related 
macular degeneration
Drusen in both BLD and AMD are associated with FAF abnormalities.215,216 Macroscopically, 
areas of increased and decreased FAF can be seen, that may display specific patterns.217 
The degree of FAF intensity will largely depend on the level of lipofuscin accumulation in 
the RPE, as well as the degree of RPE atrophy. When compared to retinal dystrophies such 
as STGD1, peripherin/RDS dystrophies, and BVMD, areas of increased FAF are generally 
less intensely autofluorescent in BLD and AMD. This probably corresponds to a milder 
elevation of lipofuscin and A2E concentrations. Individual hard and soft drusen often 
show a central area of decreased FAF, in most cases surrounded by an annulus of 
increased FAF corresponding to the outer dimension of the drusen.215 There are several 
possible explanations for this specific FAF pattern.215 
 First of all, the RPE stretched over a druse may contain a thinner layer of lipofuscin 
granules, therefore corresponding with reduced FAF.173 A second possibility may be 
that the central overlying RPE cells may release lipofuscin granules, which may then 
be phagocytosed by the RPE cells at the periphery of the druse.215 A third explanation 
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may be that drusen are associated with incipient atrophy of the overlying RPE.218 The 
observation that the overlying RPE also shows altered FAF suggests lipofuscin-related 
changes in RPE metabolism, that may eventually affect photoreceptor function.215,219,220 
This is supported by the finding that retinal areas of FAF abnormalities overlying drusen 
show dysfunction on microperimetry and scotopic and photopic fine matrix mapping 
with a modified Humphrey central visual field analyser.221,222 Histopathologic studies 
have shown that rod and cone outer segments overlying drusen show abnormalities 
that correlate with drusen size.106 A 30% reduction in photoreceptor density is seen in 
areas overlying drusen.107 Confluent drusen may become atrophic and may eventually 
lead to geographic chorioretinal atrophy, which itself is associated with several different 
FAF patterns.102,223,224 It is currently unclear if these different FAF patterns are the result 
of variable genetic backgrounds. Despite these interesting findings, the role of FAF 
imaging in clinical practice in AMD is currently negligible. The genotype-phenotype 
correlations and prognostic implications associated with specific FAF patterns in drusen 
and geographic atrophy have not been firmly established at present. The same applies to 
the role of FAF in neovascular AMD.
     
3.5.  Genotype-phenotype correlations in diseases associated with variants in 
the CFH gene
CFH-related disease: a phenotypic spectrum. CFH variants are associated with AMD, BLD, the 
severe renal diseases MPGN and atypical hemolytic uremic syndrome (aHUS), as well as 
intermediate phenotypes.195,225 As discussed in Chapter 5, the broad range of phenotypes 
associated with CFH variants constitutes a spectrum of diseases that have a common 
pathogenetic origin involving dysregulation of the alternative pathway of complement 
activation, whether in the fluid phase (plasma) or on the endothelium. Although at 
present speculative, certain variants in the CFH gene (and possibly other genes involved 
in the alternative complement cascade) could predispose to a retinal phenotype, whereas 
other variants principally cause renal dysfunction (Chapter 5). 
 Genotype-phenotype correlation model. In this thesis, we propose a genotype-phenotype 
correlation model for CFH-associated disease (Fig. 5.6). In this model, early-onset MPGN 
and aHUS, which have an onset in the first years of life and have a high mortality rate, 
are located at the severe end of the disease spectrum. These diseases are associated with 
pronounced systemic dysregulation of the complement alterative pathway. Early-onset 
MPGN and aHUS are the result of specific homozygous or compound heterozygous CFH 
mutations that lead to an absence of CFH in the serum. The clinical consequences are 
disastrous, as CFH is essential for the inhibition of the complement alternative pathway. 
Later-onset MPGN and aHUS, as well as other intermediate renal phenotypes, are caused 
by single heterozygous mutations, and their phenotypic outcome is modified by other 
genetic and environmental influences. Early-onset BLD is caused by a CFH mutation 
together with a heterozygous or homozygous p.Tyr402His CFH risk variant. AMD (with or 
without late-onset BLD) is associated with the p.Tyr402His risk variant or other specific 
CFH variants or haplotypes. In addition to these CFH variants, AMD requires other genetic 
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and environmental factors. The latter two diseases are situated at the milder end of the 
spectrum of CFH-related diseases. The classification “mild” refers to mortality rates and 
the degree of systemic and/or renal complement activation. Of course, the impact of the 
possible visual handicap caused by BLD and AMD can by no means be judged as mild. 
As in every gene that shows genotype-phenotype correlation, the proposed genotype-
phenotype correlation model for CFH is a simplification, that is meant as a global 
classification of the complex spectrum of diseases related to specific variants in this 
gene.
 Complement activation in AMD. Systemic complement activation does not only play 
a role in severe early-onset renal CFH-related phenotypes like MPGN: chronic systemic 
complement activation has also been found in AMD.226 Serum complement C3 activity 
may also be raised in AMD, although it may not be necessarily associated with the presence 
or absence of the p.Tyr402His risk variant.227 It is therefore possible that AMD associated 
with CFH and other complement gene variants is in fact a systemic disorder that becomes 
clinically manifest only in the eye. Alternatively, or in addition, AMD associated with 
complement gene variants may be the result of the triggering of the pathophysiological 
events only in a specific local environment with unique features - in this case the 
macula - that make it particularly susceptible. It should be noted, however, that the CFH 
p.Tyr402His variant also increases the risk of MPGN.228 In addition, p.Tyr402His may also 
be associated with an increased risk of cardiovascular disease, as well as Alzheimer’s 
disease,229-235 although these findings are at present not firmly established, as they 
are contradicted by other studies.236-239 The influence of the p.Tyr402His variant could 
therefore reach well beyond the macula.
 Genetic susceptibility to AMD. Preliminary studies indicate that carrying specific risk 
variants in the CFH gene may predispose to specific subtypes of AMD.207,240,241 Still, one 
must realize that AMD is a multifactorial disease, being the result of a complex interplay 
between the genetic background and environmental risk factors.242 The risk will increase 
with the summation of the number of inherited genetic susceptibility and protective 
variants, and may be modified by environmental influences. One theory, the “common 
disease/common variant” hypothesis, proposes that relatively high-frequency alleles 
within the population cause predisposition to common diseases.243 In the case of AMD, 
this has been clearly shown for the p.Tyr402His AMD risk variant in the CFH gene. Another 
theory is the “common disease/rare variant” hypothesis. This hypothesis states that the 
search of disease-causing genes for common diseases in large groups of unrelated patients 
is often pointless, as extensive allelic heterogeneity in such populations precludes the 
finding of strongly disease-associated genes.244 Proponents of this theory advocate large 
family studies to find gene variants that truly show strong disease association. 
Our analysis of the CFH gene in BLD families shows that these theories are not mutually 
exclusive. Several families with an early-onset drusen phenotype (BLD) in our study 
(Chapter 5) developed drusen only when carrying the common CFH p.Tyr402His risk 
variant in combination with a severe CFH gene alteration, such as the p.Gln408X 
nonsense mutation. The aHUS phenotype is another example of CFH-associated disease 
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with a high degree of non-penetrance and variable expressivity, that requires multiple 
factors to become clinically manifest. The risk of aHUS is also modified by common 
genetic risk polymorphisms.245-248 In addition, this disease may be triggered for instance 
by infection, pregnancy, and immunosuppressive agents.248-250 Another striking example 
of multifactorial CFH-related disease was provided by a study that described a patient 
who developed MPGN with an exceptionally late onset.251 This patient also developed 
“AMD” with BLD-like drusen and choroidal neovascularization. This patient carried 
numerous genetic risk factors for AMD, in addition to carrying a p.Cys431Tyr missense 
variant, supposedly a mutation, in exon 9 of CFH. In addition, this patient was a heavy 
smoker. Interestingly, proteomic and functional analyses detected plasma levels of CFH 
in the lower normal range and decreased levels of C3, suggesting a chronic activation of 
the alternative complement pathway. 
 These studies illustrate that carrying a rare genetic variant or mutation in CFH may 
not be sufficient to cause a certain disease. However, when these CFH variants are co-
inherited with several other common genetic susceptibility factors, they may result in 
clinical disease, especially when predisposing environmental factors are present. The 
multiple genetic and environmental factors that are assumed to be important in the 
pathogenesis of AMD are highlighted in the next section. An insight in the complex 
and captivating ontogenesis of AMD is deemed important, as it may serve as a paradigm 
for other complement-related phenotypes associated with drusen and their vision-
threatening complications, such as CFH-related BLD and drusen in MPGN.
3.6.  Pathogenesis of age-related macular degeneration: a complex paradigm for 
other phenotypes associated with drusen and CFH gene variants 
3.6.1.  Possible roles of CFH, complement activation, and other factors involved in 
inflammation
CFH and alternative complement pathway activation. CFH is expressed in several ocular 
structures including the retina, RPE and choroid, at a level that is comparable to the 
highest levels in the liver, where plasma CFH is synthesized.252 In vitro studies show that 
oxidized photoreceptor outer segments and oxidative stress in general decreases CFH 
expression by the RPE.253,254 However, individuals homozygous for the CFH p.Tyr402His 
AMD risk variant do not appear to have different levels of CFH transcription and CFH 
protein in the RPE and choroid, as compared to individuals without this risk allele.255 
They do have an approximately 2.5-fold higher level of C-reactive protein (CRP) in the 
choroid.255 CRP is a serum biomarker for chronic inflammation,256 and increased CRP 
levels significantly increase the risk of both cardiovascular disease and AMD.201,231,257 CRP 
and CFH are binding partners, and the p.Tyr402His risk polymorphism is located within 
the CRP binding site of CFH.256 As a consequence, the p.Tyr402His allele variant may 
impair proper CRP binding.258 Interaction of CRP with CFH has an inhibitory effect on 
complement AP activation, which may to a certain extent be impaired by the p.Tyr402His 
variant of CFH.199,256 Eventually, these pro-inflammatory changes and complement 
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activation lead to damage to host cells, especially in individuals with CRP haplotypes 
that result in higher levels of CRP in plasma and/or choroid.199 The increased levels of 
choroidal CRP may thus reflect a state of chronic inflammation, as a result of diminished 
complement-inhibitory activity in subjects carrying the p.Tyr402His AMD risk allele. 
Such effects may be reinforced by additional influences such as oxidative stress, which 
may decrease CFH expression by the RPE. 
 An important role for inflammatory mechanisms in drusen pathogenesis has been 
hypothesized by Hageman and colleagues.174,259,260 Drusen contain a large variety of 
inflammation-related proteins, for instance complement factors (C1q, C3, C5 and C5b-
9),174,261 acute phase proteins (such as CRP, vitronectin, and fibrinogen), complement 
regulatory proteins (such as CFH, CFB, MCP/CD46, and complement receptor 1/CR1), 
immune complexes, proteins involved in coagulation and fibrinolysis, as well as lipid 
components such as apolipoprotein E.174,253,262 Several of these complement- and drusen-
associated molecules, including CFH, CFI, CFB, C3, and C5, may also be synthesized 
and secreted by the RPE and retina itself.253,262,305 Interestingly, a similar deposition of 
complement factor C3 and immunoglobulin is also characteristically seen within the 
glomerulus of patients with membranoproliferative MPGN.263 The C5b-9 membrane 
attack complex that results from complement activation, is able to effectuate cell 
damage, for instance to the RPE and glomerular cells. 
 Classical complement pathway activation.The recently described associations of AMD 
with variants in the SERPING1 gene,264,265 which encodes the C1 inhibitor, as well as with 
variants in the C2 gene,266 could also imply a role for classical complement pathway 
activation in AMD. Although this association was not found by another study,267 such 
a role is not illogical. After all, apart from the possible cross-talk between the classical 
and alternative complement pathway,268,269 activation of the classical pathway also leads 
to the formation of C5b-9, through the terminal pathway that is shared by the three 
complement pathways. As mentioned before, this C5b-9 membrane attack complex is a 
well-known constituent of drusen and is implicated in cellular damage.174,261,270 
 Dendritic cells and toll-like receptors. Complement deposits and chemoattractant 
molecules secreted by the damaged RPE cells may recruit choroidal or blood-derived 
monocytes. These monocytes invade into Bruch’s membrane and the sub-RPE space, 
where they mature to dendritic cells,271 which form the core of the drusen. 
Dendritic cells secrete various cytokines, including TNF-α,272 which may further reinforce 
the pro-inflammatory feedback loop that is thought to lie at the basis of drusen formation 
and growth. Dendritic cells are able to sustain and amplify the local inflammatory 
activation through numerous mechanisms, including complement production and 
activation, immune complex formation, and extracellular matrix degradation.174,273 
Both dendritic cells and macrophages are also thought to play an important role in the 
stimulation of angiogenesis and the development of choroidal neovascularization in 
AMD.274-277
 Recently, a specific variant in the Toll-like receptor 3 (TLR3) gene was found to be associated 
with protection against geographic atrophy,278,279 although results on this matter are 
General discussion
6
362
somewhat conflicting.280 Toll-like receptors are a family of (recognition) receptors involved 
in innate immunity, that may trigger the expression of a multitude of pro-inflammatory 
factors. Specifically, TLR3, which is expressed both by the RPE and dendritic cells,281-283 
recognizes double-stranded RNA from viruses, may induce antiviral immune responses, 
and may trigger cellular apoptosis in response to viral infection.278,282-284 Toll-like receptors 
may also potentiate phagocytosis by the RPE and dendritic cells.284-286 Intriguingly, these 
findings could suggest a possible influence of viral infection in AMD pathogenesis.
The retinal pigment epithelium: chief conductor in health and disease of the aging retina.
 A pro-inflammatory shift in the aging macula. Aging is accompanied by a 2- to 4-fold 
increase in plasma levels of immune mediators such as tumor necrosis factor-α 
(TNF-α), interleukin-6 (IL-6), and CRP.287 An age-related immune dysfunction, known 
as immunosenescence, is reflected by changes in circulating inflammatory mediators. 
Such increased inflammatory markers are a strong predictor of AMD,199-202,288 but also 
of mortality, independently of other risk factors and co-morbidity.287 Similar changes 
in the aging immune system are seen in the neuroretina-RPE-choroid interface,289 such 
as for example an age-related increase in CFB expression.262 CFB is an activator of the 
complement AP, through its action as a C3 convertase in the presence of Factor D and 
properdin. Increased expression of CFB in the RPE is accompanied by the accumulation 
of complement C3 and C3a deposits at Bruch’s membrane and the RPE basal membrane, 
which is indicative of complement activation.262 Interestingly, TNF-α and IL-6 down-
regulate CFH synthesis by the RPE,253 whereas TNF-α up-regulates CFB production and 
C3 secretion by the RPE.262,290 An age-related increase of these inflammatory cytokines 
could therefore contribute to the shift towards increased complement AP activation and 
inflammation in the macular microenvironment. Complement AP activation appears 
to be critical in the formation of choroidal neovascularization.291-293 Therefore, it is 
plausible that specific AMD-associated variants in the CFB and/or CFH gene, and possibly 
other genes involved in the complement pathway, may alter the degree of macular 
complement activation, inflammation, drusen formation, and the development of 
choroidal neovascularization. 
 Pro-inflammatory consequences of lipofuscin formation, oxidative stress, and amyloid β deposition 
in the retinal pigment epithelium and drusen. Constituents of the age-related pigment 
lipofuscin, such as photooxidation products of A2E and bisretinoids, are able to activate 
the complement AP.294,295 In general, oxidative stress decreases CFH expression and leads to 
subretinal C3 accumulation.254,296 Oxidative damage to the RPE, damaging for instance its 
mitochondrial DNA,54,297 can increase the basal exocytosis of RPE cellular debris.290,298,299 
These RPE waste products presumably contain intracellular markers, including A2E, that 
are subsequently coated with complement.290,300 
 Drusen also contain amyloid β,270,301 a pro-inflammatory component that is also 
characteristically seen in Alzheimer’s disease plaques.302,303 Interestingly, amyloid β 
colocalizes with complement activation, not only in Alzheimer’s disease plaques,302,303 
but also in drusen, making it another candidate activator of complement in drusen.270,301 
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The amyloid β in drusen most likely originates from degenerate RPE cells.301 The 
concentration of amyloid β is highest at the edges of geographic atrophy, the region 
that is at high risk for further degeneration.304 However, it is unclear if the amyloid β 
deposition in drusen contributes to or is the result of AMD pathogenesis. Recent evidence 
suggests that direct binding of amyloid β to CFH and CFI may activate the complement 
AP within drusen by blocking the normal function of CFI, which is essential together 
with CFH for the cleavage and inactivation of C3b.305 In addition, amyloid β increases 
the production of monocyte chemoattractant protein-1 (MCP-1), and may thus attract 
and activate macrophages and microglia. These inflammatory cells may subsequently 
increase the expression of the complement AP activator CFB by the RPE, through the 
production of TNF-α and interleukin-1β.306 Therefore, amyloid β could play an important 
role in the initiation and/or propagation of local complement AP pathway activation 
and drusen formation, both through a decreased inhibition of the complement AP and 
through the indirect upregulation of an important activator, CFB. The apparently shared 
pathogenetic characteristics between AMD and Alzheimer’s disease are also supported 
by epidemiologic associations.307
 Complement coating may be beneficial for the clearance of RPE and Bruch’s membrane 
debris and retinal homeostasis.308 The preservation of a not-too-high complement 
activity may therefore prove to be important in therapeutic trials for AMD and other 
complement-related diseases that intend to use complement inhibitory therapies. 
However, in persons with an unfavorable genetic and environmental predisposition, the 
resultant exaggerated complement AP activation around sub-RPE cellular fragments and 
other waste products can form the core of drusen formation. This could be the start 
of a vicious circle of complement activation and damage, recruitment of monocytes by 
the anaphylatoxins C3a and C5a,309,310 that mature to antigen-presenting dendritic cells 
and macrophages.174,311 Apart from leukocyte recruitment, C3a and C5a may also directly 
induce expression of vascular endothelial growth factor (VEGF),312 one of the most 
prominent stimulators of angiogenesis and the formation choroidal neovascularization 
through the damaged Bruch’s membrane.313,314 It is therefore possible that induction of 
VEGF expression and leukocyte recruitment, as a consequence of oxidative damage and 
complement activation, may lead to choroidal neovascularization in AMD. 
3.6.2. Environmental factors and their interactions in age-related macular degeneration
Being a carrier of risk variants in CFH is neither necessary nor sufficient to develop AMD, as 
many carriers of these risk variants never develop AMD. Therefore, a complex interplay of 
genetic susceptibility factors must be implicated. These genetic susceptibility factors may 
interact with environmental influences, such as smoking, dietary habits, light exposure, 
infectious triggers, as well as structural factors in the anatomical microenvironment of 
the macula, such as aging changes in Bruch’s membrane.314
 Cigarette smoking. Smoking, an important source of oxidative stress, is a major 
environmental risk factor for the development of AMD, increasing the risk of AMD 2- to 
7-fold in current smokers compared to non-smokers.205,315-319 On theoretical grounds, the 
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negative influence of smoking on the development of AMD can certainly be explained. 
There are several possible links between smoking and complement activation. In vitro 
studies show that cigarette smoking alters the ability of CFH to bind C3.320 In addition, 
smoking is known to lower plasma CFH levels.321 Several studies indicate that cigarette 
smoking may work in synergy with the genetic background in conferring an increased 
risk of AMD development.199,322,323 For instance, the odds ratio of late AMD increases from 
11 in homozygous carriers of the CFH p.Tyr402His AMD risk variant, to 34 if these same 
homozygotes are current smokers,199 although another study does not support such 
an additive effect.324 As mentioned previously, synthesis of CFH by RPE cells is down-
regulated by oxidative stress and oxidized photoreceptor outer segments.253,254 Cigarette 
smoking may therefore be able to increase the level of activation of the complement AP, 
especially in subjects with specific CFH variants such as p.Tyr402His.199,325 
Besides an influence on complement AP activation, there are several other detrimental 
influences of tobacco smoke that could explain its strong association with AMD. Smoking 
damages the mitochondrial DNA,326 which is thought to play a significant role in AMD 
pathogenesis.297 In this respect, it is worth noting that the predicted LOC387715/ARMS2 
gene may encode a mitochondrial protein,327-329 and that smoking and carrying the 
p.Ala69Ser variant in this gene have a multiplicative effect.322,330 Smokers also have less 
protective macular pigment than non-smokers.322,331 In addition, plasma levels of VEGF 
are increased in smokers.332
 Dietary influences. Other important environmental factors that modify the risk of AMD 
are dietary habits. An increased risk of AMD appears to be associated with high vegetable 
fat intake,333,334 low dietary intake of antioxidants and zinc,335,336 and obesity.315,337,338 
Conversely, high dietary intake of zinc,335,339,340 the macular pigments lutein and 
zeaxanthin,340,341 as well as omega-3 poly-unsaturated fatty acids and fish may decrease 
the risk of the development of late AMD.205,334,342-345 Omega-3 poly-unsaturated fatty 
acids, that are found in high amounts in fat fish, appear to have an anti-angiogenic and 
neuroprotective effect,346-348 and the effect of dietary measures such as fish intake may 
depend on the underlying CFH genotype.325 The macular pigments lutein and zeaxanthin 
may also have a neuroprotective effect, besides their photoprotective function.99,349,350
The role of zinc and its supplementation in reducing the risk of AMD deserves special 
attention, as it illustrates the possible interactions of dietary measures with the 
underlying genotype and the resulting phenotype, as well as the difficulty to unravel these 
causal relationships. A large epidemiological study indicates that zinc supplementation 
not only results in a reduction of the risk of AMD progression, but this risk reduction 
probably differs strikingly when taking carriership of the CFH p.Tyr402His risk allele 
into account.339 Homozygous carriers of this risk allele taking zinc supplements had an 
11% reduction of the risk of AMD progression, whereas individuals with the homozygous 
low-risk genotype had a 68% risk reduction of AMD progression when taking zinc 
supplementation.339 
This effect may be explained by the possible role(s) of zinc in the complement system. 
Normally, binding of CFH to C3b leads to an acceleration of the decay of the complement 
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AP C3 convertase C3b,Bb and therefore inhibits complement AP activation. Zinc appears 
to have the same effect, and when present simultaneously at sufficient concentrations, 
CFH and zinc appear to show a cumulative effect.351 It is possible that this inhibitory 
effect of zinc on complement activation is more pronounced in the presence of the 
p.Tyr402 non-risk variant in CFH. However, the precise mechanism for this interaction 
between zinc and the CFH genotype is far from clear. As a matter of fact, some studies 
indicate that zinc is actually involved in the initiation of AMD in the zinc-rich retina.352-355 
Abnormally high zinc concentrations in the macula could initiate the oligomerization 
and precipitation of CFH proteins.354-356 CFH containing the p.Tyr402His risk variant 
shows a higher propensity to oligomerize.357 The effect of such oligomerization on CFH 
function is unclear, but some studies indicate a decreased complement AP regulatory 
effect, which would be directly contradictory to the aforementioned epidemiological 
findings. 
Whatever the mechanism may be, the aforementioned epidemiologic findings clearly 
point to a protective effect of zinc on AMD progression, that appears dependent on 
the underlying CFH genotype. These findings may therefore have huge implications for 
the development of preventive strategies. However, replication of these epidemiologic 
results is required and clarification of the underlying mechanism desired. To date, there 
is insufficient evidence that the general population should take antioxidant vitamin 
and mineral supplements to prevent or delay the onset of AMD.358 The effectiveness of 
antioxidant vitamin and mineral supplementation in halting the progression of AMD in 
patients that already have AMD comes mainly from one large trial.359
 Light exposure. Lipofuscin accumulation in the RPE, as well as FAF abnormalities, 
are not only found in monogenic retinal dystrophies, but are also seen in AMD.51,102,360 
However, it is at present unknown if lipofuscin has a direct pathogenic role in the 
development of AMD.360 There are several lines of evidence that support such a role. 
Exposure to light, especially from the short, “blue” wavelength, not only promotes the 
formation of lipofuscin and toxic lipofuscin-derived byproducts of the visual cycle such 
as A2E, but it also stimulates the formation of basal laminar deposits.51,361 These findings 
appear to correspond with the increased incidence of AMD in persons with above-average 
exposure to sunlight,362-365 although other studies did not confirm this association.366,367 
In a mouse model for ABCA4-mediated retinal dystrophies, light exposure, as well 
as vitamin A supplementation, accelerated lipofuscin and A2E accumulation in the 
RPE.127,368,369 Large case-control studies suggest that approximately 3% of AMD cases are 
associated with specific variants in the ABCA4 gene,126,370-373 the gene that causes STGD1 
when both alleles are mutated, although this association with AMD is probably mild and 
not undisputed.374-377 It could be envisioned, however, that mild variants in the ABCA4 
gene may modify the amount of A2E accumulation in AMD. With or without this link 
to ABCA4 variants, the finding of increased FAF and lipofuscin accumulation in AMD 
is interesting, as photooxidation products of A2E are able to activate the complement 
cascade and inflammation.294,295 Moreover, complement AP activation may be involved 
in light-induced photoreceptor degeneration.378 These findings therefore closely 
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approximate several factors that are associated with AMD: light exposure, RPE lipofuscin, 
oxidative damage, inflammation by complement activation, and drusen formation.
 Infectious triggers. Another intriguing finding is the association between Chlamydia 
pneumoniae exposure and AMD.379,380 In homozygous p.Tyr402His CFH risk variant 
carriers, the risk of AMD progression increases from almost 2.5-fold to approximately 
12-fold when these subjects also have high antibody titers to Chlamydia pneumoniae.381 
The possible association between Chlamydia pneumoniae infection and AMD does not 
appear to be related to the underlying CFH genotype, although Chlamydia pneumoniae is 
able to activate the complement AP.382 In addition, the association between a variant 
in the Toll-like receptor 3 (TLR3) gene and atrophic AMD opens the possibility of a role for 
viral infection in AMD pathogenesis,278 as TLR 3 is involved in the host defense against 
viruses.282 Although these possible associations with infection are far from firmly 
established, they are not that far-fetched, as the complement system plays a pivotal role 
in innate immunity against infectious invaders.383
All in all, the aforementioned findings illustrate the complex mechanism of genetic 
predisposition, systemic and local immunological factors, and environmental influences 
that may be associated with the development of drusen and its related retinal diseases. 
The aging macula is subject to a constant attack of factors that promote the activation 
of the immune system. It is therefore in great need of the scarce protective factors that 
are at its disposition, such as the complement inhibitor CFH. A hereditary sensitivity 
to an imbalance of these factors could have disastrous consequences for the macula in 
the long term. The balance in the macular immunological microenvironment could 
be further disturbed and accelerated by environmental factors such as smoking, light 
exposure, and adverse dietary habits. The propensity of lesions to evolve towards either 
chorioretinal atrophy, choroidal neovascularization, or both, could depend on variations 
in the delicate balance between these many influencing factors.
4.  Anatomical location and multifocality of lesions in retinal 
disease
The preferentially affected retinal area in hereditary retinal disease may be highly 
variable. Gene mutations that mainly affect rod physiology are of course more likely 
to cause phenotypes that affect the rod-dominated peripheral retina, such as retinitis 
pigmentosa. Conversely, some mutations may be more detrimental to the cones that 
densely populate the central macula, leading to central cone dystrophies such as 
central areolar choroidal dystrophy. The resultant phenotype is to a certain degree age-
dependent. For instance, older affected individuals are more likely to show a larger and/
or higher numbers of lesions, that are more often atrophic. However, the intrafamilial 
and intraindividual variation of lesions in individuals carrying an identical mutation can 
not be explained purely on the basis of these age differences. Apart from the previously 
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discussed modifier genes that may be involved, the following factors also likely contribute 
to such conspicuous variability.
 Gene expression of the various structures of the photoreceptor-RPE-Bruch’s membrane-
choriocapillaris complex shows considerable topographical variation.384-387 Moreover, 
the spatial expression of retinal genes may vary with age.386,388,389 There are clear age-
dependent differences in the physiology and spatial distribution between cone and rod 
photoreceptors throughout the retina: for instance, cones show a prolonged survival 
as compared to the parafoveal rods.96,390,391 Like the photoreceptors, RPE cell shape and 
density also shows topographical variation.392 Functional RPE cell properties, such as 
enzyme activity, also vary with the retinal location.393 As expected, macular RPE cells show 
the highest enzyme activity.393 Since the RPE cells in the macula have to perform at the 
highest level, as they are serving the highest density of photoreceptors, this most likely 
accounts for the largest amount of RPE lipofuscin and A2E in this part of the retina.51,394,395 
Apart from lipofuscin and A2E, the macula contains higher amounts of melanin and 
complex granules such as melanolipofuscin and melanolysosomes compared to the 
extramacular region.392,396,397 Again, the relative proportion of these substances changes 
with age. Bruch’s membrane and the choriocapillaris also show marked differences 
between macula and peripheral retina.398-400 Environmental influences that may play an 
additional modulating role, depending on an individual’s susceptibility, include factors 
such as dietary habits,341,348,401 sunlight exposure,142,362,363 and smoking.402 These factors 
may all be involved in the different propensity mutations to affect different regions of 
the retina.
 Stargardt disease/STGD1, multifocal pattern dystrophy simulating STGD1, multifocal 
vitelliform dystrophy, as well as drusen in BLD and AMD all share a remarkable feature: 
multifocality of lesions, that are interspersed by areas of normal-appearing retina. It may 
seem puzzling why some retinal areas show little abnormalities, whereas other areas are 
obviously affected. However, there are many underlying variables that may account for 
this observation.403 
The density and distribution of specific photoreceptors, for example, shows considerable 
variation. Such variation is not only seen between individuals, but also in the same 
retina, and even between two adjacent RPE cells.95,404 The relative amount of S, M, and L 
cones per RPE cell is also highly variable.404,405 A genetic defect that preferentially affects 
a specific cone subset may therefore cause dysfunction of (groups of) RPE cells that serve 
a large population of this cone subtype. In a similar manner, local variations in Müller 
cells could contribute to multifocality of lesions.101,406 Focal degenerative processes 
may thus depend on the random variation of local cell populations. The RPE itself also 
exhibits striking cell-cell variability in for instance melanin and lipofuscin content, as 
well as the expression of several proteins. 
Another explanation of multifocality and interindividual phenotypic variation may 
be found in genetic and epigenetic mosaicism and modification of the photoreceptors 
and RPE.407 The term genetic mosaicism refers to differences between groups of cells 
and even individual cells due to differential gene expression.408 Epigenetic modification 
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refers to mechanisms of genetic modification that are heritable but do not involve direct 
alteration of the DNA sequence.409 This can be accomplished through mechanisms such 
as hypermethylation of gene promoters and covalent modification of histones. As a 
result, gene expression may be altered not only on the panretinal level, but also on the 
focal level, leading to multifocality of lesions. 
 These findings illustrate the many possible interindividual, intraindividual, 
intraretinal, and even intercellular differences between the numerous retinal structures 
that are important for retinal function. In this sense, uniformity of a clinical picture 
would be more surprising than the variability that is often observed.
5. Future perspectives
There is a great need for therapies that can actually stop the progression of the 
degenerative process in inherited retinal disease, rather than trying to control end-
stage complications like choroidal neovascularization. Information about the genetic 
background gives a valuable insight into the pathophysiological mechanisms that 
underly a hereditary retinal disease. This, in turn, will undoubtedly result in future 
therapeutic regimens aimed at preventing or stopping the disease progression.410-413 
 The development of therapeutic strategies. With regard to these future treatment options, 
there are many difficult questions that need to be answered, concerning who should be 
treated, and how and when treatment should be started. Ideally, the identification of 
disease-associated genetic and environmental factors will elucidate the pathophysiological 
mechanisms to such an extent that preventive measurements can be implemented safely 
and in an optimal time frame. 
However, not all interventions require revolutionary techniques like gene therapy. 
Behavioral changes, for instance refraining from smoking and adapting optimal dietary 
habits, already appear to be realistic and effective goals in lowering the risk of AMD. The 
effectivity of these measures has, to date, not been firmly established in “monogenic” 
hereditary retinal dystrophies. 
In retinal dystrophies associated with for example peripherin/RDS and BEST1 mutations, 
but even more in AMD, the feasibility of additional interventions such as gene therapy 
is complicated by incomplete gene penetrance, a relatively low magnitude of risk 
and possible interactions with environmental factors.242,410 In these cases, it may be a 
challenging task to develop proper cost-benefit analyses of treatments that concurrently 
have the lowest probability of side-effects. Treatments such as gene therapy and cell 
transplantation will first be developed for the retinal dystrophies that are relatively 
frequent and have the highest degree of visual impairment.414,415 After all, the benefit 
of treatment will more easily outweigh the possible risk of intervention in these cases. 
However, as more experience is gained with these and other gene therapeutic strategies, 
the number of patients that are eligible for a certain form of gene therapy will undoubtedly 
expand. It could be envisioned that, in the future, the type of underlying genetic defect 
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may ultimately determine the choice of treatment for a given retinal dystrophy, and an 
individual’s response to such treatments.
 Especially in the highly variable peripherin/RDS- and BEST1-associated phenotypes 
described in this thesis, careful patient selection and proper outcome parameters are of 
the utmost importance in the design of clinical trials.416 For the right patient selection, 
it is essential to have sufficient knowledge about the natural history and clinical 
characteristics of the disease. The confounding variables should be identified, such as 
the influence of modifier genes, systemic diseases, as well as dietary and environmental 
influences. The choice of suitable outcome parameters is a delicate issue. Measurement 
of visual acuity, static and kinetic perimetry, FAF, OCT and (multifocal) ERG may all prove 
to be useful parameters. Which tests are eligible to be used as an outcome parameter, 
depends on which clinical parameters have to be included to test the treatment efficacy, 
and how sensitive these tests are to reliably record significant differences. 
The aforementioned lack of predictability of the phenotypic consequences of peripherin/
RDS and BEST1 mutations makes it particularly difficult to provide adequate genetic 
counseling to the patient. This applies not only to clinically affected individuals, but 
even more to asymptomatic carriers of genetic risk factors. In this regard, the possible 
psychological burden of knowing to be at risk for a certain disease should not be 
underestimated. 
 Suitable animal models, large-scale epidemiological studies and randomized-
controlled trials are all important for the development of appropriate preventive and 
therapeutic strategies. In the case of retinal dystrophies such as those associated with 
peripherin/RDS and BEST1 mutations, as well as retinal disease such as BLD caused by 
compound heterozygous CFH gene variants, one gene is predominantly responsible 
for the pathophysiological sequence. In these retinal diseases, it may seem a little less 
difficult to disentangle the web of causality than in AMD. However, large epidemiological 
studies are hardly feasible because these phenotypes are relatively rare. The development 
and improvement of proper animal models is invaluable in these cases, for instance to 
develop accurate gene therapeutic strategies.141,417-421 
 Pharmacogenetics and complement inhibition. Having a specific genetic profile may 
modify ones likelihood of response to specific therapies or dietary measurements. For 
example, individuals with the low-risk AMD CFH genotype (p.Tyr402/p.Tyr402) may 
benefit more from specific nutritional supplements such as zinc than those with the 
high-risk genotype (p.His402/p.His402).339 Preliminary studies indicate that patients 
who are homozygous for the CFH p.Tyr402His AMD risk allele respond less favorably to 
treatment of neovascular AMD with intravitreal injection of bevacizumab.422,423 On the 
other hand, patients with neovascular AMD who carry two “normal” p.Tyr402 alleles in 
CFH appear to fare worse after treatment with photodynamic therapy than patients with 
at least one p.Tyr402His AMD risk allele.424 Ideally, one might envision a personalized 
“pharmacogenetic” approach, using a preventive and therapeutic strategy tailored to 
the individual patient with his or her specific genetic profile and lifestyle.425 The genetic 
profile would then considerably influence decision making in the choice of a specific 
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treatment and the advice on specific dietary and lifestyle changes. 
 As AMD and BLD are tightly linked to complement activation, inhibition of such 
complement activation could be an attractive preventive and/or therapeutic approach. 
Several possible agents can be used for this purpose.426,427 Compstatin, for instance, is 
a potent and selective inhibitor of C3, the central component in the complement 
cascade.428-430 Another potential therapeutic candidate for complement inhibition 
in AMD and BLD is eculizumab. Eculizumab is a humanized monoclonal antibody 
directed against C5, that blocks the proinflammatory and cytolytic effects of terminal 
complement activation.431 In a clinical context, eculizumab has already been approved 
for the treatment of paroxysmal nocturnal hemoglobinuria.431 CD59, which blocks the 
formation of the C5b-9 membrane attack complex, is another potential therapeutic agent 
that was shown to inhibit the formation of choroidal neovascularization in mice.293 The 
supplementation with normal CFH or the upregulation of normal CFH is yet another 
possible future therapeutic route.
 But how and when should these complement inhibitors be administered? Systemic 
administration of such inhibitors does not seem an attractive approach in AMD and 
BLD, as the complement system is an essential part of innate immunity. Systemic 
complement inhibition therapy would at least have to restore the required delicate 
balance of complement activation in the complement pathways. This becomes even 
more complicated given the fact that marked inter- and intraindividual variations of 
complement concentrations are observed. Thus, intraocular delivery of complement 
inhibitors appears a safer and more feasible approach. Such topical complement 
inhibition may be achieved through intravitreal injections, an intravitreal long-term 
delivery device, or - most elegantly - eye drops. The first two options are more invasive, 
but probably more powerful in reaching their target, the retina, as eye drops face the 
problem of limited penetration to the posterior segment of the eye. 
 Even when complement inhibitors are administered locally in the eye, there are several 
potential drawbacks of such therapy. When chronically exposed to complement inhibitors, 
the eye may also become increasingly susceptible to inflammation and infections. In 
addition, one should bear in mind that the formation of drusen and its complications 
in AMD and BLD most likely is the result of many years of local complement activation 
and other processes in the web of inflammatory events. Administration of complement 
inhibitors in eyes with advanced, confluent drusen, choroidal neovascularization, 
or geographic atrophy therefore seems pointless because the time of intervention is 
probably too late in these cases. Ideally, such therapy should thus commence in the 
earlier drusen stages. However, only a small minority of such lesions eventually evolve 
to advanced AMD, and this process often takes several decades.103,104 Early invasive 
therapeutic interventions such as intravitreal injections or implants therefore appear 
unreasonable. Decision making on who should be treated will become much easier with 
solid information on a patient’s individual genetic and environmental risk profile.191,198
 The aforementioned studies illustrate that promising therapeutic perspectives 
become more and more realistic. Nevertheless, numerous unknown variables and 
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difficulties still have to be cleared up, such as unknown gene-gene interactions, gene-
environment interactions, epigenetic variations, as well different treatment options and 
variables. Again, one should definitely have regard for the psychological consequences 
for a patient of knowing to be “at risk” for a certain disease. Therefore, diagnostic and 
therapeutic decisions on these complex issues in individual patients should primarily be 
made in dialogue with the patient.
 The impact of retinal disease and visual handicap. The psychological and social 
impact of suffering from macular degeneration or a retinal dystrophy should not be 
underestimated.432-436 In patients with AMD, for instance, the rate of depressive disorder 
is twice that found generally among elderly people living in the community.432 Visually 
impaired people are overrepresented in residential care homes,437 where visual impairment 
is associated with a higher prevalence of depression.438 In this regard, increased public 
awareness of retinal disease and its impact is needed, as less than 10% of the population 
is aware of conditions such as AMD.439 Better information and support of the patient and 
his or her environment, tailored rehabilitation measures, and continuous evaluation of 
interventions may not only increase visual abilities, but also improve patient satisfaction 
and psychological well-being. 
Since the first description of AMD, BVMD, and STGD1, more than a century ago, huge 
progress has been made in the clinical and genetic characterization of these and related 
retinal degenerative disorders, as well as in the understanding of their pathogenesis, 
especially in the last decade. The first effective treatments for neovascular AMD have 
emerged and constitute a true revolution for ophthalmologists and, more importantly, 
the affected patients. To date, treatment options of patients with retinal dystrophies 
and atrophic AMD are very limited, although the exciting first steps in these areas are 
encouraging.141,163,440-445 We sincerely hope that the findings described in this thesis will 
contribute to the development of effective preventive and therapeutic interventions in 
the near future.
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Summary
More than four decades after it was postulated that different retinal dystrophies are 
determined by different genes, this hypothesis has been proven to be unmistakably 
true. However, mutations in one gene do not simply cause one disease. This thesis shows 
that a single gene mutation can be associated with a broad range of retinal phenotypes. 
Moreover, a single mutation in the same family may be associated with strikingly 
different retinal phenotypes. Such broad phenotypic variation can only be explained by 
the additional influence of modifying genes and environmental factors. Conversely, a 
particular phenotype, such as multifocal vitelliform dystrophy or basal laminar drusen, 
can be genetically heterogeneous. Some phenotypes can be remarkably similar. Central 
areolar choroidal dystrophy and basal laminar drusen, for instance, may closely mimic 
age-related macular degeneration. Multifocal pattern dystrophy simulating Stargardt 
disease/fundus flavimaculatus can be easily confused with Stargardt disease (STGD1). 
In this thesis, the clinical characteristics and molecular genetic background of several 
of these phenotypes were studied elaborately, which enables a better comparison and 
differentiation of such conditions.
 Chapter 1 serves as a general introduction on retinal anatomy and function. The 
basic principles of molecular genetics are addressed, as well as the general clinical and 
genetic aspects of retinal dystrophies and age-related macular degeneration.
 Chapter 2 offers an introduction on the theoretical and practical background 
of fundus autofluorescence (FAF). FAF imaging is able to visualize lipofuscin and its 
precursors in the retinal pigment epithelium (RPE). Lipofuscin is a mixture of substances 
that contain autofluorescent fluorophores. These fluorophores chiefly originate from the 
photoreceptor outer segments. Various retinal dystrophies demonstrate abnormalities in 
the accumulation of these fluorophores. Consequently, a broad range of characteristic 
FAF patterns may be observed in these retinal dystrophies. FAF imaging appears a useful 
additive tool in the diagnosis and follow-up of various retinal degenerative disorders, 
including those decribed in this thesis.     
 Chapter 3 is dedicated to the phenotypes caused by mutations in the BEST1 gene. 
Section 3.1 reviews the BEST1 gene and the associated ocular phenotypes caused by BEST1 
mutations. The BEST1 gene encodes the bestrophin-1 protein, which is localized in the 
RPE. Bestrophin-1 presumably functions as a volume-sensitive Ca2+-dependent Cl- channel 
that regulates ion flow across the RPE. In addition, it influences intracellular Ca2+ 
concentrations by regulating voltage-dependent Ca2+ channels. Mutations in the BEST1 
gene have been found in Best vitelliform macular dystrophy, adult-onset foveomacular 
vitelliform dystrophy, autosomal dominant vitreoretinochoroidopathy, the microcornea, 
rod-cone dystrophy, cataract, posterior staphyloma (MRCS) syndrome, and autosomal 
recessive bestrophinopathy. The latter three phenotypes are associated with ocular 
developmental abnormalities that extend well beyond the retina. This points to a role 
for bestrophin-1 in normal ocular development, in addition to its aforementioned roles 
in ion homeostasis. To a certain extent, BEST1 mutations and the associated phenotypes 
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comply with a genotype-phenotype correlation model.
 Section 3.2 is a detailed clinical and molecular genetic analysis of 20 patients 
with Best vitelliform macular dystrophy from 15 different families, who all carried a 
mutation in the BEST1 gene. Eight different BEST1 mutations were found, including two 
novel mutations. A broad phenotypic variability was observed, even in association with 
a single BEST1 mutation. As much as 60% of the macular lesions could not be classified 
as a typical stage of Best vitelliform macular dystrophy. These findings complicated the 
establishment of distinct genotype-phenotype correlations. FAF and optical coherence 
tomography, especially when used in combination, proved to be very useful non-invasive 
imaging methods for the phenotyping and follow-up of Best vitelliform macular 
dystrophy patients. These imaging techniques are able to visualize abnormalities within 
vitelliform lesions that are not seen on ophthalmoscopy and fluorescein angiography. 
As such, FAF and optical coherence tomography also provide a valuable insight into the 
pathogenesis of Best vitelliform macular dystrophy.
 Section 3.3 describes the clinical and genetic findings in multifocal vitelliform 
dystrophy. Multifocal vitelliform dystrophy is shown to be both clinically and genetically 
heterogeneous. Fifteen patients with multifocal vitelliform lesions were studied, as well 
as their affected family members. Nine of these 15 patients (60%) carried a mutation 
in the BEST1 gene. Seven different BEST1 mutations were identified, including 4 novel 
mutations. The electro-oculogram was abnormal in all patients with a BEST1 mutation. 
The age at onset of visual loss was highly variable, as was the number and size of the 
vitelliform lesions outside the macula. However, the appearance of the lesions outside 
the macula was quite similar to the central vitelliform lesion on ophthalmoscopy, 
FAF, and optical coherence tomography, despite the fact that they were smaller. The 
findings in this study indicate that a multifocal vitelliform response is associated with, 
but not exclusive to, mutations in the BEST1 gene. Multifocal vitelliform dystrophy in 
patients with a BEST1 mutation and an abnormal electro-oculogram can be considered a 
multifocal variant of Best vitelliform macular dystrophy.
 In Chapter 4, section 4.1 serves as a review of the peripherin/RDS gene and the broad 
spectrum of retinal dystrophies caused by mutations in this gene. The peripherin/RDS 
protein is a structural protein that plays an important role in the morphogenesis of the 
photoreceptor outer segments. Mutations in the peripherin/RDS gene may first of all cause 
various autosomal dominant macular dystrophies. These include three phenotypes that 
have been classified as pattern dystrophies: butterfly-shaped pigment dystrophy, adult-
onset foveomacular vitelliform dystrophy, and multifocal pattern dystrophy simulating 
Stargardt disease/fundus flavimaculatus. Other peripherin/RDS-related macular dystrophies 
are central areolar choroidal dystrophy and age-related macular degeneration (AMD)-
like late-onset macular dystrophy. Apart from these macular dystrophies, peripherin/RDS 
mutations may also cause cone-rod dystrophy, which shares ophthalmoscopic and FAF 
features with central areolar choroidal dystrophy. In addition, mutations in peripherin/
RDS are among the most frequently identified mutations in autosomal dominant 
retinitis pigmentosa. Finally, a specific peripherin/RDS mutation causes digenic retinitis 
Chapter 7
405
pigmentosa, when co-inherited with a mutation in the ROM1 gene. A single peripherin/
RDS mutation may cause an intriguingly broad range of phenotypes, even within a single 
family, which makes it difficult to recognize consistent genotype-phenotype correlations 
in peripherin/RDS-related retinal dystrophies.
 Section 4.2 is the largest clinical and genetic study that has thus far been published 
on central areolar choroidal dystrophy (CACD), describing a group of 103 CACD patients. 
Follow-up data were available for 42% of the patients, with a follow-up period up to 35 
years. This specific macular dystrophy was shown to be caused by autosomal dominant 
inheritance of a p.Arg142Trp peripherin/RDS mutation in 95% of the patients in our 
study. This high percentage of p.Arg142Trp mutations is most likely due to the fact that 
peripherin/RDS p.Arg142Trp is a relatively frequent founder mutation in the southeast 
region of the Netherlands. The remaining CACD patients, who were members of the 
same family, carried a p.Arg172Gln mutation in peripherin/RDS. Lesions corresponded to 
typical CACD stages in virtually all patients. Peripherin/RDS p.Arg142Trp-associated CACD 
was shown to be a central cone dystrophy phenotype. A remarkable variability in disease 
severity was observed, and non-penetrance was seen up to the age of 64, in up to 21% of 
mutation carriers. The overlapping age at onset and similar clinical features of CACD 
and atrophic age-related macular degeneration, together with the decreased penetrance 
of the p.Arg142Trp peripherin/RDS mutation, can make the differential diagnosis between 
these conditions challenging.
 Section 4.3 is the first study that specifically analyzed multifocal pattern dystrophy 
simulating Stargardt disease/fundus flavimaculatus (MPD), an autosomal dominant 
pattern dystrophy of the retina. Mutations in the peripherin/RDS gene were found to be 
the major cause of this phenotype. We describe nine different peripherin/RDS mutations, 
including six novel mutations, that were found in 10 different MPD families. All patients 
with peripherin/RDS-related MPD showed a retinal dystrophy characterized by irregular 
yellow-white flecks in the posterior pole. These flecks were highly similar to those 
observed in the fundus flavimaculatus subtype of Stargardt disease, which is caused 
by autosomal recessive mutations in the ABCA4 gene. Clinical characteristics of MPD 
that may help to distinguish MPD from Stargardt disease are the autosomal dominant 
inheritance pattern, the relatively late age at onset of visual loss, and the absence of 
a “dark choroid” on fluorescein angiography. However, the decreased penetrance and 
markedly variable expressivity of several of these peripherin/RDS mutations may complicate 
the differentiation between MPD and Stargardt disease. In these cases, analysis of the 
ABCA4 and peripherin/RDS genes is especially helpful.   
 Chapter 5 discusses the clinical and molecular genetic findings in phenotypes 
associated with variants in the complement factor H (CFH) gene, with an emphasis on 
the phenotypes associated with drusen, the hallmark lesions in age-related macular 
degeneration. Drusen are yellow-white deposits between the RPE and Bruch’s membrane. 
The CFH protein is a multifunctional protein, that primarily plays a role in the inhibition 
of excessive activation of the alternative pathway of the complement cascade. The 
complement cascade is an essential part of innate immunity. 
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Section 5.1 extensively reviews the spectrum of phenotypes associated with variants 
in the CFH gene. This phenotypic spectrum includes renal phenotypes, such as 
membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome, 
as well as ocular phenotypes, including basal laminar drusen and AMD. In addition, 
several overlapping clinical entities associated with CFH gene variants are discussed. An 
interesting common feature of age-related macular degeneration, basal laminar drusen, 
and membranoproliferative glomerulonephritis, is the presence of drusen, although 
these drusen appear with a different age at onset. This common feature of drusen may 
be explained by a partially similar pathogenetic background, involving an abnormally 
active alternative complement pathway.
The phenotypic consequences of CFH variants depend on their differential impact on 
the regulatory function of plasma- and surface-bound CFH. Therefore, distinct genotype-
phenotype correlations can be observed. In this thesis, we discuss these correlations, and 
we propose a genotype-phenotype correlation model for CFH-related diseases.
 In section 5.2, the role of the CFH gene was evaluated in 30 patients from different 
families with early-onset basal laminar drusen. The phenotype of basal laminar drusen 
is characterized by an innumerable amount of small drusen in the macula, and often 
scattered throughout the entire fundus. These drusen correspond to a characteristic 
“stars-in-the-sky” picture on the fluorescein angiogram. We show that basal laminar 
drusen is a genetically heterogeneous phenotype, as we found four different CFH gene 
mutations in five basal laminar drusen families. Our findings strongly support a recessive 
disease model in this subgroup of patients with basal laminar drusen. In these families, 
individuals develop early-onset basal laminar drusen when they carry a CFH mutation 
on one allele and the CFH p.Tyr402His risk variant on the other allele. The presence of 
a CFH mutation in the absence of the p.Tyr402His risk variant may contribute to the 
development of age-related macular degeneration at a later age. Thus, basal laminar 
drusen and age-related macular degeneration appear to belong to a spectrum of diseases, 
characterized by drusen, that are associated with either monogenic or multifactorial 
inheritance of variants in the CFH gene.
 Chapter 6 is a general discussion of the findings in this thesis. Similarities and 
differences between similar phenotypes are discussed, based on their clinical, genetic, and 
pathophysiological characteristics. The proposed genotype-phenotype correlation models 
are discussed. This general discussion also attempts to shed a light on the phenomena of 
phenotypic variability and non-penetrance that were regularly observed with the genes 
in this thesis, by discussing possible genetic and environmental modifying factors. Age-
related macular degeneration is the example par excellence of a multifactorial retinal 
disease associated with complement activation and drusen. Therefore, it is also discussed 
in the light of the important contributing genetic and environmental factors, and their 
pathophysiological consequences. Finally, future perspectives on gene therapy and other 
possible therapeutic approaches are discussed.
 A profound knowledge on the clinical, genetic, and pathophysiologic characteristics 
of the hereditary retinal diseases described in this thesis is important. After all, such 
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knowledge enables optimal patient information and genetic counseling. In addition, it 
may facilitate the application and evaluation of future therapeutic strategies in these 
diseases. A thorough insight in the genetic and phenotypic characteristics of hereditary 
retinal disease may determine which patients are most eligible for treatments such as 
anti-angiogenic and gene therapy.
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Samenvatting
Veertig jaar nadat werd gepostuleerd dat verschillende retinale dystrofieën worden 
veroorzaakt door verschillende genen, blijkt deze hypothese onomstotelijk waar. Het is 
echter niet zo dat mutaties in één gen ook altijd simpelweg één ziekte veroorzaken. Dit 
proefschrift laat zien dat mutaties in een specific gen geassocieerd kunnen zijn met een 
breed scala aan klinische beelden. Sterker nog, een specifieke mutatie in een familie 
kan geassocieerd zijn met opvallend verschillende retinale dystrofieën. Een dergelijke 
fenotypische variatie kan alleen verklaard worden door de invloed van modificerende 
genen en omgevingsfactoren. 
Omgekeerd kan een specifiek fenotype, zoals bijvoorbeeld multifocale vitelliforme 
dystrofie of basal laminar drusen, genetisch heterogeen zijn. Sommige klinische beelden 
kunnen opvallende gelijkenissen vertonen. Centrale areolaire chorioidea dystrofie 
en basal laminar drusen, bijvoorbeeld, kunnen sterk lijken op leeftijdsgebonden 
maculadegeneratie. Multifocale patroondystrofie met kenmerken van de ziekte van 
Stargardt/fundus flavimaculatus kan gemakkelijk verward worden met de ziekte van 
Stargardt (STGD1). In dit proefschrift werden de klinische kenmerken en de moleculair 
genetische achtergrond van een aantal van deze fenotypes uitgebreid onderzocht. Op 
die manier kan een betere vergelijking en onderscheid worden gemaakt tussen deze 
klinische beelden.
 Hoofdstuk 1 is een algemene inleiding over de anatomie en functie van de retina, de 
basisprincipes van de moleculaire genetica, evenals de algemene klinische en genetische 
aspecten van retinale dystrofieën en leeftijdsgebonden maculadegeneratie.
 Hoofdstuk 2 begint met het bespreken van de theoretische en praktische achtergronden 
van fundus autofluorescentie (FAF). Beeldvorming met FAF maakt het mogelijk om de 
opstapeling van lipofuscine en lipofuscine-gerelateerde stoffen te visualiseren, met name 
in het retinaal pigment epitheel (RPE). Lipofuscine is een mengsel van afvalstoffen dat 
autofluorescente fluoroforen bevat. Deze fluoroforen vinden hun oorsprong met name in 
de buitensegmenten van de fotoreceptoren. Verschillende netvliesdystrofieën vertonen 
afwijkingen in de opstapeling van deze fluoroforen. Derhalve kunnen allerhande typische 
FAF patronen worden waargenomen bij deze retinale aandoeningen. Beeldvorming van 
de retina met FAF lijkt een nuttig aanvullend middel te zijn in de diagnose en follow-up 
van verscheidene retinale dystrofieën, waaronder degene die beschreven worden in dit 
proefschrift.
 Hoofdstuk 3 is gewijd aan oogziekten die worden veroorzaakt door mutaties in het 
BEST1 gen. In deel 3.1 wordt een overzicht gegeven van het BEST1 gen, en de oculaire 
fenotypes die worden veroorzaakt door mutaties is dit gen. Het BEST1 gen codeert het 
bestrophin-1 eiwit, dat zich bevindt in het RPE. Bestrophin-1 is waarschijnlijk een 
volume-sensitief Ca2+-afhankelijk Cl- kanaal, dat de ion-huishouding ter hoogte van het 
RPE reguleert. Daarnaast beïnvloedt bestrophin-1 intracellulaire Ca2+ concentraties door 
regulatie van voltage-afhankelijke Ca2+ kanalen. Mutaties in het BEST1 gen zijn gevonden 
in Best vitelliforme maculadystrofie, adult-onset foveomaculaire vitelliforme dystrofie, 
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autosomaal dominante vitreoretinochoroidopathie (ADVIRC), het microcornea, 
staaf-kegeldystrofie, cataract, posterior stafyloma (MRCS) syndroom, en autosomaal 
recessieve bestrophinopathie. De drie laatstgenoemde fenotypes zijn geassocieerd met 
afwijkingen in de oculaire ontwikkeling die verder reiken dan de retina. Dergelijke 
ontwikkelingsanomalieën van het oog wijzen op een rol van bestrophin-1 in de normale 
ontwikkeling van het oog, naast zijn rol in ion homeostase. Tot op zekere hoogte voldoen 
mutaties in het BEST1 gen en de geassocieerde fenotypes aan een genotype-fenotype 
correlatie model.
 Deel 3.2 is een gedetailleerde klinische en moleculair genetische analyse van 20 
patiënten met Best vitelliforme maculadystrofie uit 15 verschillende families. Alle 
patiënten droegen een mutatie in het BEST1 gen en hadden een abnormaal electro-
oculogram. Acht verschillende BEST1 mutaties werden gevonden, inclusief twee niet eerder 
beschreven mutaties. Een opvallende fenotypische variabiliteit werd waargenomen, 
zelfs in associatie met één enkele BEST1 mutatie. Maar liefst 60% van de vitelliforme 
laesies kon niet worden geklassificeerd als een typisch stadium van Best vitelliforme 
maculadystrofie. Deze bevindingen bemoeilijkten het herkennen van duidelijke 
genotype-fenotype correlaties bij Best vitelliforme maculadystrofie. Beeldvorming 
met FAF en optische coherentie tomografie (OCT) bleken, met name wanneer ze in 
combinatie werden gebruikt, zeer nuttige niet-invasieve beeldvormingsmethoden voor 
de fenotypering en follow-up van patiënten met Best vitelliforme maculadystrofie. Deze 
beeldvormingstechnieken kunnen afwijkingen in vitelliforme laesies detecteren die niet 
zichtbaar zijn met funduscopie en fluorescentie angiografie. Op die manier vergroten 
FAF en OCT het inzicht in de pathogenese van Best vitelliforme maculadystrofie.
 Deel 3.3. beschrijft de klinische en moleculair genetische bevindingen in multifocale 
vitelliforme dystrofie. Multifocale vitelliforme dystrofie blijkt zowel klinisch als 
genetisch heterogeen te zijn. Vijftien patiënten met multifocale vitelliforme laesies 
werden bestudeerd, evenals hun aangedane familieleden. Negen van deze 15 patiënten 
(60%) bleken een mutatie in het BEST1 gen te dragen. Zeven verschillende BEST1 mutaties 
werden gevonden, inclusief vier niet eerder beschreven mutaties. Het electro-oculogram 
was abnormaal in alle patiënten met multifocale vitelliforme dystrofie en een BEST1 
mutatie. De leeftijd waarop de visusklachten begonnen was zeer variabel, net als het 
aantal en de grootte van de vitelliforme laesies buiten de macula. Het aspect van deze 
extramaculaire laesies kwam, ondanks hun kleinere afmetingen, echter behoorlijk 
overeen met de centrale vitelliforme laesie, zowel op funduscopie, FAF, als op OCT. 
De bevindingen in deze studie wijzen erop dat het beeld van multifocale vitelliforme 
dystrofie geassocieerd is met, maar niet exclusief is voor, mutaties in het BEST1 gen. 
Daarom kan multifocale vitelliforme dystrofie bij patiënten met een BEST1 mutatie en 
een abnormaal electro-oculogram beschouwd worden als een multifocale variant van 
Best vitelliforme maculadystrofie. 
 Hoofdstuk 4 bespreekt het scala aan retinale dystrofieën dat veroorzaakt wordt door 
mutaties in het peripherin/RDS gen. Deel 4.1 dient als een overzicht van het peripherin/
RDS gen en het intrigerend brede spectrum van doorgaans autosomaal dominant 
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overervende retinale dystrofieën, die worden veroorzaakt worden door mutaties in dit 
gen. Het peripherin/RDS proteïne is een structureel eiwit, dat een belangrijke rol speelt 
in de vorming van de schijfvormige buitensegmenten van de fotoreceptoren. Ten eerste 
kunnen mutaties in het peripherin/RDS gen verscheidene dystrofieën van de macula 
veroorzaken, inclusief drie fenotypes die geklassificeerd zijn als “patroondystrofieën”: 
butterfly-shaped (vlindervormige) pigment dystrofie, adult-onset foveomaculaire 
vitelliforme dystrofie, en multifocale patroondystrofie met kenmerken van de ziekte van 
Stargardt/fundus flavimaculatus. Andere peripherin/RDS-geassocieerde maculadystrofieën 
zijn centrale areolaire chorioidea dystrofie en leeftijdsgebonden maculadegeneratie-
achtige late-onset maculadystrofie (AMD-like late-onset macular dystrophy). Naast deze 
maculadystrofieën kunnen peripherin/RDS mutaties ook kegel-staaf dystrofie veroorzaken, 
een beeld dat in dit geval zowel funduscopisch als op FAF kan lijken op centrale 
areolaire chorioidea dystrofie. Mutaties in peripherin/RDS behoren bovendien tot de meest 
frequente veroorzakers van autosomaal dominante retinitis pigmentosa. Tenslotte kan 
een specifieke peripherin/RDS mutatie, in samenwerking met een mutatie in het ROM1 
gen, digene retinitis pigmentosa veroorzaken. Eén enkele peripherin/RDS mutatie kan een 
opvallend breed scala aan retinale fenotypes veroorzaken, zelfs bij leden van dezelfde 
familie. Dit bemoeilijkt het herkennen van consistente genotype-fenotype correlaties in 
peripherin/RDS-gerelateerde retinale dystrofieën.
 Deel 4.2 is de grootste klinische en genetische studie die tot op heden is gepubliceerd 
over centrale areolaire chorioidea dystrofie (CACD) en beschrijft de kenmerken van 
een groep van 103 CACD patiënten. Follow-up data waren beschikbaar van 42% van de 
patiënten, met een follow-up periode tot 35 jaar. Deze specifieke maculadystrofie bleek 
in 95% van de gevallen te worden veroorzaakt door autosomaal dominante overerving 
van een p.Arg142Trp mutatie in het peripherin/RDS gen. Dit hoge percentage p.Arg142Trp 
mutaties is hoogstwaarschijnlijk te wijten aan het feit dat peripherin/RDS p.Arg142Trp een 
relatief frequente founder mutatie is, afkomstig van een gemeenschappelijke voorouder, 
in de zuidoostelijke regio van Nederland. De overige CACD patiënten, afkomstig uit één 
familie, droegen een p.Arg172Gln mutatie in peripherin/RDS. In vrijwel alle patiënten 
kwamen de maculaire laesies overeen met een typisch CACD stadium. Peripherin/RDS 
p.Arg142Trp-geassocieerde CACD bleek een centrale kegeldystrofie fenotype te zijn. 
Een opvallende variabiliteit in de ernst van het ziektebeeld evenals non-penetrantie 
werd waargenomen tot en met de leeftijd van 64 jaar, in tot wel 21% van de dragers 
van de p.Arg142Trp mutatie. De differentiaal diagnose tussen CACD en atrofische 
leeftijdsgebonden maculadegeneratie kan uitdagend zijn, vanwege de gelijkaardige 
klinische kenmerken, de overlap in de leeftijd waarop deze aandoeningen symptomatisch 
worden, alsmede de verminderde penetrantie van de p.Arg142Trp mutatie in het 
peripherin/RDS gen.
 Deel 4.3 is de eerste studie die specifiek gericht is op de klinische en genetische 
analyse van multifocale patroondystrofie met kenmerken van de ziekte van Stargardt/
fundus flavimaculatus (MPD), een autosomaal dominante patroondystrofie van de 
retina. Mutaties in het peripherin/RDS gen bleken de belangrijkste oorzaak te zijn van dit 
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fenotype. Wij beschrijven negen verschillende peripherin/RDS mutaties in 10 verschillende 
families, inclusief zes niet eerder beschreven mutaties. Alle patiënten met peripherin/
RDS-geassocieerde MPD presenteerden zich met onregelmatige, geelwitte vlekjes 
in de achterpool. Deze vlekjes leken erg op de geelwitte laesies die worden gezien in 
het fundus flavimaculatus-subtype van de ziekte van Stargardt, veroorzaakt door 
autosomaal recessieve mutaties in het ABCA4 gen. Verschillende klinische kenmerken 
van MPD kunnen het maken van een onderscheid tussen MPD en de ziekte van 
Stargardt vergemakkelijken. Tot deze differentiaal diagnostische kenmerken behoren de 
autosomaal dominante overervingswijze, de relatief late leeftijd waarop het visusverlies 
doorgaans optreedt, evenals de afwezigheid van een “dark choroid” on fluorescentie 
angiografie. De verminderde penetrantie en de opvallend variabele expressiviteit van 
meerdere van deze peripherin/RDS mutaties kan het onderscheid tussen MPD en de ziekte 
van Stargardt echter compliceren. In dergelijke gevallen is een analyse van het ABCA4 gen 
en het peripherin/RDS gen aangewezen.
 Hoofdstuk 5 beschrijft de klinische en moleculair genetische bevindingen in fenotypes 
die geassocieerd zijn met varianten in het Complement factor H (CFH) gen. Hierbij wordt de 
nadruk gelegd op de fenotypes die geassocieerd zijn met drusen, de kenmerkende laesies 
in leeftijdsgebonden maculadegeneratie. Drusen zijn ronde, geelwitte deposities tussen 
het RPE en de membraan van Bruch. Het CFH eiwit is een multifunctioneel proteïne, 
dat hoofdzakelijk een rol speelt in het afremmen van overmatige stimulatie van de 
alternatieve route van de complementcascade. De complementcascade is een essentieel 
onderdeel van de aangeboren immuniteit. 
Deel 5.1 is een uitgebreid overzicht van het spectrum van fenotypes die geassocieerd 
zijn met varianten in het CFH gen. Dit klinische spectrum omvat nierziekten zoals 
membranoproliferatieve glomerulonefritis en het atypisch hemolytisch uremisch 
syndroom, maar ook oogziekten, zoals basal laminar drusen en leeftijdsgebonden 
maculadegeneratie. Daarnaast worden verschillende overlappende klinische beelden 
besproken die geassocieerd zijn met CFH varianten. Een interessant gemeenschappelijk 
kenmerk van leeftijdsgebonden maculadegeneratie, basal laminar drusen, en 
membranoproliferatieve glomerulonefritis, is de aanwezigheid van drusen, hoewel de 
leeftijd waarop deze drusen zichtbaar worden verschilt tussen deze aandoeningen. Het 
gemeenschappelijke kenmerk van drusen bij deze ziekten kan worden verklaard door een 
deels gelijkaardige pathogenese, die gerelateerd is aan een abnormaal verhoogde activatie 
van de alternatieve complementcascade. De klinische consequenties van varianten in het 
CFH gen hangen af van hun impact op de functie van plasma- en celoppervlak-gebonden 
CFH. Als gevolg daarvan kunnen specifieke genotype-fenotype correlaties worden 
waargenomen. In dit proefschrift worden deze correlaties besproken en stellen we een 
genotype-fenotype correlatiemodel voor CFH-geassocieerde ziekten voor.
 In deel 5.2 wordt de rol van het CFH gen geëvalueerd in 30 patiënten uit verschillende 
families met early-onset basal laminar drusen. Het ziektebeeld basal laminar drusen 
wordt gekenmerkt door een ontelbaar aantal kleine drusen in de macula, en vaak ook 
verspreid over de hele fundus. Deze drusen vertonen een karakteristiek “stars-in-the-sky” 
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(sterrenhemel-) beeld op fluorescentie angiografie. Wij tonen aan dat basal laminar drusen 
een genetisch heterogeen fenotype is, aangezien we vier verschillende CFH varianten 
in vijf basal laminar drusen families vonden. Onze bevindingen wijzen sterk op een 
recessief overervingsmodel in deze subgroep van patiënten met basal laminar drusen. In 
deze families ontwikkelt men early-onset basal laminar drusen als men een CFH mutatie 
op het ene allel draagt, en de p.Tyr402His variant in CFH op het andere allel. Het dragen 
van een CFH mutatie in de afwezigheid van de p.Tyr402His variant kan bijdragen aan 
de ontwikkeling van leeftijdsgebonden maculadegeneratie op latere leeftijd. Zo lijken 
basal laminar drusen en leeftijdsgebonden maculadegeneratie dus deel uit te maken 
van een spectrum van ziektebeelden gekenmerkt door drusen, die geassocieerd zijn met 
monogene dan wel multifactoriële overerving van varianten in het CFH gen.
 Hoofdstuk 6 is een algemene discussie van de bevindingen in dit proefschrift. De 
overeenkomsten en verschillen tussen gelijkaardige fenotypes worden besproken, 
op basis van hun klinische, genetische, en pathofysiologische kenmerken. De 
voorgestelde genotype-fenotype correlatiemodellen worden besproken. Daarnaast 
wordt in deze algemene discussie gepoogd om een licht te werpen op de fenomenen 
van fenotypische variabiliteit en non-penetrantie, die regelmatig werden geobserveerd 
in combinatie met de in dit proefschrift besproken genen. Mogelijke modificerende 
genetische- en omgevingsfactoren van deze erfelijke netvliesaandoeningen worden 
besproken. Leeftijdsgebonden maculadegeneratie, het voorbeeld bij uitstek van een 
multifactoriële netvliesaandoening geassocieerd met complementactivatie en drusen, 
wordt bediscussieerd in het licht van de belangrijke bijdragende genetische- en 
omgevingsfactoren, en hun pathofysiologische consequenties. Tenslotte worden de 
toekomstperspectieven wat betreft gentherapie en andere mogelijke therapeutische 
benaderingen besproken.
 Een grondige kennis van de klinische, genetische, en pathofysiologische kenmerken 
van erfelijke netvliesaandoeningen is belangrijk. Op die manier wordt immers een 
optimale informatievoorziening en genetisch advies aan de patiënt mogelijk. Daarnaast 
kunnen deze gegevens de toepassing en evaluatie van toekomstige therapeutische 
strategieën voor deze ziekten vergemakkelijken. Dergelijke inzichten kunnen immers 
bepalend zijn in de besluitvorming over welke patiënten het meest in aanmerking 
komen voor behandelingen met bijvoorbeeld vaatgroeiremmers en gentherapie.
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Color figures
Color figures
Figure 1.1.*  
Original fundus image of 
retinitis pigmentosa, published 
by van Trigt in 1853.
Figure 1.3.*  
Original figures published by Best, Stargardt, and Sorsby. A. Best vitelliform macular  
dystrophy, drawing published by Friedrich Best in 1905. B. Stargardt disease,  
drawing published by Karl Stargardt in 1909. C. Central areolar choroidal dystrophy,  
drawing published by Arnold Sorsby in 1939.
Figure 1..13.*   
Age-related macular degeneration (AMD). A. Soft drusen in the macula, that merge to a  
larger pigment epithelial detachment with hyperpigmentation. B. Advanced atrophic AMD, 
showing profound chorioretinal, “geographic”atrophy of the macula, surrounded by large 
drusen. C. Neovascular AMD, associated with hemorrhages within the lesion.
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Figure 2.2.*    
Pigmented choroidal naevus (black arrowheads), corresponding to focally increased near- 
infrared fundus autof luorescence (NIR-FAF, white arrowheads). The overlying retinal pigment 
epithelium (RPE) in atrophic in this patient with central areolar choroidal dystrophy. This RPE 
atrophy corresponds to decreased NIR-FAF, bordered by f lecks of mildly increased NIR-FAF.
Figure 2.3.*    
(A-C) Stargardt disease (STGD1)/fundus f lavimaculatus, caused by autosomal recessive 
ABCA4 gene mutations. A. Fundus photograph of STGD1, showing multiple yellowish,  
irregular f lecks throughout the fundus, as well as a “beaten bronze” chorioretinal atrophy of 
the macula. B. Short-wavelength fundus autof luorescence (FAF) shows increased FAF of the 
f lecks, and mottled areas of decreased FAF in the macula. C. On near-infrared fundus 
autof luorescence (NIR-FAF), the lesions are clearly larger and more numerous. On NIR-FAF, 
most lesions have a decreased intensity. (D-F) Multifocal pattern dystrophy simulating 
STGD1/fundus f lavimaculatus, caused by an autosomal dominant mutation in the 
peripherin/RDS gene. The irregular yellowish f lecks are highly similar to those in STGD1, on 
ophthalmoscopy (D), short-wavelength FAF (E), as well as NIR-FAF (F). The macular lesion in 
this patient, however, appears smaller and less atrophic.    
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Figure 3.1.*   
Protein model of bestrophin-1 (adapted from Milenkovic). The model of Milenkovic and colleagues 
was used, as their experiments have shown that only the four domains depicted in the figure are 
located in the cell membrane. The known human disease-associated  mutations are indicated with 
colours. The protein variants found in age-related macular degeneration are also shown, although 
functional studies question their significance in disease pathogenesis. Coloured residue: missense 
mutation or in-frame deletion. Coloured bar: nonsense or frameshift mutation. Abbreviations: 
BVMD, Best vitelliform macular  dystrophy; AFVD, adult-onset foveomacular vitelliform dystrophy; 
ADVIRC, autosomal dominant vitreoretinochoroidopathy; ARB, autosomal recessive bestrophinopathy; 
AMD, age-related macular degeneration. 
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Figure 3.2.*    
Best vitelliform macular dystrophy (BVMD). All patients in this figure had an abnormal 
 electro-oculogram and a positive family history for BVMD. A. Previtelliform or carrier stage  
in a 40-year-old patient carrying a p.Tyr227Asn mutation in the BEST1 gene. The visual acuity 
(VA) was 20/16. Hypopigmented, slightly atrophic retinal pigment epithelial changes are seen in 
the fovea, which remained stationary during a follow-up period of 30 years,  starting at the age 
of 10. B. Vitelliform stage in a 41-year-old patient carrying a p.Arg25Trp mutation in BEST1. 
The lesion in entirely filled with yellowish material. C. Vitelliruptive or “scrambled-egg” lesion 
in a 12-year-old patient with a VA of 20/25. This patient carried a p.Lys194_Ala195insVal 
 mutation in BEST1. Scattered yellow-white vitelliform deposits are observed throughout the 
 lesion. D. Pseudohypopyon stage in a 11-year-old patient carrying a p.Thr6Pro BEST1 mutation. 
The VA was 20/25. E. Atrophic stage in a 60-year-old patient who carried a p.Thr6Pro mutation 
in BEST1. Note the multifocal atrophic lesions besides the  central, large atrophic lesion in this 
patient, who had a VA of 10/100. F. Cicatricial stage in a 17-year-old patient, who also carried a 
p.Thr6Pro mutation in the BEST1 gene, with a VA of 20/100. G. Fundus autof luorescence (FAF) 
image of the vitelliform lesion in the patient  described with image (B), showing an intensely 
increased FAF signal. H. FAF image of the  vitelliruptive lesion of the same patient as on image 
(C), showing a dispersion of the  material of increased FAF. In addition, a small pseudohypopyon 
with increased FAF can be seen in the inferior part of the lesion. I. FAF image of the same 
 cicatricial stage lesion as on image (F), showing decreased to absent FAF in the center of the 
scar, and increased FAF at the edge of the scar, as well as at the edge of the lesion. J. Vertical 
optical coherence  tomography (OCT) section of the pseudohypopyon lesion as depicted on image 
(D). The vitelliform material in the inferior part of the lesion is hyperref lective on OCT. 
Deposition of hyperref lective material is also seen on the outer retinal surface under the fovea. 
The transparent f luid in the upper part of the lesion corresponds with hypor ef lectivity on the 
OCT image. K. High-resolution spectral domain-OCT image of the same cicatricial lesion as on 
images (F) and (I), revealing an elevation of the macula with a highly ref lective subfoveal mass, 
corresponding to the scar. All retinal layers and RPE seem to be preserved over the entire area. 
The thickened photoreceptor layer at the borders of the retinal detachment corresponds to an 
outer ring of increased FAF in panel (I). An area of partial photoreceptor loss around the central 
mass co-locates to decreased perifoveal FAF.
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Figure 3.3.*      
Autosomal dominant vitreoretino-
choroidopathy (ADVIRC), in a 25-year-old 
patient carrying a heterozygous  
p.Val86Met (c.256G>A) mutation in the 
BEST1 gene. A. On a composition image of 
colour fundus photographs,  
a circum ferential hyperpigmented band  
is seen in the (mid-)periphery. The optic disc 
has a slightly pale aspect, and  peripapillary 
chorioretinal  atrophy is noted.  
B. Photograph of the same patient,  showing 
microcornea with a corneal  diameter of less 
than 10 mm,  
as a sign of ocular developmental 
 abnormalities in ADVIRC.
Figure 3.4.*      
Autosomal recessive bestro phinopathy (ARB) 
in a 45-year old patient who carried the 
compound heterozygous mutations  
p.Asp312Asn (c.934G>A) and p.Met325Thr 
(c.974T>C). A. Composition image of colour  
fundus photographs, showing  
widespread irregular retinal  pigment 
 epithelial alterations with whitish 
 subretinal deposits throughout the retina. 
In the macula, deposition of yellow-white 
material is seen.  
B. Fundus autof luorescence (FAF) image, 
 showing diffuse, discrete small areas of 
increased and decreased FAF. C. On a 
 horizontal optical coherence tomography 
(OCT)  section of the macula, hypo ref lective 
subretinal f luid between the retinal 
 pigment epithelium and the neurosensory 
retina is seen, as well as small hypo-
ref lective cysts of intraretinal f luid.
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Figure 3.5.*     
Carrier stage. A. Fundus photograph of patient 4 (p.Thr6Pro  mutation in BEST1), the 
41-year-old father of patient 5, does not show any abnormalities. B. Fluorescein angiography 
does not show any abnormalities of the macula. C. Fundus autof luorescence image, showing 
a normal autof luorescence pattern of the macula. D. Optical coherence tomography scan 
shows a normal aspect of the retinal layers.
Figure 3.6.*     
Vitelliform stage.  
A. Fundus photo-
graph of patient 3 
(p.Thr6Pro mutation 
in BEST1), showing a 
yellowish lesion with 
some  fibrosis and 
pigmentation at the 
boundaries of the 
lesion. B. Fundus 
autof luorescence 
(FAF) of the yellow-
ish parts of the  
lesion is significantly 
 increased, but 
 becomes less intense towards the lesions margins. Zones of increased FAF are beginning to cluster 
within the lesion. C. Seven months later, the ophthalmoscopic and FAF picture evolved to a lesion 
with combined  characteristics of the scrambled-egg and pseudohypopyon stage. D. At this point in 
time, fundus f luorescein angiography (FFA) was performed, showing patchy hyperf luorescence in 
the superior part of the lesion, and a hyperf luorescent  pseudohypopyon. E. A vertical optical 
 coherence tomography (OCT) scan (arrow in panel A) shows a hyperref lective  subretinal lesion in  
the vitelliform stage.
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Pseudo hypopyon stage. F. Fundus  photograph of patient 7, who also carried a p.Thr6Pro mutation, 
showing yellowish material  inferiorly with transparent f luid in the  superior part of the lesion.  
G. The yellowish  material of the pseudohypopyon shows  substantially increased FAF, with only 
some small spots of increased FAF in the  superior part of the lesion. H. The pseudo hypopyon is 
intensely hyper f luorescent in the  mid-late phase of FFA. I. The pseudohypopyon  corresponds to 
subretinal material of  increased ref lectivity on a vertical OCT  section (arrow in panel F).  
Additional hyperref lective material is attached to the outer retina and to the bottom of the 
 subretinal space  (arrowhead). Vitelliruptive/Scrambled-egg stage. J. Fundus photograph of patient 
10 (p.Lys194_Ala195insVal mutation in the BEST1), showing a large lesion with scattered clusters of 
yellowish material within transparent f luid. K. In addition to the locations of clinically apparent 
yellowish material,  increased FAF can be observed at the borders of the lesion where yellowish 
 subretinal material  cannot readily be visualized by ophthalmoscopy. L. On FFA, the lesion shows 
patchy hyper f luorescence. M. OCT scan taken vertically (arrow in panel J), showing  elevation of the 
retina by subretinal f luid that has no ref lectance. The clusters of yellow material that were seen on 
the fundus photograph appear as prominent hyperref lective structures (arrowheads).
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Figure 3.7.*
Atrophic stage. A. Fundus photograph of patient 19 (p.Gly299Ala mutation in BEST1) showing an 
atrophic lesion. B. The fundus autof luorescence (FAF) image shows  markedly decreased FAF of the 
atrophic area, surrounded by a ring-shaped area of increased FAF. C. Fundus f luorescein  angiography 
(FFA) shows a well-circum scribed, hyperf luorescent window defect due to atrophy of the retinal pig-
ment  epithelium. D. This atrophic area  corresponds with retinal thinning with underlying hyperre-
f lectivity on the optical coherence tomography (OCT) scan (arrow in panel A). Small intraretinal cys-
toid changes can also be discerned. Cicatricial stage. E. The fundus photograph of patient 2 (p.
Thr6Pro mutation in BEST1) shows a  prominent  yellow-white subretinal scar with pigmented borders, 
surrounded by a serous retinal detachment. The visual acuity (20/25) was remarkably preserved. F. 
FAF imaging reveals significantly decreased FAF of the central scar, surrounded by small amounts of 
material of increased FAF intensity  scattered throughout the rest of the lesion. This material is not 
evident on the fundus  photograph. G. In the late phase of FFA, the scar is intensely hyperf luorescent 
due to passive  leakage of  f luorescein into the scar, whereas the surrounding part of the lesion shows 
more discrete, patchy hyperf luorescence. H. OCT (arrow in panel E) shows a prominent and hyperre-
f lective  structure, in contact with the overlying retina. This structure is surrounded by elevated retina 
with underlying spots of increased ref lectivity.
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Figure 3.8.*       
Atypical forms of Best 
vitelliform macular 
dystrophy. A. Fundus 
photograph of patient 
14 (p.Ala243Val  mutation in BEST1). A small pseudohypopyon (arrowhead) and some scattered 
 yellow deposits are combined with a spoke-like pattern of subretinal yellowish changes, resembling  
a pattern dystrophy. B. The lesion shows increased fundus autof luorescence (FAF) of the small 
pseudo hypopyon and a radial pattern of spoke-like extensions with  increased FAF on a background of 
 markedly decreased FAF. C. The spokes of increased FAF are hypof luorescent on  fundus  f luorescein 
angiography (FFA), whereas the spokes of decreased FAF are hyperf luorescent.  
D. A horizontal  optical coherence tomography (OCT) scan (arrow in panel A) shows an elevated 
 retina with  irref lective subretinal material. E. Fundus photograph of patient 20 (p.Gly299Ala 
 mutation in BEST1), who presented with multifocal vitelliform lesions. The different lesions all have 
 characteristics of the vitelliruptive stage, with circular deposition of yellowish material along the 
edges of the lesions. The lesions show some degree of fibrosis and atrophy as well. F. FAF shows that 
the yellowish deposits are intensely autof luorescent, whereas areas with atrophy and fibrosis show 
absent FAF. G. On FFA, lesions are predominantly hyperf luorescent. H. A vertical OCT scan (arrow in 
panel E) through the central  lesion reveals a serous retinal elevation with intraretinal cystoid changes. 
The underlying layer shows increased ref lectivity, probably corresponding with the fibrosis seen on 
ophthalmoscopy.
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Figure 3.9.*     
A. Fundus image of the left eye of patient 5 (p.Asp302_Asp304del mutation) at the age of  
18 years. Besides a central cicatricial lesion, a lesion superior to the optic disc with 
 characteristics of a pseudohypopyon is evident (arrowhead). At the age of 44, the lesion 
superior to the optic disc shows a “scrambled-egg” aspect (B). On the fundus 
 autof luorescence (FAF) image (C), the central lesion shows markedly decreased FAF of the 
area that corresponds with the scar on ophthalmoscopy, surrounded by a zone of mottled 
alterations of FAF intensity. The suprapapillary lesion shows spots of increased FAF at the 
edges of the lesion, which correspond with the remnants of vitelliform material on ophthal-
moscopy. D. A vertical optical coherence tomography (OCT) scan through the central lesion 
(white arrow in Fig. 3.9B) reveals a prominent hyperref lective structure, corresponding with 
the central scar seen on ophthalmoscopy. This structure is surrounded by a hyporef lective 
subretinal space, suggesting subretinal f luid. E. A vertical OCT section through the 
 suprapapillary lesion (black arrow in Fig. 3.9B) shows a dome-shaped structure with a 
 optically clear centre and a hyperref lective band above it, which possibly corresponds to the 
elevated photoreceptor layer.
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Figure 3.11.*     
A. Fundus image of the left eye of patient 12, who did not carry a mutation in BEST1. 
Multiple vitelliform lesions are visible, which can be more clearly delineated with 
 autof luorescence imaging (B). Both the central and superior temporal lesion show a pseudo-
hypopyon-like distribution of the material of increased autof luorescence. Vertical optical 
coherence tomography images of the central lesion (C, white arrow in Fig. 3.11A) and the 
lesion temporal and superior to the central lesion (D, black arrow in Fig. 3.11A) are highly 
similar, although the central lesion shows more subfoveal material of increased ref lectivity.
Figure 3.10.*     
Fundus photograph and autof luorescence image of the right eye of patient 4, carrying a  
p.Lys194_Ala195insVal mutation in the BEST1 gene (A and B, respectively). A. The fundus 
image shows extensive lesions with scattered yellow-white deposits. B. These deposits are 
intensely autof luorescent. The lesions show a generally increased autof luorescence signal, 
which enables a better appreciation of the size and extent of the lesions.
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Figure 3.12.*       
A. Fundus image of the right eye of patient 15 (no BEST1 mutation), showing a small central 
vitelliform lesion and a large arcuate lesion, below the superior temporal vascular arcade. 
B. A composition of fundus autof luorescence (FAF) images shows the large eccentric lesion 
with scattered areas of increased FAF. At the inferior edges of this lesion, pseudohypopyon-
like deposits of material of increased FAF can be observed (arrows).
Figure 4.1.*    
Protein model of peripherin/rds (adapted from Connell and Molday,37 Travis et al.,38 and Goldberg  
et al.53). The mutations associated with retinal dystrophies are indicated. Colored residue: missense 
mutation or in-frame deletion. Colored bar: nonsense or frameshift mutation. 
429
Color figures
Figure 4.5.*    
Clinical stages of central areolar choroidal dystrophy (CACD). A. Color fundus photograph of stage 
I CACD, showing slight parafoveal hypopigmentation. B. This area of hypopigmentation on 
 ophthalmoscopy corresponds with an area increased fundus autof luorescence (FAF). C. Fluorescein 
angiography shows hyperf luorescent parafoveal changes in stage I CACD. D. In stage II CACD, a 
round to oval area of hypopigmentation is seen in the macula. E. FAF in stage II shows a 
 corresponding area of speckled changes of increased and decreased FAF. Initially, increased FAF 
may predominate, but with time, as the lesion enlarges and atrophy of the retinal pigment 
 epithelium (RPE) progresses, decreased FAF may become more prominent. F. The f luorescein 
 angiogram in stage II displays a speckled hyperf luorescence of the lesion, corresponding with 
 partial atrophy of the RPE. G. Stage III CACD shows one or more patches of well-circumscribed 
chorioretinal atrophy, appearing outside the central fovea, within the area of slight 
 hypopigmentation. H. These areas of chorioretinal atrophy correspond to severely decreased to 
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absent FAF. I. Fluorescein angiography in stage III CACD clearly visualizes the remaining choroidal 
vessels in the area of chorioretinal atrophy. In the later phase of the angiogram, discrete leakage  
of f luorescein could be observed at the edge of the lesion, corresponding with incomplete atrophy  
of the choriocapillaris. J. In stage IV CACD, the well-defined area of chorioretinal atrophy involves 
the fovea, with a corresponding severe decrease in visual acuity. K. This area corresponds with  
a round to oval zone of absent FAF involving the fovea in late stage IV CACD, bordered by a small 
residual band of increased FAF. L. End-stage CACD also shows a well-demarcated area of 
 chorioretinal atrophy on the f luorescein angiogram, with enhanced visibility of the residual 
 underlying choroidal vessels. 
Figure 4.11.*      
The development of 
 lesions in multifocal 
 pattern dystrophy 
 simulating STGD1/fundus 
 f lavimaculatus.  
A. Fundus 
 autof luorescence (FAF) 
image of the 37-year-old 
daughter (E-IV:2, p.
Pro146fsX4) of proband E, 
demonstrating small dots 
of increased FAF, in the 
absence of foveal lesions. 
This picture may 
 represent an early stage of 
 multifocal pattern 
 dystrophy. B. Composition 
of FAF images of 
 individual H-II:2  
(p.Arg203fsX8), showing 
two irregular lesions with 
increased FAF in the 
 macular area and small 
irregular f lecks around 
the retinal vessels.  
Note that most of these f lecks show adjacent zones of decreased FAF. C. Fundus photograph  
of proband B (p.Asp145fsX30) taken at the age of 35, demonstrating three pigmented spots 
with a depigmented border in the macula. D. These lesions display a “dot-and-halo” aspect  
on the f luorescein angiogram, which was made before we had the possibility to perform  
FAF imaging. E. Six years later, the phenotype had evolved to a picture mimicking STGD1, 
with irregular yellow-white f lecks around the vascular arcades, which showed  predominantly 
increased FAF on the composition of FAF images (F). The macular lesion had a butterly-
shaped configuration both on ophthalmoscopy and on the FAF image (E, F).
Figure 4.5.*  continued
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Figure 4.12.*       
Advanced multifocal pattern 
dystrophy. A. Fundus  
photograph of proband F  
(p.Arg220fsX54), showing 
numerous yellowish f lecks that 
are scattered throughout the 
posterior pole, with the larger 
f lecks situated around a central 
area of well-circumscribed 
 chorioretinal atrophy.  
B. A fundus autof luorescence 
(FAF) image shows increased 
FAF, corresponding to the  
yellow lesions on 
 ophthalmoscopy, together with a complete absence of FAF in the central atrophic area.  
C. A composition of fundus photographs of proband A (p.Asp157Asn) demonstrated  
a central lesion typical for pattern dystrophy. A large ring-shaped, atrophic-appearing  
area can be seen, surrounding the macular area and optic disc. D. These lesions could be 
delineated with more detail on a composition of FAF images. The ring-shaped zone showed 
conf luence of the f lecks. Granular zones of decreased FAF were seen within this area of  
increased FAF, which ref lects the  beginning atrophy of the retinal pigment epithelium. 
Towards the periphery, the f lecks  became less conf luent and could be identified individually.
Figure 4.13.*      
Fundus photograph of patient 
E-III:14 (p.Pro147fsX4 mutation), 
showing a characteristic retinitis 
pigmentosa phenotype.
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Figure 5.9.*        
Retinal phenotypes of 
drusen patients 
 carrying the 
 combination of a 
p.Gln408X mutation 
and the  
p.Tyr402His AMD risk 
variant. (A-D) Retinal 
phenotype of patient 
A-III.5.  
A. Fundus photo-
graph of the right eye, 
showing extensive 
chorioretinal atrophy 
of the posterior pole. 
At the first examinati-
on, 17 years earlier, 
these areas correspon-
ded with large conf lu-
ent drusen with inci-
pient atrophy. B. The 
short-wavelength fun-
dus autof luorescence 
(FAF) image shows an 
absence of FAF corres-
ponding with the pat-
ches of chorioretinal 
atrophy, not only in 
the macular area, but 
also in the midperipheral retina. Moreover, diffuse changes in FAF intensity can be observed. C. 
Fundus photograph of the left eye, showing large conf luent drusen and mild chorioretinal atrophy. 
D. An infrared ref lectance photograph clearly visualizes small, round midperipheral drusen scatte-
red between the patches of chorioretinal atrophy. The drusen on infrared ref lectance corresponded 
with discrete, round, yellow-white drusen with a slightly pigmented border on ophthalmoscopy. 
(E-H) Retinal phenotype of patient B-II.1. E. Fundus photograph showing conf luent macular drusen. 
F. The macular drusen can be more easily detected on the f luorescein angiogram. G. Optical cohe-
rence tomography (OCT, oblique section) showing small dome-shaped elevations of the “outer red 
line”, corresponding with visible drusen on ophthalmoscopy (arrow). H. Like in patient A-III.5, small 
midperipheral drusen were also seen in this patient, which had a similar aspect on OCT as the macu-
lar drusen. (I-J) Patient B-III.2, the 22-year-old asymptomatic son of patient B-II.1 showed tiny hyper-
f luorescent drusen in the parafoveal area (I) and in the (mid-)peripheral retina (J) on f luorescein 
angiography, which were difficult to discern on ophthalmoscopy. His 25-year-old brother (B-III.1) had 
similar midperipheral lesions, but to a lesser extent.
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Dankwoord
Het is een voorrecht om deel uit te maken van een traditie van fundamentele interesse 
in en gedegen onderzoek naar erfelijke netvliesaandoeningen door de afdeling 
oogheelkunde van het UMC St Radboud. Deze traditie was er nooit geweest zonder het 
pionierswerk van professor Deutman en wijlen dr. Pinckers, die een schat aan kennis en 
een indrukwekkend fotoarchief hebben nagelaten. Hun onderzoek op dit gebied werd 
voortgezet door dr. Hoyng, dr. Klevering, en meer recent mijn paranimfen, dr. van Lith-
Verhoeven en dr. Go. 
Dokter Hoyng en professor Cruysberg ben ik dankbaar voor het feit dat ze mijn 
gedrevenheid en interesse voor oogheelkunde en oogheelkundig onderzoek destijds 
onderkenden en vertrouwden in mijn kunnen. 
 Voor het doen van promotieonderzoek moet je allereerst verschrikkelijk eigenwijs 
zijn. Zonder de deskundige ondersteuning en het enthousiasme van anderen was dit 
proefschrift echter nooit tot stand gekomen. Iedereen die hieraan heeft bijgedragen wil 
ik daarom uitdrukkelijk bedanken, en het is gepast om enkelen bij naam te noemen.
 Geachte dokter Hoyng, beste Carel, jou wil ik allereerst bedanken. Voor het bieden 
van alle kansen, voor je visie en enthousiasme, en tevens voor het vertrouwen waardoor 
je mij, in de mate van het mogelijke, de “artistieke vrijheid” gaf om het onderzoek te 
doen dat mij het interessantst leek.
 Geachte dokter Klevering, beste Jeroen, jij bent degene die mij het meest concreet 
heeft begeleid, waarvoor veel dank. Als geen ander versta jij de kunst om de vinger - altijd 
op een vriendelijke en directe manier - op de zere plek te leggen en vervolgens de spijker 
op zijn spreekwoordelijke kop te slaan.    
 Geachte professor Cremers, beste Frans, tot aan mijn promotie toe heb ik op twee 
gedachten gehinkt… is het nou professor Cremers of Frans?! U of jij? Dit natuurlijk deels 
vanwege mijn beleefde Vlaamse geneeskunde-opleiding. U was degene die mij met uw 
indrukwekkende expertise begeleidde en corrigeerde, als ik mij als klinisch georiënteerd 
onderzoeker weer eens op glad genetisch ijs waagde. Jij was echter ook degene die de 
afstand graag zo klein mogelijk hield en altijd direct toegankelijk was voor advies. Veel 
dank hiervoor.
 Geachte professor Keunen, vanaf het eerste moment heb ik uw enthousiasme en 
betrokkenheid bij mijn onderzoek ervaren. Ik dank u voor de motiverende begeleiding 
en belangrijke hulp.
 Beste Anneke, terwijl jij allemaal grote genen aan het ontdekken was op jouw weg 
naar de wetenschappelijke top, vond jij ook nog tijd om mij snel, vriendelijk, enthousiast 
en deskundig te helpen met mijn onderzoek en onze artikelen, zelfs vanuit de Verenigde 
Staten.
 Geachte dokter Theelen, beste Thomas, toen iedereen nog dacht dat autofluorescentie 
een irrelevant oogheelkundig modeverschijnsel voor verstokte “imaging-freaks” was, wist 
jij mij met aanstekelijk enthousiasme te motiveren om deze techniek onder de knie te 
krijgen en toe te passen. Dit proefschrift illustreert het resultaat, dat slechts het begin is. 
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 Marijke Zonneveld-Vrieling dank ik voor haar grondige en snelle genetische analyses, 
maar ook voor de prettige samenwerking. Liesbeth Hoeks bedank ik voor haar flexibele 
en deskundige electrofysiologische ondersteuning van de klinische studies. Janneke 
van Lith-Verhoeven, Sioe Lie Go, en Karin Meulendijks ben ik zeer dankbaar bij het 
concreet begeleiden van mijn eerste praktische stapjes op onderzoeksgebied. Mary van 
Schooneveld  wil ik bedanken voor de samenwerking en discussies. Jolanda Hennink ben 
ik zeer erkentelijk voor haar begrip en flexibiliteit in het vrijplannen van onderzoekstijd 
in het begin van mijn opleiding. Ivo van Kampen en Maikel Nijbroek van LAN-beheer 
oftewel de computer-ondersteuningsdienst dank ik voor hun hulp als mijn computer 
weer eens B deed als ik A wilde. Dzˇenita, mijn “opvolgster” als promovendus, bedankt 
voor de interessante discussies die we al hebben gehad.
 Ik zou nog vele pagina’s kunnen vullen met de alle mensen die ik dankbaar ben (de 
verpleegkundigen, optometristen, administratief medewerkers,…). Dit laat ik uit angst 
voor onvolledigheid achterwege, in de hoop en verwachting dat zij mijn waardering 
desondanks hebben ervaren.
 Een speciaal woord van dank komt toe aan mijn (ex-)collega’s in opleiding tot oogarts. 
Zij hebben mij, zelfs al voordat ik was begonnen als promovendus, direct het gevoel 
gegeven een welkome collega te zijn, die bij alle activiteiten werd betrokken. En later, 
tijdens het schrijfproces parallel aan mijn opleiding, tot aan de promotie toe, toonden 
zij veel begrip en betrokkenheid ondanks hun eigen intensieve opleiding. Daarom (in 
chronologische volgorde): Niels, Frederik, Sandra, Eize, Christel, Janneke, Marike, Chris, 
Sioe Lie, Frits, Wanda, Benjamin, Piet, Maartje, Hélène, Pit, Jacqueline, Marianne, en 
Rutger: veel dank daarvoor - we zijn een leuke club!
 Als laatsten degenen die op de eerste plaats komen. Mijn moeder, mijn vader, Olivier 
en Mijntje wil ik bedanken voor hun steun en interesse. Ik prijs mij gelukkig dat dit gezin 
de hoeksteen is van mijn samenleving.
 Lieve Karlijn, met jouw liefdevolle ondersteuning weet je mij altijd te motiveren, en 
op de juiste momenten laat je mij zaken relativeren.
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